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CHAPTER 1 
GENERAL INTRODUCTION 
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1.1 IMMUNE CELLS AND CYTOKINES IN ANTIBODY RESPONSES 
During life, man encounters a large variety of infectious agents such as bacteriae, fungi, 
viruses and parasites. The cytopathogenic effects of these micro-organisms may have 
detrimental consequences on body functions, and may eventually lead to severe damages 
or even the death of the infected host. The fact that most of the time these organisms do not 
get the opportunity to harm our body, is largely due to our immune system. The immune 
system consists of a specific and a non-specific part. The latter, also called innate immune 
system, is the primary defense against micro-organisms and consist of a.o. the skin, shedding 
of epithelial cells, cilia lining the trachea, mucus, acid in the stomach, cytolytic enzymes in 
secretions, phaQocytes, acute phase proteins, etc. 
The second line. of defense is formed by the specific (adaptive) immune system, which can 
be divided into a cellular and a humoral part. Cellular immunity is primarily exerted by T cells, 
consisting of cytotoxic T cells, which kill virus-infected cells and tumor cells, or helper T cells 
which regulate the function of other cells via secreted cytokines. 
In humoral immunity the immunoglobulin producing B cell plays a central role. B cells, derived 
from bone marrow, produce antibodies, proteins that are secreted in body-fluids and can bind 
to antigens with high specificity. Specificity of the antibody molecule resides in two identical 
antigen-binding sites located on the two tops of theY-shaped molecule. Effector functions of 
antibodies include neutralization, complement activation, opsonization and antibody-
dependent cell mediated cytotoxicity. Most of these effector functions are dependent on the 
structures on the tail of the Y-shaped molecule, the Fc-part, which varies between the 
(sub}classes of antibodies. Five distinct classes of immunoglobulin molecules (isotypes) are 
recognized in most higher mammals, namely lgM, lgD, lgG, lgA and lgE. These differ from 
each other in size, charge, amino acid composition and carbohydrate content. In the mouse, 
the lgG class is subdivided into four subclasses (isotypes), called lgGt, lgG2a, lgG2b and 
lgG3. The diversity of the structure of these subclasses determines the variety of functions 
of these effector molecules in immunity. 
B cells differentiate in the bone marrow where they are equipped with antigen-specific 
receptors, membrane immunoglobulin, and subsequently migrate to the peripheral lymphoid 
tissue where they can differentiate into antibody-forming cells (AFC), provided that they 
encounter the right antigen in the appropriate microenvironment. The interaction of antigen 
with membrane immunoglobulin on B cells is the first phase of all antibody responses. Most 
antigens cannot activate B cells directly, and require the help ofT cells and macrophages or 
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dendritic cells to generate an effective antibody response. Macrophages and dendritic cells 
are potent antigen-presenting cells and have a role in the initial activation and expansion of 
antigen-specific T cells. Upon activation, T cells express new surface antigens (a.o. gp39) and 
produce cytokines which enable them to activate and regulate B cell differentiation. The 
binding of a 39 kD protein (gp39) on activated T cells to the CD40 molecule on B cells 
provides the initial B cell activating signal, while the T helper cell derived cytokines regulate 
the differentiation of B cells into antibody-forming cells. Cytokines are glycosylated 
polypeptides, produced by a variety of cell types of both haematopoietic and non-
haematopoietic origin. Originally, these proteins were called lymphokines, monokines, 
interleukins based on their source or their role in the communication between leucocytes. 
However, detailed investigations revealed that most of these polypeptides were produced by 
more than one cell and exerted their regulatory role on various cell types. Therefore, the term 
cytokines is now generally used. In general, cytokine-producing cells are paracrine cells, 
meaning that their regulatory activity is directed to target cells which are localized in close 
conjunction. Evidence accumulates which suggests that the T cell derived cytokines 
interleukin 2 (IL-2), IL-4, IL-5, IL-6 and interferon-y (IFN-y) have an important role in B cell 
proliferation, differentiation and isotype switching. 
To facilitate and regulate the cell-cell interactions, immune cells are organized in tissues and 
organs called the lymphoid system. The primary lymphoid organs are the major sites of 
lymphopoiesis: the thymus produces T cells, and the fetal liver and bone marrow B cells. The 
secondary lymphoid organs include lymph nodes, spleen, bronchus associated lymphoid 
tissue and gut associated lymphoid tissue, which provide an environment for cells to develop 
an appropriate immune response against various antigens. The lymph nodes and the spleen 
can be seen as immunological filters of the lymph or blood, respectively. Experimentally 
administered antigen is processed depending on the route of entry, e.g. subcutaneous 
administration predominantly stimulates the draining lymph node, and intravenously injected 
antigen is processed mainly by the spleen. 
As already stated, the local microenvironment in secondary lymphoid tissues is important in 
the regulation of antibody production, and consists of the extracellular matrix, non-lymphoid 
cells and lymphoid cells. The non-lymphoid cells can be classified into two major groups. The 
first group are macrophages and interdigitating cells and the second group are stromal cells, 
consisting of reticular cells, follicular dendritic cells and endothelial cells. The lymphoid cells, 
producing antibodies and/or cytokines, contribute to the microenvironment in an antigen-
specific way. 
11 
All these locally active cells and factors have a steering role in antibody responses. Therefore, 
detailed knowledge of the microenvironment of lymphoid organs is required to improve our 
insight in the mechanisms involved into the generation and regulation of the antibody 
response. 
1.2 AIM OF THE STUDY 
The aim of the studies presented in this thesis was to investigate in vivo the immunological 
events taking place during the development of various types of antibody responses. Special 
emphasis was put on time-course, in situ localization and in vivo function of the different 
immunological events, e.g. antigen-presentation, T cell activation, cytokine-production, cell-cell 
interactions and antibody-formation in the spleen, as these processes are thought to have a 
decisive role in the development of in vivo antibody responses. 
1.3 THE IN VIVO APPROACH 
The responses of lymphocytes to antigens and pathogens have mainly been analyzed in vitro. 
However, whereas cells can interact relatively randomly in cell suspensions, peripheral 
lymphoid tissues like lymph nodes and spleen, are compartmentalized into distinct B and T 
cell zones. Cells are exposed to the influence of locally present immune cells, stromal cells, 
cytokines and the extracellular matrix. In vitro experiments necessarily disregard this complex 
organization of lymphoid organs. Still, they are powerful tools in the delineation of essential 
events during cell-cell interactions and may give an indication which cells and cytokines are 
active during immune responses. The in vitro approach is valuable for the investigation of the 
actual effects of specific cytokines on specific cells. As a consequence, lymphoid cell 
functions and interactions seen in vitro reflect the full potential and repertoire of such cells, 
but the events actually occurring in vivo are dictated and restricted by the lymphoid 
microenvironment. Therefore, we developed in vivo techniques and applied these in in vivo 
models. 
In vivo research is roughly performed in two ways. One approach is the utilization of in situ 
techniques, such as immunohistochemistry and in situ hybridization, which allow the in vivo 
study of the localization, activity and interactions of various cells and cytokines in relation to 
their direct microenvironment in all types of tissue at any given moment. The second in vivo 
approach is the use of modulating agents, e.g. cytokines, neutralizing-, blocking-, immune 
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cell-depleting antibodies, complement-, macrophage-depletion etc., in intact animals, which 
effects can be examined on the level of body fluids (serum) and/or tissue sections. The 
combination of these techniques are powerful tools to delineate the role of cytokines and cell-
cell interactions during in vivo antibody responses. In the studies presented in this thesis, 
both immunohistochemical and in vivo modulating techniques are used to investigate the 
immunological events in mice mounting antibody responses against various antigens. 
1.4 INTRODUCTION TO THE CHAPTERS 
The aim of this thesis was to investigate in vivo the immunological events taking place during 
the development of various types of antibody responses. The following chapters describe the 
time-course and localization of the distinct immunological events, such as antigen-handling, 
T cell activation, cytokine-production and antibody-formation in the spleen during thymus 
independent type 2 (TI-2) and thymus dependent (TD) antibody responses. 
Chapter 2 describes the complex organization of the spleen, consisting of specialized cell 
types localized in distinct splenic compartments. In view of all the cell-cell interactions that can 
occur in the spleen, the migration patterns ofT cells, 8 cells and dendritic cells are discussed. 
The experimentally used antigens are characterized. Furthermore, the vast amount of in vitro 
data dealing with antigen-presentation, cell-cell interactions, T and 8 cell activation, and the 
immunoregulatory role of cytokines is evaluated. Finally, the experimental questions 
addressed in this thesis are presented. 
In chapter 3 the localization of Tl-2 antigens in lymphoid tissue is investigated. Previous 
reports demonstrated that fluoresceinated Tl-2 antigens were taken up by marginal zone 
macrophages, suggesting that these cells played a role in the presentation of Tl-2 antigens. 
However, in vivo elimination or blocking of marginal zone macrophages did not affect the 
antibody response against Tl-2 antigens, indicating that other cells are involved in the 
induction of Tl-2 antibody responses. Therefore, a new and more sensitive technique was 
developed for the detection of administered haptenated antigens. Chapter 3 describes a TNP-
specific monoclonal antibody (mAb) conjugated to ;3-galactosidase, which is used for the 
detection of trinitrophenylated antigens. This highly sensitive approach enables the detection 
of Tl-2 antigens in the marginal zone and also in the follicles of the spleen, a hitherto 
undescribed phenomenon. The localization of administered Tl-2 antigens in the spleen and 
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lymph nodes is described and is compared with the localization of particulate Tl-1, soluble 
Tl-1 and soluble TO antigens. Furthermore, the follicular localization of TNP-Ficoll is 
characterized and its role in humoral immunity is investigated. The implications of these new 
findings with regard to the putative role of marginal zone macrophages in Tl-2 antibody 
responses is discussed. 
Chapter 4 describes the development of a method for the immunohistochemical detection of 
IFN-y-producing cells (IFN-y-PC) in murine lymphoid tissue. Immunization with Bacille Calmette 
Guerin (BCG) is used as model immune response, because in vitro experiments indicated that 
such a protocol results in high levels of IFN1• production. For the detection of IFN-y-PC, 
spleen sections of BCG immunized mice are incubated with an IFN-";-specific mAb conjugated 
to alkaline phosphatase. For the characterization of IFN-y-PC spleen sections are 
simultaneously incubated with IFN-y-specific immune-conjugate and mAb specific for 
membrane markers (CD4, CDS, Asialo-GM1), followed by a secondary conjugate. 
Furthermore, it is investigated whether the local splenic IFN-y production is also detectable 
in the serum, and if systemic application of aT cell mitogen (Concanavalin A) increases the 
local and systemic IFN-y production. 
Chapter 5 investigates in vivo the activity ofT cells and lFN-y in Tl-2 antibody responses. The 
in vivo development and localization of IFN~~-PC is investigated during antibody responses 
against various Tl-2 antigens. An IFN-y-specific ELISPOT assay is used to substantiate the in 
vivo results. Furthermore, IFNI' serum levels are measured. Double staining techniques are 
applied to determine whether IFN-y is produced by CD4+, CDS+ or NK cells. The localization 
of IFN-y-PC and TNP-specific antibody forming cells (TNP-AFC) is examined. Since in vitro 
experiments suggested that IFN-y has a regulatory role in Tl-2 antibody responses, it is 
investigated whether IFN-y-PC and TNP-AFC are co-localizing in the spleen. 
In chapter 6 the putative defect of peripheral lymph nodes to mount an antibody response 
against Tl-2 antigens is investigated. Therefore, the TNP-specific antibody response is 
determined in draining popliteal lymph nodes and spleens of mice after s.c. immunization with 
TNP-Fico!L Analysis is performed by means of immunohistochemical techniques and ELISPOT 
assays. Furthermore, the cytokine-production in the (high responding) spleen and the (low 
responding) lymph node are compared after immunization with TNP-Ficoll. To increase the 
TNP-specific antibody response in lymph nodes, mice are immunized with TNP-Ficoll 
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supplemented with Brucella abortus, a particulate Tl-1 antigen. The effect of this immunization 
protocol on the cytokine-production in popliteal lymph nodes is assessed. Evidence is 
provided that the local microenvironment of lymphoid tissue is important for the maturation 
of activated B cells during Tl-2 antibody responses. Finally, by intraperitoneal implantation of 
alginate encapsulated IL-4 and/or IL-5-producing cell lines it is tried to overcome in vivo the 
maturation defect of TNP-Ficoll activated lymph node B cells. 
In vitro studies revealed that upon activation (by ConA or anti-CD3 mAb) T helper cells 
produce cytokines and express a 39 kD protein. Binding of gp39 to the CD40 molecule on 
B cells was found to result in the activation of B cells, while added cytokines regulated the 
B cell differentiation into AFC. In chapter 7 we tried to validate these in vitro observations in 
in vivo model antibody responses. The detection and activity of gp39+ cells and cytokine-PC 
in the antibody response against a TD antigen (KLH) and a Tl-2 antigen (TNP-Ficoll) is 
described. Gp39+ cells are detected by using a specific mAb or a fusion protein of the 
receptor of gp39, CD40-IgG1. Double staining techniques are used to determine whether 
gp39 is expressed by CD4+ cells in vivo, as was demonstrated in vitro. The cytokine-PC are 
detected with specific mAb conjugated to alkaline phosphatase, horse radish peroxidase or 
p-galactosidase. It is investigated whether gp39+ cells produce cytokines. Furthermore, the 
localization of gp39+ cells and cytokine-PC in the spleen is determined. It is tried to visualize 
the in vivo interactions between antigen-specific AFC and cytokine-PC or gp39+ cells. Finally, 
we investigated the in vivo function of gp39+ cells in germinal center formation and in 
antibody responses against Tl-2 and TO antigens. 
The injection of goat anti-mouse lgD antibodies results in high increases of serum JgG1 and 
lgE. The high degree of T cell activation and cytokine-production, which is critical to the 
observed large increases of serum lgG1 and lgE, makes this model ideal for analysis of in 
vivo TD antibody responses. In chapter 8 the immunological events, such as antigen-
localization, gp39 expression, cytokine-production and antibody formation, are described after 
injection of rabbit anti-mouse lgD antibodies (RalgD). The localization of injected RalgD is 
monitored in the spleen and related to the in vivo localization and development of cytokine-
PC and gp39+ cells. Because IL-4 and !FN-y are suggested to be important for the regulation 
oflgE production, the localization, development and frequencies ofll+PC and IFN~'-PC are 
investigated. Furthermore, the cytokine profile (IL-2, IL-4 and IFN-y) of cytokine-PC is 
assessed. The localization and kinetics of development of cytokine-PC and gp39+ cells is 
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related to that of activated 8 cells and isotype-switched AFC. Finally, the functional role of 
gp39 is assessed in the (non-)specific antibody response observed after injection of RalgD. 
In chapter 9 the main points emerging from the experimental studies are discussed. These 
results will be related to the in vitro and in vivo data dealing with antigen~presentation, 
localization/migration of immune cells, cell-cell interactions and the immunoregulatory role of 
cytokines, as discussed in chapter 2. Finally, we try to bring order to the sequence of events 
that occur in the spleen after antigenic challenge, by presenting in vivo models for the cell-cell 
interactions that occur in the spleen during TO and Tl-2 antibody responses. 
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CHAPTER2 
Immune cells in the spleen: 
localization, migration and cell-cell interactions 
A great part of this chapter has been published in: 
Immunological functions and in vivo cell-cell interactions of 
T lymphocytes in the spleen 
Alfons J.M. Van den Eertwegh, Wim J.A. Boersma, and Eric Claassen 
Crit. Rev. lmmunol., 11: 337-380, 1992 
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ABSTRACT: The spleen is an important lymphoid organ. involved in immune responses against all types of antigen 
that appear in the circulation. Its complex anatomical organization. with distinct compartments containing 
specialized cell types. provides a microenvironment which allows different cell-cell interactions and determines the 
direction of developing immune responses. In this review we evaluate the vast amount of in virro data dealing with 
antigen presentation. cell-eel\ interactions, T and B cell activation, and the immunoregulatory role of cytokincs, as 
suggested to be involved in immune responses. As a basis for understanding of in rivo processes. these in vitro data 
will be related to discrete phenomena of in rivo immune responses. such as antigen localization/trapping. cell 
migration patterns of immunocompetent cells. cytokine production, and antibody formation in the different 
compartments of the spleen. Finally, we try to bring order to the sequence of events that occur in the spleen after 
antigenic challenge by presenting an in vivo model forT cell dependent and T cell independent immune responses. 
KEY WORDS: T cells, B cells, accessory cells, antibody-forming cells. cytokines. antigen, localization, migra-
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t INTRODUCTION' 
Because of its central position in the blood-
stream and the large amount of migrating lym-
phocytes, the spleen plays a central role in the 
primary defense against bloodstream infections. 
Two major critical functions of the spleen can be 
recognized: it serves as a large phagocytic filter 
and it is a major antibody-producing organ. 15 
Although the liver appears to remove the majority 
of well-opsonized bacteria from the bloodstream, 
the spleen has a principal function in the 
nonimmune host because of its ability to seques-
ter bacteria that are not well opsonized. Although 
the spleen participates significantly in host de-
fense mechanisms, it is not essential to life. Nev-
ertheless, its removal increases the risk of over-
A list of abbreviations used throughout the text appears 
after the acknowledgments section and before the refer-
ence list. 
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whelming infections by bacteria with polysaccha-
ride capsules, e.g., Streptococcus pneumoniae, 
Neisseria meningitidis, or Haemophilus influ-
enza_4.5.3S.36 
The spleen plays a central role in the antibody 
response both to intravenous antigens and poten-
tially to polysaccharides, regardless of the route 
of inoculation. After primary i.v. immunization, 
the spleen is, for most antigens, the major site of 
antibody production. 11 4--ll6 Since eight times more 
lymphocytes recirculate via the spleen than 
via all lymph nodes together, !70-!72 it is most 
likely that the entire antigen-specific Btr cell 
repertoire is available in the spleen. The complex 
anatomical organization of the spleen, with dis-
tinct compartments containing specialized cell 
types, provides a unique microenvironment al-
lowing cell-cell interactions which are essential 
for the initiation and continuation of various im-
mune responses. 38·224 
The approaches to increase our knowledge 
about immune responses can be divided in roughly 
two ways, in vitro and in vivo. In vitro experi-
ments are tools for the determination of which 
individual factors and cells may be required for 
cell activation, proliferation, and differentiation. 
However, they necessarily disregard the complex 
organization of lymphoid organs and the obtained 
results reflect the full potential of factors and cells 
ex vivo.ln vivo experiments, on the contrary, are 
tools to gain insight into the lymphoid microenvi-
ronment, which is determined by the localization 
and timing of activity of immune cells in the 
specific lymphoid compartments. Thus, it is rea-
sonable to assume that a combination of both 
approaches would markedly increase our knowl-
edge of immune responses. 
In this review we show the potential of such 
a combined approach. We discuss the architec-
ture of the spleen and the major cell types present. 
Special emphasis is placed on the localization of 
sessile and mobile immune cells within the spe-
cific splenic compartments, since the microenvi-
ronment dictates which cell-cell interactions are 
allowed and which are impossible. Furthermore, 
we discuss both in vitro and in vivo data dealing 
with the sequence of events during a variety of 
immune responses with respect to antigen rout-
ing/handling, cell-cell interactions, cytokine pro-
duction, and antibody production. Mechanisms 
leading toT cell activation and the regulatory role 
ofT cells in immune responses receive particular 
attention. 
II. ANATOMY AND FUNCTIONAL 
ARCHITECTURE OF THE SPLEEN 
Morphologically, the spleen can be divided 
into red and white pulp (Figure 1). The red pulp 
consists of erythrocytes and nucleated cells like 
lymphocytes, megakaryocytes, and macroph-
ages.217·224 In the white pulp three compartments 
can be distinguished: the periarteriolar lympho-
cyte sheath (PALS); the follicles; and the mar-
ginal zone. The PALS surrounds the central ar-
tery and the inner part consists mainly ofT cells. 
The outer part of the PALS is populated by T 
cells, B cells, and macrophages. The follicles are 
globular structures attached to the PALS, and are 
populated mainly by B cells. The follicle consists 
of a mantle zone, the lymphocyte corona, with 
small and medium-sized lymphocytes and a fol-
licle center, the germinal center,81 with large lym-
phocytes. The marginal zone surrounds PALS 
and follicles and contains predominantly B cells. 
macrophages, and relatively few T cells. 
Blood enters the spleen at the hilus through 
the splenic artery, which ramifies into trabecular 
arteries (Figure 1 ). Small arterial vessels leave the 
trabeculae as so-called center arterioles, which 
become gradually surrounded by lymphatic tissue 
called the PALS. Small terminal arterioles traverse 
the white pulp and open into the red pulp, where 
they are surrounded by a small sheath of lym-
phoid cells. Blood flows here in small channels, 
formed by reticular cells, and is subsequently 
collected by venous sinuses. Another part of the 
terminal arterioles opens into the marginal zone 
where, due to the reduced flow, the first cell-cell 
interactions between the immunocompetent cells 
like T cells, B cells, and macrophages might oc-
cur. A third type of terminal arterioles shunts the 
arterial blood flow directly through arterioles into 
the efferent venules. This latter type forms the 
closed circulation of the spleen and probably has 
relatively low importance with respect to immune 
function. 
The splenic architecture is ideal fortwo ofthe 
principal immunological functions of the spleen: 
phagocytosis and antibody production. The large 
volume of blood which passes the macrophages 
of the spleen allows it to filter soluble or particu-
late foreign material from the bloodstream.39· 181 
Furthermore, the close proximity of large num-
bers of lymphocytes allows efficient initiation 
and expansion of the specific immune response to 
this filtered material. 
Ill. LOCALIZATION OF IMMUNE CELLS 
IN THE SPLEEN 
A. T Cells 
T cells differentiate and develop in the thy-
mus and subsequently home into specific parts of 
peripheral lymphoid organs, the so-called thy-
mus-dependent areas.87 Flow cytofluorometric 
analysis of splenic T cell subpopulations of vari-
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FIGURE 1. Schematic representation of the localization of immune cells in the spleen. C, central arteriole; ip, inner 
PALS; F, follicle; Fe, follicle corona: MZ, marginal zone; op, outer PALS; R, red pulp; S, sinus; TA. trabecular artery; 
ta, lymphocyte sheath around terminal arteriole. (D) B Cell; (D) 8 cell with high lgM expression; (•) antibody~forming 
8 cell; (o) T cell; (*l FDC; (tr) IDC; (*l marginal zone macrophage;(<:;.) marginal metallophilic macrophage;(.~) red 
pulp macrophage. 
ous strains of mice demonstrates that ±26% of the 
nucleated cells are CD4+ cells and 8% CDS+ 
cells. 68•221 Studies on the localization of these T 
cell subpopulations reveal that CD4+ and CDS+ 
cells are mainly localized in the PALS (Figure 
2).217·22 1.222 Within the PALS, distribution of the 
two T cell subsets was found to be random with 
no special organization (Figure 2b, c). In this 
compartment, the majority ofT ce!ls are CD4+ 
(Figure 2b). In B cell areas like follicles, CD4+ 
cells are found, but in much lower frequencies 
than in the PALS. 182 A role for these cells in the 
activation of B memory cells which gives rise to 
the local plasma-cell reaction in the germinal 
center has been suggested. 135· 159 Virtually no 
CDS+ cells are found in the follicles (Figure 2c), 
although in some pathological conditions high 
numbers can be found. Both subpopulations of 
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CD4+ and CDS+ cells can be found scattered 
throughout the marginal zone. This is also the 
case in the red pulp where a substantial number of 
T cells can be found. It is not clear whether these 
red pulp T cells are actively involved in various 
local immune functions or merely migrating 
through the spleen. It has been suggested, on the 
basis of fluorescence intensity of Thy-1 staining, 
that T cells in the marginal zone and red pulp 
represent an immature population as compared to 
the T lymphocytes in the PALS.221 
B. B Cells 
The B lymphocytes in the spleen are mainly 
found in three compartments, i.e., the marginal 
m~ 
m 
FIGURE 2. Localization of B cells, CD4+, and CDS+ T cells 
in the spleen. (a) T lymphocytes (Thy1.2, dark membrane 
staining) and lgM-positive B cells (light membrane staining); 
almost all cells in the inner part of the PALS {iP) are T cells. 
In the outer PALS (oP), follicle (f), marginal zone (m}, and 
red pulp (r), relatively few T cells cells are present; almost 
all cells in follicle (f) and marginal zone {m) are B cells. (b) 
CD4+ cells, recognized by monoclonal MT4; the majority of 
the cells in the inner PALS (iP) are C04+ cells, and relatively 
few cells in follicle (f), marginal zone (m), and red pulp (r) 
are CD4+. (c) CDS+ cells, recognized by monoclonal Lyt2+; 
inner PALS (iP) is populated by the majority of CDS+ cells, 
and relatively few COB+ cells are found in marginal zone 
(m) and red pulp. Hardly any COB+ cells are found in the 
follicles (f). 
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zone, the follicles, and the outer PALS. The typi-
cal medium-sized B lymphocytes in the marginal 
zone have a strong membrane staining for IgM, 
whereas the small follicular lymphocytes show a 
moderate membrane staining for IgM (Plate 
lb*).51 Gray et al.78 demonstrated that marginal 
zone B cells exhibit a predominant 1-l+&- (or weak 
positive) surface phenotype, while follicular B 
cells main! y express both J.l and 0 on their surface 
(Plate la, b). The percentage of IgM+ nucleated 
cells in the spleen is strain dependent and varies 
between 40 and 60%.68 
In both rats and man, B cells with the pheno-
type of the marginal zone cells comprise about 
one third of the splenic B cells,78 whereas in mice 
only 15% of the splenic B cells have this pheno-
type.3 The marginal zone B cells are sessile cells 125 
unless they are activated by antigen. After LPS 
injection, a dramatic decrease in marginal zone B 
cells and an increase in lgM+IgD- (marginal zone 
phenotype) in the splenic follicles was observed, 
suggesting that after activation by antigens, mar-
ginal zone B cells migrate into the follicles of the 
spleen. 86 Marginal zone B cells express interleukin 
(IL)-295 and complement receptors83 and are there-
fore well equipped for mounting humoral im-
mune responses. 136· 137·218 
Primary nonantigen-stimulated follicles 
mainly consist of small resting lgM+IgD+ B cells. 
Within 4 to 8 days of antigen administration sec-
ondary follicles call "germinal centers" are formed, 
which are associated with an exponential growth 
of B cell blasts. 124 Recently, Liu et a!. suggested 
a role for germinal centers in antigen-driven B 
cell proliferation, somatic mutation. and memory 
cell and plasma cell development during TD im-
mune responses. 135 
After activation, B cell proliferate or develop 
into antibody-forming cells. We demonstrated that 
antigen-specific antibody-forming cells which de-
velop during primary thymus-dependent (TO) or 
thymus-independent (TI) immune responses are 
predominantly found in the outer PALS and in the 
sheaths of lymphoid tissue surrounding the termi-
nal arterioles in the spleen. 33 .34·40·223 Only a rela-
tively low number of antigen-specific antibody-
forming cells are localized in the red pulp, repre-
senting the antibody-forming cells which leave 
the spleen. 
* Plate I follows page 348. 
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C. Macrophages 
In the spleen, three major groups of acid phos-
phatase-positive macrophages can be distinguished 
(Plate lc). When functional and phenotypic dif-
ferences are taken into account, over II subsets 
can be distinguished.39 The most studied subsets 
are marginal zone macrophages, marginal 
metallophilics, and red pulp macrophages. Mar-
ginal zone macrophages have been identified as a 
distinct subset of spleen macrophages97 because 
they almost exclusively take up neutral polysac-
charides98·141.218 (Plate Ic, e, Figure 6). In the 
mouse, marginal zone macrophages can be spe-
cifically stained by monoclonal antibody ERTR952 
(Plate If, g) and appear as large cells with exten-
sive cell processes. They are positioned through-
out the marginal zone, from the marginal sinus to 
the border area with the red pulp. They are highly 
phagocytic and do not express major histocom-
patibility complex (MHC) class II antigens. 97 
Snook191 described a rim of cells blackened by 
silver impregnation at the periphery of the white 
pulp along the inner border of the marginal zone 
and called these cells acid phosphatase-positive 
macrophages, marginal metallophils. 191 Marginal 
metallophils in mice show very strong nonspe-
cific esterase activity and can be specifically 
stained by the monoclonal antibody MOMA-1 121 
(Plate If, g). Their function is still unclear, but 
some studies suggest a role in antigen processing 
. I . p? by these cells in partJCU ar Immune responses. --
D. Follicular Dendritic Cells (FDC) 
Weakly acid phosphatase-positive, nonpha-
gocytic cells are also found in the follicles of the 
spleen. These cells are linked with the presence of 
immune complexes and complement-opsonized 
antigen (bacteria/viruses/model antigens) (Plate 
lc. e, Figure 6).112.113.164--167.218 FDC with their 
long cell processes, which ramify extensively 
among the B cells localized in the follicle, are 
responsible for retention of these complexes and 
can be recognized by a recently developed mono-
clonal antibody.236 Immune-complex trapping is 
thought to play a role in the induction, mainte-
nance, regulation, and memory of humoral im-
mune responses.l12,118.135. 218 
E. Interdigitating Cells (I DC) 
IDC were first described in the T cell area Of 
lymph nodes227 and were also found in the main 
T cell area of the spleen, the inner PALS,226 
IDC are recognized by the antibodies NLDC-
145, 120 MIDC-8, 18 or Ml-8. 138 They consti-
tutively express MHC class II molecules, in 
contrast to macrophages where class II expres-
sion is an inducible phenomenon. 194 In vitro 
experiments have suggested that IDC are essen-
tial for the induction of primary immune re-
sponses.100·101 Because of their specific localiza-
tion surrounding the central arterioles, a role for 
IDC in the homing ofT cells has also been pos-
tulated.96 However, migration studies with labeled 
dendritic cells (DC) revealed that DC did not 
home to the splenic PALS of nude mice unless 
they were reconstituted with T cells, 127 suggest-
ing that migration of DC was regulated by 
T cells. 
F. Natural Killer Cells (NK Cells) 
NK cells form a subpopulation of non-T cell, 
CD3-negative, large granular lymphocytes which 
are capable of lysing neoplastic or virally infected 
target cells, as well as certain microorganisms 
without previous sensitization or MHC restric-
tion. Information regarding the in situ localiza-
tion of NK cells in the spleen is rather limited.211 
Recently, Brink et al. described the localization of 
NK cells in the spleens of rats, using a NK spe-
cific monoclonal antibody (designated 3.2.3.).20 
They observed that most NK cells were localized, 
sometimes in aggregates, in the red pulp (±12% 
of all nucleated cells in the red pulp), while rela-
tively few were noted in the white pulp (±0.2%). 
Fewer (as compared to the frequency in the red 
pulp) but still significant numbers of NK cells 
were detected in the marginal zone (±2% ). The 
localization pattern of NK cells in the rat spleen, 
as described by Van den Brink, is in agreement 
with our observations in murine spleens, after 
staining for asialo-GM 1, a marker which is highly 
expressed on NK cells.216 
G. MHC Class II Distribution in the 
Spleen 
MHC class II (Ia) antigens are involved in 
cellular interactions in the immune system, most 
notably in the presentation of antigens to T cells 
by antigen-presenting cells (APC). Therefore, in 
situ expression of Ia antigens may indicate in 
which compartments of the spleen antigen pre-
sentation occurs. Several groups investigated the 
Ia expression in spleens of rats and mice. 13·150·188 
A strong staining in the inner PALS was demon-
strated and most likely represents the MHC class 
II expression on IDC. 194 Since the majority of 
cells in the inner PALS are T cells, these histori-
cal data are very suggestive for antigen presenta-
tion and T cell activation in this area. The follicle 
was also found to be a compartment with an 
intense Ia staining. 13" 50· 188 Because of the close 
contact between B cells and FDC in the follicle, 
it is difficult to establish to which individual cells 
the observed Ia expression belong. Gray et aJ.82 
investigated mouse chimeras in which FDC were 
bearing H-2d of the host and B cells expressed H-
2k from the donor, providing evidence that in the 
follicles B cells were the principal cells with high 
Ia expression. Like follicular B cells. the marginal 
zone B cells showed a high expression of Ia, 
suggesting that these cells are also important APC 
in the spleen. In contrast to marginal zone mac-
rophages. the red pulp macrophages expressed 
MHC class II antigens, indicating that these mac-
rophages may have different functions in immune 
responses. 
All these studies were performed in nonim-
munized animals. In some studies the effect was 
investigated of IFN-y injection on the Ia expres-
sion of cells in different organs. 150·188 However, 
to our knowledge, no studies describe Ia expres-
sion in the spleen during immune responses against 
antigens, bacteria, viruses, or other organisms. 
Such studies could provide valuable information 
about which cells and compartments are involved 
in antigen presentation and in the initiation of 
immune responses. 
IV. MIGRATION PATTERNS OFT, B, 
AND DENDRITIC CELLS IN THE SPLEEN 
The continuous recirculation of lymphocytes 
is the basis for their contact with antigens at all 
sites of the body and for interaction with other 
immune cells in the appropriate microenviron-
ment of lymphoid organs. Therefore, knowledge 
of the routing of lymphocyte subsets in lymphoid 
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organs is important for the understanding of im-
mune responses (Figures 3 to 5). 
A. Migration of T Cells in the Spleen 
Lymphocyte migration through the spleen was 
studied by autoradiography after the injection of 
in vitro radioactively labeled thoracic duct lym-
phocytes.158·222 These experiments suggested that 
T cells entered the spleen via the marginal zone. 
Subsequently, T cells were found to leave this 
area rapidly and concentrate around the terminal 
arterioles and at the periphery of the PALS. After 
I h, T cells were already penetrating towards the 
central region of the PALS. At later stages (3 to 
6 h), T cells were still present in large numbers in 
the central areas of the PALS. In these migration 
studies, T cells were not found to enter the fol-
licles in the first 4S h. 
Willfiihr et a!. labeled thoracic duct lympho-
cytes with fluorescein isothiocyanate (FITC) and 
detected these cells after injection, using an anti-
body against FITC.232 Double staining for FITC 
and surface markers enabled the investigation of 
the migration pathways of the different lympho-
AP=43% 
MZ=43% 
cyte subsets. They showed that 15 min after injec-
tion half of the immigrant cells were found in 
compartments other than the marginal zone, espe-
cially in the red pulp, indicating that the marginal 
zone is a main entry site but not the only place 
where lymphocytes can enter the spleen (Figures 
3 to 5). T Lymphocytes, most notably CD4+ cells, 
enter the spleen through two compartments (red 
pulp and marginal zone) and the majority of these 
cells are found in only one compartment, the 
PALS, after 24 h (Figure 3). In contrast to Van 
Ewijk and Nieuwenhuis, 222 Willfiihr and co-
workers232 demonstrated that both T cell subsets 
(CD4+ and CDS+) migrated into the follicles. In 
addition, a significantly higher percentage of 
CD4 +than CDS+ cells immigrated into the PALS, 
whereas ens+ cells localized in higher frequen-
cies into the marginal zone and red pulp than 
CD4+ lymphocytes (Figure 4). From 6 h on after 
injection of thoracic duct lymphocytes, the PALS 
contained more immigrant T and B lymphocytes 
than any other single organ of the body, showing 
the important role of the spleen in both B and T 
lymphocyte recirculation.232 Michie and Rouse 
investigated T lymphocyte homing in lymph 
nodes, by using the Thy- I alloantigen as aT cell 
marker. 145 They observed a higher amount of 
RP:24% 
15 min CD4+ Lymphocytes 24h 
FIGURE 3. Distribution of C04+ cells in the different compartments of the spleen 15 min and 24 h after inject'1on. 
RP, red pulp; MZ, marginal zone; F, follicle; P, PALS. Numbers represent the percentage of C04+ cells localized 
in specific compartments of the spleen at 15 min or 24 h after injection. Arrow indicates the increase of C04+ cells 
in the PALS. (The drawing is based on data of WillfOhr, K. U. et al., Eur. J. fmmunol., 20, 903, 1990.) 
24 
MZ:47% 
15min cos+ Lymphocytes 24 h 
FIGURE 4. Distribution of CDS+ cells in the different compartments of the spleen 15 min and 24 h after injection. 
RP, red pulp; MZ, marginal zone; F, follicle; P, PALS. Numbers represent the percentage of COS+ cells localized 
in specific compartment of the spleen at 15 min or 24 h after injection. Arrow indicates the increase of CDS+ cells 
in the PALS. (The drawing is based on data of Willflihr, K. U. et al., Eur. J. lmmunof., 20, 903, 1990.) 
AP=34% 
MZ=BO% MZ=26% 
15 min B-cells 24 h 
FIGURE 5. Distribution of B cells in the different compartments of the spleen 15 min and 24 h after injection. 
RP, red pulp; MZ, marginal zone; F, follicle; P, PALS. Numbers represent the percentage of B cells localized 
in specific compartments of the spleen at 15 min or 24 h after injection. Arrow indicates the increase of B cells 
in follicles. (The drawing is based on data of Willflihr, K. U. et al., Eur. J. lmmunol., 20, 903, 1990.) 
keyhole limpet hemocyanin (KLH)-primed 
Thy-1 positive cells in the follicles of lymph ncxies 
draining the site of antigen-challenge than in fol-
licles of lymph nodes in the same mouse draining 
the site of challenge with control antigen. This 
experiment suggested that antigen-specific T 
cells preferentially localize in antigen-primed fol-
licles and may activate antigen-specific B 
memory cells in follicles during secondary im-
mune responses. Furthermore, it shows the differ-
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ences in migration patterns of T cells in immu-
nized mice compared to nontreated mice, which 
is highly relevant for the interpretation of the 
migration studies of Van Ewijk and 
Nieuwenhuis,222 and Willftihr et al.232 
B. Migration of B Cells in the Spleen 
Van Ewijk and Nieuwenhuis,222 demonstrated 
that B cells, like T cells, entered the spleen via the 
marginal zone, where they were especially asso-
ciated with follicular structures. Subsequently, B 
cells concentrated in the outer PALS with a ten-
dency to accumulate towards the junctional area 
at the base of the follicles. By 6 h after injection, 
most of the labeled cells were at the junctional 
region between the PALS and the lymphocyte 
corona. After 18 h, most labeled cells were evenly 
distributed throughout the lymphocyte corona and 
only a few labeled cells could be detected in the 
PALS or marginal zone. This picture persisted for 
at least 48 h after injection of labeled cells. Willftihr 
et a!. found that B cells predominantly enter the 
spleen through one compartment: the marginal 
zone. Subsequently they are equally distributed 
over three compartments: red pulp, marginal zone, 
and follicles (Figure 5).232 Vonderheide and Hunt 
investigated migration of antigen-primed B cells 
in lymph nodes of immunized rats.230 They found 
that antigen-primed B cells immigrated much 
better into germinal centers than nonprimed B 
cells, an observation that might be related to the 
follicular role in memory formation. 
C. Migration of DC in the Spleen 
Migration patterns of DC were described by 
Austyn et al. 10 They labeled purified splenic DC 
with a fluorochrome, injected the cells intrave-
nously, and demonstrated that the labeled cells 
first localized in the marginal zone before enter-
ing the inner PALS of the spleen. The migration 
of i.v.-injected labeled DC into the splenic PALS 
was confirmed by Fossum. 69 In addition, electron 
microscopic studies showed that the labeled cells 
found in the PALS had acquired the ultrastruc-
tural characteristics of IDC, indicating that in-
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jected cells and IDC are closely related. Larsen 
and co-workers investigated the migration of den-
dritic leukocytes from cardiac allografts into host 
spleens. 133 They found that donor-derived MHC 
class 11-positive DC were demonstrable in the 
inner PALS of the spleen, associated predomi-
nantly with CD4+ T lymphocytes, as early as 1 
day after transplantation. This supported the pos-
tulate of Austyn, 12 who suggested that DC in the 
blood originate from peripheral nonlymphoid tis-
sues where they take up antigens. From there they 
migrate to lymphoid organs like spleen and lymph 
nodes, where they have the greatest chance to 
encounter and activate specific T cells. ensuring 
the initiation of immune responses. In contrast to 
T and B ceHs, the migration pathways of DC 
seem to be entirely afferent and not recirculating, 
suggesting a final effector function of these cells 
in the spleen. 144 
D. General Remarks 
The homing of lymphocytes to the spleen 
does not involve high endothelial venules such as 
in the lymph nodes, and their migration into the 
spleen appears to be nonselective. To investigate 
the role of membrane-associated structures on 
routing in lymphocyte recirculation, lymphocytes 
have been treated in vitro with a whole range of 
substances to modify their surfaces.l9.94.170.171 
Several in vitro treatments of lymphocytes re-
vealed major differences in homing to the spleen 
and lymph nodes; many reduced homing to 
lymph nodes without having an effect on splenic 
homing (e.g., trypsin, phospholipases, dextran 
sulfate, a/~-interferon, low temperature in vitro, 
blocking of homing receptors), whereas other treat-
ments reduced lymphocyte homing both to the 
spleen and lymph nodes (neuramidase, con-
canavalin A, corticosteroids). The high rate of 
nonspecific recirculation of blood-borne lympho-
cytes, which comprises most likely the entire T/B 
cell repertoire, through the spleen may be the 
reason for the spleen not requiring the ability to 
select lymphocytes. 
When interpreting the migration studies dis-
cussed, care should be taken with regard to the 
method of cell preparation, the route of adminis-
tration (e.g., intravenous in the blood vs. thoracic 
duct in the lymph), and the rate of lymphocyte 
infusion; variation in these factors could very 
well explain differences found by several au-
thors.89 Moreover, these studies were performed 
with normal nonantigen-primed animals, not im-
munized animals, which might make an essential 
difference. 
V. CLASSIFICATION OF ANTIGENS 
Immunological investigations revealed that 
some antigens can induce humoral immune re-
sponses without the obvious cooperation of T 
lymphocytes, while many other antigens require 
the helper function of T cells for the successful 
generation of an antibody response.I05•149 The 
former class of antigens is termed thymus inde-
pendent (TI) and the latter thymus dependent (TD), 
and this operational definition has been useful 
even though improved techniques for cell separa-
tion have indicated that some antigens may be-
long in an intermediate category.2 1.1 48-' 76 In this 
review we will basically divide antigens into TD 
or TI and subcategorize them as particulate and 
soluble. In Table 1, frequently used model anti-
gens are listed with some of their properties (see 
also Laman et al. 131 ). 
A. Thymus-Dependent Antigens 
By definition, B cells cannot respond to TD 
antigens without T cell help. As a consequence, 
these antigens do not induce a humoral immune 
response in nude mice because of the lack of a 
functional thymus. The first evidence for thymus 
dependency of particular immune responses was 
found in the sheep red blood cell (SRBC) sys-
tem.155 It was demonstrated that spleen cells from 
adult thymectomized, lethally irradiated mice re-
constituted with syngeneic bone marrow gave no 
primary antibody response to SRBC. However, 
when such mice were reconstituted with a thymus 
graft, the in vitro response was normal. Subse-
quent T cell depletion studies have clearly docu-
mented that both primary and secondary anti-
SRBC humoral immune responses were T cell 
dependent. Shortly after these initial studies, 
analogous T cell dependency was demonstrated 
in a variety of protein antigens such as keyhole 
limpet hemocyanin (KLH), bovine )'-globulin 
(BGG), ovalbumin (OVA), bovine serum albu-
min (BSA) and, perhaps more importantly, to 
hapten carrier conjugates (4-hydroxy-:..5-iodo-3-
nitrophenyl hapten (NIP), 2,4-dinitrophenyl hap-
ten (DNP), and 2,4,6-trinitrobenzenesulfonic acid 
hapten (TNP). 106 
B. Thymus-Independent Antigens 
By definition, TI antigens can directly stimu-
late B cells to proliferate and differentiate into 
plasma cells in the absence ofT cell help. Direct 
activation can be achieved either by a mitogenic 
component (e.g., lipid-A in lipopolysaccharide 
[LPS]), or by crosslinking of antigen-specific 
membrane immunoglobulins (mig) on B cells. 156 
This is due to the repetitive structural character of 
the antigen, as in the case of polysaccharides of 
bacterial capsules. The different modes of direct 
activation are reflected in the subdivision of TI 
antigens into types I and 2. Bacterial capsules, 
consisting of polysaccharide and lipid-A, are typi-
cal TI-l antigens. Tl-2 antigens are model anti-
gens obtained by detoxifying TI-l antigens by 
removing the lipid-A component. Detoxified TI 
antigens are not able to mount an immune re-
sponse in deficient CBA/N and neonatal mice, 
and hence they are designated as TI-2 antigens. 186 
The most common and extensively studied Tl-2 
antigen is TNP-Ficoll, a synthetic neutral 
polysaccharide. 
VI. IN VIVO ANTIGEN ROUTING INTO 
THE SPLEEN 
Antigens in the body may reach the spleen 
directly via the circulation, e.g., from an infec-
tious infiltrate or after i.v. injection. Antigens 
may also reach the spleen indirectly, i.e., they 
may gain access to the lymph flow anywhere in 
the body and subsequently reach the circulation 
via the ductus thoracicus, after having migrated 
through one or more lymph nodes. When antigens 
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TABLE 1 
Properties of Some Experimental Antigens 
Type of antigen Uptake by Presentation by Polyclonal 
activation 
Thymus dependent 
Soluble Myoglobin, OVA, BSA, 
KLH 
Particulate 
RPM, IDC 
8 cells 
MZM (RPM) 
MZM (RPM) 
I DC, B cells 
B cell 
I DC, B cells 
I DC, B cells 
+ RcdgD, GalgD 
Liposomes with protein 
SRBC 
TNP-Lactobacillus MZM (RPM), FOC FOG, IDC, B cells 
Thymus independent type 1 
Soluble LPS 
Dextran~sulfate 
Particulate Brucella abortus 
Streptococci 
Thymus independent type 2 
MZM, RPM 
? 
MZM, F 
MZM, F 
B cells direct 
B cells direct 
MZM, B cells 
MZM, B cells 
+ 
+ 
+ 
+ 
Soluble Dextran 
TNP-Ficoii/HES 
Detoxified LPS 
Particulate Liposomes (no protein) 
MZM, B cells, FDC 
MZM, B cells, FOG 
MZM, B cells, FDC 
MZM 
FDC, B cells (MZ/F) 
FDC, B cells (MZ/F) 
FOC, 8 cells (MZ/F) 
8 cells (MZ/F), FDC 
Haptenated liposomes MZM B cells (MZ/F), FOG 
Note: F, Follicle; RP, red pulp; MZ, marginal zone; M, macrophage; RPM, red pulp macrophages (see also general 
abbreviations). 
arrive in the circulation they may remain un-
bound, or they can be bound by antibody/comple-
ment and/or be captured by granulocytes, mac-
rophages, precursors of DC or other phagocytes. 
Subsequently, they are carried into the spleen by 
the splenic arteries and are finally discharged from 
the terminal arterioles into the marginal zone. The 
fate of the antigen is largely dependent on its 
characteristics, i.e., soluble vs. particulate, pro-
tein vs. polysaccharide, complement-activating 
capability, and complex formation with antibody. 
A. Localization of Particulate Antigens 
in the Spleen 
Kotani et al. 119 and Miyakawa et al. 146 inves-
tigated which cells could be involved in the trans-
port of antigens from marginal zone to white 
pulp. They demonstrated that i.v. injected carbon 
particles localized first in the marginal zone, 
where they were taken up by macrophages. More-
over, they found evidence that these macrophages 
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transported the antigen to the germinal centers 
and inner PALS and suggested that these cells 
might play a role in the initiation of immune 
responses. However, they did not provide evi-
dence for Ia expression by these cells and did not 
test the antigen-presenting capacity of these cells. 
Studies by Van Ewijk et al. showed that SRBC 
i.v. injected in mice are trapped in the red pulp 
and marginal zone. 220 After 48 h, SRBC-contain-
ing macrophages were found within the T cell-
dependent areas of the white pulp, in the same 
areas where IDC are found and where T cell 
activation is observed after SRBC immunization. 
Recently, we investigated the localization pattern 
in the spleen of various i.v. injected particulate 
antigens (TD: TNP-SRBC, BSA-liposomes; TI: 
TNP-liposomes, Brucella ahortus). 23 ·39 Two 
hours after injection of particulate antigen, irre-
spective of its nature, the majority of antigen in 
the spleen was found at sites where blood flows 
into the organ: the marginal zone, taken up by 
marginal zone macrophages and marginal 
metallophilics (Plate ld). Twenty-four hours after 
injection some particulate antigen was also ob-
served in the macrophages of white and red pulp. 
Although immune responses against particulate 
antigens show large differences (Table 1), we 
found a similar localization pattern for all particu-
late antigens. These data suggest that the localiza-
tion pattern of particulate antigens does not nec-
essarily play a crucial role in directing the type of 
immune response. 
In vitro studies demonstrated that preprocess-
ing of particulate antigens by macrophages was 
crucial for the generation of immune re-
sponses.102·234 Such a critical role for marginal 
zone macrophages in the generation of a humoral 
immune response was also suggested by the ex-
periments of Van Rooijen and co-workers. They 
observed a marked decrease of the immune re-
sponse against liposome-associated human serum 
albumin 199 and against TNP-SRBC49 after in vivo 
elimination of inarginal zone macrophages. 
Therefore, it was suggested that marginal zone 
macrophages were required for the preprocessing 
of particulate antigens, which subsequently 
passed over processed antigens to other APC. 
Marginal zone B cells, with high MHC expres-
sion95 and located between the cytoplasmic pro-
cesses of marginal zone macrophages,52 were 
suggested to be the most likely candidates for the 
acceptance of processed antigens. 
The data discussed here clearly show that the 
initial localization of all types of particulate anti-
gens in the spleen is similar. Further investigation 
should aim at the eventual localization of frag-
ments of these particulate antigens after they are 
processed and transported. 
B. Localization of TD Antigens in the 
Spleen 
Several investigations have demonstrated 
that intravenously injected soluble antigens are 
removed from the bloodstream in the marginal 
zone of the spleen and then move toward the 
follicles in the white pulp to remain there for a 
long period of time. 164· 1M We observed that 
haptenated TD antigen, like TNP-KLH and 
TNP-BSA, localized exclusively in the red pulp 
macrophages on the first days after injection. 21 ~ 
The localization in red pulp macrophages could 
very well represent the scavenging of bulk anti-
gen, whereas the antigen which is involved in the 
induction of the humoral immune responses may 
be localized in other compartments. The impossi-
bility to detect these immunologically relevant 
antigens in situ could be due to the very low 
amount of antigen in APC or due to proceSsing by 
APC which may change their antigenic structure. 
After i.v. administration of horseradish per-
oxidase into mice, Chen et al. detected the antigen 
on FDC and macrophages, but not in the T cell 
area. 3° Clearance of antigen by macrophages 
which reside in sites at which antigens first enter 
the spleen may leave only small (undetectable) 
amounts of antigen with access to the T cell area 
itself. Although antigen localization studies for 
soluble TD antigens were not able to localize 
these antigens in the inner PALS, experiments of 
Kyewski et al. suggested that TD antigens were 
indeed presented by splenic DC. 129 In their study, 
they found that after i.v. injection of myoglobin, 
splenic DC were the major cell types that could 
stimulate myoglobin-specific T cell clones, al-
though the antigen could not be detected in 
splenic tissue. Mathur et al. 139 examined, using 
immunohistochemical techniques, the localiza-
tion of live replicating virus in murine spleens 
during Japanese encephalitis virus infection. They 
found that i.p. injected virus first replicated in the 
peritoneal macrophages and subsequently entered 
the spleen via the circulation, spreading to the 
marginal zone of the spleen by day 3 and then 
extending into PALS and perifollicular areas on 
day 5. The virus localization in the PALS was 
accompanied by an increased proliferation of T 
cells in this area. These results suggest that anti-
gen presentation and T cell activation occur in the 
inner PALS during Japanese encephalitis virus 
infection. 
In the primary immune response, immune 
complexes will be formed as soon as antigen-
specific antibodies appear in the circulation 112 
(Plate le). Immune complexes are also formed if 
specific antibodies against the antigen are already 
present in the circulation when the antigen is ad-
ministered, e.g., during secondary immune re-
sponses. Antibody-complexed antigens can be 
digested by macrophages as discussed for 
nonantibody-complexed antigens. Phagocytosis 
of small and soluble antigens in antigen-antibody 
complexes will be facilitated especially in com-
parison with their nonopsonized counterparts. A 
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PLATE 1. Localization of immune cells in different compartments of the spleen. (a) lgD · B cells are predominantly localized 
in the follicle, whereas marginal zone (M) B cells and germinal center B cells (arrow) express hardly any mlgD; (b) lgM is highly 
expressed on marginal zone and germinal center (arrow) 8 cells. whereas the expression on follicular B cells is relatively low 
[compare with serial section-a]; (c) cryostat section of spleen 1 dafter TNP-Ficoll injection; acid-phosphatase positive macro-
phages (red) are localized in red pulp (r), marginal zone, and PALS (P): TNP-Ficoll (turquoise) is localized in marginal zone 
macrophages (double stained cells in the marginal zone), but not in the marginal metallophllics (arrows); in addition TNP-Ficoll 
is localized in follicles in association with FOG and B cells; (d) 4 h after i.v. injection Oil labeled group B. Streptococci are 
predominantly localized in the marginal zone of the spleen; (e) 5 dafter injection TNP-Ficoll is localized in the marginal zone, 
whereas TNP-specific antibody-forming cells (red) and IFN-"'1-producing cells (violet) are found in juxtaposition in the outer-
PALS and around the terminal arterioles (note TNP-specific antibodies (red) in follicle); {f) marginal zone macrophages {red) 
stained with the monoclonal antibody ERTR9 are forming the outer ring, whereas marginal metallophilics {brown) are detected 
with MOMA-1 in the inner ring of the marginal zone: (g) high power magnification of figure f; (h) double-staining for CD4 (red) 
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and IFN--y (turquoise) in cryostat section of spleen of mice 5 d after TNP-Ficoll immunization; violet (double staining) cells in 
the PALS are CD4- cells producing IFN-c; (i) double staining for CDS (brown) and IL-4 (turquoise) in cryostat section of the 
spleen 3d after TNP-KLH injection; green (double staining) cells are cos- cells producing IL-4: U) lgE positive (red) antibody-
forming B cells are localized in same compartment as IL-4 producing cells (turquoise) 4 dafter TNP-KLH immunization: (k) TNP-
specific antibody-forming B cells (red) are localized in the same compartment (around terminal arterioles) as IL-2 producing 
(turquoise) cells 4 d after TNP-KLH immunization: (I) IL-2-producing cells (turquo'1se), IFN--y-produc'lng cells (red) and double 
staining (violet) cells producing both IL-2 and IFN--y (Th1 cells) are localized around terminal arterioles 3d after TNP-KLH 
immunization; (m) IL-2-producing cells (brown), IL-4-producing cells (turquoise) and double staining (green) cells producing 
both IL-2 and IL-4 (ThO cells) in the spleen 4 dafter RalgD injection; (n) IL-4-producing cells (turquoise; Th2), IFN--y-producing 
cells (red) and double staining (violet) cells producing both IL-4 and IFN--y (ThO cells) in the spleen 3d after TNP-KLH 
immunization. 
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small proportion of the antibody-complexed anti-
gens is trapped in the follicle centers by the cell 
processes of the FDC and can be retained there 
for long periods of timell2.ll3.130.l64.207 via Fe 
receptors or complement receptors. The trapped 
complexed antigen plays a crucial role in B cell 
memory and regulation of humoral immune re-
sponses.w·112 Recently, Gray and Matzinger 
demonstrated that T cell memory for the soluble 
protein KLH was short-lived in the absence of 
the antigen. 83 FDC are the only cells known 
which can preserve native antigens for months to 
years. Therefore, it was suggested that T cell 
memory was dependent on antigen presentation 
by memory B cells, indicating that follicular 
trapped antigen may play a role in the mainte-
nance ofT cell memory. 
In conclusion, the discussed data suggest 
that antigen localization for soluble TD antigens 
is not identical for primary and secondary im-
mune responses. In both responses macrophages 
take up the bulk of antigen. However, after the 
first antigenic challenge, antigen localizes in the 
inner PALS containing DC and T cells, and play 
a role in the induction of primary immune re-
sponses; whereas after a secondary challenge the 
follicle, containing FDC, B, and T memory cells, 
is the important compartment where antigen lo-
calizes and which is crucial for induction and 
maintenance of secondary immune responses. 
C. Localization of Tl Antigens in the 
Spleen 
Recently, the localization of thymus-inde-
pendent type 2 (TI-2) antigens in murine spleens 
was monitored. 218 Within minutes after i.v. in-
jection, Tl-2 antigens (TNP-Ficoll, TNP-HES) 
localized in the marginal zone attached to mar-
ginal zone macrophages and B cells. Twenty 
minutes after injection the antigen was also de-
tected in the follicles and gradually accumulated 
there up until 7 h after injection. Thereafter, the 
amount of follicular antigen gradually decreased 
but was still detectable up to 14 dafter immuni-
zation (Figure 6). The immediate follicular local-
ization of TNP-Ficoll was complement depen-
dent and not antibody mediated. In addition, in 
the case of administration of high doses, a rela-
tively large amount of TI-2 antigens was ob-
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served in marginal zone macrophages, the cells 
which are the predominant phagocytes of capsu-
lar bacteria (Plate ld). Double staining revealed 
that TNP-Ficoll was bound to B cells, FDC, and 
macrophages. In vivo macrophage elimination 
drastically increased the amount of TNP-Ficoll in 
the follicles, and enhanced the humoral immune 
response at low doses of antigen.37 In contrast, 
complement depletion of mice abrogated the lo-
calization ofTI antigens in the follicles, and led to 
a decreased humoral TI-2 immune response. 
These results suggested that follicular localiza-
tion of antigen is a prerequisite for the induction 
of humoral TI-2 immune responses. 
Injection of particulate TI-l antigens showed 
a similar antigen distribution in the spleen as was 
observed for TNP-Ficoll (Plate ld). After injec-
tion of Dil-labeled group B streptococci, the en-
capsulated bacteria was localized in marginal 
zone macrophages and in the follicles, although 
the follicular localization was less as compared to 
haptenated TI-2 antigens (Plate le, f). This find-
ing was in agreement with experiments of Chao 
and MacPherson29 and Kraal eta!., 123 which sug-
gested that the main function of marginal zone 
macrophages was to clear encapsulated patho-
gens from the circulation via the TI-2 antigen 
receptor. The observed localization pattern also 
supports the hypothesis of Van Rooijen who pos-
tulated that marginal zone macrophages are in-
volved in the processing of particulate antigens 
and subsequently transfer the processed antigens 
to B cells in the marginal zone.225 These B cells 
are thought to present the antigens, such as 
soluble antigens, to T cells in the PALS and dif-
ferentiate into antibody-forming cells after re-
ceiving appropriate T cell help. 
In conclusion, it is clear that TD and TI anti-
gens localize differently in the spleen; the fact 
that TI antigens are directly trapped in the fol-
licles correlates well with their ability to directly 
stimulate B cells and their independence of 
(pre-)processing. 
VII. CELLS INVOLVED IN IMMUNE 
RESPONSES 
There is general agreement that at least three 
different cell types are involved in TD immune 
FIGURE 6. Localization of TNP-Ficoll in representative spleen sections of mice at various 
time points after injection. Cryostat sections were stained with a ~-galactosidase conjugated 
monoclonal antibody directed to TNP: (a) 5 min; (b) 20 min; (c) 2 h; (d) 2 d; (e) 7 d; 
(f) 10 d; (g) 14 d; and (h) 21 dafter injection of 100 ~g TNP-Ficoll. Note both uptake of TNP-
Ficoll by marginal zone macrophages and trapping of TNP-Ficoll in follicles. 
A. Antigen Presentation to T Cells responsesY B Cells, which produce specific an-
tibodies and are regulated by T cells, which in 
tum require the appropriate signals provided by 
the processed antigen and the APC, such as mac-
rophages, IDC, or B cells. 
APC like B cells, macrophages, and DC, are 
able to present the appropriate antigen fragment 
and MHC protein to aT cell in such a way that a 
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stable interaction is formed and the T cell is acti-
vated. The two major APC in the spleen are DC 
and B cells. 11 l.1 44·195 T Cells recognize, via their 
T cell receptor, proteolytic degraded fragments of 
antigenic proteins that are presented at the cell 
surface by either MHC class I or class II mol-
ecules. Each type of presentation is recognized by 
a specific T cell subpopulation: CDS+ T cells 
recognize peptides presented by MHC class I 
molecules and CD4+ T cells recognize peptides 
presented by MHC class II molecules. Activated 
CDS+ T cells are usually cytolytic in vitro and are 
therefore referred to a cytolytic T cells (CTL) 
despite their capacity to produce cytokines. CD4+ 
T cells produce various cytokines required for the 
synthesis of antibodies and for the proliferation of 
CDS+ T cells, and are therefore referred to as T 
helper (Th) cells, but they also include CTL. 
In contrast to macrophages, DC orB cells do 
not take up large amounts of model antigens in 
vitro as well as in vivo. This suggests that the 
study of antigen presentation in these APC might 
seem misplaced, but the opposite view could also 
be argued. The bulk of an internalized load in an 
actively endocytic cell such as the macrophage 
may be degraded down to the level of amino acids 
since these cells are specialized for scavenging 
and microbicidal activity. 39 This function can be 
enhanced by the presentation of processed anti-
gen to T cells, activating these cells to exert their 
effector functions, e.g., cytolysis or secretion of 
cytokines, such as macrophage-activating factors. 
In contrast, B cells and especially DC, because 
they show so little bulk endocytic activity, seem 
to utilize endocytosis primarily as a presentation 
mechanism and are, accordingly, the specialized 
APC in immune responses. 
1. Antigen Presentation by DC 
DC are highly effective in presentation of 
antigen in the context of class I or class II MHC 
molecules, which in general is attributed to both 
qualitatively and quantitatively superior MHC 
expression. 143 One distinctive feature of DC, 
which may influence their capacity to find infre-
quent clones of antigen-specific T cells, is their 
ability to form and retract cell processes, particu-
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larly broad veils which are 10 mm or more in 
extension. In primary in vitro responses, it has 
been observed that DC physically associate or 
cluster with T cells and that DC T cell clustering 
is essential forT cell activation. 11 DC and T cells 
can cluster in a special way independent of anti-
gen and MHC.99 It has, therefore, been suggested 
that DC initially cluster with resting T cells in an 
antigen-independent manner. In the presence of 
antigen, DC will present antigen and activate the 
antigen-specific T cells. The irrelevant T cells 
will leave the clusters after a short time9 and the 
activated T cell will proliferate. Antigen presen-
tation by DC provides an efficient pathway for 
inducing the large numbers of active and specific 
lymphoblasts, while presentation by B cells is 
essential for helperT-cell-dependent antibody for-
mation. DC were found to be required in vitro for 
the initial priming of T cells, 193 which in tum 
could regulate the differentiation/proliferation of 
antigen-specific B cells.99 The latter could be dem-
onstrated in the apparent absence of DC in an 
antigen-specific, MHC-restricted fashion. In vitro, 
DC do not make Ig or cytokines and are not 
phagocytic. Therefore, when DC present antigen, 
the effect seems to be unidirectional on the T cell, 
generating large numbers of antigen-specific lym-
phoblasts. 
So far, no soluble TD antigen has been dem-
onstrated in the T cell area of the spleen, the 
compartment where DC are localized. It is not 
unlikely that antigens can be bound and processed 
in other compartments or organs and arrive in the 
T cell area ready to be presented. This was indeed 
observed by Kyewski et al., 129 who observed after 
i.v. injection of myoglobin that splenic DC were 
the major cell types that could stimulate myoglo-
bin-specific T cell clones, although they could not 
be detected in splenic tissue. Crowley et al. ex-
tended these results by comparing the antigen-
presenting capacity of isolated splenic macroph-
ages and DC after i.v. injection of myoglobin.46 
This study provided evidence that DC were the 
main cell type in the spleen which carries myo-
globin in a form that is immunogenic for antigen-
specific T cells in the spleen. The capacity of DC 
to take up antigen and present it in the spleen was 
also supported by experiments of Larsen et aJ. 133 
They demonstrated that donor-derived MHC class 
II-positive DC from a cardiac allograft were mi-
grated into the inner PALS of the host spleen, 
associated predominantly with CD4+ T lympho-
cytes, I d after transplantation. 133 Somasse and 
co-workers pulsed isolated dendritic cells with 
the TD antigens: myoglobin and gamma-globu-
lin, and injected them i.v. into syngeneic mice. 192 
After 5 d, mice were injected with the same TD 
antigen and a strong humoral immune response 
was observed. whereas control mice produced 
only a low specific antibody response. A similar 
approach was used by Francotte and Urbain,70 
who demonstrated that purified DC and macro-
phages pulsed in vitro with tobacco mosaic virus 
were potent APC in TD antibody responses in 
vivo. although macrophages were found to be 
about 100 times less efficient. All these studies 
suggest a role for DC in initiating and augment-
ing primary immune responses against TD anti-
gens. 
Thus, DC appear to acquire antigen from 
nonlymphoid organs or circulation, and present 
processed antigen in the T cell areas of the spleen, 
in the path of the recirculating T cell pool, and are 
thereby in a very strategic position to select and 
expand antigen-specific T cell clones. 
2. 8 Cells as Antigen-Presenting Cells 
In contrast to DC, B cells are not able to 
activate resting T cells, as was demonstrated by 
Lassila et a1. 134 They showed that for the initia-
tion of in vivo humoral immune responses, T cells 
must recognize antigen presented by different 
types of cells, first a non-B cell and then the 
antigen-specific B cell which is also the recipient 
of the regulatory factors released by the T cell. It 
was not clear whether the requirement of a non-
E cell for the first antigen-presentation step re-
flects an actual inability of B cells to activate 
resting T cells or whether the initial step leads to 
expansion of the resting T cells, thereby increas-
ing the probability of finding the appropriate B 
cell. This study indicated a more prominent role 
for B cells in T cell activation during secondary 
immune responses. 
The fact that B cells are clonal and capable of 
relatively high-affinity and specific interactions 
with one vs. many antigens is a striking distinc-
tion from DC, which lack antigen specificity. B 
cells are specialized to pick up antigens in the 
bloodstream by their antigen-specific receptor 
(mig). In addition, later in primary or during sec-
ondary immune responses B cells may encounter 
antigen in the germinal center. where there is a 
depot of extracellular antigen on follicular 
cells. 205·207 It has been demonstrated in vitro that 
antigen-specific B cells specifically capture anti-
gen via their antigen-specific receptor and present 
it more than a thousand times more efficiently as 
compared to control B cells. 132· 179 Sanders et a!. 
demonstrated that when the affinity of the B cell 
antigen receptor increased, as in memory cells, 
the efficacy of the B cell as an APC increases 
too. 1S5 In addition, the efficacy of antigen presen-
tation by B cells can also be improved by clonal 
expansion and antigen-dependent selection of B 
cells, mechanisms which are part of the memory 
response or secondary response. Antigen-pre-
senting properties of B cells have drawn a lot of 
attention.7 In vitro studies revealed that B cells 
are generally less potent as low-density APC. 
However, resting B cells still may be effective 
APC in vivo, where their large number and stra-
tegic location may compensate for lower capabil-
ity for antigen presentation per cell. Moreover, 
in ritro studies showed that antigens bound to B 
cell surface was 100 to I 000 times more efficient 
than unbound antigen, implying that antigen-spe-
cific antigen presentation by B cells might have a 
significant role in in vivo immune responses. 132. 179 
Ron and Sprent showed that in vivo B cell-
depleted mice failed to mount a proliferative 
response to KLH, whereas in the presence of 
exogenous B cells the response reached control 
values. 180 Moreover, Kurt-Jones et a!. demon-
strated in vivo that mice reconstituted with FITC-
specific B cells responded to FITC-OVA much 
better than to TNP-OV A, although both antigens 
were equally immunogenic in normal mice. 128 On 
the whole, these studies provide consistent and 
convincing arguments that antigen-specific B cells 
play a central role in presentation of protein anti-
gens toT lymphocytes in vivo. 
Antigen presentation by B cells is bidirec-
tional in its consequences. B Cells activate T 
cells, which in their tum stimulate B cells by cell-
cell interaction and cytokines to proliferate and/or 
differentiate into antibody-forming cells. 
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It is not dear whether B cells play a role in 
presenting antigens to those T cells which be-
come CTL or T cells which mediate macrophage 
activation and delayed-type hypersensitivity 
(DTH). The role of B cells in the presentation of 
particulate, viral, or microbial antigen in vivo is 
not clear yet, as these antigens may first require 
phagocytic uptake and subsequent extensive deg-
radation for presentation. Such a mechanism for 
viral antigen handling was suggested by experi-
ments of Rizvi eta!. who showed that preprocess-
ing of dengue type 2 virus proteins by macroph-
ages was required before an immune response by 
B cells with the degraded form of viral proteins 
was possible."178 
The data discussed suggest that during pri-
mary humoral immune responses T cells are acti-
vated by non-B cell APC, prior to their encounter 
with antigen-specific B cells. This in contrast to 
secondary immune responses where the antigen is 
preferentially captured by high-affinity memory 
B cells and presented to memory T cells, both of 
which cell types are present in relatively large 
numbers. In primary as well as in secondary im-
mune responses, antigen-presenting B cells will 
activate T cells, the latter cells in tum will regu-
late the differentiation of B cells into antibody-
forming cells. 
B. Antigen Presentation to B Cells 
After immunization, immune complexes are 
formed as soon as antibodies appear in the circu-
lation.112 A small proportion of these antibody-
antigen complexes are trapped in the follicles on 
the cell processes of the FDC and retained for 
long periods of time207 via Fe receptors 164 and/or 
complement receptors. 113·117 It has been demon-
strated that antigen which is preserved extracellu-
larly in an undegraded form as immune complex 
associated with FDC has a crucial role in the 
generation of B memory cells 112 and is required 
for the maintenance of B cell memory. 80 In addi-
tion, it has been suggested that the exposure and 
obscuring of epitopes present in immune com-
plexes may fine-tune the titer of circulating anti-
bodies. 207 Recent electron microscopic and in vitro 
evidence206 indicates that FDC may release im-
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mune complex-coated beads termed "iccosomes". 
These iccosomes are ingested by antigen-specific 
germinal center B cells, processed, and subse-
quently presented to T cells, 117 which are acti-
vated to initiate an immune response. 
The antigen presentation of FDC to B cells 
and the presentation of dengue virus by macroph-
ages to B cells, discussed in the previous section, 
are examples of antigen presentation to B cells. 
The relative importance of such mechanisms of 
antigen presentation in vivo is not yet known, but 
the system described may provide sophisticated 
processes for the enhancement of the ability of 
the immune system to deal with a pathogen. 
C. T and B Cell Activation in TD Immune 
Responses 
The activation of B cells is a complex mecha-
nism and has been excellently discussed by sev-
eral groups 160- 162·175 (Figure 7). Briefly, TD anti-
gens bind to B cells expressing complementary 
mig receptors. The crosslinking of the mig does 
not result in B cell activation. but may be a signal 
for the B cell to process the selected antigen and 
present it to T cells. Indeed, Casten and Pierce 
observed up to 100-l 000 times increase in the 
capacity of B ce!ls to present cytochrome c to aT 
cell hybridoma when the antigen was covalently 
coupled to anti-Ig.28 The potent activity of the 
cytochrome c-antibody conjugates appeared to be 
due to the B cell targeting features of the conju-
gated lg, because cytochrome c was not more 
effectively presented in the presence of 
unconjugated antibodies as compared with cyto-
chrome c alone. The recognition of complexes of 
processed antigens and MHC on the B cell by T 
cells is responsible for the initial class II-re-
stricted, antigen-specific. physical interaction be-
tween T and B ce!ls. These T and B cells form 
conjugates which are stabilized by the binding of 
ICAM-1 to LFA-1 and CD4+ to monomorphic 
domains of the class II proteins. This interaction 
induces T cell activation, resulting in the expres-
sion of novel surface proteins on the membranes. 
These newly expressed membrane proteins on 
activated Th cells together with resident Th mem-
brane proteins fonn the major growth stimulus 
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FIGURE 7. Cell-cell interactions during a TO immune response (see text 
for explanation). 
forB cells. Recently, Noelle et al. demonstrated 
that blocking of the prominent Th surface mol-
ecules, LFA-1, CD4, ICAM-1, CD3, or the T cell 
receptor (TCR) did not inhibit the capacity of 
activated Th cells to induce B cell cycle entry .163 
In contrast, CD40-Ig fusion proteins, or antibod-
ies specific to the CD40 ligand, blocked B cell 
activation by activated Th cell, suggesting that 
the CD40 molecule expressed by B cells is the 
receptor of the Th cell activation antigen. This 
activation antigen was identified as a 39-kDa pro-
tein that was selectively expressed on activated 
Th cells. 163 The initial B cell activation by acti-
vated Th cells requires no soluble factors and 
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induces enhanced B cell RNA synthesis (00 __, 
G 1 ). After activation, B cells develop the compe-
tence to respond to cytokines, which are produced 
by activated T cells. These cytokines act solely or 
predominantly at different steps in the B cell 
activation pathway. Cytokines, like IL-l, IL-2, 
and IL-4, support the growth of activated B cells, 
while others such as IL-4, IL-5, IL-6, and IFN-y 
participate as differentiation factors. 1·2 
The experiments described above imply that 
T-B cell conjugate fonnation is an important event 
for the induction of TD immune responses. This 
interaction is not a short event but requires con-
tact for a least 48 h in vitro to obtain the maxi-
mum proliferative response of B cells. 106 In addi-
tion, cytokine production by T cells was found to 
require the continuous presence of the stimulating 
signal in vitro.204 suggesting that for the genera-
tion of an effective immune response. T-B cell 
conjugate fonnation is required for at least 24 to 
48 h. Such a T-B cell interaction was recently 
demonstrated by Kupfer et al in vitro. 126 They 
showed that after in vitro mixing of antigen-spe-
cific T-helper, B cells, and antigen, T-helper-B 
cell couples were formed up to 29 h later. This 
interaction resulted in cytokine production by these 
T cells near the antigen-specific B cells. The 
cytokines were not seen in the T cells prior to 
their interaction with the B cells and their produc-
tion was strictly antigen-specific. They proposed 
that T cells were in this way able to induce selec-
tive and specific B cell responses. 126·173 The in 
vitro mixing ofT and B cells resulted in forma-
tion of 1: I T-B couples, dependent on the initial 
T/B ratio. In 60% of the more complex conju-
gates, which had three T helper cells simulta-
neously bound to one B cell, not all the cytokine 
production was found toward the bound B cell. 
Also in the case of very low concentrations of 
antigen, no polar cytokine production at the T -B 
contact site was observed. 126 
All these in vitro experiments demonstrate 
that for both T cell as well as B cell activation a 
close physical T-B cell interaction is required. It 
is most likely that such an interaction also occurs 
in vivo. The duration of such an interaction and 
the T -B cell ratio required for the generation of an 
immune response is still controversial. Studies on 
the existence and characteristics of T-B cell con-
jugates in vivo are now underway in our labora-
tory. 
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D. T and B Cell Activation during Tl 
Immune Responses 
The role of T cells, accessory cells, and 
cytokines in TI immune responses is still under 
discussion (Figure 8). The original definition of 
TI antigens reflects its ability to stimulate hu~ 
moral responses in nude mice in vivo or in T cell-
depleted cultures in virro. These criteria are rela-
tively nonstringent, insofar as nude mice and the 
T cell-depleted cultures have been shown to pos-
sess both small numbers ofT cells as well as large 
numbers of NK cells, which are both able to 
secrete cytokines. 103· 175 Rigorous elimination of 
T cells consistently and significantly reduces the 
in vitro immune response to TI antigens, indicat-
ing that these antigens are T cell dependent to a 
significant degree. 2 1.53·148 ·176 Thompson et al. 
demonstrated that the degree of T cell depen-
dency of these antigens in vitro depends on the 
state of activation of B cells.209 TI Antigens were 
extremely efficient in eliciting immune responses 
in large-sized B cells compared to small 
nonactivated B cells (cells in G0). Responsive-
ness could be enhanced by the addition ofT cell-
derived cytokines like IL-2. 53·149 The mechanism 
ofT cell activation by TNP-Ficoll was investi-
gated by Dekruyff et a!., who demonstrated that 
TNP-Ficoll-activated B cells were able to stimu-
late directly T cells to proliferate and secrete 
cytokines.48 They suggested that these T cell fac-
tors activated accessory cells to supply the addi-
tional factors required forTI immune responses. 
Accessory cells were found to be essential for an 
optimal TI immune response. In addition, it was 
demonstrated in vitro that, in contrast to T cell 
activation, accessory cell function in TI B cell 
activation did not involve presentation of pro-
cessed antigen in the context of Ia molecules and 
could be entirely replaced by recombinant IL-
t,77.l87 The Ia independency ofTI-1 immune re-
sponses was confirmed in vivo by Fultz et al. who 
observed no changes in the humoral immune 
against TNP-Ficoll in mice suppressed from birth 
with anti-Ia antibodyJ 1 All these data point to B 
cells as the principal cells in the induction of 
humoral TI immune responses. B Cell activation 
studies with haptenated antigens revealed that 
TNP-Brucella abortus and TNP-Ficoll were able 
to activate TNP-binding cells, via migM, to enter 
the cell cycle.24 No activation was detected after 
a 6. cell apitope + Complement 
I 
' 
6 COmp'"'""~""''" proOo{ : : : : : J 
G, 
J 
G, 
l 
Complement receptor 
I 
B· cell proliferation 
B- cell differentiation 
T·cell activation 
=0 ~ •. ~ 
Cytokines 
FIGURE 8. Cell-cell interactions during a Tl-2 immune response {see text for 
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challenge with the haptenated TD antigens TNP-
SRBC and TNP-OV A. Carteret ai.26·27 demon-
strated synergistic signaling of complement re-
ceptor and mig, as measured by intracellular cal-
cium mobilization, indicating that complement 
could provide an additional activation signal for 
B cells. This is in agreement with observations by 
Griffioen et al., who showed that polysaccha-
rides, TI-2 antigens, were able to activate comple-
ment via the alternative pathway. 84 Moreover, 
they demonstrated that polysaccharides 
complexed with a degradation product of comple-
ment (C3d) were able to bind to the complement 
receptors of B cells. These data suggest that TI-2 
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antigens complexed with C3d are able to activate 
B cells directly, thereby providing an activation 
pathway in TI-2 immune responses. Several in 
vivo studies indicated that complement was only 
synergistic after immunization with relatively low 
doses of TI antigens. In the case of high-dose 
immunizations, complement was not found to be 
obligatory for the generation of maximal humoral 
immune responses.l40.210.231 
In conclusion, B cell activation by soluble TI-
2 antigens in vitro occurs directly via the antigen-
specific mig without requiring antigen processing 
by accessory cells and is enhanced by comple-
ment. Cytokines produced by T cells and acces-
sory cells seem to be required for the clonal ex-
pansion and further differentiation of activated B 
cells (Figure 8). 
E. Cytokines in In Vitro Immune 
Responses 
1. Cytokine Profile of Th Subsets In 
Vitro 
Mosmann et al. studied a large panel of anti-
gen-specific Th cell clones. 151 .1~ 2 Virtually all 
clones fell into one of two groups. depending on 
the pattern of cytokines secreted: the first type of 
T cell clone, designated Thl, synthesized IL-2 
and IFN-y but not IL-4, whereas the second type 
of clone (Th2) produced IL-4 and IL-5, 32 but not 
IL-2 and IFN-y (Table 2). All Thl clones, in 
contrast to the Th2 clones, were able to mediate 
DTH reactions. 31 The functional capabilities of 
murine Thl and Th2 cells correlate well with the 
cytokines they secrete such as IFN-y, 
lymphotoxin, and granulocyte macrophage 
colony-stimulating factor (GM-CSF).66 The sig-
nals necessary to induce the differentiation of Th 
cells into Thl or Th2 are not well defined.45 One 
explanation could be the different specificity rep-
ertoires of Thl and Th2 cells. However, at the 
moment there is not much evidence for a relation 
between T cell repertoire and Th l(fh2 cell devel-
opment. 
DTH responses mediated by Th I cells and 
antibody responses predominantly stimulated by 
Th2 cells are mutually exclusive reactions, sug-
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gesting that these cells are reciprocally regulated 
in vivo. IL-4, a Th2 product, was found to support 
the growth of Th2 cells,202 whereas IFN-y, a Thl 
product, inhibited the proliferation of Th2 
cells.72.73 The search for cytokines that were pro-
duced by Th2 cells and inhibited either prolifera-
tion or cytokine production by Th 1 cells resulted 
in the characterization of a new cytokine, cytokine 
synthesis inhibitory factor (CSIF, IL-10),63.208 
that inhibits the production of cytokines by Th 1 
cells responding to antigen and APC. However, 
several lines of evidence suggest that IL-10 acts 
via the APC rather than directly on the Th I cell.64 
The establishment of Thl/Th2 cells was 
largely derived from clones which were selected 
for other purposes and had been maintained in 
vitro for long periods of time. Cytokine profile 
analysis of CD4+ clones shortly after isolation 
demonstrated that a high proportion of these 
clones secreted a broad spectrum of cytokines, 
including IL-2, IL-3, IL-4, IFN-y. and tumor ne-
crosis factor (TNF).65 It was suggested that these 
cells, tenned ThO cells, were either precursor sub-
sets of Th l(fh2 cells or transition cells in a path-
way leading from one subset to the other. Also. 
studies of Kelso and Gough revealed the exist-
ence of clones coexpressing the cytokines of both 
subsets. 10R The lack of dissociation of IL-4 and 
IFN-yproduction by CD4+ cells was attributed to 
the short-tenn in vitro activation of these cells. It 
is nevertheless clear that in vitro culture condi-
tions and in vivo priming can influence the rela-
tive frequencies of clones expressing different 
cytokine profiles. Analysis of whole-tissue 
cytokine gene expression showed that this was 
dependent on the priming protocol. 110 Graft-ver-
sus-host reaction showed a high IFN-y and a low 
IL-4 gene expression, while KLH immunization 
led to high IL-4 and low IFN-y expression. The 
upregulation of Th2 cells by IL-4, and the cross-
downregulation by IFN-y and IL-10 of Th2 and 
Thl ce!ls, respectively, could explain the Th sub-
set obtained after in vitro cloning. Dominance of 
IL-4 would lead to a preferential in vitro develop-
ment ofTh2 clones, whereas an IFN-y-dominated 
immune response would result in Th l 
clones. 197·203 From the data discussed it is clear 
that the subdivision of CD4+ T cell clones into 
Thl and Th2 subsets, as originally described by 
Mosman and Coffman 152 does not represent the 
TABLE 2 
In Vitro Cytokine Profiles of Murine T Cells 
CD4+: THO TH1 TH2 CDS+ 
IL-2 ++' ++ ++ 
IL-3 ++ ++ ++ + 
IL-4 ++ ++ + 
IL-5 ++ ++ + 
ll-6 ++ ++ + 
IL-10 ++ ++ 
IFN-y ++ ++ ++ 
TN F-a ++ ++ + + 
a Relative cytokine production. 
full range of phenotypes that can be expressed by 
murine T cells. 
2. B Cell Regulation by Th Cell Subsets 
One major function of Th cells is to provide 
the signals necessary for activation, proliferation, 
and differentiation of B cells that have been ex-
posed to antigen. The ability of Th cell clones to 
provide B cell help in vitro depends on the con-
centration and type of cytokines being secreted 
by the T cell clones at the time ofT -B cell inter-
action (Table 3). If the levels of IFN-y are low, 
Th 1 clones are able to provide help to B cells in 
the production of antibody, primarily of the 
IgG2a isotype.43 If high levels of IFN-y are 
present during a strong Th I response, these 
cytokines have an inhibitory effect on B cell 
responses. Thus, Th 1 cells can both help and 
suppress antibody production. Conversely, Th2 
clones effectively help B cells in the production 
of IGM. lgG I, lgA, and IgE, due to their ability 
to secrete the B cell growth and differentiation 
factors IL-4, IL-5, and IL-6. Moreover, it was 
demonstrated in vitro that IL-4 was an essential 
maturing factor for immature resting B cells, with 
a low Ia expression, to secrete lgG2a upon IFN-
y stimulation. 196 The lgE response is mainly con-
trolled by the cytokines IL-4 and IFN-y. IL-4 
induces a switch to lgE in preactivated B cells, 
whereas IFN-y inhibits this response.42 
The capacity of Th 1 and Th2 cells in the 
induction of antibody responses was recently de-
scribed.93·162 Noelle et al. showed that B cells 
stimulated by isolated membranes of an activated 
Thl clone or a Th2 clone plus IL-4 and IL-5 
produced similar levels of lgM, IgG 1, and 
IgG2a. 162 Hodgkin et al. extended these results by 
testing more Th 1 or Th2 clones in their ability to 
stimulate B cells in the secretion of the whole 
range of isotypes.93 Though the mechanism is 
still not completely resolved, the results of both 
groups provide strong evidence that the actual 
cytokine repertoire, and not the cell contact-de-
livered signals of Th 1 cells, are responsible for 
their inability to provide stimulation of B cell 
differentiation. The fact that Th I and Th2 cells 
can only be characterized by the pattern of 
cytokine secretion might be the reason that no cell 
surface marker has been described yet that exclu-
sively distinguishes Th 1 from Th2 cells. 
Bradley et al. examined the kinetics of in vivo 
development of antigen-specific CD4+ T cells 
which arose in the primary immunization with 
KLH and characterized the cytokines that were 
produced. 17 In this study, mice were immunized 
subcutaneously with KLH in Freund's complete 
adjuvant and draining lymph nodes were re-
moved at various time points. CD4 positive cells 
were isolated and restimulated in vitro with KLH 
and 24 h later supernatants were assayed for 
IL-2. IL-3. IL-4. IL-5, and IFN-r. All the 
cytokines were detectable as early as 3 d after 
immunization and peaked at day 5 to 7. Similar 
kinetics were observed for the development of all 
cytokine-producing CD4+ T cells, indicating that 
T cell activation for all cytokine-producing T cells 
(ThO, Thl, and Th2) follows a similar mecha-
nism. However, the amount of cytokine produced 
differed for each cytokine. The effector T cells 
produced relatively high levels of IL-2 and IL-4, 
and little IFN-y or IL-5, as far as they are compa-
rable. Mice thymectomized 6 months before 
showed a reduced capacity to generate cytokine-
producing CD4+ cells compared to control mice, 
indicating that the majority of cytokine-secreting 
cells were derived from short-lived, presumably 
naive precursor cells. The effector T cells pro-
vided excellent helper activity for in vitro anti-
body production of B cells, which produced prin-
cipally the immunoglobulins lgG I and IgM. The 
required in vitro restimulation of CD4+ cells with 
KLH suggested that these antigen-specific T cells 
in vivo only produce cytokines when they en-
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TABLE 3 
In Vitro Effects of Cytokines on Immune Cells 
B cells I so types T cells Accessory cells 
IL-1 Proliferation (i) Costimulatory Chemotactic, I L -1 (i) 
Acute-phase 
proteins(i) 
IL-2 Proliferation lgM (t) Proliferation 
IL-4 !a-Expression (i) !gGt and lgE {i) TH2 proliferation (i) Macrophage Ia (i) 
Activation, FccR (i) lgG2a, lg2b, and IL-2R (t) Mast cells (i) 
lgG3 (~) 
IL-5 Proliferation lgA, lgM, and Proliferation and 
IL-2R Expression (i) lgG (t) differentiation of 
eosinophils 
IL-6 Proliferation lg secretion (i) Activation factor 
IFN-y Differentiation factor lgG2a (t) TH2 proliferation (J..) Ia, FcyR expression (i) 
Antagonist of IL-4 lgG1 and lgE (~) Antiviral/microbial 
For References see Vitetta, E. S. et al., Adv. fmmunol., 45, 1, 1989. 
counter the appropriate antigen presented by B 
lymphocytes or other APC. In this study the 
cytokine production by individual cells was not 
assessed and therefore this study did not provide 
infonnation about the activity of Th subsets in 
this immune response. 
In conclusion, it is clear that Th subsets or 
function in vivo can only be detennined by deter-
mining the actual cytokine profile in vivo or in 
situ. 
3. Th Cell Subsets in Infectious 
Diseases 
Th2 Clones are considered to be important 
regulating cells in allergic or immediate hyper-
sensitivity responses. IgE is bound by mast cells 
and eosinophils and is the antigen-specific recep-
tor for induction of hypersensitivity reactions. IL-
4 stimulates IgE production by B cells. In addi-
tion, the growth and differentiation of mast cells 
and eosinophils is also stimulated by the Th2 
cytokines IL-3, IL-4, and IL-5. Animals infected 
with many parasites display high IgE levels,57 
eosinophilia, and mast cell hyperplasia. 107 Nu-
merous other features of immune responses to 
helminth parasites suggest a preferential involve-
ment ofTh2 cells. Street and Mosmann found that 
spleen cells isolated from Nippostrongylus 
brasiliensis-infected mice secrete dramatically 
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increased levels of IL-4, IL-5, and IL-l 0, but 
reduced levels of IL-2 and IFN-y after in vitro 
mitogen stimulation. 198 Coffman et al. investi-
gated the in vivo role of IL-4 and IL-5 in parasit-
ized mice.44 They demonstrated that injection of 
a neutralizing monoclonal antibody to IL-5 com-
pletely suppressed the blood eosinophilia and the 
infiltration of eosinophils in the lungs of 
Nippostrongylus brasiliensis-infected mice, 
whereas serum lgE was not affected. In contrast, 
injection of an IL-4-neutralizing antibody inhib-
ited the parasite-induced lgE serum levels but not 
the eosinophilia, indicating that lgE and eosino-
phil production in vivo are regulated by different 
cytokines produced by Th2 subsets. A similar 
outcome was observed in mice infected with 
Heligmosomoides polygyrus.213 
In contrast, the Th l subset is probably the 
most capable of helping against intracellular para-
sites such as viruses, intracellular bacteria, and 
protozoans. IFN-y stimulates IgG2a production, 
which is a complement-activating/cyto-
toxic isotype, 169 and has a high affinity for Fe 
receptors on macrophages. 212 Also, the ability to 
induce DTH reactions contributes to the defense 
against intracellular parasites, as this reaction leads 
to the recruitment of macrophages and granulo-
cytes to the area of infection. Furthennore, Th 1 
cells activate macrophages, by secreting IFN-y 
and lymphotoxin, to capture and kill infected 
cells.66 
The cross-inhibitory effects of Thl and Th2 
cytokines appear to determine the predominance 
of either of the two subsets during in vitro im-
mune responses against microorganisms, e.g., Th2 
cells in parasitic diseases9l.l98 and Thl cells dur-
ing mycobacteria infections.s8.184.233 
Not only the nature of antigens, but also the 
genetic make-up of inbred mice can be an impor-
tant factor in the development of Thl or Th2 
cells. Murray et al. 157 demonstrated that human 
collagen type IV or even a single peptide of this 
protein activated CD4 cells from H-25 mice to 
secrete Thl cytokines (IL-2 and IFN-y), whereas 
CD4 cells from H-2b.d were stimulated to produce 
Th2 cytokines {IL-4 and IL-5). In particular cases 
such a differential activation of Thl or Th2 cells 
can have dramatic consequences, which is illus-
trated in a mouse model of Leishmania major 
infection. Leishmania major is an obligate intra-
cellular parasite that causes death when injected 
into susceptible mice, i.e., BALB/c (H~2d), but 
causes only limited disease in resistant mice, i.e., 
C57BL/6 (H-2b). During infection BALB/c mice 
exhibit a Th2-like response (high IL-4 and lgE), 
whereas C57BL/6 mice produce a Th !-like re-
sponse (high IFN-y and strong DTH).90 Treat-
ment of BALB/c mice with IL-4-neutra\izing an-
tibodies beginning at the time of infection al-
lowed these mice to heal and develop· effective 
immunity. 183 In contrast, injection of anti-IFN-y 
antibodies in resistant mice abrogated the natural 
resistance to infection with L. major. 14 These stud-
ies indicated that IL-4 (Th2 cells) and IFN-y(Th 1 
cells) are crucial cytokines (Th subsets) in the 
defense against L major. 
4. Cytokine Profile of CDS' T Cells 
Most of the data discussed above deal with 
the cytokine profile of CD4+ cells. However, 
cog+ cells are also capable of secretion of a 
variety of cytokines (Table 2). Kelso et al. de-
scribed cos+ clones which transcribed and/or 
secreted any of the cytokines assayed (IL-2, IL-3, 
IL-4, IL-5, IFN-y. GM-CSF). 110 However, 
alloreactive CD4+ T cell clones on average pro-
duced higher levels of cytokine mRNA and se-
creted more protein than CDS+ clones. Fang and 
Mosmann67 analyzed a panel of a!loreactive 
cos+ clones and observed that they all expressed 
a Th I cytokine profile and did not secrete IL-4 
and IL-5. Most of the CDS+ clones of Kelso eta!. 
secreted a Thl-like profile, but in addition some 
did transcribe and/or produce IL-4, IL-5, and IL-
6. The amount of (Th2) cytokines produced was 
lower for CDS+ than for CD4+ clones. It was 
suggested that these observations support the in-
terpretation that the difference between the two 
types of clones is quantitative rather than qualita-
tive.109 Experiments of Cardell et ai.25 con finned 
this suggestion by demonstrating that cos+ cells 
were able to produce the cytokines IL-2, IL-4, 
and IL-5 in a lower amount as compared to CD4+ 
cells. 
It is clear from the data presented above that 
both CD4+ and cos+ cells can have the same 
cytokine profile. The quantitative differences in 
cytokine production between C04+ and COS+ cells 
found by several groups could very we!! be attrib-
uted to in vitro culture conditions and may not 
reflect the actual cytokine production of these 
cells in vivo. 
5. Type 1/2 Pathway-Regulated Immune 
Responses 
The data discussed above, concerning the 
Thl{fh2 cell subsets in in virrolin vivo immune 
responses, indicate that such a sharp dichotomy 
does not exist in vivo. It appears that CD4+ and 
cos+ cells have in potential an unrestricted 
cytokine profile. Which cytokines are produced 
in immune responses is dependent on a variety of 
factors: genetic make-up of animal; type, dose, 
route, and nature of antigen; and activity of 
cytokine-producing cells prior to immunization. 
In some immune responses IL-4 is the predomi-
nant cytokine, such as in helminthic infections in 
BALB/c mice, and in other immune responses 
IFN-y, e.g., L. major infection in C57BL/6 mice. 
In both immune responses the cytokine profiles 
ofT cells can have all possible combinations and 
the high frequency of either of the two Th subsets 
found in vitro is most likely due to artefacts. The 
differential secretion of cytokines by CD4+ or 
cos+ cells most likely detennines their regula-
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tory function in vivo. Since IFN-y and IL-4 are 
representing the cytokines of Thl and Th2, re-
spectively, and have important antagonistic func-
tions in vitro as well as in vivo, this distinction is 
valuable for immunological research. However, 
since CDS+ cells can have similar cytokine pro-
files as Th subsets, it is more realistic to speak of 
type 1 or type 2 pathway-regulated immune re-
sponses. Furthermore, the experiments discussed 
shoW clearly the necessity of in vivo research on 
the activity and profiles of cytokine-producing 
cells in immune responses. 
VIII. IN VIVO IMMUNE RESPONSES IN 
THE SPLEEN 
The responses of lymphocytes to antigen and 
pathogens have mainly been analyzed in vitro. 
However. whereas cells can interact relatively 
randomly in cell suspensions, peripheral lym-
phoid tissues like lymph nodes and spleen are 
compartmentalized into distinct B and T cell 
zones. Cells are exposed to the influence of lo-
cally present accessory cells, cytokines, and the 
extracellular matrix. In vitro experiments neces-
sarily disregard this complex organization of lym-
phoid organs. They can provide information about 
essential events during cell-cell interactions and 
immune cell activation. They give us an idea 
about which cells and cytokines might be active 
during immune responses. The in vitro approach 
can be valuable for the investigation of the effects 
of specific cytokines on specific cells. As a con-
sequence, lymphoid cell functions and interac-
tions seen in vitro reflect the full potential of such 
cells, but the events actually occurring in vivo are 
dictated and restricted by the lymphoid microen-
vironment. Therefore, techniques were developed 
to investigate the localization and activity of an-
tigen, immunocompetent cells, and cytokine-
genes/proteins during in vivo immune responses. 
The determination of whole-tissue RNA is a 
method to demonstrate which cytokine-genes are 
activated in a particular organ during various 
immune responses and in this respect will prob-
ably reveal data which lie close to those obtained 
by bulk in vitro data. Immunohistochemistry or in 
situ hybridization a!lows the in vivo study of the 
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specific localization and activity of various cells 
and cytokines in relation to their direct environ-
ment or cell-cell interactions in all types of tissue 
at any given moment. 
A. In Vivo Cytokine Gene Expression 
Although it is not certain that cytokine 
mRNA levels are directly correlated with rates of 
cytokine secretion, because of possible variations 
in the rates of cytokine mRNA translation, they 
give an indication about the timing and intensity 
of cytokine gene expression in immune re-
sponses. Gauchat et al.74 found a good correlation 
between the percentage of cells containing 
mRNA for a cytokine and the steady-state level of 
the same mRNA measured on the whole popula-
tion of peripheral blood mononuclear cells, sug-
gesting that changes in the production of 
cytokines mainly reflects differences in the fre-
quency of cells that are recruited for synthesis of 
these cytokines. Kelso et al. found that protein 
production and mRNA of IFN-yor IL-4 of stimu-
lated T cell clones was not strongly correlated. 1 10 
The lack of correlation could be due to differ-
ences in translational or secretory regulation of 
protein production, of which the latter was ob-
served in alveolar macrophages. 8 Resting alveo-
lar macrophages and activated macrophages were 
found to have similar ~-transforming growth fac-
tor gene expression. while the activated macro-
phages produced significantly higher amounts of 
this cytokine.8 Moreover, lack of correlation 
could also be attributed to clonal heterogeneity in 
the kinetic relationship between mRNA accumu-
lation and protein secretion. Thus, data concern-
ing cytokine-gene expression should be inter-
preted carefully and require additional experi-
ments for the determination of actual protein ac-
tivity. 
1. Cytokine Gene Expression during 
Model Immune Responses 
Using the reverse transcriptase polymerase 
chain reaction, Svetic et al. examined the gene 
expression of seven cytokines in spleens of mice 
injected with goat antibodies to mouse IgD 
(GalgD)_:wo This treatment gives an in l'ivo 
polyclonal activation stimulus, leading to the pro-
duction of large amounts of lgG I and lgE, 57 Ig 
isotypes whose production depends largely upon 
the presence of IL-4.42·223 The injected GalgD 
antibody binds to and crosslinks mouse B cell 
membrane lgD. activating the B cells. 55 GalgD is 
internalized and processed, and presented to goat-
specific T cells, leading to a massive T cell acti-
vation. At day 2 an increase was observed of the 
gene expression of IL-2 and IL-9. which reached 
maximum values 3d after GcdgD injection; IL-4 
and IL-6 gene expression peaked between days 3 
and 6 at values more than 100-fold over baseline. 
IL-l 0 Gene expression showed a small peak at 
day 1 and subsequently followed a similar pattern 
as observed for IL-4. IFN-y Increased at day 3 and 
reached peak levels 5 to 7 days after GalgD 
injection. The sequential production of cytokine 
mRNA of IL-2 and IL-4 demonstrated in the 
GalgD model was also observed by Mohler and 
Butler in lymph nodes after sensitization with 
picril chloride. 147 The observed early IL-2 activ-
ity in both systems and the fact that IL-2 is aT cell 
growth factor, 214 suggest that IL-2 stimulates the 
proliferation ofT cells producing cytokines like 
IL-4 and IFN-y which in their tum act as differ-
entiation factors in these model immune responses. 
Cytokine gene expression analysis of isolated 
CD4+ cells from GalgD-treated mice revealed 
that CD4+ cells were the main source of most of 
the cytokines examined. In contrast, only the gene 
expression of IL-6 and IFN-y was detected in the 
CD4-negative spleen cell population. One of the 
limitations of this approach is its inability to de-
termine cytokine profiles of individual cells. Nev-
ertheless, as the genes of the IL-2 and IFN-y, 
which are both Thl cytokines, were found to be 
expressed at different time points, and the gene 
expression ofThl (IFN-y) and Th2 (IL-4, IL-10) 
were elevated at about the same time, it is evident 
that the observed cytokine gene expression pat-
terns were not consistent with the Th l(fh2 di-
chotomy .154 These results confirm recent find-
ings which showed that different T cell clones 
isolated relatively early in an immune response 
produce every possible combination of 
cytokines. 65· llO 
2, Cytokine Gene Expression during 
Infectious Diseases 
Poston and Kurlander investigated the activ-
ity of IFN-y in murine spleens during primary 
infection with Listeria monocytogenes. 177 Analy-
sis of IFN-ymRNA revealed high expression 1 d 
after infection, followed by a gradual decline. 
IFN-y serum levels developed according to a 
similar pattern as observed for the IFN-y gene 
expression. The spontaneous IFN-y release by 
isolated splenocytes showed high levels only at 
day I. However, when cells were cultured for 
48 h with heat~killed Listeria monocyto&enes, a 
strikingly different release pattern of IFN-y was 
observed in vitro. with maximum levels at 6 d 
after infection. This peak probably reflects the 
clonal expanded Listeria monocytogenes-specific 
memory T cells which produce high levels of 
IFN-y upon stimulation with antigen, but does not 
demonstrate the actual frequency of active IFN-y-
producing cells. In vivo, these potential IFN-y-
producing cells will only be active after encoun-
tering Listeria monocytogenes-infected macroph-
ages. These findings demonstrate clearly the po-
tential limitations of in vitro assays as tools for 
the determination of in vivo cytokine production. 
The role of IFN-y in L. monocytogenes infection 
is probably the recruitment and activation of 
macrophages early during listeriosis. As maximal 
bacterial destruction is observed 5 to 7 d after 
infection, these data strongly suggest that IFN-y 
in itself cannot be the crucial factor during the 
T cell-dependent resolution of infection. Alter-
natively, the in vivo localization of these 
potential IFN-y-producing cells in relation to 
L. monocytogenes-infected macrophages might 
be more important than their quantity. In that 
case, IFN-ycould still be crucial for the reduction 
of bacterial load, as suggested by in vivo modula-
tion studies.22 Poston and Kurlanderl77 did not 
determine the source of IFN-y, but based on the 
observed early IFN-y activity the authors sug-
gested that NK-like lymphocytes could be the 
early producers of IFN~y during listeriosis. Re-
cently, Hiromatsu et al. demonstrated that y/0 T 
cells, producing IFN-y, appeared at a relatively 
early stage of listeriosis.92 Depletion studies re-
vealed that y/0 T cells were the principal cells in 
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host defense at the early stage of infection, whereas 
the a/~ T cells contributed to the host protection 
at the stage after L monocytogenes infection. All 
together, these data suggest that the early-appear-
ing y/0 T cells play a role, at least in part by 
secreting IFN-y, in the primary host defense against 
L monocytogenes. 
Heinzel et al. detennined mRNA levels of 
various cytokines from lymphoid organs of sus-
ceptible BALB/c and resistant C57BL/6 mice 
after Leishmania major infection.90 IL-2 mRNA 
levels in infected organs of BALB/c and C57BL/ 
6 mice were similar after infection, but IFN-y and 
IL-4 mRNA levels were reciprocaliy expressed. 
IL-4 mRNA levels in BALB/c mice were high 
and possibly the cause of susceptibility of these 
mice to L. major. Treatment of BALB/c mice 
with anti-IL-4 antibodies significantly attenuated 
the progression of leishmaniasis. Therefore, it 
was postulated that IL-4 might inhibit the devel-
opment of IFN-y-producing cells (Thl cells) 
which are crucial in the defense against L. major. 
IFN-y mRNA level was high in C57BL/6 mice 
and was in agreement with in vivo studies which 
demonstrated that IFN-y treatment improves the 
course of L. major infection in mice. Finally, T 
cell subset (Cn4;Cn8) depletion studies sug-
gested that CD4+ cells were the principal produc-
ers of IFN-y and IL-4 in C57BL/6 and BALB/c 
mice, respectively. This in vivo study demon-
strated the existence of an IFN-y/IL-4 dichotomy 
rather than a Thl!fh2 dichotomy in chronically 
infected mice, as IL-2 mRNA showed the same 
level of activity in both mice. Type !-pathway 
regulation of L. major infection prevented the 
progression of disease, whereas type 2-pathway 
regulation led to dissemination of the parasite and 
eventually to death. 
Kasaian and Biron investigated the activity of 
IL-2 mRNA in splenocytes during lymphocytic 
choriomeningitis virus (LCMV) infection. 104 
They demonstrated that the time course, peaking 
at day 7, of IL-2 transcription corresponded to 
CTL activation, Cn4/Cn8 proliferation, and to 
the production of IL-2 by splenocytes. It was 
demonstrated that IL-2 was essential for the ex-
pansion of CD4- and CDS-positive cells. Further-
more, Cn4+ and ens+ cells were both producing 
IL-2 during this virus infection, indicating that 
cytotoxic ens+ cells can produce their own 
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helper factors. This study demonstrated that IL-2 
is active in vivo during LCMV infection and sup-
ports the suggestion that IL-2 mediates CTL pro-
liferation. 
B. In Vivo lsotype Switching 
Several different in vitro models have been 
used to study the effects of cytokines on prolifera-
tion and differentiation of B cells 190 (Table 3). 
Snapper and Paul demonstrated a central role for 
IL-4 in the regulation of lg isotype secretion by 
LPS-stimulated B cells in vitro; 189 IgG I and IgE 
was induced by IL-4 in a concentration-depen-
dent manner, while IgM, IgG2b, and lgG3 secre-
tion was decreased. In contrast, IFN-y stimulated 
the expression oflgG2a and inhibited the produc-
tion oflgG3, IgGI, IgG2b, and IgE. 189 IL-5 was 
found to enhance proliferation/differentiation of 
B cells into IgM- and IgGl-secreting cells. 16 
IL-2 was also found to enhance B cell prolifera-
tion following LPS and anti-Ig treatment in 
vitro.235 McHeyzer-Williams demonstrated that 
the isotypes secreted by LPS-stimulated B cells 
could be regulated using combinations of IL-2, 
IL-4, and IL-5 that were acting in synergy .142 All 
these in vitro observations so far do not prove that 
these cytokines were active or had similar effects 
during in vivo antibody responses. In in vitro 
experiments cell numbers, cell types, cytokines, 
and LPS are all chosen arbitrarily. Possibly, a 
cytokine found to have a particular effect in vitro 
might not be active or present in the necessary 
quantity at the required place at the right time to 
have the same effect in an in vivo immune re-
sponse. Moreover, in vitro experiments may have 
omitted stimulating or inhibiting factors that 
might be simultaneously active in vivo. There-
fore, in vivo validation of in vitro observations is 
required to delineate the precise role of cytokines 
in immune responses. Such in vivo validation 
studies have been performed for IL-4 and IFN-y 
in several models.60 The investigation of the ac-
tual in vivo participation of cytokines in immune 
responses has been discussed in the previous sec-
tion. Below we will discuss some in vivo modu-
lation studies that are dealing with the in vivo role 
of cytokines in isotype selection. 
Eight days after injection of anti-Ign anti-
bodies as many as one third of spleen cells secrete 
IgG I and a 1 OO~fold increase of serum IgG 1 and 
IgE levels is observed. 55 These in vivo data sug-
gest that IL-4 may be a crucial cytokine in the 
upregulation of IgG 1 and IgE antibody responses. 
When mice were injected with GalgD and simul-
taneously received anti~IL-456 or anti-IL-4 recep-
tor antibodies,62 an almost complete inhibition of 
IgE production was observed. Furthermore, it was 
demonstrated that anti-IL-4 antibodies also inhib-
ited primary in vivo polyclonal IgE responses by 
99% in mice infected with Nippostrong_y/us 
brasiliensis. indicating that in these models IgE 
production is also IL-4 dependent in vivo. How-
ever, neither anti-IL-4 nor anti-IL-4 receptor sig-
nificantly inhibited the lgG l responses generated 
8 d after GaigD injection. These observations 
indicate that IgG 1 production in GalgD-stimu-
lated mice, unlike IgG 1 production in some in 
vitro experiments, must be largely independent of 
IL-4 in vivo. In vivo modulation studies of 
Finkelman et al. revealed that between day 3 and 
day 5 after immunization T cell help, in general, 
and IL-4 in particular, was required for the gen-
eration of an IgE response. 59 This was in agree-
ment with our in vivo study, in which the presence 
of high numbers of IL-4-producing cells in the 
spleen was demonstrated 3 and 4 d after injection 
of RaigD.219 
In vitro studies have demonstrated that 
IFN-y can inhibit IgE and lgG 1 responses and 
promote lgG2a responses. Finkelman et a!. tried 
to verify these in vitro observations in vivo.58 
GalgD-treated mice were injected with high doses 
of IFN-y. which led to a significant decrease of 
IgE and IgG 1 serum levels, whereas lgG2a serum 
levels were increased. Injection of anti IFN-y-
antibodies in GalgD-treated mice led to an in-
crease of lgG 1 and lgE serum levels, indicating 
that IFN-ywas produced endogenously. This was 
in accordance with our experiments, in which we 
demonstrated immunohistochemically that IFN-y 
was active, though to a lesser degree than IL-4, in 
the immune response to RcdgD. Killed and fixed 
Brucella abortus stimulate a polyclonal IgG2a 
response, but relatively little or no lgE or lgG l. 
Treatment of mice with anti-IFN-y antibody con-
siderably, but not completely, inhibited the B. 
abortus-induced IgG2a response. 58 This in vivo 
modulation study indicated that IFN-y is one of 
the principal cytokines that regulate IgG2a pro-
duction by B cells in the response to B. abortus. 
From the above data, the following conclu-
sions can be drawn. First, IL-4 and IFN-y are the 
principal cytokines that regulate in vivo IgE pro-
duction by B cells. Second, in vitro data can be 
obtained under more controlled conditions but 
may not always reflect the actual in vivo situation. 
IX. In vivo cell-cell interactions and cytokine 
production in the spleen 
In this review, the immune cells and 
cytokines that are assumed to be involved in 
immune responses were discussed. Further-
more, the characteristic localization of T cells, 
B cells, macrophages, DC, antibody-forming 
cells and other immune cells was described. 
However, data presented do not show 
whether, when and where these immune cells 
are active during in vivo antibody responses. 
These questions are addressed in this thesis. 
The development, localization and role of 
immune cells during various types of antibody 
responses are investigated in vivo. The localiz-
ation of injected antigens is related to the type 
of antigen and to the cells in the spleen 
involved in the handling and processing of 
antigens. 
It is investigated whether and where activated 
T cells, expressing gp39, are found during Tl~2 
or TD antibody responses. The localization and 
kinetics of development of gp39+ cells is 
related to that of antigen, resting/activated B 
cells and antigen-specific B cells. The cells 
expressing gp39 are characterized in vivo, and 
the role of gp39 in in vivo Tl-2 and TO antibody 
responses is assessed. Furthermore, it is in-
vestigated whether gp39+ cells are able to 
produce cytokines in vivo. Methods are devel-
oped for the in situ detection and characteriz-
ation of cytokine-producing cells {ll-2-, IL-4-, 
IL-5-, and IFN-y-PC), which are suggested to 
have an important regulatory role in B cell 
differentiation. The localization and develop-
ment of these cytokine-PC is related to that of 
antigen, gp39+ cells, resting-, activated-, 
antigen-specific B cells and to the isotypes 
produced by these B cells. Finally, functional 
studies are performed to the role of cytokines 
during the development of in vivo antibody 
responses. 
The main points emerging from the experimen-
tal studies will be related to the in vitro and in 
vivo data dealing with antigen-presentation, 
localization/migration of immune cells, cell-cell 
interactions and the immunoregulatory role of 
cytokines, as was discussed in this chapter. 
Finally, in vivo models are presented which 
show the cell-cell interactions that occur in the 
spleen during TO and Tl-2 antibody responses. 
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APC 
BCG 
BSA 
BOG 
CTL 
DC 
DNP 
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FDC 
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LCMV 
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Antigen-presenting cells 
Bacille Calmette Guerin 
Bovine serum albumin 
Bovine y-globu!in 
Cytolytic T cell 
Dendritic cell 
2,4-Dinitrophenyl 
Delayed-type hypersensitivity 
Follicular dendritic cells 
Fluorescein isothiocyanate 
Goat antibodies anti-IgD 
Hour 
Human serum albumin 
Major histocompatibility complex 
class II 
Interdigitating cells 
Immunoglobulin 
Interleukin 
Interferon 
Keyhole limpet hemocyanin 
Lymphocytic choriomeningitis virus 
Lipopolysaccharide 
Major histocompatibility complex 
Minutes 
Membrane immunoglobulin 
Natural killer cell 
4-Hydroxy-5-iodo-3-ni tropheny I 
Ovalbumin 
Periarteriolar lymphocyte sheath 
RoJgD 
SRBC 
Th 
Rabbit antibodies anti-IgD 
Sheep red blood cell 
T Helper 
TD 
TI-l (2) 
TNP 
TNP-HES 
Thymus dependent 
Thymus-independent type 1 (2) 
2,4.6-trinitrobenzenesulfonic acid 
TNP-Hydroxyethyl starch 
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1 Introduction 
Follicular localization of TI-2 antigens 
Complement-mediated follicular localization of 
T-independent type-2 antigens: the role of 
marginal zone macrophages revisited 
719 
In this study we demonstrate a hitherto undescribed phenomenon, namely that 
thymus-independent type-2 antigens (TI-2 Ag) localize in splenic follicles within 
1 h after administration. The follicular localization of 2,4,6-trinitrophenyl 
(TNP)-Ficoll was not antibody mediated. In addition in case of high-dose 
administration we observed a relatively large amount ofTl-2 Ag in marginal zone 
macrophages. However, after \ow-dose administration we observed a preferential 
localization of TNP-Ficoll in the splenic follicles. Detection of TNP-haptenated 
Ag in cryostat sections of murine spleens was performed with a high-affinity' 
TNP-specific monoclonal antibody conjugated to f)-ga\actosidase.Within minutes 
after injection the Tl-2 Ag localized in the marginal zone. attached to marginal 
zone macrophages and B cells. Twenty minutes after injection the Ag was also 
detected in the follicles and gradually accumulated there until 7 h after injection. 
Thereafter. the amount of follicular Ag gradually decreased but was still 
detectable up to 14 days after immunization. The follicular localization of 
TNP-Ficoll was complement dependent in contrast to the binding to and uptake 
by marginal zone macrophages. Double staining revealed that Ag was bound by 
macrophages, B cells and follicular dendritic cells. Haptenated thymus-depen-
dent (TD) Ag localized exclusively in the red pulp macrophages. In vivo 
macrophage elimination drastically increased the amount of TNP-Fico\l in the 
follicles, and enhanced the humoral immune response at low doses of Ag. 
Moreover. complement deprivation of mice abrogated the localization ofTI-2 Ag 
in the follicles, and led to a decreased humoral TI-2 immune response. In 
conclusion, we demonstrate for the first time that TI-2 Ag localize in follicles. 
Moreover_ the presented results provide further evidence that B cells and 
!ollicular localized Ag pia)' an important role in the induction of humoral TI-2 
1mmune responses. 
The spleen plays an important role in the protection 
against, e.g. Streptococcus pneumoniae, Neisseria meningi-
tides and Haemophilus influenzae [1 ]. Following splenecto-
my patients are at high risk for fulminant infections due to 
these bacteria. The protective immune response against 
these micro-organisms is directed mainly against the poly-
saccharide component of the bacterial capsule. classified as 
a thymus-independent type-2 (TI-2) Ag [2]. The presence of 
the spleen seems to be important in the primary encounter 
of the Ag whereas secondary humoral immune responses 
can also be evoked at sites outside the spleen [3]. This has 
led to the suggestion that in the spleen, specific subsets of 
B cells may be present or that the splenic microenviron-
ment as such may be crucial for the response of B cells to 
TI-2 Ag. In particular, the marginal zone macrophage~ of 
the spleen have received much interest in this respect. These 
macrophages. which take up and retain carbohydrate 
macromolecules such as FITC/TNP-Ficoll (model TI-2 
Ag). have been suggested to play a role in the processing 
and presentation of TI-2 Ag [4-7]. However, after in vivo 
elimination of marginal zone macrophages we observed no 
change in the humoral immune response toTI-2 Ag [8-11 ]. 
In spleen autotransplantation studies we found that the 
humoral immune response was already restored after 
4 weeks, despite the fact that the marginal zone macro-
phages did not return until 10 weeks after transplantation. 
indicating that these cells are not obligatory in the humoral 
Tl-2 immune response [8]. Furthermore. blocking of 
polysaccharide uptake by marginal zone macrophages did 
not affect TI-2 immune responses [9]. These studies demon-
strated that marginal zone macrophages do not play a major 
role in humoral immune responses against TI-2 Ag. In case 
of low-dosage immunization with TNP-Ficol\ we observed 
an unexpected relative increase of the immune response 
after elimination of marginal zone macrophages. suggest-
ing that the role of these macrophages was Ag removal 
rather than Ag presentation [12]. These results led to the 
suggestion that other cell types then the marginal zone 
macrophages were involved in the presentation ofTI-2 Ag. 
In a parallel line of research we developed a high-affinity 
mAb directed to TNP. This mAb conjugated to ()-galacto-
sidase was found to be extremely suitable for the immuno-
histochemical detection of very low amounts (3 [J.g/mouse) 
of injected trinitrophenylated Ag as compared to fluores-
ceinated Ag [4-7, 9]. This conjugate enabled us to re-
[I 9768] 
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evaluate the localization of Tl~2 and consequently to 
identify other cell types which might be involved in the 
presentation of Tl-2 Ag. 
2 Materials and methods 
2.1 Animals 
BALB/c and BCBA.F1 mice were bred at T)-!0. Rijswijk. 
The ).!etherlands. and were used at 12-16 weeks of age. 
CBA/N mice were obtained from Bomholtg:1rd. Ry. Den-
mark. Rabbits (Flemish Giant) were randomly bred at 
TNO and were used as rabbit RBC donors. 
2.2 Chemicals 
Alkaline phosphatase (P-6774. type VII-T. 1020 U/mg pro-
tein). 3-amino-9-ethy\carbazole (A-5754). Fast blue BB 
Base (F-0125). levamisole. MHS (maleimidohexanoyl-
n-hydroxysuccinimide ester, Pierce, Rockford. IL), naph-
thol AS MX phosphate (3-hydroxy-2-naphtoie acid, 2.4-
dimethyl-anilide ), TNP sulfonic acid (TNBS, grade I) were 
obtained from Sigma. St. Louis. MO. B-Galactosidase 
(E. coli-derived B-D-galactoside galactohydrolase. molecu-
lar weight 540000) and X-Gal (5-bromo-4-chloro-3-indolyl-
B-o-galactopyranoside) were obtained from Boehringer-
Mannheim, Mannheim, FRG. All reagents used were 
analytical grade or better. ~ 
2.3 Ag 
TNP-Ficoll. TNP-KLH, TNP-BSA, TNP-chicken gamma-
globulin and TNP-lysine were prepared as previously 
described [13]. TNP-hydroxyethyl starch (TNP-HES) was a 
kind gift from the late Prof. Dr. J. H. Humphrey, Royal 
Post-graduate Medical School, London, GB [7]. 
2.4 Reagents 
The murine mAb SH4.1C9. directed against TNP, has been 
described before [14]. The rat mAb MOMA-2, which 
recognizes monocytes and macrophages [15] was a kind gift 
of Dr. G. Kraal, Free University. Amsterdam, The Nether-
lands. Rabbit anti-rat Ig conjugated to horseradish perox-
idase (HRP), rabbit anti-mouse Ig conjugated to HRP, and 
rabbit Ab against peroxidase complexed with peroxidase 
(PAP) were obtained from Dakopatts. Copenhagen, Den-
mark. The affinity chromatography-purified anti-TNP mAb 
(SH4.1C9) was conjugated to ~-galactosidase according to 
the procedure described by Decider and De Water [ 16]. 
2.5 Experimental design 
To study the localization of TNP-Fico!l in murine spleens, 
BALB/c mice were immunized i.v. with 100 [.lgTNP-Ficoll in 
200 [.ll PBS. Mice were anesthetized and killed at various 
time intervals: immediately and 5, 10,20 and 40 min, 2 and 
7 h, 1, 2, 3, 4, 5, 6, 7. 10, 14 and 21 days after injection of 
Ag. To study the detection limit of injected TNP-Ficoll, 
BALB/c mice were injected i.v. with 0, 1, 3, 6, 13, 25, 50 and 
100 ~tg TNP-Ficoll and killed after 7 h. To investigate 
localization of injected T~P-Ficol! in CBA/N and BCBA. 
F1 mice. mice were injected i.v. with 100 [.lgT).!P-Fico11 and 
killed 7 h after injection. To study the role of route of 
administration on TNP-Ficoll localization. BALB/c mice 
were injected i. p. or s.c. with 100 [l.g TNP-Ficoll and killed 
after 7 h. To study the localization ofvariousTI and TD A g. 
BALB/c mice were injected i.v. with either 100 [.lg TNP-
HES. TNP-KLH. TNP-BSA. TNP-chicken gammaglobulin 
or TNP-lysine and killed after 7 h. To~ rule ;ut that 
T).!P-cross-reacting Ab were mediatingTNP-Ficolllocaliza-
tion. BALB/c mice were injected i.v. with either 2 mg 
TNP-lysine. TNP-BSA or PBS. 3 h before i.v. injection of 
50 [.lg TNP-Ficoll. Mice were killed 4 h later. 
BALB/c mice were injected i.v. with 1 mg PAP. After 3 h 
mice were injected with 50 [l.gTNP-Ficoll and subsequently 
killed 7 h later. Spleens and liver were removed and 
immediately frozen in liquid nitrogen and stored·at -70 cc 
if not used immediately. 
2.6 C depletion and immunization 
To investigte the involvement of C in the localization of 
TT\:P-Ficoll in murine spleens, BALB/c mice were injected 
i.v. twice with 2 ~tg cobra venom factor (CVF: Sigma) in 
PBS with an 8-h interval [17]. TNP-Ficoll (10 flgor 100 ~tg) 
was administered 16 h after the last CVF injection. Control 
mice received heat-inactivated CVF (65 oc. 60 min). Seven 
hours afterTNP-Fico!! injection mice were bled and killed. 
Spleen and liver were removed and immediately frozen in 
liquid nitrogen and stored at -70 oc. After clotting of the 
blood at 20 "C for 1.5 h. serum was separated by centrifu-
gation and subsquent\y stored at -70 oc until use. Deter-
mination of the alternative C pathway activity was per-
formed according to the procedure described by Van Dijk et 
al. [18]. using rabbit RBC as indicator cells. Alternative C 
pathway activity was expressed in AP50 U/ml. in which l 
AP50 U causes 50% lysis of the rabbit RBC. 
2. 7 Macrophage elimination with 
dichloromethylene-phosphonate 
(CI2MDP)-containing liposomes 
ChMDP-containing liposomes were used to eliminate 
macrophages in vivo and were prepared as described earlier 
[11, 19]. Two days after injection of (empty or C!2MDP) 
liposomes, 50 [.tgTNP-Ficoll was injected i.v. and mice were 
kiUed 7 h later. Macrophage elimination in the spleen was 
confirmed by acid phosphatase staining and with the mAb 
MOMA-2. as described previously [20]. 
2.8 Immunohistochemistry 
Cryostat sections ( -20 °C, 8 [.tm) of spleens, one of every 
mouse, were picked up on the same glass slide and kept 
overnight under high humidity at room temperature. Slides 
were air dried and stored in air-tight boxes at 4 "C until use. 
Cryostat sections were fixed for 10 min in acetone (p.a.) 
containig 0.02% H 20 2 (freshly prepared). Subsequently 
slides were rinsed with PBS and incubated horizontally 
overnight at 4 oc with the anti-TNP mAb conjugated to 
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f)-galactosidase. For double staining for macrophages and 
Ag, acid phosphatase activity was revealed, prior to 
incubation with the anti-TNP-f)-galactosidase conjugate. 
Acid phosphatase activity was demonstrated by incubation 
with naphthol AS-BI phosphate and p-rosaniline for 
30-45 min at 37°C [10]. Staining with the mAb MOMA-2 
was performed as previously described [20]. For double 
staining for B cells and Ag, sections were incubated 
overnight with HRP-rabbit anti-mouse lg, followed by 
HRP histochemistry. Thereafter, detection of Ag was 
performed. To detect PAP complexes [21], sections were 
fixed in acetone without H 20 2 followed by peroxidase 
staining. Detection of TNP-specific antibody-forming cells 
(AFC) was performed with TNP-alkaline phosphatase 
conjugates according to Claassen eta!. [13]. All reagents 
were diluted in PBS containing 0.1% BSA and titrated to 
obtain optimal results. Histochemical revelation of the 
HRP activity was demonstrated as previously described 
[22]. f)-Galactosidase activity was demonstrated according 
to the procedure described in Bondi et aL [23]. Sections 
were rinsed with PBS. counterstained with hematoxylin 
and mounted in glycerin-gelatin. 
2.9 Statistical evaluation 
Results were analvzed bv the t\vo-sample Student's /-test 
for comparison O"f two empirical means in a normally 
distributed population. 
3 Results 
3.1 Localization and kinetics of TNP-Ficoll 
We studied the localization of TNP-Ficoll in spleens of 
BALB/c mice from .5 min until21 days after i.v. injection of 
100 ~tg TNP-Fico\1 (Fig. 1 and Table 1). For a detailed 
schematic representation of compartments and cell types in 
the spleen sec [24]. Already 5 min after injection. a small 
amount of Ag \Vas detectable in the marginal zone 
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Figure I. Localization of TNP-Ficoll in representative spleen 
~ections of mice at various time points after i.v. injection of 100 !lg 
TNP-Fico!l. Detection of TNP-Fico!l was performed \Vith TI\"P-
spccific mAb conjugated to f)-galactosidase. (a) 5 min, T:'\P-Ficoll 
is onlY located in marginal zone. (b) 7 h. T:'\P-Ficoll is located in 
marginal zone, follicle (maxima! amount) and red pulp, (c) 3 days, 
and (d) 10 days after injection of TNP-Ficoll (see also Table l). 
(Fig. la). The amount of TNP-Ficoll increased gradually in 
the marginal zone and spreaded slowly to the follicular 
areas. At 2 h after TKP-Ficoll injection all the splenic 
follicles were heavily loaded with T~P-Ficoll and this 
remained so for the next 7 h (Fig. lb). Thereafter. the 
amount of follicular TNP-Ficoll decreased gradually but 
was still detectable up to 14 days after injection. Through-
out the experimental period (0-21 days) we observed a 
relatively large amount of TNP-Ficoll in the macrophages 
of the marginal zone. Up to 40 min after TNP-Ficoll 
injection, hardly any Ag \Vas detected in the red pulp 
(Fig. la). Subsequently, the amount of Ag in the red pulp 
increased gradually up to 2 days after injection (Fig. 1h). 
Thereafter, the localization of Tl\P-Ficoll in the red pulp 
decreased gradually and 21 days after injection no Ag was 
observed in the red pulp. 
Table l. Localization and kinetics of i.v. injected TNP-Ficoll in different compartments of murine spleens 
Timeal TNP-Ficolllocalization 
Marginal Follicle Red pulp 
zone 
5 min ++bl 
lOmin +++ 
20min +++ ± 
40min +++ + ± 
2h ++++ +++ ++ 
7h ++++ ++++ +++ 
1 dav ++++ +++ ++++ 
2 daYs ++++ ++ ++++ 
3 days ++++ ++ +++ 
4 days +++ ++ +++ 
5 days +++ ++ +++ 
6 days +++ ++ +++ 
7 days ++ ++ +++ 
10 days ++ + ++ 
14 days ++ ± + 
21 days + 
62 
TNP-specific antibodies 
Follicular TNP-AFC 
complexes 
± + 
+ ++ 
+++ ++++ 
++++ ++++ 
++++ ++++ 
+++ +++ 
++ ++ 
+ ++ 
± ++ 
c) 
b) 
Time after injection of 100 fJ,g TNP-Ficoll 
(each time point represents three to five 
mice). 
Subjective scale for the amount ofTNP-Ficoll 
localization: -. 0%. ±. 0%-5%: +. 5%-
25%: ++.25%-50%: +++.50%-75%: 
++++. 75%-100% of maximal observed 
amount of TNP-Ficoll in the different splenic 
compartment~. 
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Table 2. Localization of TNP-Ficoll after injection of different doses in different compartments of murine spleens after various 
treatments 
Treatment•) Control 
Dose TNP-Ficoll (!-lg) 100 10 
Marginal zone macrophages ++++b) ± 
B cells + ± 
Follicles FDC ++++ ++ 
B cells ++++ ++ 
Red pulp +++ 
PALS 
CVF 
100 10 
++++ ± 
± 
± 
+++ 
ChMDP 
50 5 
+++++ +++ 
+++++ +++ 
± a) Treatment of mice: CVF repre-
sents C-depleted mice and 
C\zMDP represents macro-
phage-depleted mice. 
b) Subjective scale for the amount ofT~P-Ficolllocalization: -, 0%. ±. 0%-5%; +. 5%-25%: ++. 25%-50%: +++. 50%-75%; 
+ ++ +. 75%-100%; +++++. 100%-125% of maximal observed amount of TNP-Ficoll in the different splenic compartments. 
To test the detection limit of the anti-TNP conjugate we 
injected various doses (1-100 ~tg) ofTNP-Ficoll and killed 
the mice 7 h later. We observed after injection of 3-12 [.tg 
TNP-Ficoll a preferential localization of Ag in the follicular 
areas of the spleen (Table 2). After administration of low 
doses of TNP-Ficoll we could hardly detect any TNP-Ficoll 
in the marginal zone and red pulp macrophages. In 
contrast. after injection of high doses (50-100 !J.g) of 
TNP-Ficoll we observed. besides the follicular localization. 
a high amount of TNP-Ficoll in the marginal zone and red 
pulp. 
Seven hours after i.p. or s.c. injection of 100 !J.g of 
TNP-Ficoll we observed a low amount ofTNP-Ficoll in the 
red pulp. while the localization of TNP-Ficoll in the 
marginal zone and follicles was similar to what we found for 
i.v. i7ljected TNP-Ficoll. The localization of TNP-Ficoll in 
spleens of BCBA.F1 and CBA/1'\ mice was similar to that 
described for BALB/c mice. 
3.2 Characterization ol" TNP-Fkoll-binding cells 
To detemine which cells were binding T;\!P-Ficoll. we 
performed double-staining experiments for TNP-Ficoll and 
B cells or macrophages (Table 2). Double staining for 
B cells, using HRP-conjugated Ab against mouse 
Ig(G + M), and TNP revealed that almost all the Ag was 
localized in the same areas where B cells were found. The 
staining of Ig(G + M) in the follicular areas of mice 7 h after 
TNP-Fico\1 injection was of the same intensity as in the 
follicular areas of PBS-treated mice. However, from 3 to 
14 days after injection we observed a more intensive 
Ig(M +G) staining in the splenic follicles of TNP-Fico\1-
trcated mice than in control mice (data not shown). The 
observed staining pattern was typical for immune com-
plexes trapped in the follicles and was most likely caused by 
anti:fNPAb bound byTNP-Ficolllocalized in the follicles. 
These results suggest that the follicular localization in the 
beginning of the immune response is not mediated by 
TNP-cross-reacting Ab. As soon as TNP-specific Ab are 
formed they will bind to follicular localized Ag. as we 
observed 3 clays after immunization. In the red pulp and 
marginal zone we observed Tl'\P-Ficoll-binding cells double 
staining with anti-Ig(G + M). suggesting that in the~e 
compartments B cells were binding TNP-Ficoll. 
Double staining for TNP-Ficoll and macrophages, using 
acid phosphatase or the mAb MOMA-2. revealed that 
marginal zone macrophages were heavily loaded with 
TNP-Ficoll. In the white pulp we observed no TNP-
Fico\1-binding macrophages at all. This was in contrast to 
the red pulp where we observed a high frequency of 
macrophages having TNP-Fico\1 in their cytoplasm. 
Follicular dendritic cells (FDC) are characterized by their 
ability to bind immune complexes. This capability can be 
demonstrated by peroxidase histochemistry of spleens of 
mice. after injection of PAP complexes [21]. To investigate 
whether localization of TNP-Ficoll in the follicular areas 
was similar to the localization of PAP complexes in the 
spleen. we performed double-staining experiments on 
spleen sections of mice injected with PAP complexes and 
TNP-Ficoll for both Ag. We observed a more intense 
staining of TNP-Ficoll than of PAP complexes in the 
follicles. but both Ag were confined to the same follicular 
areas. 
3.3 Localization of haptenated TD and TI Ag 
To investigate whether the localization pattern of TNP-
Fico\1 was typical for this TI-2 Ag only. we tested several 
other (haptenated) TD and TI-2 Ag. Injection of another 
TI-2 Ag, TNP-HES. resulted in a localization pattern of the 
Ag similar to that found for TNP-Ficoll. Seven hours after 
injection of TD Ag like TNP-BSA. TNP-KLH and TNP-
chicken gammaglobu!in the Ag were mainly found in the 
reel pulp. No haptenated TD Ag was localized in the 
follicular areas. in contrast to our observations with 
TNP-Ficoll and TNP-HES. Double staining revealed that 
the haptenated TD Ag were mainly captured by red pulp 
macrophages. For TNP-Iysine we found a staining pattern 
comparable to that of haptenated TD Ag. These results 
demonstrate that the localization pattern of TI-2 Ag in 
marginal zone. follicles and red pulp of the spleen is typical 
for this kind of Ag. 
3.4 Effect of pre-injection of high doses haptenated 
(non-TI) Ag on localization ol" TNP-Ficoll 
In non-immunized mice a proportion of the circulating Ab 
can cross-react with the hapten TNP [25]. To determine 
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whether the observed localization pattern of TNP-Ficoll 
was due to trapping of complexes formed by these TNP-
cross-reacting Ab and TNP-Ficol!, we injected mjce i.v. with 
a high dose (2 mg) of TNP-BSA or TNP-\ysine, which will 
bind the majority ofT;\!P-cross-reacting Ab, or with PBS as 
control. After 3 h we injected i.v. 50 flg of TNP-Ficoll in 
each pre-injected mouse, which we killed after another 4 h. 
Staining forTNP revealed that the characteristic staining of 
TNP-Fico!! localization in splenic follicular areas was 
similar in TNP-BSA!TNP-lysine pre-injected mice and in 
control mice. The staining observed had the same intensity, 
suggesting that circulatingTNP-cross-reacting Ab were not 
mediating the specific localization of TNP-Ficoll in the 
murine spleen. 
3.5 Localization and kinetics of TNP-spedtic Ab and 
TNP-AFC 
To investigate whether TNP-Ficoll localization was 
mediated by (circulating or localized) TKP-cross-reacting 
Ab, we incubated spleen sections of mice from day 0-21 
with TNP-alkaline phosphatase conjugates. Up to 2 days 
aftcrTNP-Ficol\ injection we observed noTNP-binding Ab, 
·. 
: 
Fig we 2. Localization of T"'P-speeifie Ah in representative cryo-
'itat section~ of murine spleens <1ftcr injection of T"'P-Ficoll. 
Sections were stained with a Tl\P-alkal inc phosphatase conjugate. 
(A} No TNP-spccific Ab 7 h after TNP-Ficoll injection. whereas in 
tlw alternate section (Fig. 1 B) the t"ollick is hcavilv londed with 
TNP-FicoiL (8) Ah of Ah-Ag complexes arc dctcc:t~d in follicle of 
spkcn 3 dav~ at.t..::r immunization. l'.'hcrcas in Fig. IC the Ag of 
A b-Ag com.plcxc-.; are detected in the same follicl~ of an altcr~atc 
section. :'-JotcTI\P-AFC in Oltter-PALS. terminal arteriole;; and red 
pulp (sec alsoT<thle 1}. 
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indicating that no TNP-specific binding sites were available 
(Figs. 1 b and 2a ). This provided additional evidence against 
the assumption that TNP-cross-reacting Ab might mediate 
the follicular localization of TNP-Ficoll. After 3 days the 
TNP-binding Ab in the splenic follicle increased gradually 
together with the number of TNP-AFC in outer periarter-
io!ar lymphocyte sheath (PALS) around the terminal 
arterioles and in the red pulp (Table 1) and reached 
maximum levels 4 days after immunization. In serial spleen 
sections of mice 3-10 days after TNP-Ficoll injection a 
similar localization ofTNP-Ficoll and TNP-specific Ab was 
observed, indicting that after3 days complexes (TNP-Ficoll 
anti-TNP) were present in the follicles (Figs. 1c and 2b). 
The follicu"lar localization of TNP-specific Ab decreased 
gradually· from 6 days after immunization, but was still 
demonstrable up to 21 days after injection. 
3.6 Effect of C depletion on localization of TNP-Ficoll 
Studies with Ag-Ab complexes have already demonstrated 
that C mediates the follicular localization of such com-
plexes [26]. Moreover, several studies have demonstrated 
that TI-2 Ag. like polysaccharides, are able to activate the 
alternative C pathway [27-30]. Consequently, it is conceiv-
able that C mediates the follicular localization of TNP-
Ficoll. by forming polysaccharide-C3d complexes. There-
fore, we investigated the effect of C depletion, by CVF 
treatment, on localization of TNP-Fico\1 in murine spleens. 
After injection of 10 ~tg TNP-Ficoll the typical follicular 
localization ofTNP-Ficoll in spleen sections of CVF-treated 
mice was totally abrogated. After injection of a high dose of 
TNP-Fico!l (100 f.Lg) we observed in CVF-treated mice a 
substantial reduction of the typical follicular localization of 
TNP-Ficoll in the splenic compartments (compare Figs. lb 
and 3, Table 2). C depletion did not affect the capacity of 
marginal zone macrophages to bind and retain TNP-Ficoll 
(Fig. 3). 
The sera of CVF-treated mice had AP~11 values below 
measurable levels(< 3 U/ml, data not shown). The AP50 of 
heat-inactivated CVF-treated mice after injection of 100 ~tg 
Fig we 3. TNP-Ficoll localization in complement depleted mice. 
TNP-Ficoll localization. detected with TNP-spccific: mAb conju-
gated to [·)-galactosidase. in a representative cryostat section of a 
spleen of CVF-trcated mice 7 h after injection of 100 ~g TNP-
Ficoll. Note the relatively IO\\· amount of follicular TNP-Ficoll as 
compared to untreated mice (Fig. lb. see also li1blc 2). 
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Figure 4. TNP-Ficolllocalization in mice depleted of maerophages 
by Cl1MDP containing liposomcs. 7 h after TNP-Ficoll injection. 
Detection of TI\"P-Ficoll was performed with TNP-specific mAh 
conjugated to f)-galactosidase. 1\"ote the absence of T:.IP-Ficoll in 
the marginal zone and the relatively large amount ofTNP-Fieoll in 
the follicles as compared to untrcah'd mice (Fig. lb. see also 
Table 2). 
TNP-Fico!l was significantly lower than after injection of 0 
or 10 f.tgTNP-FicolL indicating that TNP-Ficoll activates C 
(Fig. 5). These experiments demonstrate that the follicular 
localization of TNP-Ficoll in murine spleens is C3 depen-
dent. 
3.7 Effect of macrophage elimination on l"ollicular 
localization of TNP-Ficoll 
To investigate whether the presence of macrophages 
influences the localization of TNP-Ficoll, we treated mice 
with Cl:2MDP-containing liposomes to eliminate the red 
pulp and marginal zone macrophages in vivo, prior to 
TNP-Ficoll administration [11]. As demonstrated in Fig. 4 
and Table 2. noTNP-Fico\1 was present in the marginal zone 
after elimination of macrophages. Moreover, the amount of 
TNP-Ficol! in the red pulp >vas markedly reduced, when 
compared to control mice. This was in contrast to the 
follicular localization of T:\!P-FicolL which increased 
markedly after macrophage elimination. These results 
" EN..ECTEO Tl>P-F,coll (>.01 
Figure 5. TNP-Ficol! activates C in vivo. Alternative C pathway 
activity of sera of heat-inactivated CVF-treated mice 7 h after 
injection of 0, 10 or 100 J.lg TNP-FicolL Alternative C pathway 
activity is expressed as AP~o U/ml, in which 1 AP50 U causes 50% 
lysis of the rabbit RBC Horizontal lines in gate represent 
means. 
suggest that red pulp and marginal zone macrophages form 
a physiological boundary, which bind part of the injected 
TNP-Ficoll preventing it to localize in the follicles. 
4 Discussion 
4.1 General remarks 
The major novel finding oft his study is that TI-2 Ag localize 
in splenic follicles within 1 h after administration. After 
low-dose administration (3-12 [lg) TNP-Fico!! localizes 
preferentially in the follicles, whereas in the marginal zone 
macrophages hardly any Ag can be detected. We demon-
strate that the follicular localization of TI-2 Ag is C 
mediated and different from the Ab-mediated trapping of 
A g. which is observed during the peak of every (TI and TD) 
humoral immune response. In addition to this new phe-
nomenon we confirmed earlier reports that Tl-2 Ag are 
taken up by marginal zone macrophages. albeit in a 
C-independent way as could be expected in view of studies 
on the putative TI-2 Ag receptor [9, 31]. 
4.2 Follicular localization of TI-2 Ag 
This study demonstrates for the first time that TI-2 Ag 
localize in splenic follicles. Previous studies investigated 
the localization of TI-2 Ag using fluorescein isothiocyanate 
conjugates of HES and Ficoll Ag (100 [lg or more/mouse) 
[4-7. 9]. The high affinity forTNP of the mAb we used and 
the high sensitivity of immunohistochemical techniques 
[32] allowed us to detect TNP-Ficoll in follicular areas of 
murine spleens after injection of dosages as low as 
3 [.tg/mouse of this TI-2 Ag. 
This early follicular localization of Tl-2 Ag can be 
explained by two mechanisms. First. TI-2 Ag may activate 
C directly and bind to CR of follicular dendritic cells (FDC) 
and B cells. Second,TI-2 Ag may bind to cross-reacting Ab 
and subsequently bind to FeR or after C activation to CR of 
FDC and B cells. Nossal et al. [33] demonstrated that TD 
Ag localize in follicles of lymph nodes bound to FDC, by an 
Ab-dependent mechanism, within minutes after injection. 
We also demonstrated that at the moment of TNP-specific 
Ab production these Ab where involved in the follicular 
localization of TI-2 Ag. However. the early observed 
follicular localization of TI-2 Ag was found to be C 
mediated. We demonstrated that a role of TNP-cross-
reacting Ab in the early follicular localization of TI-2 Ag 
was highly unlikely. 
Double-staining experiments indicated that part of the 
injected TNP-Ficoll was bound by B cells in the marginal 
zone, follicles and later also in the red pulp of the spleen. 
However, the double staining forB cells and TNP-Ficoll in 
the follicles could also indicate that TNP-Ficoll was bound 
to FDC Double-staining for injeced PAP complexes [21], 
which bind to FDC, and TNP-Ficoll revealed an identical 
staining pattern, suggesting that TNP-Ficoll indeed may 
also be bound by FDC. The C dependency of the follicular 
localization of TNP-Ficoll indicates that both B cells and 
FDC may be theTI-2 Ag-binding cells in the follicles, since 
both cell types have CR [34]. The dendrites of the FDC 
form an intricate network, ca1Jed the follicular web, where 
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follicular B cells lie in dose association with FDC. This 
close contact hampers the immunohistochemical identifica-
tion of which cells bind Ag in the follicles [33, 35]. 
The population of CR-positive B cells in CBA/T\ mice is 
significantly smaller than in other strains of mice [36]. 
Injection ofTNP-Ficoll in CBA/N mice resulted in a splenic 
localization ofTNP-Ficol! similar to that found in spleens of 
other strains of mice. If B cells were the principal TNP-
Ficol!-binding cells in follicles, we would expect to see no. 
or at least a lower amount of TNP-Ficoll in splenic follicles 
of CBA/N mice. Thus, these results are more supportive for 
FDC rather than B cells as TNP-Ficoll-binding cells in 
splenic follicles. 
4.3 Role of marginal zone macrophages in handling of" 
TI~2 Ag 
Double-staining for macrophages and Tl'\P revealed that a 
part of the injected Th'P-Ficoll was detectable in macro-
phages of marginal zone and red pulp. Macrophage elimi-
nation. using CI2MDP-containing liposomes, resulted in 
abrogation of the TNP-Ficoll localization in the marginal 
zone and a substantial reduction ofTNP-Ficolllocalization 
in the red pulp, indicating that macrophages both in the 
marginal zone and in the red pulp retail TNP-Ficoll. 
However, the follicular localization ofTNP-Ficoll increased 
markedly after macrophage elimination. indicating that 
these macrophages prevent TNP-Ficoll to localize in the 
follicular areas and that they may have a negative influence 
on the induction of TI-2 immune responses. This supports 
previous in vivo experiments in which after low dose 
immunization with T;\!P-Ficoll a relative increase of the 
humoral TI-2 immune response was observed when the 
splenic marginal zone macrophages of mice were elimi-
nated [12]. In bacterial infections a primary requirement 
for protection of the individual is reduction of the number 
of micro-organisms, i.e. Ag load. Elimination may be the 
task of marginal zone macrophages, while the specific 
immune response may be initiated by antigen-presenting 
cells, like FDC and B cells. 
Seven hours after injection of high doses of TNP-Ficoll, we 
observed an intensive staining for TNP-Ficoll in the red 
pulp, whereas after lower doses of TNP-Ficol\ hardly any 
TNP-Ficoll could be detected in the red pulp macrophages 
(Table 2). In case of high doses, either administration i.p. 
or s.c. we also observed a relatively low amount of 
TNP-Ficoll in the red pulp. This is probably due to the slow 
release of Ag into the circulation. We conclude that 
TNP-Ficoll is primarily taken up and retained by marginal 
zone macrophages, FDC and B cells, while in case of high 
doses this primary Ag handling system is overloaded. 
leading to additional TNP-Ficoll uptake by red pulp 
macrophages. 
4.4 Immune response against TI~2 Ag 
Matsuda et a!. [37] found in CVF-treated mice after the 
administration of low doses (1-10 ~Jog) Ag an impaired 
humoral immune response against haptenated TI-2 Ag. 
However, the immune response against high doses (100 [.lg) 
was not affected by CVF treatment, suggesting that C plays 
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only a role in immune responses against low doses TNP-
Ficoll. Our C depletion studies revealed that the in vivo 
localization ofTNP-Ficoll was mediated by C3. In addition 
to this, we found that after C depletion and administration 
of a high dose of TNP-Fico\l (100 ~tg) a small amount of 
TNP-Ficoll still localized in the follicles (Figs. lb and 3, 
Table 2). whereas C depletion in case of a IO\.\'er dose 
(10 [.lg) of TNP-Ficoll complete!)' abrogated the localiza-
tion of TNP-Ficoll in the splenic follicles. The lack of 
follicular Ag localization in CVF-treated animals injected 
with low doses of TNP-Ficoll thereby may explain the 
difference in antibody responses after high- and low-dose 
administration of Ag, as reported by Matsuda et al. [37]. 
The low amount of TNP-Ficoll found in splenic follicles of 
CVF-treated mice after a high dose of Ag could be due to 
binding ofTNP-Ficoll toTNP-specific B cells which pass the 
follicles during their migration throught he spleen [38], or 
to residual C-binding activity remaining after CVF treat-
ment. Furthermore. C-independcnt localization of TNP-
Ficoll after high-dose injection could also be due to the 
mechanical trapping by the follicular web formed by 
dendritic cell processes, as discussed previously for immune 
complexes [20]. 
In vivo CR blocking studies demonstrated a marked 
decrease of the humoral immune response particularly after 
administration of suboptimal doses (1-10 ~tg FITC-Ficol!) 
of TI-2 Ag [39. 40]. These studies indicated that CR of 
B cells and FDC are important for the generation of an Ab 
response against Tl-2 Ag. A role of C in Tl B cell 
stimulation was already suggested by Pryjma in 1974 [30]. 
Moreover, several reports have demonstrated that polysac-
charides and bacteria are able to activate the C alternative 
pathway [27-30] and that C3 subsequently is able to 
activate B cells [41-43]. Our experiments. in which we 
found that follicular localization of TNP-Ficoll is C depen-
dent and that injection of lOO ~tg TNP-Ficoll resulted in a 
significant decrease of the alternative C activity in sera of 
these mice, also show that Cis active during TI-2 immune 
responses. 
These results together with data obtained earlier [8-12] 
suggest the following sequence of events in the generation 
of Ab responses against TI-2 Ag. After injection, TI-2 Ag 
will activate C and subsequently bind to B cells, in marginal 
zone and follicles, and to FDC. The TI-2 Ag will activate 
these B cells directly, without requiring a processing step by 
marginal zone macrophages. Apart from direct B cell 
activation in the marginal zone as suggested by MacLennan 
eta!. [44, 45], TI-2 Ag will be exposed by FDC to B cells· 
which migrate through the follicles. resulting in activation 
of part of these B cells. TNP-Ficoll drives these resting 
TNP-Ficoll binding B cells into the G 1 stage of the cell cycle 
[41, 42]. These activated B cells will eventually differen-
tiate into TNP-AFC. 
In conclusion, the role of marginal zone macrophages is not 
primarily Ag presentation but rather removal of (soluble) 
Ag, killing and processing of particulate Ag/bacteria as 
already has been suggested [46], whereas B cells and FDC 
are most likely involved in the actual induction of immune 
responses to Tl-2 Ag. 
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DIFFERENTIAL UPTAKE AND TRAPPING OF Tl-2 ANTIGENS: AN UNEXPECTED 
ROLE FOR FOLLICULAR DENDRITIC CELLS IN THE INDUCTION OF Tl-2 IMMUNE 
RESPONSES 
AJ.M. Van den Eertwegh, M.M. Schellekens, W.J.A. Boersma and E. Claassen 
Department of Immunology and Medical Microbiology, TNO Medical Biological 
Laboratory, P.O. Box 45, 2280 AA, Rijswijk, The Netherlands 
INTRODUCTION 
The spleen plays an important role in the protection against capsulated micro-
organisms e.g. Streptococcus pneumoniae, Neisseria meningitides and Haemophilus influenzae1• 
The protective immune response against these micro-organisms is directed mainly against 
the polysaccharide component of the bacterial capsule, classified as a TI-2 antigen2• 
Following splenectomy patients are at high risk for fulminant infections due to these 
bacteria. The presence of the spleen seems to be important in the primary encounter of the 
antigen, whereas secondary humoral immune responses can also be evoked at sites outside 
the spleen3• This has led to the suggestion that in the spleen, specific subsets of B cells may 
be present or that the splenic micro-environment as such may be crucial for the response 
of B cells to TI-2 antigens. In particular the marginal zone macrophages of the spleen have 
received much interest in this respect. These macrophages, which take up and retain 
carbohydrate macromolecules such as TNP-Ficoll/FITC-Ficoll (model 11-2 antigens), have 
been suggested to play a role in the processing and presentation of TI-2 antigens4•7• 
However, recent in vivo modulation studies demonstrated that marginal zone macrophages 
are not required in humoral immune responses against 11-2 antigens~·10• 
Evidence for an important role of B cells in TI-2 immune responses was found in 
experiments with neonatal mice and CBNN mice, which carry an X-linked immuno-
deficiency. which were both unable to mount a humoral response against TI-2 antigensn. 
The B cells of these mice have many properties in common with immature B lymphocytes 
so that their defect is probably due to immaturity, in case of neonatal mice, or due to a 
maturation arrest in case of the CBAJN mice. Griffioen et al. 12 showed that polysaccharides, 
TI-2 antigens, were able to activate complement via the alternative pathway. Moreover, they 
demonstrated that polysaccharides complexed with C3d, a degradation product of 
complement, were able to bind to CR2 of B cells. In addition, Carter er al. 13•14 demonstrated 
synergistic signaling of CR2 and membrane immunoglobulin, as measured by intracellular 
calcium mobilization. These data provide an alternative activation pathway of B cells in TI-2 
immune responses. However, the localization studies for FITC-Ficoll indicated the marginal 
zone macrophages as the principal 11-2 binding cells in the spleen. which is not consistent 
with the above discussed (direct) B cell activation models. Therefore. we re-evaluated the 
localization of TI-2 antigens using a highly sensitive immuno-histochemical approach. 
Materials and Methods 
Animals BALB/c and BCBAFl mice were bred at TNO, Rijswijk, The Netherlands and 
were used at 12-16 weeks of age. CBA/N mice were obtained from Bomholgtl.rd, Rye, Denmark. 
Chemicals 3-amino-9-ethy!carbazole (A-5754.), TNP sulfonic acid (TNBS, grade I) were 
obtained from Sigma, St. Louis, MO, USA MHS (maleimidohexanoyl-n-hydroxysuccinimide ester, 
Pierce, Rockford, IL, USA); ft-galacwsidase (E. Coli-derived ,8-D-galactoside galacwhydrolase, MW 
540 KD) and X-Gal (5-bromo-4-chloro-3-indolyl-.8-D-galactopyranoside) were obtained from 
Boehringer, Mannheim, FRG). 
Antigens and bacteria TNP-Ficoll was prepared as previously described 15• TNP-hydroxyethyl 
starch (TNP-HES) was a kind gift from the late Prof. Dr. J.H Humphrey, Royal Post-graduate 
Medical School, London7• Group B strcpwccoci (Dr. G. Teti, Istituta di Microbiologia, Messina, 
Italy) were labeled with 1,1,-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (Dil), a 
fluorescent lipophylic dye which diffuses into cell membranes16• 
Reagents The murine monoclonal antibody SH4.1C9, directed against TNP, has been 
described before17• The rat mAb MOMA-2, which recognizes monocytes and macrophages was a kind 
gift of Dr. G. Kraal, Free University, Amsterdam, The Netherlands 18• Rabbit-horseradish-peroxi-
dase (HRP) anti-rat Ig, rabbit-horse-radish-peroxidase anti-mouse Ig was obtained from Dakopatts, 
Copenhagen, Denmark. The affinity-chromatography purified anti-TNP mAb (SH4.1C9) was 
conjugated to ,8-galactosidase according to the procedure described by Decider and De Water with 
some modifications 19·::o. 
Experimental design BALB/c mice were immunized i.v. with 100 }J.g TNP-Ficoll in 200 }.1.1 
PBS. Mice were anaesthetized and killed at various time intervals: immediately and 5 min, 10 min, 
20 min, 40 min, 2 hr, 7 hr, 1, 2, 3, 4, 5, 6, 7, 10, 14, 21 days after injection of the antigen. 
CBNN and BCBAFI mice were injected i.v. with 100 }J.g TNP-Ficoll and killed 7 hr after injection. 
BALB/c mice were injected i.p./f.p. with 100 }J.g TNP-Ficoll and killed after 5 hr. 
BALB/c mice were injected i.v. with 500 }.Lg Dii labeled Group B streptococci and killed 7 hr after 
injection. Spleens and lymph nodes (i.e. of footpad immunization) were removed and immediately 
frozen in liquid nitrogen and stored at -7(J'C if not used immediately. 
Complement depletion and immunization Complement depletion was performed .according 
to Van de Berg et al.:1• Complement depleted mice were i.v. injected with 10 }J.g or 100 }J.g TNP-
Ficoll and were bled and killed 7 hr later. Spleens were removed and immediately frozen in liquid 
nitrogen and stored at · 7(J'C. Complement depletion of serum was confirmed according to the 
procedure described by Van Dijk et a!.::::. 
Macrophage elimination with dichloromethylene-phosphonate (CI1MDP) containing 
liposomes Cl:MDP containing liposomes were used to eliminate in vivo macrophage.~ and were 
prepared as described earlicr'-3. Macrophage depleted mice were i.v. injected with 5 or 50 Jl£ 
TNP-Ficoll and killed 7 hr later. Macrophage elimination in the spleen was confirmed, as described 
previousiyB. 
Immunohistochemistry Immunohistochemistry was performed as earlier described~o.:4• 
TNP-Ficoll serum levels TNP-Ficoll serum levels were determined by ELISA. 96 well plate 
were coated with purified SH4.1C9 (5 fLg.ml· 1) in PBS; then blocked with 0.1% gelatin. Seriel 
dilutions of mouse sera were added to wells, followed sequemially by Rabbit anti-TNP, Goat anti-
Rabbit alkaline phosphatase, and substrate (p-nitrophenyl phosphate). Standard curves were prepareq 
from TNP-Ficoll diluted in normal mouse serum. 
RESULTS AND DISCUSSION 
We studied the localization and kinetics of TNP-Ficoll in spleens of BALB/c mice from 5 
min until 21 days after injection:::o (Fig. L2). Already 5 min after injection of 100 f-Lg 
TNP-Ficoll there was a small amount of antigen detectable in the marginal zone. The 
amount of TNP-Ficoll gradually increased in the marginal zone and was slowly spreading 
to the follicular areas. At 2 hr after TNP-Ficoll injection all the splenic follicles were heavily 
loaded with TNP~Ficoll and this remained so for the next 5 hr. Thereafter, the amount of 
follicular TNP~Ficoll decreased gradually, but was still detectable 14 days after injection. 
During the whole experimental period (0 - 21 days) we observed a large amount of 
TNP-Ficoll in the macrophages of the marginal zone. From 40 min up to 2 days after 
TNP-Ficotl injection the amount of TNP-Ficoll in the red pulp gradually increased. 
Thereafter, the localization of TNP-Ficoll in the red pulp decreased gradually and at 21 days 
after injection no antigen was observed in the red pulp. 
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Fig. 1 TNP-Ficoll localization in the spleen 7 hours after i.v. injection. F, follicle; 
M, marginal zone, P, periartcriolar sheath, R, red pulp. 
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Fig. 2 Kinetics of i.v. injected TNP-Ficoll (100 }.Lg) in sera and in splenic compartments of mice. 
TNP-Ficoll concentrations of serum were determined by ELISA The amount of TNP-Ficoll was 
related to the maximal observed amount of TNP-Ficoll in follicle or marginal zone. 
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Two hours after injection we observed a striking decrease of TNP-Ficoll serum levels, 
simultaneously with a marked uptake of TNP-Ficol! by splenic cells (Fig. 2). We found in 
all tested strains of mice a similar localization pattern as we found in BALB/c mice. In a 
previous report we ruled out that antibodies were mediating the follicular localization of 
TNP-Ficoll"'. 
Double staining forB cells and TNP-Ficoll revealed that a part of the injected TNP-
Fico\1 was bound by B cells in the marginal zone, in the follicles and later also in the red 
pulp of the spleen. However, the follicular localization pattern of TNP-Ficoll could also 
represent binding of TNP-FicoH to follicular dendritic cells, as was observed for immune 
complexes later in the immune response. The close contact of B cells and follicular dendritic 
cells hampers the immunohistochemical identification of which cells bind TNP-Ficoll in the 
follicle. 
Complement depletion resulted in a total abrogation of follicular TNP-Ficoll after injection 
of 10 l'g of TNP-Ficoll (table 1). After injection of a higher dose of TNP-Ficoll (100 l'g) 
we observed a substantial reduction of follicular TNP-Ficoll. As the population of 
complement receptor positive B cells in CBNN mice is markedly lower than in BALB/c 
mice25, the similar observed follicular localization pattern after TNP-Ficoll injection together 
with the complement dependency of this localization are more supportive for follicular 
dendritic cells than B cells as the TNP-Ficoll binding cells in the follicles. 
Double staining revealed that TNP-Ficoll was taken up by the macrophages of marginal 
zone and red pulp. Macrophage elimination resulted in a drastic decrease of TNP-Fico\l in 
the marginal zone and red pulp, whereas follicular TNP-Ficoll increased markedly( table 1). 
Table 1. Folli-cular TNP-Ficoll is correlated with humoral TI-2 immune response 
in case of low dose immunizations 
Treatment" CVF CL,MDP 
Dose of TNP-Ficoll (pg) 100 10 50 
Follicular TNP-Ficollb j l 
Humoral immune response ="~ ~ 16 =27 
• Treatment of mice: CVF represents complement-depleted mice and 
C~MDP represents macrophage-depleted mice 
b Follicular localization is related to staining patterns of control 
5 
l 
f ~7 
The above described complement depletion and macrophage elimination techniques enabled 
us to study the role of follicular TNP-Ficoll in the humoral TI-2 immune response (table 
1 ). Matsuda et al.:;6 observed in complement depleted mice, corresponding with a decrease 
in follicular TNP-Ficoll, a significant decrease of the antibody response against TNP-Ficoll 
in case of immunization with 10 p.g of TNP-FicolL In addition. we observed in macrophage 
depleted mice, corresponding with an increase in follicular TNP-Ficoll, a significant increase 
of the humoral immune response against TNP-Ficoll!7. These results indicate that the 
amount of follicular TNP-Ficoll is correlated with the titer of the antibody response against 
relatively low doses of TNP-Ficoll, suggesting a role for follicular TNP-Ficoll in the 
induction of TI-2 immune responses. 
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Fig. 3 Localization of TNP-Ficoll (100 Jlg) in a popliteal lymph node 7 hours after footpad injection. 
DC, deep cortex; F, follicle. 
We also investigated the localization of TNP-Ficoll in popliteal lymph nodes after footpad 
immunization (Fig. 3). We observed the presence of a large amount of TNP-Ficoll in the 
subcapsular macrophagcs and in the macrophages of the medulla. Like in the spleen, we 
found a high amount of TNP-Ficoll in the follicles of the lymph nodes. Gaud et a!.~ 
demonstrated that antibody responses against 11-2 antigens did not occur in lymph nodes. 
Since we found that both macrophages and follicular dendritic cells were binding and/or 
taking up TNP-Ficoll in the lymph node, our results indicate that other factors in the lymph 
node microenvironment, such as a deficiency of specific cytokine-producing cells and/or 
specific subsets of B cells/macrophagcs, may be the cause of this inability. 
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Fig. 4 Localization of Dye I labeled Group B streptococci in the spleen 5 hours after Lv. injection. 
F, follicle; M, marginal zone; R, red pulp. 
After injection of Dii labeled Group B streptococci. a particulate TI-l antigen, we found 
that the bacteria localized, like TI-2 antigens, in marginal zone macrophages and to a lower 
degree in red pulp macrophages (Fig. 4). This is in agreement with experiments of Chao 
and MacPherson:>':~, which suggested that the main function of marginal zone macrophages 
was to clear encapsulated pathogens from the circulation via the Tl-2 antigen receptor. We 
observed hardly any antigen in the follicles, suggesting that only after pre-processing by 
macrophages fragments of the bacterial capsules may be bound by B cells and follicular 
dendritic cells30• 
Based on the available data concerning TI-2 immune responses we have postulated a model 
for 11-2 humoral immune responses30• We hypothesize that the role of marginal zone 
macrophages is not primarily found in antigen-presentation but rather in removal (i.e. of 
TI-2 antigens), killing and pre-processing of particulate antigen/bacteria, whereas fo!licular 
dendritic cells and B cells are most likely involved in the induction of immune responses to 
TI-2 antigens. 
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In Vivo Detection, Kinetics, 
and Characterization of 
lnterferon-y-Producing Cells 
During a Thymus-Dependent 
Immune Response 
An Immunohistochemical Study 
Alfons]. M. van den Eertwegh, Marianne J. Fasbender, 
Wim J. A. Boersma, and Eric Claassen 
TNO Medical Biology Laboratory, Rijswijk, The Netherlands 
Interferon-y (IFN-y) is a cytokine of central importance in the regulation of the immune 
system that also displays nonimmune effects (1). The knowledge concerning the 
mechanisms of production and action of IFN-y is mainly based on in vitro experiments. 
This is somewhat surprising considering the fact that in vitro manipulations like cell 
separation and culture may introduce artefacts and essentially change the microenviron-
ment of the cells. Immunohistochemical techniques, on the contrary, enable the study of the 
cells in their unchanged original microenvironment, which is of great importance, since 
regulation of immune responses by cytokines is most likely a !ocal and strongly com-
partmentalized process. 
There are several reports which describe the detection of cytokine-producing cells at 
the single cell level (2), in human tissues (3-5), and in tissues of mice (6,7) with cytokine-
specific antibodies. In the present study, we investigate the potentials of immuno-
histochemical techniques in the in vivo analysis of a cytokine-mediated immune response. 
Therefore, we conducted an experiment analogous to the in vitro experiments performed 
by Wada et al. (8) and in particular with reference to the in vivo activity and cellular source 
of !FN-y. 
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MATERIALS AND METHODS 
Animals 
van den Eertwegh et al. 
Male BALB/c mice were bred at T.N.O., Rijswijk, The Netherlands, and were used at the 
age of 20-26 weeks. 
Bacteria and Mitogen 
Uve lyophilized BCG (bacille ca!mette-Guerin), a kind gift of Dr. I. Claassen (RIVM, 
Bilthoven, The Netherlands), were killed by exposure to 60°C for 90 min and were 
suspended in phosphate-buffered saline (PBS). Ccncanavalin A (Ccn A) was purchased 
from Pharmacia, Fine Chemicals Inc., Uppsala, Sweden. 
Treatment of Mice 
Three groups of mice were injected i.p. with heat-killed BCG (3.3 x 107) in 400 ~I PBS, 
and stimulated 3 weeks later with 200 11g Con A i.v. Subsequently, mice were bled and 
sacrificed 0, 1.5, 3.0, 4.5, 6.0 hr after Con A stimulation. Three mice were injected i.p. with 
400 ~PBS. Subsequently, these mice were stimulated with 200 )J.g Con A i.v. Control mice 
were treated with PBS. Mice were bled and sacrificed after 3 hr. 
Reagents 
DB-1, a mouse antirat monoclonal antibody (MAb) with a high specificity for mouse 
IFN-y, was a kind gift of Dr. P. H. van der Meide (9). DB-1 was conjugated to alkaline 
phosphatase (AP) according to the procedure described by Claassen et al. (10). The rat 
MAb Lyt-2+ (CDS) (clone 53.6.7.2) (11), L3T4 (CD4) (clone GK-1.5) (12), and MOMA2 
(panmacrophage marker) (13), kindly provided by Dr. G. Kraal (Amsterdam, The Nether-
lands), were used as cell markers. Rabbit antiasialo GM1 serum (natural killer [NK] cell) 
(14) was obtained from VV..A.KO Chemicals GmBh, West Germany. As control antibodies, 
the mouse MAb directed to human immunoglobulin (!g) G1 (clone 3-1.1) (15) and lgG3 
(clone 330-2.2) (16) conjugated to alkaline phosphatase (AP) were used. Second-step 
conjugates were rabbit antirat conjugated to horseradish peroxidase (HRP) (Dakopatts, 
Copenhagen, Denmark) and goat antirabbit-HRP (Miles-Yeda, Ltd., Rehovot, Israel). 
Immunocytochemistry 
Spleens were removed and snap-frozen in liquid nitrogen. Cryostat sections (8 ~-tm) were 
fixed for 10 min in fresh acetone, containing 0.02% H202. Slides were rinsed with PBS and 
incubated overnight at 4°C with Db-1-AP. For the double-staining experiments, Db-l-AP 
was simultaneously incubated with one of the above-described reagents. Slides were again 
washed with PBS and incubated for 30 min at room temperature with second-step con-
jugates. Sections were washed three times with PBS and histochemical revelation of AP 
was performed prior to the histochemical revelation of HRP, as described previously (10). 
Slides were counterstained with hematoxylin for 15 sec, and mounted in glycerol/gelatin. 
IFN-yELISA 
Serum samples were assayed for IFN-y according to the procedure described by Cher-
winski eta!. (1 7). 
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RESULTS AND DISCUSSION 
We investigated cryostat sections of spleens of three groups of BALB/c mice after priming 
with heat-killed BCG and stimulation with Con A. After incubation with DB-l-AP and 
histochemical revelation the IFN-y-producing cells characterized by a blue cytoplasm, 
were detected (Fig. la). No staining was seen in control slides from any specimen treated 
by omission or substitution of primary antibody. Preincubation of DB-l-AP with IFN-y 
completely abolished the cytoplasmic staining. The IFN-y-producing cells were found in 
small clusters of two to five and were located in the T-cell-dependent areas like the 
periarteriolar lymphocyte sheaths and the coaxial sheaths of lymphoid tissue surrounding 
the terminal arteriolar branches (Fig. lb). Analysis of the kinetics of the IFN-y-producing 
cells showed that the maximum number of IFN-y-producing cells was detected in spleens 
of BCG-primed mice that were not stimulated with Con A (Fig. 2). The IFN-y-producing 
cells in the Con A-stimulated and BCG-primed mice had an enlarged cytoplasm, staining 
more intensively than in the unstimulated BCG-primed mice, suggesting an increased 
IFN-y production. In unprimed mice there were hardly any IFN-y-PC detectable at 0 and 
3 hr after Con A stimulation. The kinetics of the IFN-y serum levels and of the IFN-y-
producing cells developed according a similar pattern after the first 4.5 hr of Con A 
stimulation (Fig. 3). However, the IFN-y serum levels of mice 6 hr after Con A stimulation 
showed a striking increase, whereas the number of IFN-y-producing cells remained at the 
same level. 
Possibly the BCG sensitizes a part of the spleen cells to produce and secrete IFN-y in 
low concentrations. Con A may stimulate these cells to assemble and secrete IFN-y in 
larger quantities, causing an increase of the IFN-y serum levels after 6 hr. Double staining 
of the spleen sections for IFN-y and surface antigens revealed that :t 60% of the IFN-y-
producing cells were expressing the CD4 antigen (see Fig. lc) and :t 30% the CDS antigen. 
NK cells and macrophages producing IFN-y were not demonstrated. These results are 
in agreement with the experiments of Wada et al. (8), who found in BCG-primed and 
Con A-stimulated mice, after in vivo T -cell depletion with :MAb, that T cells were the 
principal cells directly or indirectly responsible for the IFN-y production, without important 
participation of macrophages and NK cells. In our experiments we demonstrated directly 
in vivo that T cells were the main IFN-y producers in the immune response to heat-killed 
BCG. 
In conclusion, this study demonstrates the potentials of the immunohistochemical 
approach in the in vivo analysis of a cytokine-mediated immune response. We 
demonstrated its value for the investigation of the in vivo activity of IFN-y in a thymus-
dependent immune response. Moreover, this technique enables the study of the in vivo 
localization and cellular origin of IFN-y. Provided that specific antisera are available, 
this method is also suitable to detect and characterize other cytok.ine-producing cells 
in vivo, thereby opening the way for validation of in vitro findings. Furthennore, this 
technique will facilitate, in combination with other techniques, the analysis of the 
local events and interactions of B-, T -, and antigen-presenting-cells during an in vivo 
immune response. 
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Figure 1 (a) IFN-y-producing cells in a cryostat section of a spleen of a BCG-primed and 
Con A-stimulated mouse. Section was incubated with DB-l-AP (MAb specific for IFN-y) and after 
AP cytochemistry the IFN-y-producing cells with a blue cytoplasm were detected. Sections were 
counterstained with hematoxylin. For double-staining experiments, the sections were simultaneously 
incubated with DB-l-AP and rat MAb directed to different cell markers. followed by rabbit antirat-
HRP. (b) After AP and HRP cytochemistry, the IFN-y-producing cells and macrophages (110MA2) 
were detected. Note the IFN-y-producing cells in the coaxial sheath of lymphoid tissue surrounding 
the terminal arterioles in the spleen. (c) After AP and HRP cytochemistry, the IFN-y-producing cells 
(cytoplasmic staining) and CD4 (membrane staining) were detected. 
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Figure 2 Kinetics of the IFN-y-producing cells in spleens of mice after BCG priming and Con A 
stimulation. BALB/c mice were primed Lp. with heat-killed BCG (3.3 x 107) and stimulated i.v. with 
200 f.lg Con A 3 weeks later. Subsequently, mice were sacrificed at the indicated intervals. Control 
mice were injected i.p. with 400 !-ll PBS. The INF-y-producing cells in cryostat sections of spleens 
were stained and counted. Data presented are expressed as the mean :1:: SD of three different mice from 
each group. 
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Figure 3 Kinetics of the IFN-)' serum levels of mice after BCG priming and Con A stimulation. 
BALB/c mice were primed i.p. with heat-killed BCG (3.3 x 107) and stimulated i.v. with 200 flg 
Con A 3 weeks later. Control mice were injected i.p. with 400 f.1l PBS. Subsequently, mice were bled 
at the indicated intervals. Sera were assayed for IFN-y by a two-site sandwich EUSA. Data presented 
are expressed as the mean± SD of three different mice from each group. 
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Using immunohistochemical techniques, we stud-
ied IFN-')'-producing cells (IFN-')'-PC] in vivo during 
immune responses to thymus-independent type-2 
(TI-2) Ag. Detection of IFN-1'-PC in cryostat sections 
of spleen-tissue was performed with an enzyme la-
beled mAb directed against IFN-1'. After TNP-Ficoll 
immunization, IFN--y-PC and TNP-specific antibody-
forming cells (TNP-AFC] displayed similar kinetics 
reaching a maximum number at day 5 to 7. The IFN-
-y-PC were localized in the same compartment as 
TNP-AFC and a part of them in juxtaposition to TNP-
AFC. Immunization with other TI-2 Ag resulted also 
in a significant increase of the number of IFN-')'-PC. 
In a parallel experiment we found both in vivo and 
in an ELISA-spot assay a significant increase of the 
number ofiFN--y-PC and IFN--y-spot-forming-cells, re-
spectively, in spleens of mice 6 to 7 days after TNP-
Ficoll immunization. Double staining of spleen sec-
tions for IFN--y and surface Ag revealed that 5 to 7 
days after TNP-Ficoll immunization, ± 40% of the 
IFN-')'-PC expressed the MT4 Ag (CD4), ± 50% the 
Lyt-2+ Ag (CDS) and± 10% the asialo-GMl Ag (NK 
cell). This study represents the first description of 
the in vivo activity and characterization of IFN--y-
PC during a TI-2 immune response. Moreover, the 
presented data confirm suggestions from in vitro 
investigations that IFN-1' and T cells may play a 
direct role in the in vivo regulation of a primary 
immune response against a TI-2 Ag. 
The spleen plays an important role in the protection 
against Streptococcus pneumoniae, Neisseria menin-
gitides, and Haemophilus ir!f1-uenzae, for example (1). 
After splenectomy patients are at high risk for fulminant 
infections due to these bacteria. The protective immune 
response against these microorganisms is directed 
mainly against the polysaccharide component of the bac-
terial capsule, classified as a Tl·22 Ag (2). The original 
definition of TI Ag reflects Its ability to stimulate humoral 
immune responses in nude mice in vivo or in T cell-
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Depleted cultures in vitro. These criteria are relatively 
nonstringent insofar as nude mice and the T cell-depleted 
cultures have been shown to possess both small numbers 
ofT cells as well as large numbers of NK cells. which are 
able to secrete cytokines (3. 4). Rigorous elimination ofT 
cells consistently and significantly reduces the in ,·;tro 
immune response to TI Ag. indicating that these Ag are 
T cell dependent to a significant degree (5-7). The. rr Ag 
are divided into type 1 and type 2 (TI-2) Ag. based on their 
ability to stimulate an immunodeficient strain of mice 
[CBA/N) to produce antibodies (8-10). The most common 
and extensively studied Tl-2 Ag is TNP-Ficoll. As purified 
cytokines and antibodies directed to cytokines became 
available, their role in the immune response to TNP-Ficoll 
has been evaluated. Addition of IL-l to cultures of lymph 
node cells plus TNP-Ficoll appeared to induce an increase 
in the number of TNP plaque-forming cells (11. 12). 
Several reports have shown that responses of purified 
populations of B cells to TNP-Ficoll were reduced mark· 
edly. compared with unfractionated spleen cells. and that 
their responsiveness could be restored by addition of IL-
2 or T cells (3. 13). In contrast. IFN·-y reduced signifi· 
cantly the number of TNP plaque-forming cells and in-
hibited thymidin incorporation in cultures of TNP-spe-
cific B cells. suggesting that the suppressive effect on the 
TNP-Ficoll response is mediated. at least in part. by 
inhibition of the clonal expansion of TNP-Ficoll respon-
sive cells (5). These in vitro experiments demonstrated 
that IFN--y could play a downregulating role in TI-2 im-
mune responses. However, these studies did not investi-
gate the active participation of IFN--y in in vivo Tl-2 
immune responses. In in vivo experiments, in contrast to 
in vitro experiments, there is no need to use manipula· 
tions like cell separation and culture, which may intro-
duce artefacts and change essentially the context of im-
mune cells. Furthermore, in vivo experiments, by means 
of immunohistochemical techniques, enable the study of 
immune cells in their natural context that is of great 
importance because regulation of immune responses by 
cytokines is predominantly a local and compartmental-
ized process (14). Therefore we conducted an in vivo study 
to the origin and activity of IFN--y in the immune response 
to TI-2 Ag by means of immunohistochemical techniques. 
Several reports have described the detection of cytokine 
producing cells at single cell level (15), in human tissues 
(16-18) and in murine tissues (19, 20) with cytokine 
specific mAb. The present study details the in vivo detec-
tion, localization, kinetics and characterization of IFN--y-
PC during a primary TI-2 immune response. Evidence 
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that IFN--y and T cells are active in the primary in vivo 
Immune response to TNP-Ficoll is presented. 
MATERIALS AND METHODS 
Mice. Female BALB(c mice were bred at TNO. Rijswijk. The Neth-
erlands and were used at 12 to 16 wk of age. 
Chemlca.!s. AP {P-6774, type VII-T. 1020 U/mgproteln). 3-amlno-
9-ethylcarbaz:ole (A-5754). 5-BCIP (5-bromo-4-chloro-3-indolyl-
phosphate; B-8503), Fast blue BB Base (F-125), levamtsole, naphthol 
AS MX phosphate (3-hydroxy-2-naphtolc acid 2.4-dlmethyl-an!llde). 
phosphatase substrate (Sigma I 04, Sigma Chemical Co., St. Louts. 
MO). TNP sulfonic acid [TNBS, grade I) were obtained from Sigma. 
Con A was purchased from Pharmacla Fine Chemicals Inc .. Uppsala. 
Sweden. All other reagents were analytical grade or better. 
Ag. TNP·Ftcoll was prepared as previously desci1bed {21). TNP-
HES was a kind gtft from the late Prof. J. Humphrey. Royal Post-
graduate Medical School, London (22). Tl-2 Ag charactenst!cs based 
on the spec!flc local!zation pattern In marginal zone macrophages 
were checked, as we described before (23). Dextran 81355 was a 
kind gtft of Dr. J. Blomberg, Untverstty of Uppsala. Department of 
Immunology. Uppsala. Sweden (24]. All the polysaccharides were 
extensively dlalysed against PBS before administration. 
Antibodies. The murine mAb DB-I and DB-2. specific for rat IFN-
'Y and cross-reacting wtth murine !FN--y, and affinity chromatogra-
phy-pui1f1ed rat r!FN-,. were a kind gtft of Dr. P. H. van der Meide 
{25. 26). TNO Institute for applied Radiobiology and Immunology. 
RijswiJk. The Netherlands. Controls consisted of lsotype and concen-
tration-matched mAb directed to human IgGl (27) and IgG3 (28). 
The mAb XMG1.2 and XMG6.1. directed to murine lFN--y. were a 
kind gift of Dr. R. L. Coffman (29]. DNAX Research Institute. Palo 
Alto. CA The rat mAb MOMA-2. which recognizes monocytes and 
macrophages (30]. and cells of the rat hybi1domas Lyt-2+ {53.6.7), 
which marks the CD8 subset of T lymphocytes {31) and MT4 
(H129.9). which recognizes the CD4 subset ofT lymfocytes {32) were 
a kind gift of Dr. G. Kraal. Free University. Amsterdam, The Neth-
erlands. Hybi1domas were grown in RPM! 1640 with 10% FCS and 
obtained antibodies were purified from culture supernatants using 
affinity chromatography wtth a goat anti-rat Ig column. Rabbit anti-
A.GMl serum was obtained from WAKO Chemicals GmbH. FRG 
{33). Rabblt-HRP anti-rat lg. Rabblt-HRP anti-mouse lg, rabbit-per-
oxidase antt-peroxtda~ complex. Dakopatts. Copenhagen. Denmark 
and goat-HRP antl-rabbit-Ig. Mlles-Yeda Ltd .. Rehovot. Israel were 
used as secondary antibodies. AP-conjugated goat anti-mouse lgM 
(or lgM + lgG] was obtained from Tago. Burl!ngame, CA 94010. 
Streptavtdtn-AP conjugate was obtained from Jackson Immuno Re-
search Labs. West Grove. PA. 
Preparation HRP(AP conjugates. DB-1 and control mAb were 
conjugated to AP and HRP as prevlously desci1bed {34). TNP-AP was 
prepared as described before {35). 
Experimental design. BALB/c mice were Injected t.v. either with 
16 ~ TNP-Ftcoll. 20 ~TNP-HES. 20 l'g Dextran 81355, or wtth 20 
~ (unhaptenated) Ftcoll In 200 !'l PBS. The TNP-Ficoll Immunized 
mice (three mice/day) were anaesthetized, bled, and k!lled Immedi-
ately thereafter and 1. 3. 5, 7, 10, 14. 21 days after Immunization. 
Mice (five mice/day) Injected wtth TNP-HES. Ftcoll, and PBS were 
ktlled after 5 and 7 days. Dextran B1355 Injected mtce {five mtce( 
day] were ktlled after 4. 5, 6. and 7 days lmmunlzatlon. Spleens were 
removed and Immediately frozen Ln liquid nitrogen and stored at 
-70'C tf not used Immediately. Sera were stored at -20'C. 
Immunostalning. Cryostat secttons of spleens. one of every 
mouse, (-20'C. 8 Iilli] were picked up on the same glass slide and 
kept overnight under high humidity at room temperature. Slldes 
were air di1ed and stored In air-tight boxes at 4'C unt!l use. Cryostl1,t 
sections were fixed for 10 mtn in acetone (p.a.) containing 0.02% 
H20 2 {freshly prepared]. Subsequently sl!des were rinsed wtth PBS 
and Incubated horizontally overnight at 4'C with reagents (081-AP. 
and/or MT4 or t..yt-2+ or MOMA-2 or antl-asialo-GMl). All reagents 
were diluted in PBS containing 0.1% BSA and titrated to obtain 
optimal results. Subsequently, slides were washed with PBS {three 
times for 5 min) and Incubated for 30 min at room temperature with 
secondary conjugates diluted optimally In PBS containing 0.1% BSA 
and 1% normal mouse serum. Histochemical revelation of the AP 
activlty was done according to Claassen and Adler {34). Thereafter 
sUdes were washed with PBS. and HRP acttvlty was demonstrated 
as previously descnbed {34). Detection of TNP-AFC was performed 
as described before {21]. BI1efly. spleen sections of TNP-Ftcoll Im-
munized mice were Incubated. hortzontally overnight at 4'C, wtth 
TNP-AP {10 l'g·ml"1)1n PBS+ 0.1% BSA and treated for AP histo-
chemistry. 
Inhibition assay qJ JFN-y specific staining. A total of 25 p.g-ml"' 
of t]1,e conjugate DB-l-AP was prelncubated with d!luttons {12.5-
200 l'g-ml-') of affinity pui1fted JFN-y for 2 h in the presence of 
0.1% BSA. Subsequently. this solution was centi1fuged (12,000 x g) 
for 2 min and acetone-fixed cryostat sections of spleens of three 
different mice. 5 days after TNP-Flcoll Immunization, were incu-
bated with supernatants overnight at 4'C. After histochemical rev-
elation, the stained cells were quantitated by laser-scan microscopy. 
Quantltatlon of IFN-y-PC and TNP·AFC. The image of each 
spleen-section was acquired with an HTHMX-1 camera {Htgh Tech-
nology Holland bv, Eindhoven. The Netherlands]. By means of Image 
analysis (MCID software; Imaging Research Inc .. Brock University-
St. Cathartnes. Ontano. Canada] the total stzeof every spleen section 
In mm2 was determined {36). The number of IFN--y-PC or TNP-AFC 
was determined by laser scan microscopy {LSM-41: Carl Zeiss. Ob-
erkochen. FRG] interfaced to a Micro Dutch-100 computer for data 
acquisition and processing (37). A He-Ne laser scanned the micro-
scopic fields of spleen sections {sections of all mice within one 
expei1ment were picked up on the same glass sllde). Transmltted 
light was received by a photo multiplier and digitized (eight bit) in a 
format of 512 x 512 pixels, each with a range of 255 possible gray 
values representing the amount of absorbed light. The images were 
displayed on a high resolution black and white monitor, to make real 
Ume(on line control of data acquts1t!on possible at all times. Image 
analysis was performed by the Technical Command Language-image 
processor (developed by TNO-TPD. Delft. The Netherlands, in collab-
oration wtth the Technical University of Delft). The total stained 
surface of every spleen section was measured. The mean staining 
per cell was determined by analyzing 500 TNP-AFC or 500 lFN--y-
PC. respectively. The number of IFN-y-PC or TNP-AFC was calcu-
lated by the dtvlsion of the total spleen .<>talntng by the mean cell 
staining and was expressed as the number of IFN--y-PC or TNP-AFC 
per mm2 spleen section. Five spleen sections of each mouse were 
analyzed. 
Detection of serum TNP-speciftc antibody levels. Serum antibod-
ies to TNP were determined by means of a direct ELISA, as described 
previously {38]. 
Preparation of cell suspensions. Spleens were aseptically re-
moved and single cell suspensions were prepared by gently teasing 
them through nylon gauze filters Into balanced salt solution (39). 
Concentrations of spleen cells were determined with a Coulter Coun-
ter {Coulter Electronics. Luton. U.K.). 
Enumeration IFN--y-spotjormtng cells. To quantitate the fre-
quency of IFN--y-spot-formtng cells. an ELISA-spot assay was used 
according to the procedure desci1bed by Tagucht et a!. (40) with 
minor modifications. BI1efly. mtcrottter plates were coated overnight 
at 4'C wlth 100,..! of l1<g XMG1.2.ml" 1 In PBS, followed by blocking 
with 150 1'1 PBS containing 1% BSA for 30 min at 37'C. Spleen cells 
{l x lO~to 1 x 10"/well)suspended In RPM! plus I% BSA were added 
to individual wells and stimulated with Con A {5 Jtg· ml"'l- Cells were 
Incubated for 3 hat 37'C with 5% CO, in air. The plates were washed 
once with H00 plus 0.05% Tween-20 and three times wtth PBS 
containing 0.1% BSA plus 0.05% Tween-20 and Incubated overnight 
at 4'C wtth 100 111 of 0.2 11g XMG6.1-btotln·ml"' In PBS containing 
0.1% BSA and 0.05% Tween-20. Subsequently plates were washed 
three times wtth PBS containing 0.1% BSA plus 0.05% Tween-20 
and incubated with 100 1<l of a I/1800 dtlutton of a streptavldln-AP 
conjugate in PBS containing 0.05% Tween-20 plus 0.1% BSA for 
120 min. Trays were washed ftve times with PBS containing 0.1% 
BSA plus 0.05% Tween-20. Spots representing single IFN--y-secret-
tng cells were developed wtth 100 1'15-BCIP {10 mg. ml-'] in 2-amtno· 
2·methyl-l propanol buffer. pH 10,25. The number of spots was 
enumerated with the aid of a dissecting microscope. 
ELISA for serum IFN--y. Serum samples were assayed tn duplo 
according to the procedure as desci1~d for the ELISA·spot assay. 
Instead of spleen suspensions serum samples and mouse riFN--y 
standards diluted In RPM! plus I% BSA were added to each well. 
Absorbance was measured as desci1bed for the antl·TNP ELISA. 
Statistical evaluation. Results were analyzed by the two-sample 
Student's t-test for comparison of two empii1cal means tn a normally 
distributed population. 
RESULTS 
Detection of IFN-"(-PC. We Investigated cryostat sec-
tions of spleens of BALB/c mtce 0 to 21 days after TNP-
Ficoll immunization. After Incubation with the conjugate 
DB-l-AP and histochemical revelation, the lFN--y-PC 
characterized by a blue cytoplasm were detected (Fig. la). 
No statntng was seen in control slides from any specimen 
treated by omission or isotype matched substitution of 
prtmary antibody. To vertfy the specificity of the staining, 
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Figure 1. Immunohistochemical vls-
;allzatlon and characterization of IFN-"1-
PC and/or TNP-AFC In spleens of TNP-
Ficalilmmunlzed mice. a, Cryostat section 
was Incubated with DB-l-AP and after AP 
cytochemistry the IFN--y-PC with a blue 
cytoplasm could be seen around the ter-
minal arteriole. Section was counter-
stained with hematoxylin. For double 
staining experiments the sections were 
Incubated simultaneously with DB-l-AP. 
and antibodies directed to different cell 
markers, followed bv secondarv HRP-con-
jugates. AP and HRP cytochemistry re-
vealed: b to d. JFN-"!·PC {blue cytoplasm), 
C04 cells (red membrane staining) In the 
PALS and C04 cells producing IFN--y {dou-
ble-stained cells) around the terminal ar-
terioles. c to d, The difference between a 
single stained cell(d) and a double stained 
cell (c] was appreciated best under high 
power magniflcal!on {X2000). e toj, Over-
view and detail of IFN-"I·PC (blue cyto-
plasm) In red pulp, COB (red membrane 
staining) predominantly in PALS and COB 
cells producing !FN-"1 (double-stained 
cells) In PALS, red pulp, and terminal ar· 
ter1oles. g. Cryostat section was incubated 
wllh rabbit·HRP antl·IgG±M and HRP cy· 
tochemlstry was performed. Subse· 
quently this section was mcubated with 
DB-l-AP and AP cytochemistry was per-
formed. JFN-rPC (blue cytoplasm) were 
localized around terminal arterioles. 
PALS. and red pulp. Note the absence of 
IFN·y-PC In the follicle (within white rim!. 
h. Crvostat secuon was incubated with 
08-l:HRP and TNP-AP fallowed by PAP 
After cytochemistry lFN·"f·PC (red cyto-
plasm! were found juxtaposed to TNP-AFC 
'blue cytoplasm!. c, central arteriole:]. fol-
1\cle: m, marginal zone: op. outer PALS: p. 
PALS: r. red pulp: 1. terminal arteriole. 
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we performed a competition and an inhibition assay on 
spleen sections of mice 5 days after TNP-F!coll immuni-
zation. Simultaneous incubation of DB-l-AP (20 ~g·ml- 1 ) 
with DB-2 (2000 ~g-ml-'). a mAb directed to the sarrie 
epitope as DB-I. eliminated completely the staining of 
the IFN-,.-PC. The ratios of the concentrations of the 
competing mAb in this assay. were similar to the ratios 
used in a competition ELISA. previously described by Van 
der Meide et al. [26). Preincubation of DB-I (25 ~g-ml- 1 ) 
with IFN-I" (200 ~g-ml- 1 ) completely abolished the cyto-
plasmic staining of the IFN-,.-PC in these spleen sections. 
Preincubation of D8-1 with lower concentrations lFN-,. 
resulted in the detection of only a part of the IFN-r-PC 
that were observed after preincubation with PBS (Fig. 2). 
Localization qf IFN--y-PC and TNP-AFC. Morphologi-
cally. the spleen can be divided in red and white pulp. 
The red pulp consists of E and all types of nucleated cells 
such as lymphocytes, megakaryocytes. and macro-
phages. The splenic white pulp consists of three major 
compartments (38). The PALS, the major T cell area. 
surround the central arteries and branch off terminal 
arterioles, that traverses through the different compart-
ments of the white pulp toward the red pulp. The follicles 
are globular structures attached to the PALS and contain 
mainly 8 cells. The marginal zone surrounds the PALS 
and follicles and contains B cells. macrophages. and 
relatively few T cells. Neutral polysaccharides, Tl-2 Ag. 
are almost exclusively retained in the marginal zone mac-
rophages, suggesting that this compartment may play an 
important role in the processing and presentation of Tl-
2 Ag (23). As described in previous studies (21), we found 
TNP-AFC predominantly in the lymphocyte sheaths 
around the terminal arterioles. in the outer parts of the 
PALS. whereas relatively few were located in the red pulp. 
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Figure 2. !nhlb!Uon assay of IFN-,-speclfic staining. A total of 25 l'g' 
mr' of the mAb DB-1 was pre-Incubated w1th the indicated dilutions (0-
200 ~-ml"'l of IFN--r for 2 h tn the presence of 0.1% BSA. S<.~bsequently 
the solutions were centrifuged at 12.000 x g for 2 min and cryostat 
sections of spleens of mice 5 days after TNP-Ftcoll lmmuntzat!on were 
Incubated with supernatants. After lmrnunohlstochem!cal revelation the 
number of !FN--y-PC were quantitated by lase;-scan microscopy as de-
scrtt>ed In Materials and Methods. Data presented are expressed as the 
mean± SD of three different mice. 
Figure 3. Kinetics of the IFN-r-PC In spleens of mice after TNP-Ficoll 
Immunization. BALB/c mice were Immunized Lv. with 16 l'g TNP-Ficoil 
and killed after 0 to 21 days. Subsequently the INF·""r·PC in cryostat 
sections (five of each mouse) were stained and quantitated by laser-scan 
microscopy as described in Materials and Methods. Data presented are 
expressed as the mean± SO of three different mice from each group. 
In our experiments the IFN-")'·PC were usually found in 
clusters of two to eight cells in the same compartment as 
the TNP-AFC. Double staining demonstrated that a part 
of the IFN--y-PC were in direct cell contact with the TNP-
AFC (Fig. lh). No IFN--y-PC were observed in the follicles 
and marginal zone. The IFN--y-PC were found in roughly 
the same numbers in each section throughout the entire 
spleen. Double staining for mouse IgG + IgM and IFN--y 
showed that IFN--y-PC were juxtaposed to antibody-form-
ing cells and were not found in 8 cell areas like follicles 
(Fig. lg). 
Kinettcs of IFN--y-PC. IFN--y-PC were quantitated by 
laserscan microscopy. As shown in Figure 3., hardly any 
IFN--y-PC were detectable 0 to 3 days after immunization 
with TNP-Ficoll. Thereafter, thenumberofiFN--y-PC cells 
increased very rapidly and reached its maximum at day 
5 to 7. Ten days after TNP-Ficoll immunization. the 
number of IFN--y-PC was markedly decreased and re-
mained at this level for the next II days. The effect of 
various polysaccharides on the number of IFN-"'(-PC in 
spleens of mice is shown in Table I. The number of IFN-
-y·PC in spleens of mice injected with the unhaptenated 
Ficoll was not different from the PBS-injected mice. In-
jection of TNP-HES resulted In a significant increase of 
the number of IFN--y-PC in spleen sections of mice 5 and 
7 days after immunization. Dextran 81355 immunized 
TABLE I 
IFN·""r-PC in spleen sections qfter administration qf uar!ous 
po!!Jsacchartdesa 
TNP·Flcoll 
TN?·HES 
Dextran Bl355 
Flcoll 
PBS (control) 
8.6" ± 1.2' 
7.6 ± 1.0" 
3.7 ± o.r 
1.1 ± 0.3 (NSJ 
1.2 ... 0.4 
~" 
8.0:!: 0.6" 
4.6 ± 0.3" 
1.9:!: 1.8 (NS) 
0.7 ± 0.3 (NS) 
0.8 ... 0.3 
GBALBfc mice were injected l.v. w1th (non·)haptenated polysaccha-
rides. Mice were killed and spleens were removed at the indicated Inter-
vals. Cryostat sections were stained and IFN·""r·PC were quantitated ac· 
cording to procedure described In Mater!a/s and Methods. 
"Number of IFN·""r·PC/mm0 of spleen section ± SD. 
<Statistical evaluation was performed by the two sample Student"s t· 
test. p value against control. 
"p<O.OOl. 
mice showed a significant increase of the number of lFN-
-y-PC after 4 (2.9 ± 0.5), 5 (3.7 ± 0.7). and 6 (4.4 ± 0.3) 
days. 
Phenotypic characterization qf IFN--y-PC. To deter-
mine the origin of IFN·-y. spleen sections were simulta-
neously incubated with DB-l-AP, and antibodies toNK-
cells or CD4 cells or CDS cells or macrophages. followed 
by secondary antibodies conjugated to HRP. Whereas 
cells with a blue cytoplasm were IFN--y-PC. cells with a 
red membrane staining expressed the CD4 or CDS or NK 
cell Ag (Fig. l, b, e. and .fl. Thus, double stained cells, 
characterized by a violet cytoplasm were either NK cells 
(not shown) or CD4 (Fig. 1, band d) or CDS cells (e andj) 
producing IFN--y. The double stained cells were appreci-
ated best under high power magnification (Fig. 1, c and 
d). Light microscopic quantitation revealed that during 
the peak of the response (day 5-7) 3S.6(± 21.6)% of the 
lFN--y-PC were CD4. 49.4(± 19.2)% were CDS and 9.6(± 
4.8)% were NK cells. We investigated the kinetics of 
separate celltypes producing IFN--y at different stages 
during the immune response to TNP-Ficoll (Fig. 4). As 
presented in Table II, we found that during the entire 
immune response to TNP-Ficoll the majority of the IFN-
)"·PC were CD4 or CDS cells. The total number of IFN--y-
PC per section was in the same range as the total double 
stained IFN-...,-PC, indicating that the majority of the IFN~ 
-y-PC were expressing the above mentioned surface mark-
ers. No cells were double staining for MOMA-2 and IFN-
,. 
Kinetics of TNP-AFC. As previously described (21), the 
number of TNP-AFC began to rise 3 days after TNP-Ficoll 
immunization and attained maxima 5 to 7 days after 
immunization. Thereafter the number of TNP-AFC de-
creased gradually. 
Anti-TNP serum levels. The anti-TNP IgM response to 
TNP-Ficoll strongly increased after day 3 and reached a 
peak at days 7 to 10. The anti-TNP IgG response in-
creased gradually after day 5 but remained low as com-
pared to the IgM response. 
Number of IFN--y-SFC and IFN--y-PC 6 and 7 days 
after TNP-Ficoll immunizatlon. We assessed both in vivo 
and in vitro the number of cells producing IFN--y in 
spleens of mice after TNP-Ficoll immunization. Therefore 
we quantitated the number of IFN--y-PC, detected by im-
munohistochemistry, in one half of each spleen. and the 
number of IFN--y spot-forming cells. by means of an 
ELlSA-spot assay. in the other half of each spleen (eight 
mice/day). The control mice were injected with PBS. As 
demonstrated in Figure 5. the in vitro Con A stimulated 
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Figure 4. Klnet!cs of separate cell types producing INF-1' in spleens of 
mice after TNP-FlcolllmmunlzaUon. BALB/c mice were immunized l.v 
with 16 ~tgTNP-Ficoll and kllled after 0 to 21 days. Subsequently cryostat 
sections were simultaneously Incubated with antibodies specific for IFN-
1' and the Indicated cell markers. After lmrnunohlstochemical revelation 
the single and double stained cells were counted. Data presented are 
expressed as the mean= SD of three different mice from each group. 
splenocytes of the control mice were already producing 
IFN-I' in the ELISA-spot assay, whereas hardly any IFN-
-y-PC in spleens of these mice were found. After TNP-
Ficoll immunization the number of IFN--y-SFC in vitro as 
well as the number of IFN--y-PC in vivo increased signif-
icantly on days 6 and 7 (Fig. 5). 
IFN-1 serum levels. To investigate whether IFN--y pro-
duction was also detectable at systemic level, we meas-
ured IFN--y serum levels of TNP-Ficoll immunized mice 
and controls. Only in two mice, at 7 days afterTNP-Ficoll 
immunization, an increase of the lFN--y serum level was 
found (310 and 455 ng-ml- 1). All other TNP-Ficoll im-
munized mice had IFN--y serum levels similar to controls 
(5-15 ng-ml- 1) (data not shown). 
DISCUSSION 
In this study we demonstrated in vivo that IFN-1 is 
active during immune responses to various TI-2 Ag. More-
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over, we showed that IFN--y-PC and TNP-AFC display 
similar kinetics and are localized in the same compart-
ment. A part of the IFN-y-PC were juxtaposed to TNP-
AFC. T cells were the main source of IFN--y during the 
immune response to TNP-Ficol!. 
The original classification of TI Ag was based on their 
common ability to induce immune responses in nu/nu 
mice. Antibody responses to TI-2 Ag were later shown to 
beT cell regulated. IL-l and IL-2 appeared to promote the 
Tl-2 immune response, whereas IFN--y suppressed the in 
vitro immune response to TI-2 Ag (5-7, 11-13). However, 
these studies did not show that lFN--y participated ac-
tively in in vivo Tl-2 immune responses. Therefore we 
•investigated the in vivo IFN--y production of spleen cells 
during TI-2 immune responses. Cleveland et al. (19) 
found, using indirect immunofluorescence techniques, 
an increased in vivo JFN-1 production in spleens of mice 
undergoing graft vs host disease. However, in their in 
vitro experiments they observed no increased IFN--y pro-
duction. They demonstrated that this discrepancy was 
due to the mixing of different cell populations, which 
destroyed the relative separation of these populations and 
changed their microenvironment These data suggested 
that in vitro studies may not always truly represent the 
in vivo immune status of an animal. These studies and 
the fact that immunohistochemical techniques enable 
the investigation and characterization of immune cells in 
their original histologic context are the reasons for using 
these techniques . 
After immunization of BALB/c mice with various Tl-2 
Ag, IFN-1-PC were identified in spleen sections with an 
AP-labeled mAb (DB-1) specific for IFN--y (Fig. la). The 
specificity and affinity of DB-I has been extensively 
tested by Vander Meide et al. (25). Previously Ljungdahl 
eta!. (42) used DB-1 for the in vivo detection of IFN--y in 
the central nervous system of the rat. To validate the 
specificity of DB-1 for the detection of IFN--y in murine 
tissue sections. a number of controls and verifying ex-
periments were included in this study. In our experi-
ments, the substitution or omission of DB-l-AP resulted 
in a lack of staining. Additional evidence for the specific-
ity of this staining was provided by preincubation of DB-
l-AP with IFN--y. that resulted in a complete inhibition 
of the staining of IFN--y-PC (Fig. 2). Simultaneous incu-
bation with DB-2 completely abolished the staining of 
lFN--y-PC. In our studies the cytoplasm of IFN--y-PC 
stained intensively. The possibility that cytoplasmic 
staining represents uptake of IFN--y rather than produc-
tion, has already been n1led out previously by Andersson 
et al. (43). They observed that incubation of mononuclear 
cells with high concentrations of JFN--y did not lead to 
any detectable IFN-1 staining. Moreover, the kinetics and 
localization of IFN--y-PC we found after TNP-Ficoll im-
munization is also more suggestive for IFN--y production 
than uptake. Administration of the same amount of un-
haptenated Ficoll did not result in an increase of the 
number of IFN--y-PC, indicating that haptenization of an 
intrinsically poor immunogen such as Ficoll (44) is re-
sponsible for the increased IFN--y production, as ex-
pected. The number of IFN--y-PC induced by dextran 
81355. an unhaptenated TI-2 Ag, was lower than found 
in mice after immunization with the same amount of 
TNP-haptenated TI-2 Ag (Table I). This is possibly due to 
the less potent immunogenicity of this polysaccharide as 
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TABLE II 
Actual number q[ /FN·"t·PC per spleen section dlspla!Jlng the sw:face Ag 1 to 21 days after TNP-Ftcolllmmunizatlon" 
Phenotype Day 5 7 10 14 21 
Aslalo-OMl l.:tl" 1:!:1 4±2 4±1 2±> 1± I <±' 
MT< 0±0 2:tl 14±7 18:!: 9 6:t3 Z:tl 2::t2 
LYT2+ >±O 2±1 23 ±8 19:!: 3 4.:!:2 5 .:':: 4 1:!:1 
MOMA-2 0 0 0 0 0 0 0 
Total double stained cells' 
" " " ' 
Total number of lfN-r-PCa 2±> <±2 46 ... 12 37± 8 11 :1: 5 ,., o± 2 
~Three groups of BALB/c mice were Immunized l.v. with 16 pg TNP-f!coll. Mice were l<!lled and spleens were removed 
at the Indicated intervals. Cryostat sections were simultaneously Incubated with antibodies for !FN-')' and the different 
cell surface antigens. After histochemical revelation the double stained cells were counted. 
"Number of double staining IFN-"{·PC per spleen section. Number of cells is shown as mean ± SD deviation from three 
mice. 
<The total number of double staining IFN--r-PC from three spleens. each stained for a different cell marker. 
dThe total number of IFN--y-PC {double stained cells Included) per spleen section. Number of cells is shown as mean : 
SD from three mice . 
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Figure 5. Effect of TNP-F!coll immunization on the numbers of lFN-
y-PC and IFN--y·SFC in spleens of mice. BALB/c mice were Immunized 
Lv. with 16 ~g TNP-F!coll and ktlled after 6 and 7 days. Subsequently the 
IFN-y-PC In cryostat sections and the !FN·-y·SFC In cell suspensions of 
spleens of the same mice were quantitated. according to the procedures 
described in Materials and Methods. Every point represents one mouse. 
Control mice were injected w!th PBS and were killed after 6 days. Mean 
values of eight mice from each group are shown. Statistical evaluation 
was performed by the two-sample Student"s t-test. 
compared to haptenated polysaccharides. as previously 
was demonstrated by Koch et al. (45). The kinetics of 
IFN-)"-PC we observed in this TI-2 immune response. 
starting at day 3 and attaining maxima on days 5 and 7. 
were remarkably consistent with the results of Gessner 
et al. (20) in lymphocytic choriomeningitis virus infected 
mice, considered as a thymus-dependent immune re-
sponse. 
To investigate whether spleen cells of mice. 6 and 7 
days after TNP-Ficoll immunization. were also produc-
ing/secreting IFN-I" in vitro we performed an ELISA-spot 
assay. We found a two- to three-fold increase of the 
number of IFN-)"-SFC 6 and 7 days after TNP-Ficoll im-
munization. These results were again in agreement with 
the experiments of Gessner eta!. i20), who found a 2.4-
fold increase of the number of IFN-)"-SFC in spleens of 
mice infected with lymphocytic choriomeningitis virus. 
The number of IFN-1'-PC. determined with immunohis-
tochemical techniques, in the same spleens showed a 40-
fold increase after TNP-Ficoll immunization. This con-
sistent gradual difference is probably due to the Con A 
addition to the spleen cell suspension during the ELISA 
spot assay. This mitogen may stimulate cells that produce 
lower quantities of IFN-1' to assemble and secrete higher 
amounts of IFN-)". facilitating their detection. However, 
for the in vivo approach there was no amplification step 
applled. and probably therefore a low number of IFN-)"-
PC in the nonimmunized mice and a marked increase in 
number of these cells was detected after TNP-Ficoll im-
munization. 
We investigated whether the rise in local IFN-1' produc-
tion also resulted in an increase of the JFN-1' serum levels. 
Increased IFN-1' serum was found in only two mice (day-
7 TNP-Ficoll immunization). Possibly the amounts of IFN-
1' produced locally in the spleen are not sufficient to cause 
an increase in the IFN-1' serum levels. e.g., Buchmeier 
and Schreiber (46) were unable to detect raised IFN-)" 
serum levels in primary Listeria-infected mice, although 
in Vitro splenic cells were found to produce increased 
amounts of IFN-)". Another possibility is complement-
mediated inactivation of IFN-)" in sera (47). 
In our studies. using TI-2 Ag, the IFN-1'-PC cells were 
often found in clusters of two to eight cells. located in the 
PALS. around the terminal arterioles and in the red pulp. 
The localization pattern of IFN-1'-PC in our experiments 
was comparable with results of other groups. Gessner et 
al. (20) have examined the IFN-1'-PC in spleens of mice 
infected with lymphocytic choriomeningitis virus. In this 
thymus-dependent immune response IFN-1'-PC were lo-
cated in small clusters predominantly in the white pulp 
and less frequently in the red pulp. In graft vs host 
disease studies IFN-1' was mainly localized in the periar-
teriolar lymphocyte sheaths regions. and no IFN-1' im-
munofluorescence was found in the red pulp (19). In this 
study the IFN-)" production was proven to be T cell de-
pendent and derived from the donor T cells. 
We demonstrated that IFN-)"-PC were localized in the 
same compartment as TNP-AFC. Furthermore a part of 
the IFN-1'-PC were found in close conjunction to the TNP-
AFC, suggesting a direct cell-cell interaction. Such an 
interaction was recently demonstrated by Kupfer et al. 
(48) in vitro who showed that after in vitro mixing of Ag-
specific Th and B cells Th-B couples were formed. This 
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interaction resulted in cytokine production by these T 
cells near the Ag-specific B cells. Kupfer et al. (48) pro-
posed that T cells were in this way able to induce selective 
and specific B cell responses. Dekruyff et aL (49) showed 
in vitro that a direct interaction between Ag-specific T 
cells with Ag-activated 8 cells was a prerequisite for T 
cell activation and cytokine production by T cells in Tl-2 
immune responses. They demonstrated that 72-h precul-
turingofB cells with TI-2 Ag resulted in maximal capacity 
of these B cells to stimulate Ag-specific T cells. This 
indirect activation pathway could be the explanation of 
the relatively late appearance of IFN--y-PCin Tl-2 immune 
responses. Mohler et al. (50) concluded from their exper-
iments, using reverse transcription-polymerase chain re-
action. that the generation of immune responses in vivo 
might develop according a specific sequential production 
of cytokines. They showed that the majority of IL-2 
mRNA expression occurs from 1 to 3 days after antigenic 
exposure. whereas IL-4 mRNA expression occurred from 
day 3 through day 5. They suggested IL-2 was an up-
regulating cytokine and IL-4 a down-regulating cytokine 
in this immune response. The late appearance of IFN--y-
PC in Tl-2 immune responses and the juxtaposition of 
these cells to TNP-AFC observed in our experiments is 
also more suggestive for a maturing/regulating than for 
an inducing role of IFN--y in TI-2 immune responses. This 
has also been suggested by Mond and Brunswick (51). 
who demonstrated in vitro that IFN-1 suppressed the 
number of plaque forming cells to TNP-Ficoll, whereas 
addition of IFN-1 neutralizing mAb enhanced the re-
sponse to TNP-Ficoll. The in vivo localization and kinetics 
of IFN-,-PC and TNP-AFC together with the in vitro data 
(51) discussed above suggest a (down)-regulating role of 
IFN-1 in the immune response to TNP-Ficoll. Further in 
vivo studies. by treating mice with IFN--y or their neu-
tralizing antibodies. are required to exactly elucidate the 
regulating role of IFN--y in TI-2 immune responses. 
The double staining experiments we performed allowed 
the phenotypical characterization of IFN--y-PC during a 
Tl-2 immune response. Analysis of the JFN--y-PC at the 
peak of this response (days 5~ 7) revealed that± 40% of 
the IFN--y-PC were CD4 cells, ± 50% CDS cells. and only 
± 10% NK cells (Fig. 4). No cells double staining for IFN-
'Y and MOMA-2 were detected, indicating that IFN--y is 
not produced by macrophages. We found that the total 
number of IFN--y-PC per section was in the same range 
as the total double-stained IFN--y-PC, indicating that the 
majority of the IFN--y-PC were expressing the above men-
tioned surface markers (Table II). These results are in 
agreement with studies of Gessner eta!. (52) in lympho-
cytic choriomeningitis virus-infected mice, who showed 
in an ELISA-spot assay. that after negative selection ± 
50% of the IFN--y-PC were either CD4 or CDS. We have 
demonstrated that both the major T cell subsets (CD4/ 
CDS) were the main IFN-1 producers. whereas only a 
small proportion of the IFN--y producers were NK cells, 
suggesting an important role ofT cells in the regulation 
of the immune response to TNP-Flcoll. However, Mond 
and Brunswick (51) concluded from their experiments 
that NK cells may have a significant role in the responses 
to TI-2 Ag. They showed that responses ofT cell-depleted, 
NK-depleted B cells to TNP-Ficoll were enhanced in the 
presence of IL-2. Responses from T cell-depleted B cell 
cultures from which NK cells were not eliminated or to 
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which IFN--y was added were significantly lower, sug-
gesting a suppressive role for NK cells or IFN-)"" in the 
immune response to TNP-Ficoll. The apparent discrep-
ancy between these in vitro experiments and our in vivo 
results may be due to the localizing effect of the anatom-
ical barriers in in vivo experiments, as earlier demon-
strated by Gleveland et al. (19). These in vivo barriers 
may limit the contact between the TNP-AFC and NK cells. 
This in contrast to in vitro experiments, where the IL-2-
activated NK cells may be able to produce lFN--y close to 
the TNP-AFC. allowing them to regulate the TNP-specific 
plaque-forming cells. 
In conclusion. this study describes for the first time 
the in vivo kinetics and characterization of IFN--y-PC 
·during primary Tl-2 immune responses. The potentials 
of immunohistochemical techniques in the analysis of in 
vivo cytokine-mediated immunes response are demon-
strated: we showed that IFN-'Y is produced by CD4. CDS, 
and NK cells and that the IFN--y-PC are localized in jux-
taposition to and in the same compartment as TNP-AFC. 
Evidence that IFN--y and T cells are active in the in vivo 
Tl-2 immune response is presented. Further investiga-
tions into the details of the regulating role of IFN--y in the 
immune response to TNP-Ficoll are underway. 
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ABSTRACT 
The putative defect of peripheral lymph nodes (PLN) 2 to mount an antibody response against 
thymus independent type 2 (TI-2) antigens was investigated. Mice were immunized with TNP-
Ficoll and draining PLN were examined immunohistochemically, using a TNP-alkaline 
phosphatase conjugate, for the presence of TNP-specific antibody forming cells (TNP-AFC). 
Unexpectedly, high frequencies of TNP-AFC were detected in PLN of TNP-Ficoll immunized 
mice. Splenectomy experiments indicated that these TNP-AFC did not originate from the 
spleen. ELlS POT assays did not reveal the presence of TNP-specific secreting cells (TNP-
ASC) in PLN of TNP-Ficoll immunized mice, whereas in the spleen of these mice high 
frequencies of TNP-ASC were observed, suggesting that TNP-Ficoll activated B cells in PLN 
do produce antibodies, but are not able to secrete them. Only after simultaneous injection of 
Brucella abortus (BA), a particulate TI-t antigen, together with TNP-Ficoll, relatively high 
frequencies of TNP-ASC were detected in PLN. Four and five days after immunization with 
TNP-Ficoll relatively high frequencies of cytokine-PC (IL-2, IL-4, IL-5 and IFN-y) were observed 
in the outer-periarteriolar sheath (PALS) and around the terminal arterioles ofthe spleen. TNP-
AFC were localized in the same compartment as cytokine-PC indicating that these activated 
8 cells were differentiating in a cytokine-rich microenvironment. In contrast, low frequencies 
of activated T cells and cytokine-PC were observed in PLN after TNP-Ficoll immunization, 
suggesting that the lack of cytokines in PLN was responsible for the maturation defect of 
TNP-AFC. Indeed, simultaneous immunization with TNP-Fico!l + BA induced high frequencies 
of activated T cells and cytokine-PC in draining PLN and also resulted in increased 
frequencies of TNP-ASC in PLN. However, in vivo administration of IL-4 and/or IL-5 could not 
overcome the putative maturation defect of TNP-Fico!l activated B cells in PLN. 
In conclusion, this study shows that TNP-Ficoll is able to prime TNP-specific B cells in PLN. 
Data presented suggest that the differential capacity of PLN and spleens to generate fully 
differentiated TNP-ASC after TNP-Ficoll immunization is due to differences in cytokine 
production in these lymphoid organs. Furthermore, results suggest that combinations of 
cytokines or other cytokines than IL-4 and IL-5 are required for the in vivo maturation of Tl-2 
antigen activated PLN B cells into TNP-specific antibody-secreting cells. 
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INTRODUCTION 
The original definition of thymus independent (TI) antigens reflects their ability to stimulate 
humoral immune responses in nude mice in vivo or in T cell depleted cultures in vitro. These 
criteria are relatively non~stringent insofar as both nude mice and T cell depleted cultures 
have been shown to possess small numbers of T cells. Rigorous elimination of T cells 
consistently and significantly reduces the in vitro immune response to Tl antigens (1 ,2,3,4), 
indicating that these antigens are T cell dependent to a significant degree. The Tl Ag are 
divided into type 1 and type 2 (TI-2) Ag, based on their ability to stimulate an immunodeficient 
strain of mice (CBA/N) to produce antibodies (5). The polysaccharide component of the 
bacterial capsule of bacteriae is classified as a Tl-2 antigen (6). The spleen plays a critical role 
in the protection against capsular bacteria, e.g. Streptococcus pneumoniae, Neisseria 
meningitides and Haemophilus influenzae (7). Therefore, research has been focused on the 
delineation of the unique role of the spleen in Tl-2 antibody responses. The most common 
and extensively studied Tl-2 Ag is TNP-Ficol!. In vitro experiments indicated that cytokines 
produced by T cells or accessory cells are required for the development of an effective 
antibody response against Tl-2 antigens in the spleen (2,3,4). In addition, in vivo experiments 
demonstrated that activated cytokine-producing T helper cells were active in the spleen during 
Tl-2 immune responses (9). A!! these studies were performed in spleens in vivo or with 
splenocytes in vitro. Ex vivo analysis of Tl-2 antibody responses in lymph nodes indicated that 
PLN B cells did not differentiate into TNP-specific antibody-secreting cells (TNP-ASC) after 
immunization with TNP-Ficoll (1 0). Only the addition of splenic accessory cells or IL-1 to in 
vitro PLN cultures enabled lymph node cells to mount an antibody response against TNP-
Ficoll. Since PLN were able to mount an antibody response against TNP-BA, a Tl-1 antigen, 
mice were immunized with TNP-Ficoll + BA, which resulted in high frequencies of TNP-ASC 
in draining PLN, comparable to the frequencies observed in the spleen of TNP-Fico!! 
immunized mice (1 0). These results suggest that the differential ability of lymph nodes and 
spleens to mount an antibody response against Tl-2 antigens originates in the differences of 
the microenvironment in these secondary lymphoid organs during Tl-2 immune responses. 
The delineation of the differences in the organ-specific microenvironment is important, 
because it may give us new information about the unique role of the spleen in the 
development of Tl-2 antibody responses. 
We have previously shown that injected TNP-Ficolllocalized in the marginal zone and follicles 
of the spleen (11 ). Evidence was provided which showed that the typical follicular localization 
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of TNP-Ficoll is important for the development of Tl-2 antibody responses. Furthermore, it was 
demonstrated that IFN-y producing T cells colocalize with antigen-specific-AFC after 
immunization with Tl-2 antigens (12). These data suggested that the localization of antigens 
and activity of cytokines are important factors in the microenvironment of lymphoid tissues 
during Tl-2 antibody responses. 
Therefore, in this study we explored the possible role of the lymphoid microenvironment in 
the development of Tl-2 antibody responses. The in vivo localization of TNP-Ficoll in draining 
lymph nodes was compared to that of the spleen. The activity of activated T cells, cytokine-
producing cells and TNP-specific antibody-forming cells in the spleen and lymph nodes of 
mice was investigated after immunization with TNP-Ficoll. Finally, by treating mice with IL-4 
and/or IL-5, we investigated the capacity of these cytokines to restore the in vivo antibody 
response of PLN 8 cells against Tl-2 antigens. 
MATERIALS AND METHODS 
Animals. BCBA.F1 (C57BL x CBA) mice were bred at the TNO breeding facilities, Rijswijk, The 
Netherlands. Animals were used at 11-19 weeks of age and were kept under standard 
protocol with free access to pelleted food and acidified water (pH 3). Experiments were 
periormed under auspices of the Dutch Veterinary Inspection, as described in the Law on 
Animal Experiments. 
Chemicals. Alkaline phosphatase (AP; P-6774, type VI I-T, 1020 U/mg protein), 3-amino-9-
ethylcarbazole (AEC; A-5754), 5-BCIP (5-bromo-4-chloro-3-indolyl-phosphate; B-8503), Fast 
blue BB Base (F-0125), Fast red, horse radish peroxidase (HRP), levamisole, naphthol AS-MX 
phosphate (3-hydroxy-2-naphtoic acid 2,4-dimethyl-anilide), TNP sulfonic acid (TNBS, grade 
I) were obtained from Sigma, St. Louis, MO, USA; N-hydroxysuccinimidyl-(biotinamido)-
hexanoate and MHS (maleimidohexanoyl-n-hydroxysuccinimide ester) were obtained from 
Pierce, Rockford, IL, USA; fl-galactosidase (8-gal; E. coli-derived fl-O-galactoside 
galactohydrolase, MW 540 KD), and X-Gal (5-bromo-4-chloro-3-indolyl-fl-D-galactopyranoside) 
were obtained from Boehringer, Mannheim, FAG. 
Antigens. Brucella abortus (BA) was a kind gift of Dr. S.H.M. Jeurissen, Central Veterinary 
Institute, Lelystad, The Netherlands. TNP-Ficoll and TNP-OVA were prepared according to 
previously described methods (13). 
Reagents. AP-conjugated goat lg anti-mouse lgM or lgG were obtained from Tago, 
Burlingame, CA 94010. Avidin-HRP and avidin-AP were obtained from Sigma, St. Louis, MO, 
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USA. The control hamster antibodies, the hamster mAb directed to gp39 (MR1 ; 14), and the 
murine mAb specific for rat/hamster lgK (RG-7; 15) chain were a kind gift of Dr. R.J. Noelle 
(Department of Microbiology, Dartmouth School, Lebanon, NH 03757, USA) and purified by 
means of protein-A affinity chromatography. The murine mAb DB-1 directed to mouse IFN-y, 
was a kind gift of Dr. P. H. van der Meide (16) from our institute. S4B6, directed to mouse 
IL-2, was a kind gift of Dr. T. Mosmann (17). The cells of the rat mAb 11 B11, directed to 
mouse IL-4, and IL-4 were a kind gift of Dr. W.E. Paul, Laboratory of Immunology, National 
Institute of Allergy and Infectious Diseases, N.I.H., Bethesda, Maryland (18). The mouse-IL-5-
specific rat mAb, TRFK5, was obtained from Dr. R.L. Coffman, DNAX Research Institute, Palo 
Alto, CA, USA (19). Control rat mAb (2A4, 1 G11) were a kind gift of Dr. A. Zantema, Sylvius 
Laboratory, Leiden, The Netherlands (20). Recombinant mouse IL-2 was obtained from 
Genzym, Cambridge, MA, USA. The X631 0 cell lines producing mouse IL-4 or IL-2 were a kind 
gift of Dr. F. Melchers, Basel Institute of Immunology, Basel, Switzerland (21 ). All rat 
antibodies were purified from culture supernatants using a goat anti-rat lg column, obtained 
from Dr. J. Radl, lWO, TNO, Leiden. Cytokine-specific and control antibodies were 
conjugated to AP and HRP as previously described (22). Biotinylation was performed as 
previously described (23). Conjugation to fi-gal was performed according to the procedure 
described by Deelder and De Water (24) with minor modifications (11 ). TN P-AP was prepared 
according to previously described methods (13). 
Experimental design. To investigate the development of TNP-specific antibody forming cells 
(TNP-AFC) mice were immunized s.c. in the footpad with 50 1'9 TNP-Ficoll in PBS and were 
killed at day 1, 4, 5, 6, 7, and 10. Serum was prepared and spleens and PLN were removed. 
To investigate the TNP-specific antibody response after immunization with TNP-Ficoll 
supplemented with BA, mice were immunized s.c. in both footpads with 50 l'g TNP-Ficoll, 50 
l'g TNP-Ficoll and 1 mg BA, BA, or PBS and killed after five days. One PLN from each mouse 
was used for immunohistochemical analysis, while the other PLN was used for the EUSPOT 
assay. To investigate the role of the spleen in the antibody response against TNP-Ficoll in 
PLN, splenectomized mice and sham-splenectomized mice were immunized s.c. in both 
footpads with 50 ,ug TNP-Ficoll, 50 l'g TNP-Ficoll and 1 mg BA, or PBS and killed after five 
days. One PLN from each mouse was used for immunohistochemical analysis, while the other 
PLN was used for the ELISPOT assay. 
To investigate the effect of the in vivo administration of IL-4 and/or IL-5 on the TNP-specific 
antibody response, mice were implanted at day -2 with 2 x 106 CV/IL-4, 2 x 106 CV/IL-5, 2 x 
106 CV/ IL-4 + 2 x 106 CV/IL-5, or empty Cytodex-3 beads encapsulated in alginate and 
immunized s.c. with 50 l'g TNP-Ficoll in both footpads at day 0. Mice were sacrificed at day 
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5 and 7 and one PLN was prepared for immunohistochemistry, while the contralateral PLN 
was tested in the ELISPOT assay. For immunohistochemical analysis, lymphoid organs were 
frozen in liquid nitrogen and stored at -70°C. 
Splenectomy. Mice were anaesthetized with nembutal. An incision was made in the 
peritoneum and the spleen was excised. The incision was closed with three sutures. The 
sham-splenectomized mice underwent the same operation procedures, but were not 
splenectomized (26). 
Alginate encapsulation. Cells from the IL-4 or IL-5 producing cell line were encapsulated in 
alginate as described earlier (27). Monkey CV-1 cells were stably transfected with the murine 
IL-4 or IL-5 gene under control of the SV40 promotor. Cells were grown on Cytodex 3 beads 
(Pharmacia, Uppsala, Sweden). Fully covered beads were harvested after 2 days of culture 
and washed 3 times with sterile saline. The volume of the pellet was determined and 1 volume 
of saline followed by 2 volumes of a 1.2% sterile solution of alginate (FMC Bioproducts, 
Rockland, PA, USA) were combined in a syringe. This suspension was squirted through a 25 
gauge needle into a fresh 80 mM CaCI2 solution. The encapsulated cells were washed 3 times 
with saline and 2 x 106 encapsulated cells in 1 ml were injected i.p. with a 19 gauge needle. 
Immunohistochemistry. Splenic cryostat sections (-20 °C, 8 pm), one of every mouse, were 
picked up on the same glass slide and kept overnight under high humidity at RT. Slides were 
air-dried and stored in air-tight boxes until use. Slides were fixed for 10 minutes in acetone 
containing 0.02% H20 2 . Detection of cytokine-PC was performed as described previously 
(9, 12,28). Slides were incubated horizontally overnight at 4 'C with cytokine-specific antibody-
conjugates diluted in PBS containing 0.1% BSA, which were titrated to obtain optimal results. 
Immunohistochemical demonstration of gp39 was performed with MR1, followed by a 
hamster-lg-specific mAb, RG-7, conjugated to HRP (9). Detection of TNP-specific antibody 
forming cells (TNP-AFC) was performed according to previously described methods (13). 
Detection of TNP-Ficoll was performed with a TNP-specific mAb (SH4.1 C9) conjugated to {3-
gal as previously described (11 ). Subsequently, slides were washed with PBS (three times 5 
min) and immuno-histochemical revelation was performed, as described previously; AP (22), 
HRP (22) and {3-gal (24). To ensure that no over- or understaining occurred, slides with 
adherent substrate solution were monitored by light microscopy during histochemical 
reactions. Sections were counterstained with haematoxylin and mounted in glycerin-gelatin. 
Antibody-forming cells, gp39+ cells and cytokine-PC were counted, and image-analysis of 
spleen sections was performed as previously described (12). A minimum of three sections of 
each mouse were examined. For the analysis of the in situ antibody response in PLN cryostat 
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sections were made of the entire lymph node. At least 20 sections of each PLN were 
examined for the presence of TNP-AFC. From the total number of sections of one PLN and 
the number of sections examined for each assay, the total frequencies of TNP-AFC per PLN 
were calculated. The frequency of cytokine-PC in PLN was expressed in number of cells per 
mm2 and was based on at least 1 0 cryostat sections. 
TNP-specific ELISA. Mouse serum TNP-specific JgM and lgG were determined by means of 
a direct enzyme-linked immunosorbent assay as described earlier (25). The TNP-specific titer 
was expressed as the dilution at which 50% of the maximal absorbance was found. 
ELISPOT assay. To quantitate the frequency of TNP-ASC, an ELISPOT assay was used 
according to the procedure described by Taguchi et al. with minor modifications (29). Spleens 
were aseptically removed and single cell suspensions were prepared by gently teasing them 
through nylon gauze filters into RPM I plus 0.5% FCS. Cell suspensions were washed three 
times with RPM I plus 0.5% FCS. Microtitre plates were coated overnight at 4 °C with 50 ,ul of 
5Jlg OVA-TNP ml'1 in PBS, followed by blocking with 100J1I PBS containing 0.5% gelatine in 
PBS at 37 'C. Spleen cells (3 x 102 to 1 x 1 05/well) suspended in RPM I plus 0.5% FCS were 
added to individual wells and incubated for 3 h at 37 oc with 5% C02 in air. To remove the 
cells, plates were washed once with H20 plus 0.05% Tween-20 and three times with PBS 
containing 0.1% gelatine plus 0.05% Tween-20 and incubated 1 hr at 37 'C with 50111 of goa1 
anti-mouse-lgG/IgM conjuga1ed to AP in PBS con1aining 0.1% gelatine. Subsequently plates 
were washed three times with PBS containing 0.05% Tween-20. Spots representing single 
an1ibody-secreting cells were developed with 100 J1I5-BCIP (1 0 mg.ml'1) in 2-amino-2-methyl-
1-1 propanol buffer (pH=10,25). The number of spots was enumerated with the aid of a 
dissecting microscope. 
RESULTS 
TNP-Fico/1 localizes in macrophages and follicles of the lymph node. 
TNP-Ficolllocalizes in the marginal zone macrophages and follicles of the spleen, irrespective 
of route of administration (11 ). Evidence was provided for an important role of follicular TNP-
Ficoll in the induction of Tl-2 antibody responses in the spleen (11 ). Therefore, the localization 
ofTNP-Ficoll in the draining PLN node was investigated after s.c. immunization. Using a TNP-
specific mAb conjugated to jJ-galactosidase, TNP-Ficoll was detected in the follicles of PLN 
at 7 h after injection (Fig. 1 be). a similar localization pattern as was observed in the spleen 
(Fig. 1 a; 11 ). TNP-Ficoll predominantly localized in the medullary macrophages and to a 
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lesser degree in the subcapsular macrophages of the PLN. After s.c. immunization, TNP-Ficol! 
was also detected in the marginal zones and follicles of the spleen (Fig. ta). Ten days after 
injection of TNP-Ficoll, the Tl-2 antigen was still detectable in the follicles and macrophages 
of lymph nodes and the spleen. 
PLN can mount an in situ antibody response against TNP-Fico/1. 
To investigate whether murine PLN develop an in situ antibody response against Tl-2 
antigens, we examined PLN at different time-points after s.c. immunization with TNP-Ficoll. As 
shown in fig. 2, about 250 TNP-AFC were present in PLN at 4 days after TNP-Ficoll 
immunization. Maximum frequencies (± 2000/PLN) of TNP-AFC were observed 7 days after 
TNP-Ficoll immunization. TNP-AFC were predominantly found along the medullary cords of 
PLN (Fig. t d, f). Besides the development ofTNP-AFC, relatively high amounts ofTNP-specific 
antibodies were observed in the follicles of lymph nodes 4 days after immunization (Fig. 1 d, 
f). In serial sections we could demonstrate that TNP-Ficoll and TNP-specific antibodies had 
a similar localization pattern in the follicle, indicating that the observed staining represented 
trapped TNP-Ficoll-anti-TNP-antibodies immune complexes (Fig. t c, d). 
Figure 1) Localization of injected TNP-Ficoll, TNP-AFC and IL-5-PC in lymphoid organs 
after immunization. Cryostat sections of murine lymphoid tissue were incubated with specific 
immune-conjugates, followed by immunohistochemical revelation. a) spleen section 7 h after 
injection of TNP-Ficoll: TNP-Ficoll, detected with a TNP-specific mAb conjugated to (3-
ga!actosidase, is localized in the marginal zone macrophages and follicles of the spleen; b) 
PLN 7 h after injection of TNP-Ficoll; TNP-Ficoll is predominantly localized in the medullary 
macrophages and in the follicles of PLN; c) PLN 5 days after injection of TNP-Ficoll; TNP-
Fkoll is localized '1n the medullary macrophages and in the foll'lcles of PLN (see serial section 
figure 1 d); d) PLN 5 days after injection of TNP-Ficoll; TNP-specific antibodies, detected with 
TNP-alkaline phosphatase conjugate, are trapped in the follicle as immune complexes (see 
serial section figure 1 c); e) PLN 5 days after injection of TNP-Ficoll + BA; TNP-AFC are 
localized along medullary cords and in deep cortex of PLN; f) PLN 5 days after injection of 
TNP-Ficoll; TNP-AFC are localized in the medulla and immune complexes in the follicles of 
PLN; g) PLN 5 days after injection of TNP-Ficoll + BA; IL-5-PC, detected with IL-5-specific 
mAb conjugated to alkaline phosphatase conjugate; h) IL-5-PC in spleen section, 4 days after 
immunization with TNP-Ficoll. c, central arteriole; d, deep cortex; f, follicle; m, medulla, mz, 
marginal zone; o, outer-PALS; p, PALS. 
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Figure 2) TNP~AFC appear earlier in the spleen than in the PLN after s.c. immunization with TNP-Ficoll. 
BCBAF1 mice were injected s.c. with so pg TNP-Ficoll and sacrificed at the indicated time-points. Spleens were 
removed and immunohistochemistry and image analysis was performed as described in the materials and methods 
section. In the spleen values represent the mean ± SO of number of positive cells per mm2; in PLN values 
represent the mean ± SD of the total frequencies of TNP-AFC per PLN from three m1ce. Broken line represents the 
development of TNP-AFC in the spleen, while the solid line represents the development of TNP-AFC in PLN. 
The in situ TNP-specific antibody response in the spleen revealed maximum frequencies of 
TNP-AFC 4-5 days after s.c. immunization with TNP-Ficoll, 2 days earlier as compared to PLN. 
Thereafter, the frequency of TNP-AFC decreased gradually and remained at a constant level 
after day 7 of immunization. The TNP-AFC were predominantly found in the outer-PALS and 
around the terminal arterioles of the spleen, as described earlier (13). 
TNP-AFC in PLN are not derived from the spleen. 
The frequency of TNP-AFC in PLN reached maximum levels two days later than in the spleen, 
suggesting 1hat TNP-AFC in the PLN originated from the spleen. To investigate this possibility, 
splenectomized mice were immunized s.c. with TNP-Ficoll. As shown in table I, no differences 
were found in the frequencies ofTNP-AFC in PLN between splenectomized and control mice. 
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Table I 
Effect of splenectomy on TNP-AFC and TNP-ASC in PLN after TNP-Ficoll immunization 
Immunization splenectomy TNP-AFC/PLN TNP-ASC/PLN 
TNP-Ficoll 1295 ± 755 < 10 
TNP-Ficol! + 1287 ± 759 < 10 
TNP-Fico!l + BA 90632 ± 2n5o 5170 ± 403 
TNP-Ficoll + BA + 87639 ± 246·15 1266 ± 341 
BA not tested 170 ±7 
a Splenectomized mice and sham-splenectomized mice were immunized s.c. in both footpads with 50p.g TNP-Ficoll 
and/or 1 mg BA or PBS. b Mice were killed at day 5 after immunization and draining PLN were removed. In one 
PLN the frequency of TNP-AFC was determined immunohistochemically, while TNP-ASC were determined in the 
contralateral PLN by using the ELISA-spot assay.c, dData represent the mean ± SD number of TNP-AFC or TNP-
ASC per PLN from four mice. 
TNP-specific antibody-secreting cells are not detectable in PLN after TNP-Fico/1 immunization. 
The TNP-AFC observed in PLN after TNP-Ficoll immunization represent the potential 
TNP-specific antibody-secreting cells. However, of all TNP-AFC only a part will be secreting 
antibodies at any given moment. Therefore, the frequency of TNP-ASC in PLN was determined 
afterTNP-Ficoll immunization, by using an ELlS POT assay. In agreement with the experiments 
of Goud et al. (1 0) no TNP-ASC were observed in lymph nodes of TNP-Ficoll immunized mice 
(table 1). Only s.c. injection of TNP-Ficoll along with BA induced high frequencies of TNP-ASC 
in draining PLN (table 1), as was described earlier (1 0). Immunization of splenectomized mice 
with TNP-Ficoll + BA resulted in significantly lower frequencies of TNP-ASC in PLN than in 
sham-splenectomized mice, whereas the frequency of TNP-AFC was similar in draining PLN 
of these mice (Fig. 1 d, table 1). In contrast to the PLN, high frequencies of TNP-ASC were 
observed in the spleen after s.c. immunization with TNP-Ficoll (table Ill). 
Low production of cytokines in lymph nodes relative to the spleen after immunization with 
TNP-Fico/1. 
The previous experiments showed that TNP-Ficoll immunization induces the development of 
TNP-AFC in the PLN. However, the TNP-AFC failed to secrete TNP-specific antibodies, as was 
demonstrated in the ELISPOT assay, suggesting that PLN were lacking the factors which are 
essential for the final differentiation into TNP-ASC. Since high frequencies of TNP-ASC were 
detected in spleens ofTNP-Ficoll immunized mice, these factors are most likely present in this 
secondary lymphoid organ. Therefore, we compared the expression of gp39+ and cytokines 
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Figure 3) Development of activated T cells and cytokine-producing cells in the spleen after immunization with TNP-
Ficolf. BCBA.F1 mice were injected s.c. with 50 ,ug TNP-Ficoll and sacrificed at the indicated time-points. Spleens 
were removed and immunohistochemistry and image analysis was performed as described in the materials and 
methods section. Values represent mean ± SO of number of positive cells per mm2 from three mice. 
in spleens and PLN after immunization with TNP-Ficoll. Gp39 is a ligand tor the CD40-
molecule on B cells and is only expressed on activated T helper cells in vitro (14) and in vivo 
(9). Analysis of gp39 expression in spleens of TNP-Ficoll immunized mice revealed high 
frequencies of gp39+ cells in the outer-PALS and around the terminal arterioles. Maximum 
frequencies were observed 4 and 5 days after immunization with TNP-Ficoll (Fig. 3). In 
contrast, hardly any gp39+ cells were found in PLN of TNP-Ficoll immunized mice, indicating 
that low frequencies of activated T helper cells were present in these PLN (Fig. 4). 
To investigate whether cytokine-production was locally deficient in PLN of TNP-Ficoll 
immunized mice, the expression of cytokines in PLN and spleens was compared after 
immunization with TNP-Ficoll. Cytokines were detected with direct enzyme immune-conjugates 
as described previously (9,12,28). High frequencies of IL-5-PC were observed in spleens of 
TNP-Ficoll immunized mice, reaching maximum levels at day 4 and 5 after immunization (Fig. 
3). IL-2-, IL-4- and IFN-y-PC developed according to similar kinetics as observed for IL-5-PC, 
though their frequencies were lower. Cytokine-PC were localized in the outer-PALS and 
around the terminal arterioles, as was described for IFN-y-PC after immunization with TNP-
Ficoll (12). The analysis of the in situ cytokine-production in PLN from TNP-Ficoll immunized 
mice revealed markedly lower frequencies of cytokine-PC than in the spleen (Fig. 4). In 
summary, these results show a differential cytokine-production in PLN and spleens after TNP-
Ficoll immunization, which may be the reason for the putative maturation defect of TNP-Ficoll 
activated B cells in the PLN. 
104 
30 
!li1ili1iijTF sham 
CJTF splenectomy 
I >:·>>1 TF+BA sham 
z 
_j 
!li1ili1iij TF+BA splenectomy 
Q_ 20 
NE 
E 
---(f) 
iO 
(]) 
() 
T 
T k jj Tu ~ r .. 0 
IL-2-PC IL-4-PC IL-5-PC IFN-7-PC gp39 
Figure 4) Effect of splenectomy on the frequency of activated T ceffs and cytokine-producing cells in PLN after 
immunization with Tf antigens. BCBA.F1 mice were injected s.c. with 50 ~~g TNP-Ficoll or with 50 ,ug TNP-Ficoll 
supplemented with 1 mg SA and sacrificed 5 days after immunization. Draining PLN were removed and 
immunohistochemistry and image analysis was performed as described in the materials and methods section. 
Values represent mean ± SO of number of positive cells per mm2 from three mice. 
Co-immunization of BA with TNP-Fico/1 increases the frequencies of activated T cells and 
cytokine-PC in PLN. 
Gaud et a!. (1 0) showed that simultaneous immunization of TNP-Ficoll + BA induced high 
frequencies of TNP-ASC in draining PLN. To investigate whether these increased frequencies 
of TNP~ASC were related to the increased cytokine-production in PLN, we assessed the 
frequencies of gp39+ cells and cytokine-PC in draining PLN after immunization with TNP-Ficoll 
+ BA. As shown in fig. 4, relatively high frequencies of gp39+ cells and cytokine-PC were 
found after this immunization protocol. In PLN of mice immunized with TNP-Ficoll + BA, 
higher frequencies of IL-4-PC and IL-5-PC relative to IL-2-PC and IFN-y-PC were observed at 
day five of immunization. The cytokine-PC were predominantly localized in the medullary 
cords of the PLN, the same compartment where the majority of TNP-AFC were observed. 
Splenectomy experiments suggested that cytokines or cells from the spleen stimulated the 
differentiation of TNP-ASC in PLN after immunization with TNP-Ficoll + BA (table 1). To 
investigate whether the cytokine-PC investigated in this study were derived from the spleen, 
the cytokine-production in PLN of splenectomized mice was assessed after immunization with 
TNP-Ficoll + BA. As shown in fig. 4 the production of IL-2, IL-4, IL-5 and IFN-y was not 
significantly changed after splenectomy. 
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Table II 
Effect of in vivo IL-4 and/or IL-5 treatment on the frequency of TNP-AFC and TNP-ASC in PLN 
after TNP-Ficoll immunization 
TNP-AFC I PLN TNP-ASC I PLN 
lmmunizationa cytokineb day 5 day 7 day 5 day 7 
TNP-Ficoll 485::!;: 169c 1683 ± 399 ' 
TNP-Ficoll IL-4 1487 ± 803 2416 ± 393 
TNP-Ficoll IL-5 1663 ± 951 1408 ± 312 
TNP-Ficoll IL-4 + IL-5 693 ::!;: 249 2530 ± 296 
PBS IL-4 + IL-5 66 ± 13 47 ± 39 
aM ice were immunized in both footpads with 50 ,ug TNP-Ficoll or PBS. orwo days earlier mice were infused i.p. with 
2 x 106 cytokine-producing CV1 cells grown on cytodex beads and encapsulated in alginate. Mice were killed at 
day 5 or 7 and PLN were removed. In one PLN the frequency of TNP-AFC was determined immunohistochemically, 
while TNP-ASC were determined in the contralateral PLN by using the ELISA-spot assay.c· dData presented are the 
mean ± SO number of TNP-AFC or TNP-ASC per PLN from four mice. 
In vivo administration of /L-4 and/or IL-5 cannot restore the maturation defect of TNP-Fico/1 
activated B cells in PLN. 
To test whether the absence of IL-4 and/or IL-5 in PLN of TNP-Ficoll immunized mice could 
account for the absence of TNP-ASC in PLN, these cytokines were administered continuously 
to mice immunized with TNP-Ficoll. This was performed by injecting mice i.p. with alginate-
encapsulated CV-1 cells that were stably transformed with the murine IL-4 or IL-5 gene. Both 
Table Ill 
Effect of in vivo IL-4 and/or IL-5 treatment on the serum lgM-antibody titers and TNP-ASC in spleens 
after TNP-Ficolt immunization 
TNP-speciTic lgM-Ab titer TNP-ASC /106 splenocytes 
lmmunizationa cytokineb day 5 day 7 day 5 day 7 
TNP-Ficoll 1300 ± 200c 700 ± 200 2700 ± 112-d 801 ± 132 
TNP-Ficoll IL-4 1300 ± 200 700 ± 383 2390 ± 959 857 ± 393 
TNP-Ficoll IL-5 1400 ± 239 BOO ± 0 3500 ::!;: 1060 1460 ± 830 
TNP-Ficoll IL-4 + IL-5 1600 ± 542 525 ± 150 3700 ± 1700 809 ± 251 
PBS IL-4 + IL-5 138 ± 189 75 ± 87 259 ± 407 117±132 
aM ice were immunized in both footpads with 50 ,ug TNP-Ficoll or PBS. orwo days earlier mice were infused i.p. with 
2 x 106 cytokine-producing CV1 cells grown on cytodex beads and encapsulated in alginate. Mice were bled at day 
5 or 7 and spleens were removed. TNP-specific lgM-antibodytiters were determined in ELISA, while TNP-ASC were 
determined in the spleen by using the ELISA-spot assay. c·mers are expressed as the mean ± SO of the dilution 
at which 50% of the maximum absorbance was found. ctoata represent the mean± SO number of TNP-ASC I 106 
splenocytes from four mice. 
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PLN of mice were removed at day 5 and 7 after TNP-Ficoll immunization and tested for the 
presence of either TNP-ASC or TNP-AFC. As shown in table II, administration of IL-4 and/or 
IL-5 did not increase significantly the frequency of TNP-AFC nor that of TNP-ASC in PLN of 
TNP-Ficoll immunized mice. In agreement with these results, no significant increases in the 
frequency of TNP-ASC in spleens and in the titers of TNP-specific antibodies in sera of TNP-
Ficoll immunized mice were observed after in vivo treatment with IL-4 and/or IL-5 (table Ill). 
DISCUSSION 
In this report we investigated the inability of PLN to generate TNP-specific antibody-secreting 
cells after immunization with TNP-Ficol!. We demonstrated that TNP-Ficoll is able to induce 
the activation and proliferation ofTNP-specific B cells in PLN. However, the microenvironment 
of PLN after TNP-Ficol~ immunization was not capable to provide the signals required for the 
differentiation ofTNP-specific antibody forming cells into TNP-specific antibody-secreting cells. 
Presented data suggest that the inability of TNP-Ficoll activated lymph node B cells to 
differentiate into TNP-specific antibody-secreting cells is due to the low frequencies of 
activated cytokine-producing T cells in PLN. 
The fact that the spleen and PLN show a differential capacity to generate TNP-ASC upon 
TNP-Ficoll immunization suggests that the microenvironment of the spleen contains essential 
cells or cytokines which are lacking in PLN. In a previous report we presented data which 
suggested that the follicular localization of TNP-Ficoll in the spleen plays an important role 
in the generation of a Tl-2 antibody response (11 ). Analysis of the localization of TNP-Ficoll 
in draining PLN revealed that TNP-Ficoll was taken up by the PLN macrophages and trapped 
in the follicles, in a similar way as observed in the spleen, suggesting that the way of antigen 
handling in PLN is not responsible for the putative defect. 
The in situ examination of the Tl-2 antibody response revealed, to our surprise, a significant 
number ofTNP-AFC in draining PLN. Splenectomy experiments indicated that TNP-AFC were 
not derived from the spleen (table 1). The usage of hapten-enzyme conjugates for the analysis 
of the in situ antibody production reveals all hapten-specific antibody-containing cells, and 
cannot determine if such a cell is actually secreting antibodies. The ELlS POT assay is an ex 
vivo method, which only detects antibody-secreting cells. By using this method for the 
analysis of the antibody-production in PLN, we demonstrated that no TNP-ASC were present 
in draining PLN of TNP-Ficoll immunized mice. These results suggest that TNP-Ficoll can 
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indeed activate TNP-specific lymph node B cells to produce antibodies, but that the lymph 
node microenvironment is not able to provide the stimuli required for the final differentiation 
of TNP-AFC into TNP-ASC. Only after immunization of TNP-Ficoll supplemented with BA, 
these TNP-AFC were able to differentiate into fully maturated antibody-secreting cells (table 
1). Similar conclusions were drawn from in vitro experiments by Gaud et al. (30). They 
demonstrated, by using limiting dilution experiments, that TNP-Ficoll immunization led to an 
increased frequency of TNP-specific precursor B cells in lymph nodes. Only the addition of 
cytokines in vitro resulted in the final differentiation of TNP-Ficoll primed B cells into TNP-ASC, 
as was demonstrated in a plaque-forming assay (30). These results together suggest that the 
maturation defect of TNP-AFC might be due to a decreased cytokine production in PLN 
relative to the spleen after immunization with TNP-Ficoll. Indeed, after immunization of TNP-
Ficoll no IL-2-PC and IFN-y-PC were observed in draining PLN, whereas in spleens relatively 
high frequencies of these cytokine-PC were observed (Figs 3 and 4). In the spleen we 
detected about 30 times more IL-4-PC and IL-5-PC as compared to the PLN. These cytokine-
PC were localized in the same splenic compartment as TNP-AFC, like was described for IFN-
y-PC (12), suggesting a regulating role of these cytokines in Tl-2 antibody responses. In a 
previous report we demonstrated that high frequencies of activated T helper cells were 
present in spleens of TNP-Ficoll immunized mice (9). These activated T helper cells were 
detected with a mAb specific for gp39, the CD40 ligand. Although gp39 was not found to be 
critical for the induction of Tl-2 antibody responses (31 ), these results indicated that T cells 
are activated in vivo after immunization with T!-2 antigens. In this study, in contrast to the 
spleen, only very few activated T helper cells were found in PLN atterTNP-Ficoll immunization. 
This observation is in agreement with the low frequencies of cytokine-PC found in PLN (Fig. 
4). Since BA co-administration results in increased frequencies of TNP-ASC, the effect of such 
an immunization protocol on the cytokine production in PLN was examined. As expected, 
supplementation of BA to TNP-Ficoll markedly increased the frequency of activated T helper 
cells and cytokine-PC in the draining PLN. Like was observed in the spleen, cytokine-PC and 
TNP-AFC were also colocalizing in PLN after immunization with TNP-Ficoll + BA, which 
suggests that these cytokines may have a regulatory role in this antibody response. All these 
data point to the relatively low cytokine-production in PLN after TNP-Ficol! immunization as 
the cause of the maturation defect of TNP-AFC. 
The role of cytokines in Tl-2 antibody responses was investigated by several groups. IL-1 
produced by accessory cells was found to increase the in vitro antibody response against 
TNP-Ficoll (1 0,32,33). In some studies the addition of IL-2 was found to augment the in vitro 
Tl-2 antibody response (2,33,34), whereas other studies did not report such an effect (1 o, 30). 
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Several studies demonstrated that the in vitro antibody response· against Tl-2 antigens was 
unchanged after the addition of IL-4 (30,34). In contrast, the addition of IL-5 to cultures did 
increase markedly the TNP-specific antibody response against TNP-Ficoll (30,34). 
To investigate whether in vivo cytokine-treatment could overcome the cytokine-defect in PLN 
ofTNP-Ficoll immunized mice, alginate encapsulated IL-4 and/or IL-5-producing cell lines were 
i.p. implanted. In a previous report is was demonstrated that the i.p. injection of these IL-4-
producing cell lines resulted in a consistent IL-4 production for periods up to two weeks, 
which was proven to be sufficient to transform in vivo lgE non-responder mice into lgE high -
responder mice (27). In vivo treatment with IL-5 producing cell lines resulted in increased 
frequencies of eosinophils in the circulation and bronchoalveolar lavage fluid of guinea pigs 
(35). However, the injection of these IL-4 and/or IL-5 producing cells in TNP-Ficoll immunized 
mice did not result in increased frequencies of TNP-AFC and TNP-ASC in draining PLN after 
TNP-Ficoll immunization (table II). Analogous to PLN, no significant increases of TNP-AFC 
(data not shown) or TNP-ASC were found in spleens of cytokine treated mice, which was also 
reflected by the TNP-specific lgM serum titers at day 5 and 7 after TNP-Ficoll immunization 
(table Ill). The observation that TNP-Ficoll immunization alone induced a significant IL-4 and 
IL-5 production in the spleen may explain the observation that the cytokine treatment did not 
augment the splenic Tl-2 antibody response. The absence of a significant effect on in vivo Tl-2 
antibody responses in PLN might be due to the fact that these treatments do not give rise to 
the cytokine-levels in PLN, which are required for the maturation into TNP-ASC. However, 
since these cytokine-treatments have proven to be effective in other in vivo models (35,27), 
this possibility is not very likely. The absence of a significant effect may indicate that other 
cytokines than IL-4 and IL-5 are required for the maturation of TNP-AFC. In vitro experiments 
showed that the frequency of TNP-ASC after the addition of IL-5 to TNP-Ficoll primed PLN 
cells was much lower as compared to the cultures stimulated with BA, suggesting that more 
and other cytokines were involved in the maturation of TNP-AFC after TNP-Ficoll + BA 
administration. 
In figure 4 it is shown that splenectomy did not affect the production of cytokines (IL-2, IL-4, 
IL-5 and IFN~') in PLN after TNP-Ficoll + BA immunization. However, splenectomy did 
markedly reduce the TNP-ASC after TNP-Ficoll + BA (table 1), although it did not alter the 
frequency of TNP-primed B cells (TNP-AFC), indicating that the activity of investigated 
cytokines was not sufficient to restore the Tl-2 antibody response in the PLN to the level 
observed in non-splenectomized mice. Gaud et al. (1 0) demonstrated that the addition of 
adherent splenic cells or IL-1 to TNP-Ficoll primed lymph node cultures did increase the 
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frequency of TNP-ASC, suggesting that BA immunization induces the migration of adherent 
splenic cells, producing IL-1, to the PLN. The function of BA in this scenario would be the 
induction of chemotactic cytokines, e.g. 1FN-y, in PLN which would result in the migration of 
splenic macrophages to the PLN. The possibility that high local cytokine-production in the 
spleen might influence the microenvironment of PLN is not likely, since TNP-Ficoll 
immunization in draining PLN was not affected by BA immunization in the contralateral foot 
pad (1 0, and data not shown). 
The observation that hardly any activated T cells or cytokine-PC were observed in PLN after 
TNP-Ficoll immunization suggests a defect in the activation of PLN T cells. The process ofT 
cell activation has been described by two groups. DeKruyff et al. (36) showed that Tl-2 
antigen activated 8 cells were able to activate T cells in vitro. Similar results were described 
by Zisman et al. (37), who demonstrated that T!-2 antigens bind to class II molecules of 
adherent splenic antigen-presenting cells, enabling them to activate T cells in vitro. 
Accordingly, a deficiency in Tl-2 antigen-presenting cells might explain the low frequencies 
of activated cytokine producing T cells in PLN as compared to the spleen. In that respect, the 
findings of Janeway et al. (38) are of interest. This group showed that in contrast to B cell 
depleted spleens, B cell depleted resting lymph nodes were not able to activate T cells in 
vitro, suggesting that resting lymph nodes are deficient in non-B cell antigen-presenting cells. 
Thus, it appears that the absence of a particular Tl-2 antigen presenting cell in PLN is the 
cause of the low frequency of activated cytokine-PC in PLN. Because of the low cytokine-
production in draining PLN of TNP-Ficoll immunized mice, splenic adherent cells are not 
stimulated to migrate to the PLN and consequently cannot regulate the differentiation ofTNP-
ASC. This all together makes the microenvironment of the PLN not suitable for the maturation 
of TNP-AFC after TNP-Ficoll immunization. Probably, BA, as a particulate antigen, uses 
different antigen-presenting cells for the activation of T cells in PLN than Tl-2 antigens do. 
The analysis of Tl-2 antibody responses in PLN appears to be a valuable approach for the 
in vivo identification of the particular Tl-2 antigen-presenting cells and cytokines, which are 
essential for the activation and maturation of B cells during Tl-2 antibody responses. Such an 
approach may give us more insight in the unique microenvironment of the spleen which is 
critical in the protection against infections with Streptococcus pneumoniae, Neisseria 
meningitides and Haemophifus influenzae. 
In conclusion, the present study suggest that a lack of cytokines in PLN after TNP-Ficoll 
immunization is responsible for the maturation defect of TNP-Ficoll activated PLN B cells. 
Furthermore, results indicate that combinations of cytokines or other cytokines than IL-4 and 
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IL-5 are required for the in vivo maturation of TNP-Ficoll activated PLN B cells into TNP-ASC. 
Finally, this in vivo study shows that activated T cells and cytokines are actively participating 
in Tl-2 antibody responses. 
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ABSTRACT 
T-B cell interactions have a central role in the development of antibody responses. Upon 
activation, Th cells express the ligand for CD40, gp39, which is essential forTh cell dependent 
B cell activation. The cytokines produced by activated Th cells have a regulatory role in B cell 
differentiation. In this study we investigated, using immunohistochemical techniques, the in 
vivo time course and localization of gp39-expression and cytokine-production in relation to 
the specific-antibody production. Both the immunization with KLH, a thymus dependent (TD) 
antigen, and TNP-Ficoll, a thymus independent type 2 (TI-2) antigen, induced Th cells to 
express gp39. The expression of gp39 was restricted to Th cells in the outer-periarteriolar 
lymphocyte sheaths (outer-PALS) and around the terminal arterioles (TA). Incidently, gp39+ 
Th cells were found in the corona of follicles, whereas gp39+ cells were never found in the 
germinal centers (GC) or marginal zones of the spleen. Maximum frequencies of gp39+ cells 
were observed 3 and 4 days after primary and secondary immunization with KLH. After 
injection of TNP-Ficoll, a marked increase in gp39+ cells was observed confirming previous 
observations that activated T cells are involved in Tl-2 antibody responses. Analysis of the in 
vivo cytokine production revealed that IL-2-, IL-4- and IFN-y-producing cells (IFN-y-PC) 
developed according to similar kinetics as observed for gp39+ cells. IL-2-PC and IL-4-PC were 
present in higher frequencies as were IFN-y-PC in the immune response against TNP-KLH. 
Double staining experiments revealed gp39+ Th cells producing IL-2, IL-4 or IFN-y, suggesting 
that these cells were involved in both the initial activation as well as the differentiation process 
of B cells into antibody-forming cells. Dual immunohistochemical analysis revealed 
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gp39' T cells and cytokine-PC in close proximity to antigen-specific antibody-forming B cells. 
In conclusion, this study shows that in vivo gp39 is expressed on activated Th cells after 
immunization with TO and Tl-2 antigens. Furthermore, the time course and 
compartmentalization of gp39+ expression, cytokine production and antibody-formation after 
immunization suggest that cognate T-B cell interactions and T cell-regulated B cell 
differentiation occur in the outer-PALS and around the terminal arterioles of the spleen. 
INTRODUCTION 
The initiation of thymus-dependent (TO) antibody responses requires cognate interactions of 
class 11-restricted antigen-specific Th cells with B cells. None of the molecularly cloned 
cytokines, alone or in combination, can replace the contact-dependent requirement forB cell 
activation (1-3). The molecule which mediates the contact-dependent signal was identified 
as a membrane protein that is expressed on the suriace of activated Th cells (4, 5). This 
membrane protein, gp39, was identified as the ligand for the B cell membrane protein CD40. 
In vitro studies using gp39-bearing plasma membranes from activated Th cells showed that 
these plasma membranes induce the activation of resting B cells (6, 7). A soluble, C040-Ig 
fusion protein and a gp39-specific mAb were able to block the activation of B cells by these 
plasma membranes (5). Recently, several groups showed that mutations in gp39 are 
responsible for the defective antibody production in patients with X-linked hyper-lgM 
syndrome, indicating that this molecule expressed by activated Th cells is essential for 
humoral immunity (8-11 ). Isolation of eDNA clones encoding murine (4) and human gp39 (12) 
showed that this molecule encodes a type II membrane protein. Comparison of the predicted 
gp39 amino acid sequence with those of other published protein sequences shows that gp39 
is homologous to TN F-a and -[3 (12, 13). 
After the initial B cell activation by gp39, Th cell derived cytokines regulate the differentiation 
of B cells into antibody-forming B cells (6, 7). The pattern of cytokine secretion by Th cells 
has been suggested to be decisive in the selection of isotype produced by antibody-forming 
B cells (15-17). It has been shown in vitro that Th1 cells (14), which secrete IL-2 and IFN-y, 
promote lgM and lgG2a secretion by B cells, whereas Th2 cells (IL-4 and IL-5) stimulate B 
cells to produce antibodies of lgG1 and lgE isotypes (15-17). The putative central role of gp39 
and cytokines in the initiation and development of humoral immunity is mainly based on in 
vitro studies. To date, no data has been presented about the simultaneous expression of 
gp39 and cytokines during in vivo antibody responses. Furthermore, the role of gp39 in in 
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vivo antibody responses has not been addressed. A companion paper demonstrates that 
gp39 is essential for the induction of in vivo antibody responses against various TO antigens 
(18). This study describes the in vivo development and localization of gp39+ cells and 
cytokine-producing cells in relation to antigen-specific antibody-formation. 
MATERIALS AND METHODS 
Animals. BCBA.F1 (C57Blx CBA) mice were bred at the TNO breeding facilities, Rijswijk, 
The Netherlands. Animals were used at 16-24 weeks of age and were kept under a standard 
protocol with free access to pelleted food and acidified water (pH 3). Experiments were 
performed under auspices of the Dutch Veterinary Inspection, as described in the law on 
Animal experiments. 
Chemicals. Alkaline phosphatase (AP; P-6774, type VII-T, 1020 U/mg protein), 3-amino-9-
ethylcarbazole (AEC; A-5754), Complete Freunds Adjuvant (CFA), 3,3-diaminobenzidine-
tetrahydrochloride (DAB), Fast blue BB Base (F-0125), Fast red, horse radish peroxidase 
(HRP), Incomplete FreundsAdjuvant (IF A), levamisole, naphthoiAS-MX phosphate (3-hydroxy-
2-naphtoic acid 2,4-dimethyl-anilide), were obtained from Sigma, St. Louis, MO, USA. N-
hydroxysuccinimidyl-(biotinamido )-hexanoate and MHS ( maleimidohexanoyl-n-
hydroxysuccinimide ester) were obtained from Pierce, Rockiord, IL, USA. p-galactosidase (j3-
gal; E. coli-derived fi-D-galactoside galactohydrolase, MW 540 KD), and X-Gal (5-bromo-4-
chloro-3-indolyl-fi-D-galactopyranoside) were obtained from Boehringer, Mannheim, FRG. 
Reagents. TNP-Ficoll and TNP-KLH were prepared as previously described (19, 20). The 
rat mAb Lyt2+ (CD8)(clone 53.6.7.2)(21) and L3T4 (CD4)(clone GK-1.5)(22) were used as cell 
markers. The control hamster antibodies and ascites from the cell lines MR1 (5), a mAb 
directed to gp39 and RG7, a mAb specific for rat/hamster lgK (RG-7; 23) chain were purified 
by means of a protein-A column. Anti-human lgG1 (3.1.1; 24) and Human lgG1 were obtained 
from Nordic lmmunol. Labs, Til burg, The Netherlands. The murine mAb DB-1 directed to IFN-y, 
was a kind gift of Dr. P. H. van der Meide (25) from our Institute. The cells of the rat mAb 
11 B11, directed to IL-4, and IL-4 were a kind gift of Dr. W.E. Paul, Laboratory of Immunology, 
National Institute of Allergy and Infectious Diseases, N.I.H., Bethesda, Maryland (26). The IL-2 
specific mAb, S4B6, was a kind gift of Dr. T. Mosmann (14). Control rat mAb (2A4, 1 G11) 
were a kind gift of Dr. A Zantema, Sylvius Laboratory, Leiden, The Netherlands (27). 
Recombinant mouse IL-2 was obtained from Genzyme, Cambridge, MA, USA. The X631 0 cell 
lines producing IL-4 or IL-2 were a kind gift of Dr. F. Melchers, Basel Institute of Immunology, 
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Basel, Switzerland (28). Antibodies were purified from culture supernatants using an affinity 
chromatography goat anti-rat lg column. Cytokine-specific, gp39-specific and control 
antibodies were conjugated to AP and HRP, as previously described (29). Conjugation to (3-
gal was performed according to the procedure described by Deelder and De Water (30) with 
minor modifications (31 ). TN P-AP and KLH-HRP was prepared according to the previously 
described methods (19, 20). 
Experimental design. BCBA.F, mice were injected i.v. with 100 11g of KLH or TNP-KLH or 
20 11g of TNP-Ficoll and killed after 0, 1, 2, 3, 4, 5, 6, and 7 days. Another group of mice was 
injected with 100 11g of KLH, boosted 16 weeks later with 100 11g TNP-KLH and killed after o, 
1, 2, 3, 4, 5 and 7 days. In a parallel experiment, mice were immunized s.c. with TNP-KLH in 
CFA, boosted 4 weeks later s.c. with 20 ,ug TNP-KLH in IFA and killed 6 days after injection. 
Spleens and draining popliteal lymph nodes were removed and immediately frozen in liquid 
nitrogen and stored at -70'C. 
Immunohistochemistry. Splenic cryostat sections (-20 °C, 8 J-Im), one of every mouse, 
were picked up on the same glass slide and kept overnight under high humidity at RT. Slides 
were air-dried and stored in air-tight boxes until use. Slides were fixed for 10 minutes in 
acetone containing 0.02% H20 2. Slides were incubated horizontally overnight at 4 oc with 
primary cytokine-specific antibody-conjugates diluted in PBS containing 0.1% BSA and titrated 
to obtain optimal results. Immunohistochemical demonstration of gp39 was performed in two 
ways: first, with a gp39-specific hamster mAb, MR-1, followed by a hamster-lg-specific mAb, 
RG-7, conjugated to peroxidase; second, with a fusion-protein of the gp39 receptor, 
CD40-IgG1 (5), followed by a human-lgG1-specific mAb conjugated to peroxidase. For double 
staining of gp39 and CD4 or CDS, spleen sections were incubated simultaneously with MR-1-
AP and L3T 4-HRP or Lyt2+ -HRP. Detection of KLH-specific antibody forming cells (KLH-AFC) 
and TNP-AFC were detected according to previously described methods (19, 20). Slides were 
washed with PBS (three times 5 minutes) and immuno-histochemical revelation was performed 
as described previously; AP (29), HRP (29) and (3-gal (30). For double staining the 
immunohistochemical revelation of AP was performed prior to HRP, and the (3-gal staining 
prior to AP or HRP, because both the peroxidase substrate and the AP substrate were found 
to inhibit the (3-gal activity. To ensure that no over- or understaining occurred, slides with 
adherent substrate solution were monitored by light microscopy during histochemical 
reactions. Sections were counterstained with hematoxylin and mounted in glycerin-gelatin. 
AFC, gp39+ cells and cytokine-PC were counted, and image-analysis was performed as 
previously described (32). A minimum of three sections of each mouse were examined. 
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RESULTS 
Gp39 expression in immune spleen. 
Spleen sections from mice immunized with KLH were stained for the expression of gp39. Two 
gp39-specific reagents were used for detection: first, MR1, a gp39-specific mAb, and second, 
CD40-IgG1, a soluble, recombinant fusion protein of the gp39 receptor and lgG1. In serial 
spleen sections CD40-IgG1 and anti-gp39 identified the same number of cells, which were 
localized in identical anatomical locations (Fig. 1 a,b, table 1). Moreover, MR1 blocked the 
staining with CD40-IgG1 in a dose-dependent manner, confirming the fact that MR1 and 
CD40-IgG1 recognize the same molecule, gp39 (5). Immunohistochemical double staining, 
using anti-gp39 and anti-CD4 mAb, showed that gp39 expression was restricted to the CD4 
lineage cells (Fig. 1 c). 
Table 1. Localization of gp39+ cells in different compartments of the spleen after immunization with 
thymus (in)dependent antigens 
Immunization" Dayb Reagentc 
Saline 4 MR+1 
TNP-KLH: primary 4 CD40-Ig 
4 MR-1 
TNP-KLH: secondary 4 MR-1 
TNP-Ficoll: primary 5 MR-1 
Fe' 
O' 
0 
0 
1 ±1 
0 
White pulp 
GC iP 
0 0 
0 0 
0 0 
0 0 
0 0 
Red pulp 
oP MZ TA 
2±2 0 7±5 0 
16:::7 0 115±16 0 
20±5 0 106±30 0 
36±12 0 165±19 0 
60±18 0 222±30 0 
a.Mice were immunized and sacrificed at the indicated dayb. ccryostat sections were prepared from spleens and 
·,mmunohistochemical demonstration of gp39 was performed with a anti-gp39 mAb, or with C040-Ig followed by 
secondary peroxidase-conjugates. Cells were counted in each anatomical compartmentd of the spleen: Follicular 
corona, Fe; germinal center, GC;inner-PALS, iP; outer-PALS, oP; marginal zone, MZ; terminal arterioles, TA. "Values 
represent mean !: SD number of positive cells in each compartment of spleen sections from three mice. 
Localization and kinetics of gp39' cells in lymphoid tissue. 
Gp39' Th cells were found predominantly in the outer-periarteriolar lymphocyte sheaths 
(PALS) and around the terminal arterioles (TA) of the spleen (Table I, Fig. 1 a, 5b). Double 
staining for CD4+ and gp39 clearly revealed that CD4+ cells in primary follicles were not gp39 
positive (Fig. 1 c). After secondary immunization, only a few gp39' cells were observed in the 
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follicular corona, but not in the GC of secondary follicles (Fig. 1 a). Examination of lymph node 
sections of TNP-KLH immunized mice revealed that gp39+ cells were localized in the deep 
cortex and along the medullary cords (Fig. 1 b). Incidently, gp39+ cells were observed in the 
corona, but not in the GC, of follicles in lymph nodes (data not shown). 
At day 3 and 4 after injection of KLH we observed the maximum number of gp39+ cells (Fig. 
2). Thereafter, the number decreased and remained stable during the next three days. 
Another group of mice was boosted 16 weeks later with KLH. Already during the first two 
days after secondary immunization we observed a striking increase of the number of gp39+ 
cells, which was markedly higher as compared to the the primary response. After four days, 
the gp39+ cells reached maximum numbers, which were about two times higher as we 
observed during the primary immune response against KLH (Fig. 2). Immunization with 
TNP-Ficoll, a Tl type II antigen, resulted in an increase in the frequency of gp39+ Th cells, 
attaining maximum frequencies 5 days after injection (Fig. 3). As was observed for TO 
antigens, in the antibody response against TNP-Ficoll, gp39+ cells were localized in the outer-
PALS and around theTA of the spleen (Fig. 5b). No gp39 expression was observed in the 
splenic follicles of mice immunized with TNP-Ficoll. 
Localization and kinetics of cytokine-producing cells in the spleen. 
Th cell-derived cytokines have a decisive role in isotype-selection (15-17). As antibody 
responses against TNP-KLH are dominated by 1gG1 antibodies, we investigated whether a 
Th subset (Th1!Th2) was preferentially activated and where these cytokine-PC were localized 
in the spleen. Detection of cytokine-PC was performed with cytokine-specific mAb conjugated 
to different enzymes on splenic cryostat sections of TNP-KLH immunized mice. The IL-4-
specific mAb (11 B11) conjugated top-gal was used for the in situ demonstration of IL-4-PC. 
After immunohistochemical revelation, IL-4-PC characterized by a turquoise cytoplasm were 
detected (Fig. 1 d). No staining was observed in control slides from any specimen treated by 
omission or substitution of the primary antibody. Preincubation of 11811 conjugated to ,8-gal 
with recombinant IL-4 inhibited the staining of IL-4-PC, in a dose-dependent manner. 
Moreover, the specificity of the staining was confirmed on cytospin prepararations of cells 
from an IL-4-producing cell line (X631 0-IL-4). IL-2-PC were demonstrated with an IL-2-specific 
mAb (S4B6) conjugated to HRP and were characterized by a red stained cytoplasm, 
respectively (data not shown). Control immune-conjugates showed no staining. Furthermore, 
the specific staining was inhibited by recombinant IL-2 in a dose dependent manner. In 
addition, specificity was confirmed on cytospin preparations of cells from an IL-2-producing 
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Figure 1) Immunohistochemical localization and characterization of gp39+ cells in lymphoid organs. Cryostat 
sections of murine lymphoid tissue were incubated with specific immune-conjugates, followed by immunohisto-
chemical revelation. Conjugates and substrates used are indicated between the square brackets. a) 4 days after 
secondary i.v. immunization wrth KLH; red stained cells are gp39+ cells localized in outer-PALS (o}, around the 
terminal arteriole (t) and in the follicle (f) of the spleen (MR1 + RG?-HRP; AEC]. b) cryostat section of lymph node 
6 days after secondary s.c. immunization with TNP-KLH; red stained cells are gp39+ cells localized in deep cortex 
and along the medullary cords. In this section no gp39+ cells are localized in the follicle (f) [MR1 + RG?-HRP; 
AEC]. c) 3 days after KLH immunization; red membrane positive cells are CD4+ cells, while violet double staining 
cells are CD4+ cells expressing gp39 (arrow). (note that CD4+ cells are present in the follicle (f), while CD4+ cells 
expressing gp39 are found around terminal arterioles (t) and not in the primary follicle (f) [L3T4-HRP, AEC; MR1-AP, 
Fast blue] d) 4 days after KLH immunization, red stained cells are gp39+ cells, turquoise stained cell are IL-4-PC, 
whereas violet stained cells are gp39+ cells producing IL-4 (arrows). [MR1-AP, Fast red; 11611-P·Gal, X-Gal]. 
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Figure 2) Kinetics of gp39+ T cells and KLH-AFC after primary and secondary immunization with KLH. BCBA.F1 
mice were injected i.v. with 1 DO 11g KLH (18) and sacrificed at the indicated time-points. Another group of BCBA.F1 
mice was injected with 100 J.lg of KLH, boosted 16 weeks later with 100 pg KLH i.v. and sacrificed at the indicated 
time-points. Spleens were removed and immunohistochemistry and image analysis was performed as described 
in materials and methods section. Values represent mean ± SD of number of positive cells per mm2 from three 
mice. Closed triangles, KLH-AFC; closed circles, gp39-bearing cells. 
cell line (X631 0-IL-2). The specific demonstration of IFN-y-PC, with an IFN-y specific mAb (DB-
1) conjugated to alkaline phosphatase, was performed as described previously (32, 33). In 
all spleen sections examined, cytokine-PC were observed in the outer-PALS and around the 
terminal arterioles (TA) of the spleen. Cytokine-PC were never observed in the follicles or 
marginal zone of the spleen. Analysis of the kinetics of cytokine-PC revealed higher 
frequencies of IL-2-PC and IL-4-PC, relative to IFN-y-PC, in the antibody response against 
TNP-KLH, reaching maximum frequencies at 3-4 days after immunization (Fig. 4). 
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Figure 3) Kinetics of gp39+ ceffs and TNP-AFC may be superimposed after immunization with TNP-Ficoll. BCBA.F1 
mice were injected i.v. with 20 ;19 TNP-Ficoll and sacrificed at the indicated time-points. Spleens were removed and 
immunohistochemistry and image analysis was performed as described in the materials and methods section. 
Values represent mean ± SO of number of positive cells per mm2 from three mice. Closed squares, TNP-AFC; 
closed circles, gp39-bearing cells. 
Cytokine-production by gp39 positive cells. 
Gp39+ cells are a prerequisite tor B cell activation in vitro (5) and TO antibody responses in 
vivo (18). Thereafter, cy1okine-producing Th cells are thought to be active as regulators of 
antibody responses. In order to investigate whether gp39+ cells have the capacity to produce 
cytokines, as was suggested by in vitro experiments (34), we performed double~staining 
experiments. MR-1 (gp39) was conjugated to AP, whereas S4B6 (IL-2) and 11811 (IL-4) were 
conjugated to HRP and p-galactosidase, respectively. Double staining for IFN-y and gp39 was 
performed with a direct IFN-y-specific conjugate and MR-1 followed by a secundary HAP-
conjugated mAb directed to hamster lg. Double staining tor IL-2 and gp39 revealed red 
stained cells producing IL-2, blue stained gp39+ cells and violet double staining cells, 
representing gp39+ cells producing IL-2 (data not shown). In case of IL-4 and gp39, the 
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Figure 4) Cytokine-PC and TNP-AFC develop according to similar kinetics after immunization with TNP-KLH. 
BCBA.F1 mice were injected i.v. with 100f<9 TNP-KLH (18) and sacrificed at the indicated time-points. Spleens were 
removed and immunohistochemical demonstration of IL-2-, IL-4-, IFN-y-PC and TNP-AFC was pertormed as 
described in materials and methods section. Values represent mean :t SD of number of positive cells per mm2 from 
three mice. 
turquoise stained cells were IL-4-producing cells, the red stained cells were gp39 positive, 
whereas double staining violet cells were gp39' cells producing IL-4 (Fig. 1 d). After double 
staining for IFN-y and gp39, we observed blue stained IFN-y-PC, red stained gp39' cells and 
double staining violet cells, representing gp39' cells producing IFN-y (data not show). In the 
spleen, gp39' cells producing IL-2, IL-4 or IFN-y e found both during TO and Tl-2 antibody 
responses. 
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Figure 5. Gp39+ cells and antigen-specific B cells are co/oca/izing in the immune spleen a) Four days after 
secondary KLH immunization; KLH-AFC, stained red, were found in close proximity to gp39+ cells, stained blue 
[KLH-HRP, AEC; MR1-AP, Fast blue] b) Five days after TNP-Ficoll immunization; Gp39+ cells, stained red, and 
TNP-AFC, stained blue, are found in the same compartments. (Note the gp39"'" cells !it:mp:~J;!ft#!00~11~ TNP-AFC 
in outer-PALS and around TA, but not in follicles and marginal zone. Immune-complexes are found in the follicles) 
[TNP-AP, Fast blue; MR1 +RG7-HRP, AEC]. c= central arteriole, f= follicle, m= marginal zone, o= outer-PALS, r= 
red pulp, t= lymphocyte sheath around terminal arteriole. 
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Kinetics and localization of antigen-specific AFC. 
Using KLH-HRP and TN P-AP conjugates, we were able to study the development of KLH-AFC 
and TNP-AFC in the spleen after immunization with KLH or TNP-KLH (35). As demonstrated 
in figure 2 and 4, in both experiments the kinetics of KLH-AFC or TNP-AFC developed 
according to similar patterns attaining maximum frequencies at 4 days after immunization. The 
frequency of TNP-(hapten)-specific AFC was about 10 times higher than the detected 
frequency of AFC specific for the carrier (KLH). After boosting with KLH we found about 8 to 
1 0 times more KLH-AFC as compared to the primary immunization at the peak of the 
response (Fig. 2). Immunization with TNP-Ficoll resulted in a gradual increase of the number 
ofTNP-AFC attaining the maximum number at day 5 after immunization (Fig. 3). 
Gp39 positive cells co-localize with antigen-specific B cells. 
As gp39+ Th cells have been found to be essential for the activation of 8 cells in vitro and in 
vivo, their anatomical localization in relation to resting and antibody-producing B cells was 
examined. Double immunohistochemical staining for resting 8 cells (membrane lgM-bearing) 
or B plasma blasts (cytoplasmic lg) and gp39, revealed that the majority of gp39' Th cells 
were co-distributed amongst both B cell types in the outer-PALS and TA (data not shown). 
In addition, when antibody-forming 8 cells, specific for the immunizing antigen, were revealed, 
the KLH-AFCfTNP-AFC were found in close proximity to the gp39' Th cells (Fig. 5a). Also in 
the immune response against TNP-Ficoll we observed antigen-specific 8 cells (TNP-AFC) co-
localizing with gp39' cells in the outer-PALS and around theTA (Fig. 5b). 
DISCUSSION 
The present study demonstrates that during in vivo antibody responses gp39 expression and 
cytokine-production develop simultaneously and are predominantly localized in the outer-
PALS and around the TA of the spleen. The gp39' cells and cytokine-PC are found in close 
proximity to antigen-specific B cells. These results suggest that the initial Th eel! induced B 
cell activation and the subsequent Th cell regulated 8 cell differentiation occur in restricted 
compartments of the spleen. Furthermore, high frequencies of IL-4-PC, relative to IFN-y-PC, 
are found in the immune response against TNP-KLH. 
In the primary antibody response against KLH, maximum frequencies of gp39+ Th cells were 
observed 3-4 days after i.v. immunization (Fig. 2). Later during the course of the immune 
response, reduced numbers of gp39+ Th cells were present. Parallel studies using 
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KLH-primed mice showed that upon secondary immunization with KLH, a significant increase 
in gp39+ Th cells was observed within 24 hrs (Fig. 2). Maximum frequencies in the secondary 
response were reached at day 4 and were about twice as high as those observed during 
primary responses. This observation is in agreement with the results described in the 
accompanying paper (18), which shows a twofold increase in helper activity after adoptive 
transfer of SRBC immunized spleen cells. Furthermore, the kinetics of appearance of gp39+ 
Th cells and KLH-AFC were superimposable (Fig. 2)./n vitro studies using Th cell clones have 
demonstrated that gp39 is rapidly expressed upon triggering with anti-CD3 mAb (5). Data 
presented herein document that in vivo administration of antigen induces a rapid expression 
of gp39 on CD4 + Th cells. The simultaneous development of gp39+ cells and KLH-AFC, 
together with the demonstration of gp39+ Th cells in close proximity to KLH-AFC, suggest that 
gp39 expression plays a role in the specific antibody production. This is substantiated by 
experiments described in the accompanying paper which show that anti-gp39 mAb were able 
to significantly reduce the antibody responses to KLH in vivo (t 8). 
It is well known that rigorous T cell depletion completely abrogates the anti-TI-2 antibody 
response, indicating that T cells are necessary for a bona fide Tl-2 response (36-38). The 
observed high frequency of gp39+ Th cells after immunization with TNP-Ficoll was surprising, 
given the fact that the antibody responses to TNP-Ficoll were unaffected in vivo following 
administration of anti-gp39 mAb (18). This finding shows that gp39 expression on T cells in 
the spleen by itself is not enough to activate B cells or could indicate that gp39 detected in 
the spleen sections is not the same gp39 that seems to be necessary tor TO antibody 
responses in vivo. The process of T cell activation, revealed in vivo as an increase in the 
number of gp39+ Th cells, could be explained as suggested by DeKruyff et al. (39), who 
showed in vitro that in Tl-2 immune responses activated B cells were responsible for the 
activation ofT cells. Similar results were described by Zisman et al. (40), who demonstrated 
that Tl-2 antigens, composed of 0 amino acids which bind to class !I molecules of antigen-
presenting cells, were able to activate T cells. These activated T cells can produce cytokines, 
as was demonstrated in vitro (40) and in vivo (32), and may regulate the proliferation and 
differentiation of B-cells activated by Tl-2 antigens (41 ). 
Analysis of the kinetics of cytokine-PC revealed that IL-2-PC and IL-4-PC were predominant 
in the antibody response against KLH with maximum frequencies at 3-4 days after 
immunization. The IFN-y-PC were also found to be active in this immune response, reaching 
maximum levels at day 3, but the number of IFN .... ;-PC was low as compared to the number 
of IL-2- and IL-4-PC. Bradley et al. (42) observed that the kinetics of appearance of effector 
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CD4+ T cells that produce cytokines upon restimulation with KLH in vitro were similar for each 
of the cytokines investigated. These results confirm our in vivo findings and suggest that after 
immunization and subsequent antigen presentation, T cells with potency to produce IL-2, 
and/or IL-4, IL-5 and/or IFN-y are activated at about the same time and differentiate into 
cytokine-PC, following a similar time course. At the peak of the immune response, we 
observed relatively high frequencies of IL-2-PC and IL-4-PC in the outer-PALS and around the 
TA. As these cytokine-PC were observed in close conjunction, it is likely that these cells 
create a microenvironment which is rich in IL-2 and IL-4. Such a microenvironment has been 
suggested to be essential for the development IL-4-PC, as was demonstrated in vitro (43-45). 
These experiments suggested that IL-2 was required for the optimum proliferation of cytokine-
producing T cells (43-46), while IL-4 would propagate the preferential development of IL-4-PC 
(43, 44). After double staining we were able to detect TNP-AFC in close proximity to cytokine-
PC (data not shown), suggesting that these cytokines have a role in B cell differentiation. 
Nossal and Riedel (47), demonstrated a rapid rise in precursors of KLH-binding lgGt-
secreting 8 cells in the spleen 5 to 7 days after KLH immunization. ll-4 has been suggested 
to play a role in B cell switching to lgGt and in the propagation of lgGt + AFC (17). 
Consequently, the close proximity of IL-4-PC to KLH-specific B cells may stimulate the 
preferential development of lgGt + B cells. 
In this study we observed incidently (<1%) gp39+ cells in the corona of the follicles, but no 
gp39+ cells or cytokine-producing T cells were found in the GC. These observation are 
compatible with studies in humans (48, 49, 50) and mice (32,52), which demonstrated that 
none of the B cell differentiation factors, such as IL-2, IL-4 and IFN-y, were localized in the 
follicles of lymphoid tissue. Butch et al (51) showed in vitro that IL-4 mRNA was the only 
cytokine expressed by germinal center T cells, whereas these T cells expressed no mRNA of 
the other 9 tested cytokines. As this group examined cytokine mRNA expression in vitro, 
which is not always correlated with protein synthesis in vivo (53), these data are not 
incompatible with our in vivo results. 
Recently, Lederman et al. (54) demonstrated in human lymphoid tissue that the T-ceii-B-cell 
activating molecule (T-BAM), the human equivalent of gp39, was expressed on CD4+ cells in 
the PALS of the spleen and in lymphoid follicles of tonsils, lymph nodes and spleens. 
Essentially the human and murine studies give identical localization patterns for gp39 
expressing T-cells. The observed difference in the number of positive cells in the follicles is 
most likely due to the fact that the murine studies are periormed with a non-replicating 
antigen whereas the human material is most probably chronical inflamed (more activated T-
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cells). 
During primary immune responses, antibody production in PALS and around TA precedes the 
germinal center formation, indicating that the init'1al B cell activation occurs outside the follicles 
(55,56,57). This is in agreement with the results presented in this report, showing no gp39+ 
cells and cytokine-PC in the follicles, but in the outer-PALS and around the terminal arterioles. 
Only after secondary immunization, we observed a low frequency of gp39+ cells in the corona 
of lymphoid follicles. The similar localization of AFC (35), gp39+ cells and cytokine-PC as 
observed in the immune response against KLH or TNP-Ficoll, suggests that T-B cell 
interactions during primary and secondary antibody response against TD or Tl-2 antigens 
occur in the same splenic compartments, e.g. the outer-PALS and terminal arterioles. 
Furthermore, it validates in vitro experiments demonstrating that the kinetics of cytokine 
production and CD40-Iigand expression are superimposable (7). The observation that during 
the entire experimental period antigen-specific AFC and gp39+ cells were found in close 
proximity, in addition to in vitro experiments which showed that extended contact (more than 
48 hrs) is required for maximal proliferative responses (58) or cytokine production (59), 
suggests that T-B conjugates may persist tor several days in vivo. 
Figure 6 shows a model for the development of TD antibody responses in the spleen based 
on presented data and on the localization and migration of immune cells (52). We suggest 
that during the primary antibody response, TO antigens are presented by interdigitating cells 
in the PALS, leading to increasing numbers of antigen-specific T cells which subsequently 
encounter antigen-specific B cells in the PALS, forming T-B cell conjugates (60, 61 ). During 
this cognate T-B cell interaction, CD4+ Th cells will be activated by antigen-presenting B cells 
and express the ligand for CD40. Gp39 will trigger B cell growth and differentiation. Part of 
the activated B cells migrates to the follicles to undergo follicular processes, such as B cell 
selection, somatic mutation, affinity maturation and memory formation (55, 56). Another part 
of the activated B cells migrates to the TA and differentiates into antigen-specific AFC 
regulated by activated cytokine-producing T cells. After secondary immunization, antigen-
specific memory B cells acquire the antigen in the follicle, where it is presented by follicular 
dendritic cells in the form of immune complexes (55, 56). These B cells will migrate to the 
PALS and meet antigen-specific T cells and will subsequently follow the pathway as described 
for primary immune responses. In case of secondary TO antibody responses, the follicles 
already contain relatively high frequencies of antigen-specific B cells, which increases the 
likelihood that B cells encounter antigen-specific T cells in the PALS. This may explain the 
relatively high frequency of activated gp39+ T cells and antigen-specific AFC found during 
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Figure 6) Schematic representation of the activation and migration ofT and B cells in the spleen during the TO 
immune response. Arrows indicate migration of B and T cells in the spleen. C= central arteriole, ip= inner-PALS, 
F= follicle, Fe= follicle corona, MZ= marginal zone, iP= inner-PALS, oP= outer-PALS, R= red pulp, S= sinus, 
ta= lymphocyte sheath around terminal arteriole. • = antigen, ® = resting 8 cell, 4D = memory B cell, 
4D = differentiating antigen-specific B cell4> = antibody-forming 8 cell, C!>= resting T cell,<!f!= activated 
antigen-specific T cell (gp39 positive), fl = cytokine-producing T cell, 11- = FDC, ~ = I DC. 
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secondary immune responses. The observation of higher frequencies of antigen-specific AFC 
relative to gp39+ T cells (Fig. 2), suggests that one T cell may be able to activate more than 
one B cell. Alternatively, the relatively low frequencies of gp39+ T cells could be due to the 
shorter lasting expression of gp39 by T cells (7, 62) as compared to the expression of 
antigen-specific antibodies by B cells. 
In conclusion, this study demonstrates that gp39+ T cells and cytokine-PC are simultaneously 
upregulated in vivo after immunization. These gp39+ cells and cytokine-PC are observed in 
close proximity to antigen-specific B cells. The data presented suggest that the initial cognate 
B cell activation and the subsequent regulation of B cell differentiation by T cells occur in the 
non-follicular areas of the spleen, namely the outer-periarteriolar sheaths and around the 
terminal arterioles. 
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INTRODUCTION 
The initiation of thymus-dependent (TO) antibody responses requires class 
11-restricted antigen-specific helper T cell cognate interactions with B cells. None of the 
molecularly cloned cytokines, alone or in combination, can replace the contact-dependent 
requirement for B cell activation 1. The molecule which mediates the contact-dependent 
signal is a 39 kD membrane protein which is expressed on the suriace of activated T-
helper (Th) cells'·'. This membrane protein, gp39, was identified as the ligand for the B 
cell membrane protein CD40. CD40, a mitogenic receptor expressed on all mature B 
lymphocytes', is a type I membrane protein and member of the TNF receptor family'. 
Evidence that CD40 is an important receptor on B cells is derived from studies that anti-
CD40 mAb and cofactors such as anti-immunoglobulin (lg) and cytokines initiate both B 
cell growth and differentiation6·7 . 
The ligand for CD40, gp39 is a type II membrane protein which is homologous to TN F-a 
and -f13'9 . It is transiently expressed on activated CD4+ cells in vitro3 . It was demonstrated 
that gp39-bearing plasma membranes (PM) from activated Th cells can activate resting 
B cells 10• A soluble, CD40-Ig fusion protein and a gp39-specific monoclonal antibody 
(mAb) were able to block the activation of B cells by these PM'. After activation, the lg-
secretion of activated B cells is regulated by Th cell derived cytokines"·"·". Recently, we 
demonstrated that gp39+ cells are upregulated after immunization with Tl-2 and TD 
antigens and are localized in juxtaposition to antigen-specific antibody-forming cells in 
restricted compartments of the spleen 13. It was demonstrated that these putative gp39-
CD40 interactions are critical for the development of secondary antibody responses 
against soluble TO antigens14. 
Germinal centers (GC) are clusters of B lymphoblastoid cells which develop after antigenic 
stimulation in follicles of peripheral lymphoid organs and are thought to play a major role 
in the generation of B cell memory''- GC formation is known to be TD16, although it is not 
known how T cells are involved in the induction of the GC reaction. In vitro studies 
suggested that the CD40-molecule is important for GC formation n Therefore, we 
investigated in this study the localization of CD40-Iigand bearing cells in the spleen during 
the formation of GC. Furthermore, the in vivo localization of gp39-CD40 interactions in the 
spleen, and their role in primary antibody responses and GC formation was assessed. 
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MATERIALS AND METHODS 
Animals BCBA.F1 (C57BL x CBA) and BALB/c mice were bred at the TNO 
breeding facilities, Rijswijk, The Netherlands. Animals were used at 16-24 weeks of age and were 
kept under a standard protocol with free access to pelleted food and acidified water (pH 3). 
Chemicals Alkaline phosphatase (AP; P-6774, type VII-T, 1020 U/mg protein) 3-
amino-9-ethylcarbazole (A-5754), Fast blue BB Base (F-0125), horse radish peroxidase (HRP), 
levamisole, naphthol AS-MX phosphate (3-hydroxy-2-naphtoic acid 2,4-dimethyl-anilide), TNP 
sulfonic acid (TNBS, grade I) were obtained from Sigma, St. Louis, MO, USA 
Reagents TNP-Ficoll and TNP-KLH were prepared as previously described18• The 
control hamster antibodies and ascites from the cell lines MRI (3}, a mAb directed to gp39 and 
RG7, a mAb specific for rat/hamster lg,o.: (RG-719) chain were purified by means of a protein-A 
column. TNP-AP was prepared according to the previously described methods16• 
Experimental design BCBA.F, mice were injected i.v. with 100 J.lg of TNP-KLH 
or 20 f.Jg of TNP-Ficoll and killed after 0, 1, 2, 3, 4, 5, 6, and 7 days. To determine the functional 
role of gp39+ cells in TD and Tl-2 antibody responses, BALB/c mice were injected i.v. with either 
100 pg of TNP-KLH or 20 pg TNP-Ficoll on day 0. Subsequently, at day 0, 2, 4 mice were given 
250 pg of purified anti-gp39 mAb (MRi) or 250119 purified hamster lg or PBS, i.p., as previously 
described14• Mice were bled at day 7 and 14, sacrificed at day 14 and serum was prepared. In all 
experiments spleens were removed and immediately frozen in liquid nitrogen and stored at -70°C. 
Immunohistochemistry Immunohistochemistry was done as earlier described"1'22 • 
TNP-specific ELISA TNP-specific lgM and lgG were determined in mouse serum 
by means of a direct ELISA as described earlier3 . The isotype-specific capture ELISA was 
performed as described by Vos et al.24 . The TNP-specific titer was the dilution at which 50% of 
the maximum absorbance was found. Titers of each isotype were related to that of a control (PBS) 
group, which was set at 100%. 
RESULTS AND DISCUSSION 
Localization and kinetics of gp39+ cells in lymphoid tissue. Spleen sections from 
immunized mice were stained for the expression of gp3913 . Gp39+ Th cells were found 
predominantly in the outer-periarteriolar lymphocyte sheaths (PALS) and around the 
terminal arterioles (TA) of the spleen (Fig. 1 ), but not in the follicles or marginal zone of 
the spleen. At day 3 and 4 after injection of TNP-KLH we observed the maximum number 
of gp39+ cells 13. Thereafter, the number decreased and remained stable during the next 
10 days. Immunization with TNP-Ficoll, a Tl type 2 antigen, resulted in an increase in the 
frequency of gp39+ Th cells, reaching maximum frequencies 5 days after injection 13 . 
Similar as observed for TO antigens, in the antibody response against TNP-Ficoll gp39' 
cells were localized in the outer-PALS and around the TA of the spleen. 
Fig. 1. Gp39+ cells (arrow) are found in close conjunction to TNP-AFC around the terminal 
arterioles of the spleen 4 days after immunization with TNP-KLH 
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Gp39+ cells co-localize with antigen-specific B cells. 
As gp39+ Th cells are essential for the activation of B cells in vitro and in vivo, their 
anatomical localization in relation to resting and antibody-producing 8 cells was examined. 
Double immunohistochemical staining for resting 8 cells (membrane lgM-bearing) or B 
plasma blasts (cytoplasmic lg) and gp39, revealed that the majority of gp39+ Th cells were 
co-distributed amongst both B cell types in the outer-PALS and TA (data not shown). In 
addition, when antibody-forming B cells, specific for the immunizing antigen, were 
revealed, the TNP-AFC were found in close conjunction to the gp39+ Th cells (Fig. 1). Also 
in the antibody response against TNP-Ficoll we observed antigen-specific B cells (TNP-
AFC) co-localizing with gp39+ T cells in the outer-PALS and around theTA. These results 
suggest that during Tl-2 as well as TD antibody responses T-B cell interactions occur in 
the non-follicular compartments of the spleen 13. 
Anti-gp39 administration inhibits the primary lgG antibody responses to TD antigens. 
In vitro studies indicated that anti-gp39 mAb blocked the Th-dependent activation of B 
cells'. We observed high frequencies of gp39+ cells in juxtaposition to TNP-AFC at 2·4 
days after TNP-KLH immunization. In order to investigate whether these putative gp39-
CD40 interactions were essential for the primary antibody response against TNP-KLH in 
v;vo, mice were treated with anti-gp39 mAb after immunization. The primary anti-TNP 
antibody response was completely inhibited when we examined the lgG subclasses (Fig. 
2). The antigen-specific lgM response was not completely inhibited after treatment with 
anti-gp39 mAb, confirming that this part of the response was not fully T cell (gp39)-
dependent25. 
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Anti-gp39 administration does not inhibit the antibody response to Tl-2 antigens 
We observed that gp39+ cells were upregulated after administration of TNP-Ficoll, a~d 
localized in close conjunction to TNP-AFC, suggesting that gp39-CD40 interactions play 
a role in the initiation of Tl~2 antibody responses. In order to address this possibility we 
treated TNP-Ficoll immunized mice with anti-gp39 mAb. Figure 2 demonstrates that the 
in vivo lgM, lgG2a and lgG3 antibody responses against TNP-Ficoll were not blocked by 
gp39-specific antibodies. These results ·Indicate that the gp39 is not functional in the 
induction of Tl-2 antibody responses. The gp39+ cells localized in juxtaposition to TNP-
AFC may represent interactions between activated cytokine-producing Th cells and 
antibody-forming cells22 . The demonstration of activated T cells in the spleen after TNP-
Ficoll immunization substantiates previous reports, which showed that T cells are 
important for the development of antibody responses against Tl-2 antigens26•27 . 
Anti·gp39 administration inhibits GC formation 
GC formation is a T cell dependent process. Nude mice do not develop GC upon 
antigenic challenge, but are able to produce GC after reconstitution with T cells 16• To 
investigate whether gp39+ (activated) T cells play a role in GC formation, we studied the 
influence of the anti-gp39 treatment on the formation of GC at day 14 after TNP-KLH 
immunization. Interestingly, anti-gp39 treatment completely inhibited GC formation. Since 
we demonstrated in previous reports 14 that gp39+ cells are not depleted after injection of 
anti-gp39, these results suggest that gp39-CD40 interactions play a role in GC formation. 
Gp39+ cells were never observed in the follicles of spleens after primary immunization, 
indicating that the initial B cell activation occurs outside the follicles, as was earlier 
suggested"·"·". Apparently, after activation by gp39+ cells, B cells get the competence 
to proliferate in the microenvironment of follicles, which will lead to the development of 
germinal centers. 
Conclusions 
Data presented and previous studies on the localization and migration of immune cells30 
suggest that during primary antibody responses, TO antigens are presented by 
interdigitating cells in the PALS, leading to increasing numbers of antigen-specific T cells 
which subsequently encounter antigen-specific 8 cells in the PALS, forming T-B cell 
conjugates. During this cognate T-B cell interaction, Th cells will be activated by antigen-
presenting B cells and express the ligand for CD40. Gp39 will trigger B cell growth and 
differentiation. Part of the activated B cells migrates to the follicles to undergo follicular 
processes, such as somatic mutation and memory formation 15 . Another part of the 
activated B cells migrates to theTA and differentiates into antigen-specific AFC regulated 
by activated cytokine-producing T cells 13·30. In conclusion, presented data suggest that 
the gp39-CD40 interactions which occur in the outer-PALS and around the terminal 
arterioles of the spleen are essential for the induction of TD antibody responses as well 
as germinal center formation. 
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ABSTRACT 
In thymus dependent (TO) antibody responses a physical interaction between T and B cells 
is required for the activation of Th cells. After activation, Th cells will express a 39 Kd protein 
(gp39) on their membranes and produce cytokines. Binding of gp39 to the C040 molecule 
on B cells provides the initial B cell activating signal, while the Th cell derived cytokines 
regulate the B cell differentiation into antibody-forming cells. In order to determine the timing 
and localization of these phenomena during in vivo TO antibody responses, we investigated 
in vivo the successive events of antigen localization, gp39 expression, cytokine production 
and antibody production after injection of rabbit anti-mouse lgD (RalgD) antibodies. Shortly 
after immunization, injected RalgD was observed in all the follicles of the spleen. At 36 h after 
RalgD injection, the frequency of gp39+ cells started to increase and attained maximum levels 
at day 4. Double staining revealed gp39+ cells producing IL-2, IL-4, or IFN-y, and explains the 
observation that the kinetics of cytokine-producing cells (cytokine-PC) were superimposable 
to that of activated gp39+ Th cells. IL-2-PC and IL-4-PC were observed in markedly higher 
frequencies as were IFN-y-PC. Analysis of the in vivo cytokine profile revealed low frequencies 
of cells producing IL-2 and IFN-y, or IL-4 and IFN-y, or IL-2 and IL-4 consistent with the Th2 
character of this response. All gp39+ cells and cytokine-PC were predominantly localized in 
the peri-arteriolar lymphocyte sheaths (PALS) and around the terminal arterioles (TA) of the 
spleen, whereas the injected RalgD was preferentially localized in the follicles, implicating that 
antigen-acquisition and presentation occur in different compartments. Three and four days 
after RalgD injection, high frequencies of gp39+ cells and cytokine-PC were observed in 
juxtaposition to lgM+ cells, which preceded the high lgE and lgG1 production observed after 
day 7. Treatment of RalgD immunized mice with anti-gp39-specific mAb, resulted in an almost 
complete suppression of the polyclonal antibody response after RalgD injection. The 
possibility that the anti-gp39 treatment depleted gp39+ cells and cytokine-PC in vivo, was 
ruled out by showing that injection of anti-gp39 mAb did not affect the expression of gp39 
and cytokines in vivo. 
In conclusion, presented data suggests that cognate T-B cell interactions, leading to isotype-
switching and antibody-production, occur predominantly in the PALS and around the terminal 
arterioles of the spleen. Furthermore, it was demonstrated that IL-2 and IL-4 are two of the 
principal active cytokines in the in vivo immune response to RalgD. Moreover, the in vivo 
localization, kinetics and function of gp39+ cells, cytokine-PC, in relation to lgM+ cells and lgG 
and lgE antibody production, indicate a major regulating role of gp39+ Th cells and their 
products in the antibody response after RalgD injection. 
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INTRODUCTION 
T-B cell interactions have a central role in the development of humoral immunity. B cells 
capture antigen via their antigen-specific receptor and present the processed antigen to 
specific Th celts. The recognition of complexes of processed antigens in context of MHC on 
8 cells, together with the interactions of the costimulatory molecule 87 on 8 cells with CD28 
on Th cells (1 ), leads to the initial class II restricted, antigen-specific activation of Th cells. 
These activated Th cells express novel surface proteins on their membranes and produce 
cytokines, which enable them to activate the B cells. The activation of B cells requires a 
physical contact with activated Th cells which cannot be replaced by presently known 
cytokines (2, 3). Recently, it was demonstrated in vitro that a 39 kD surface protein (gp39), 
selectively expressed on activated Th cells, and its receptor CD40 on B cells were critical for 
the initial Th dependent 8 cell activation (4, 5}. After the initial B cell activation, Th cell derived 
cytokines are thought to regulate the differentiation of B cells into antibody-forming cells 
(2,6,7). The pattern of cytokine secretion of Th cells appears to be crucial in the selection of 
isotype produced by antibody-forming 8 cells (8,9, 1 0). It has been shown in vitro that Th1 
cells (11 ), which secrete interleukin-2 (IL-2) and interferon•; (IFN-y), promote lgM and lgG2a 
secretion by 8 cells, whereas Th2 cells (IL-4 and IL-5) stimulate B cells to produce antibodies 
of lgG1 and lgE isotypes (8,9, 1 0). 
Most of the above discussed data are derived from in vitro experiments. However, whereas 
cells can interact relatively randomly in cell suspension, peripheral lymphoid tissues like lymph 
nodes and spleen have distinct compartments, each consisting of particular cell types, which 
dictate the cell-cell interactions that are allowed or impossible. in vitro experiments necessarily 
disregard this complex organization of lymphoid organs, and may therefore not be applicable 
to in vivo immune responses. In order to get insight in the microenvironment of lymphoid 
tissues, studies were initiated, which addressed the in vivo activity and anatomical 
compartmentalization of immune cells during antibody responses (12). In vivo analysis of TO 
antibody responses have demonstrated that the frequency of gp39' cells and cytokine-
producing cells (PC) were upregulated after administration of KLH, a TD antigen (13). These 
effector Th cells were found in juxtaposition to activated KLH-specific 8 cells. In a separate 
report evidence was provided that gp39 was essential for antibody responses against TO 
antigens (14). For the investigation of the role of cytokines in isotype switching several in vivo 
models are used (15). Injection of mice with goat antibodies directed to mouse lgD (GalgD) 
leads to a strong polyclonal activation of the murine immune system (16, 17). These antibodies 
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bind to and cross link mouse B cell membrane lgD, resulting in the activation of B cells. 
Gal gO is internalized, processed, and presented to goat-lg-specific T cells, leading to massive 
T cell activation and cytokine production (18, 19). Recognition of the injected anti-lgD antibody 
as foreign is required for the induction of lgG1 and lgE production (17, 20), isotypes which 
are suggested to be regulated by a.o. IL-4 (8,9,1 0). The high degree ofT cell activation and 
cytokine-production, which is critical for the large antibody production, make this model ideal 
for analysis of the sequence of immunological events during in vivo TD immune responses. 
To get insight in the splenic microenvironment during antibody responses, we analyzed the 
localization and development of antigen-handling, gp39 expression, cytokine-production and 
antibody-formation in spleens of mice after injection of RalgD. Furthermore, we investigated 
the in vivo role of gp39+ cells in this polyclonal antibody response. 
MATERIALS AND METHODS 
Animals. BALB/c and BCBA.F, (C57BL x CBA) mice were bred at the TNO breeding 
facilities, Rijswijk, The Netherlands. Animals were used at 16-24 weeks of age and were kept 
under standard protocol with free access to pe!leted food and acidified water (pH 3). 
Experiments were performed under auspices of the Dutch Veterinary Inspection, as described 
in the law on Animal experiments. 
Chemicals. Alkaline phosphatase (AP; P-6774, type VII-T, 1020 U/mg protein), 3-amino-9-
ethylcarbazole (AEC; A-5754), 3,3-diaminobenzidine-tetrahydrochloride (DAB), 5-BCIP (5-
bromo-4-chloro-3-indolyl-phosphate; B-8503), Fast blue BB Base (F-0125), Fast red, horse 
radish peroxidase (HRP), levamisole, naphthol AS-MX phosphate (3-hydroxy-2-naphtoic acid 
2,4-dimethyl-anilide), were obtained from Sigma, St. Louis, MO, USA; N-hydroxysuccinimidyl-
(biotinamido)-hexanoate and MHS (maleimidohexanoyl-n-hydroxysuccinimide ester) were 
obtained from Pierce, Rockford, IL, USA; fl-galactosidase (fl-gal; E. coli-derived fl-O-
galactoside galactohydrolase, MW 540 KD), and X-Gal (5-bromo-4-chloro-3-indolyl-fl-D-
galactopyranoside) were obtained from Boehringer, Mannheim, FRG. 
Reagents. RalgD, goat-lg (Gig) specific for mouse lgE conjugated to HRP, anti-human 
lgG1 (3.1.1; 21) and human lgG1 were obtained from Nordic, Tilburg, The Netherlands. AP-
conjugated Gig to mouse lgM or lgG were obtained from Tago, Burlingame, CA 94010. Gig 
anti-mouse lgG2a was obtained from Southern Biotechnology, USA. Biotinylated Rig anti-
mouse lgG2a was obtained from Pharmagen, San Diego, USA. Rabbit antibodies against 
peroxidase complexed with peroxidase (RPAP), and swine anti-Rig conjugated to HRP were 
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obtained from Dakopatts, Copenhagen, Denmark. Avidin~HRP and avidin~AP were obtained 
from Sigma, St. Louis, MO, USA. The control hamster antibodies and ascites from the cell line 
MR1 (5), a mAb directed to gp39 and RG7, a mAb specific for rat/hamster lgK (RG-7; 22) 
chain were purified by means of a protein-A column. The murine mAb DB-1 directed to IFN-y, 
was a kind gift of Dr. P. H. van der Meide (23) from our Institute. The cells of the rat mAb 
11 B11, directed to IL-4, and IL-4 were a kind gift of Dr. W.E. Paul, Laboratory of Immunology, 
National Institute of Allergy and Infectious Diseases, N.I.H., Bethesda, Maryland (24). S4B6, 
directed to IL-2, was a kind gift of Dr. T. Mosmann (11 ). Control rat mAb (2A4, 1 G11) were a 
kind gift of Dr. A Zantema, Sylvius Laboratory, Leiden, The Netherlands (25). Recombinant 
mouse IL-2 was obtained from Genzyme, Cambridge, MA, USA. The X631 0 cell lines 
producing IL-4 or IL-2 were a kind gift of Dr. F. Melchers, Basel Institute for Immunology, 
Basel, Switzerland (26). Antibodies were purified from culture supernatants using an affinity 
chromatography goat anti~rat lg column. Cytokine~specific and control antibodies were 
conjugated to AP and HRP as previously described (27). Biotinylation was performed as 
previously described (28). Conjugation to (1-gal was pertormed according to the procedure 
described by Deelder and De Water (29) with minor modifications (30). TN P-AP and KLH-HRP 
was prepared according to the previously described methods (31 ). 
Experimental design. BCBA.F, mice were injected i.v. with 800f.lg of RalgD and killed after 
1.5, 3, 4, 5, 6, 7, 9, and 11 days. Mice were bled and serum was prepared. Spleens were 
weighed, removed and immediately frozen in liquid nitrogen and stored at ~70°C. 
To determine the functional role of gp39+ cells in this antibody response, high responder 
BALB/c mice were injected i.v. with 800 ,ug of RalgD on day 0. Subsequently, on day 0, 2, 4 
mice were given 250 ,ug of purified anti-gp39 mAb (MR1) or 250 ,ug purified hamster lg or 
PBS, i.p .. Mice were bled and sacrificed at day 7, and serum was prepared. Spleens were 
removed, weighed and a part was immediately frozen in liquid nitrogen and stored at ~70°C. 
The other part of the spleen was used for ELISPOT assay. To investigate the effect of anti-
gp39 treatment on the splenic expression of gp39 and cytokines, BCBA.F1 were injected with 
800 ,ug RalgD on day 0. Subsequently, on day 0, 2, 4 mice were given 250 ,ug of purified anti-
gp39 mAb (MR1) or 250 ,ug purified hamster lg or PBS, i.p .. At day 4, 2 h after the last 
injection of anti-gp39 mAb, mice were killed and spleens were removed. 
Immunohistochemistry. Splenic cryostat sections (-20 °C, 8 ,um), one of every mouse, 
were picked up on the same glass slide and kept overnight under high humidity at RT. Slides 
were air-dried and stored in air-tight boxes until use. Slides were fixed for 10 minutes in 
acetone containing 0.02% H20 2. Detection of cytokine-PC was performed as described 
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previously (t3,32). Slides were incubated horizontally overnight at 4 'C with cytokine-specific 
antibody-conjugates diluted in PBS containing O.t% BSA and titrated to obtain optimal results. 
Specificity was confirmed on cytospin preparations of cells from an IL-2- or IL-4-producing cell 
line (X63t O-IL-2). Immunohistochemical demonstration of gp39 was performed in two ways 
(t3): first, with a gp39-specific hamster mAb, MR-t, followed by a hamster-lg-specific mAb, 
RG-7, conjugated to HRP; second, with a fusion-protein of the gp39 receptor, CD40-IgGt (5), 
followed by a human-lgGt-specific mAb conjugated to HRP. For double staining of gp39 and 
IL-2 or IL-4, spleen sections were incubated simultaneously with MR-1-AP and cytokine-
specific ·Immune-conjugates. Detection of KLH-specific antibody forming cells (KLH-AFC) and 
TNP-AFC was performed according to previously described methods (3t ). lgM and lgG 
positive cells were detected with specific antibodies conjugated to AP. Subsequently, slides 
were washed with PBS (three times 5 minutes) and immuno-histochemical revelation was 
performed, as described previously; AP (27), HRP (27) and ;1-gal (29). For the double staining 
experiments, the !mmunohistochemical revelation of AP was performed prior to HRP, and the 
,8-gal staining prior to AP or HAP, because both the peroxidase substrate as well as the AP 
substrate were found to inhibit the fi-gal activity. To ensure that no over- or understaining 
occurred, slides with adherent substrate solution were monitored by light microscopy during 
histochemical reactions. Sections were counterstained with haematoxylin and mounted in 
glycerin-gelatin. Antibody-forming cells, gp39+ cells and cytokine-PC were counted, and 
image-analysis was performed as previously described (32). For quantitation of follicular 
RalgD, all positive follicle were counted and expressed as the percentage of all follicles in 
each cryostat section. A minimum of three sections of each mouse were examined. 
ELISA Microtitre plates (Flow labs, PVC flat-bottomed, 96 wells, # 77-t72-05 highly 
activated) were coated overnight at 4'C with 100 J.ll of 5 J.lg RalgD mr', or 5 J.lg OVA-TNP mr', 
or 5 J.lg KLH mr' in PBS, followed by blocking with t 50 fll 0.5% Gelatine in O.t M sodium 
phosphate buffer + 0.9% NaCI. The plates were washed with PBS plus 0.05% Tween-20. 
Subsequently, plates were incubated with sera from immunized mice for 1 hr at 37 °C, 
washed and incubated with appropriately diluted goat-anti mouse lgM or lgG antibodies 
conjugated to alkaline phosphatase for 1 hr at 37 °C. Plates were again washed five times 
with PBS + O.t% Tween-20 and 100 fll of substrate solution (t g p-nitrophenylphosphateJ' 
in 10 mM diethylene! glycol + t 0 mM MgCI 2 , pH 9.6) was added to each well. The 
absorbance at 405 nm was measured after 30 min, on an automated micro-ELISA reader 
(Titertek Multiskan, Flow Lab., Irvine, Scotland). The antigen-specific titer was expressed as 
dilution at which 50% of the maximal absorbance was found. Total serum lgM, lgE, lgGt, and 
lgG2a were measured by isotype-specific ELISA (33). 
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ELISPOT assay. To quantitate the frequency of antibody-secreting cells, an ELISPOT assay 
was used according to the procedure described by Taguchi et al. with minor modifications 
(34). Spleens were aseptically removed and single cell suspensions were prepared by gently 
teasing them through nylon gauze filters into RPM I plus 0.5% FCS. Cell suspensions were 
washed three times with RPM I plus 0.5% FCS. Microtitre plates were coated overnight at 4 
oc with 50 pi of 5 pg RalgD ml'' in PBS, followed by blocking with 100 pi PBS containing 0.5% 
Gelatine in PBS at 37 °C. Spleen cells (3 x 102 to 1 x 1 05/well) suspended in RPM I plus 0.5% 
FCS were added to individual wells and incubated for 3 h at 37 ac with 5% C02 in air. The 
plates were washed once with H20 plus 0.05% Tween-20 and three times with PBS containing 
0.1% gelatine plus 0.05% Tween-20 and incubated 1 hr at 37 °C with 50 pi of Goat anti-
mouse-lgG/IgM conjugated to AP in PBS containing 0.1% gelatine. Subsequently plates were 
washed three times with PBS containing 0.05% Tween-20 and spots representing single 
antibody-secreting cells were developed with 100 pi 5-BCIP (1 0 mg.ml'') in 2-amino-2-methyl-
1-1 propanol buffer (pH=10,25). The number of spots was enumerated with the aid of a 
dissecting microscope. 
Statistical evaluation. Results were analyzed by the two-sample Student's !-test for 
comparison of two empirical means in a normally distributed population. 
RESULTS 
Injected RalgO localizes in the follicles of the spleen. 
Injected RalgD was detected with Rig-specific antibodies conjugated to HRP and was found 
in all splenic follicles at 36 h after injection (Fig. 1 a, 2). In an experiment separately performed, 
already six h after injection we observed RalgD in all follicles of the spleen (data not shown). 
Staining for mouse lgD revealed an identical follicular localization pattern, indicating that 
immune-complexes consisted of RalgD and mouse-lgD. The localization strongly resembled 
the staining pattern as is observed after injection of preformed immune-complexes (30, 35, 
36), suggesting that circulating in vivo formed mouse-lgD-RalgD-immunecomplexes were 
trapped by follicular dendritic cells. After 36 h, the frequency of RalgD positive follicles 
decreased, but at 7 days after RalgD injection the staining of follicular RalgD intensified 
simultaneously with the development of Rig specific antibody-forming cells, albeit the number 
of RalgD positive follicles did not increase significantly (Fig. 2). Staining with RPAP, showed 
that beyond day 6 after immunization the follicular immune complexes consisted of Rig-
specific mouse-lg. 
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The frequency of gp39+ cells is upregu/ated after injection of Ra/gD. 
The in situ demonstration of gp39+ cells in splenic cryostat sections was performed as 
previously described (13). Incubation with the gp39 specific mAb (MR1) was followed by anti-
hamster-HAP and after immunohistochemical revelation the gp39+ cells stained red (Fig. 
1 b,c). Analysis of gp39 expression, revealed already at 36 h after injection RalgD an increase 
in the frequency of gp39+ cells which reached maximum levels at day 4 (Fig. 2b). Thereafter, 
the frequency of gp39+ cells decreased gradually. The gp39+ cells were localized in the PALS 
and around theTA, like was described in the antibody response against KLH (13). Relatively 
few gp39+ cells were found in the splenic follicles (Fig. 1 b, table 1). 
Cytokine production in the spleen. 
Detection of cytokine-PC was performed with cytokine-specific mAb conjugated to different 
enzymes (13,32). The IL-4-specific mAb (11 811) conjugated to fJ-gal was used for the in situ 
demonstration of IL-4-PC. After immunohistochemical revelation, IL-4-PC, characterized by a 
turquoise stained cytoplasm, were detected (Fig. 1 d, e, g). IL-2-PC were demonstrated with 
an IL-2-specific mAb (8486) conjugated to HRP and were characterized by a red stained 
cytoplasm (Fig. 1f, h). The specific demonstration of IFN-y-PC (Fig. 1f), with an IFN-y specific 
mAb (08-1) conjugated to AP, was performed as described previously (32,37). All cytokine-PC 
investigated, were observed in the PALS and around theTA of the spleen. No cytokine-PC 
were observed in the follicles or marginal zone of the spleen (table 1). Double staining for 
RalgD and individual cytokines showed clearly, that in all cases the injected antigen localized 
Figure 1. Immunohistochemical visualization of antigen, cytokine-PC , gp39+ cells and antibody-forming celfs in 
the spleen after injection of RalgD. Cryostat section of spleens of RalgD treated mice were incubated with specific-
conjugates, followed by immunohistochemical revelation. Conjugates and substrates used are indicated between 
the square brackets a) 1 day after RaJgD injection: red staining represents RalgD which is localized in the splenic 
follicles (F) and not in the PALS (P) [Swine anti-Rig-PO; AEC]; b) 4 days after RalgD injection: gp39+ cells [MR1 
+ RG7-HRP; AEC] are localized in PALS (P) around central arteriole (C), around TA (T) and incidently in the 
follicles (F); c) 4 days after RalgD injection: red stained gp39+ cells [MR1 + RG7-HRP; AEC] are localized in close 
conjunction to blue stained lgM+ 8 cells [GigM-AP; Fast blue]; d) 4 days after RalgD injection: red stained IL-4-PC 
(11811-biotine + avidin-HAP; AEC] are localized in close conjunction to activated cytoplasmic-lgM+ 8 cells 
[GalgM-AP; Fast blue]; e) 4 days after RalgD injection: red stained cells are gp39+ cells [MR-1-AP; Fast red], the 
turquoise stained cells are IL-4-PC [11811-,8-gal; X-Gal]. while the double staining violet cells are gp39+ cells 
producing IL-4; f) 4 days after RalgD injection: red stained cells are IL-2-PC [S486-PO; AEC], blue stained cells 
are IFN-y-PC [08-1-AP; Fast blue], while double staining violet cells are producing IL-2 and IFN1'; g) 4 days after 
RalgD injection: turquoise stained cells are IL-4-PC (11 811-,8-gal; X-Gal], brown stained ceJis are IL-2-PC [S486-PO; 
DAB], while the double staining green cells produce both IL-2 and IL-4; h) 4 days after RalgD injection: red stained 
cells are IFN1'-PC [DB-1-AP; Fast red], the turquoise stained cells are IL-4-PC [11811,:9-gal; X-Gal], while the 
double staining violet cells produce both IFN1' and IL-4. 
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in the follicles, a compartment different from that where cytokine-PC were found. After 
injection of RalgD, high frequencies of IL-2-PC and IL-4-PC, relative to IFN-y-PC, were 
observed attaining maximum levels at day 3 and 4 (Fig. 2b). Thereafter, the frequencies of 
cytokine-PC decreased and were still detectable at day 11 after injection. 
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Figure 2. Fo!ffcular localization of antigen and the development of gp39+ cells, cytokine-PC and Rlg-AFC are 
sequential events in the immune response against RalgD. BCBA.F1 mice were injected with 800 f..19 RalgD and 
sacrificed at the indicated time-points. In order to detect injected RalgD, gp39, IL-2, IL-4 and Rlg-AFC, splenic 
cryostat sections were incubated with specific immune-conjugates, followed by the appropriate substrates, as 
described in the materials and methods section. Follicular localized RalgD is expressed as the percentage positive 
follicles in each cryostat section. Cytokine-PC, gp39+ cells and antibody-forming cells were counted and expressed 
as the number of positive cells per mm2 spleen section. Data presented are the mean ± SO of three mice at each 
time-point. 
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Table 1 
Localization of gp39+ cells and cytokinewPC in the different compartments of the spleen 
after RalgD immunization. 
Cell typec White pulp Red pulp 
Fe• GC PALS MZ TA 
GP39+ cell 1.4 ±1.1b 0 43.8 ±9.4 0 54.8 ±9.5 0 
IL-2-PC 0 0 30.4 ±5.4 0 69.6 :t5.4 0 
IL-4-PC 0 0 39.3 ±8.8 0 60.7 ±8.8 0 
IFN-y-PC 0 0 31.7 ±6.8 0 68.3 ±6.8 0 
BCBA.F1 mice were injected with RalgD and sacrificed at day 4. Cryostat sections were prepared from spleens and 
immunohistochemical demonstration of gp39 and cytokine-PC was pertormed as described in the materials and 
methods section. Cells were counted in each anatomical compartmentaofthe spleen: follicular corona, Fe; germinal 
center, GC; periarteriolar lymphocyte sheaths, PALS; marginal zone, MZ; terminal arterioles, TA. bValues represent 
the specific cell typesc localized in each compartment of the spleens and are expressed as the mean ± SO 
percentage of the total number of positive cells found in examined spleen section. Results are based on spleen 
sections from three mice. 
Cytokine-PC can produce all combinations of cytokines. 
To determine whether cytokine-PC were able to produce simultaneously more then one 
cytokine and whether the cells doing so would belong to either the ThO, Th1 or Th2 subset, 
we pertormed double staining experiments for all combinations of the three cytokines 
investigated. Figure 1f, shows red stained IL-2-PC and blue stained IFN-y-PC, while the double 
staining violet cells are cells that produce both cytokines. About 3-11% of the IFN-y-PC were 
found to produce IL-2 in the immune response against RalgD. In figure 1 g, the brown stained 
IL-2-PC and the turquoise stained IL-4-PC turquoise are demonstrated. The double staining 
green cells are cells that produce both IL-2 and IL-4. After injection of RalgD, about 1-4% of 
the IL-2-PC were found to produce IL-4. In figure 1 h, the red stained cell is an IFN-y-PC and 
the turquoise stained cell an IL-4-PC, while the double stained violet cell produces IL-4 as well 
as IFN-y. During the whole experimental period we found that 1-11% of the IFN-y-PC were 
producing IL-4. 
In vitro experiments suggested that after activation, Th cells express the ligand for CD40 
simultaneously with the production of cytokines (7). In accordance with these in vitro 
observations, we detected in vivo gp39+ cells producing IL-2, IL-4 or IFN-y in spleens of mice 
after RalgD injection (Fig 1 e). 
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/gM expression increases and /gO expression decreases on follicular B cells after injection 
of RalgD. 
In non-immunized mice, B cells in the marginal zone of the spleen are characterized by a 
relatively high expression of membrane lgM and low expression of membrane lgD, whereas 
the follicular B cells have a relatively low expression of membrane lgM and high expression 
of membrane lgD (12). Thirty-six h after injection of RalgD, a striking increase of lgM 
expression on especially the follicular 8 cells, was observed. After day 3, a marked increase 
in the frequency of cytoplasmic-lgM+ cells (clgM+)was observed, localized in the same 
compartment as where gp39+ cells and cytokine-PC were observed: in the PALS and around 
theTA. These cytoplasmic lgM+ cells, were large cells with a central nucleus and a high 
nuclear to cytoplasmic ratio, and appeared therefore rather activated B cell blasts than mature 
plasma cells (Fig 1 c). In contrast, 36 h after RalgD injection, lgD+ B cells were almost 
completely absent in the spleen. Only the follicles, which trapped RalgD-IgD immune-
complexes, were found to be positive for mouse-lgD. 
Cytokine-PC and gp39+ cells are localized in close conjunction to lgM+ B cells 
Since gp39+ cells and cytokines have a role in B cell activation and 8 cell differentiation, 
respectively, the localization of gp39+ cells and cytokine-PC in relation to lgM+ B cells was 
studied. After double staining, gp39+ cells were found in close conjunction to activated B cells 
(clgM+) in the PALS and around TA. Since gp39+ cells produce cytokines it was not 
surprising to find cytokine-PC, most likely expressing gp39, juxtaposed to lgM+ in the same 
compartment as where gp39+ cells were observed. Analogous to the observation of higher 
frequencies of IL-4-PC and IL-2-PC, relative to IFN1'-PC, we found also more IL-2-PC and IL-4-
PC in juxtaposition to clgM+ B cells after injection of RalgD (Fig. 1 d). 
Majority of the antibody-forming cells in the spleen are lgG+ and in part Rig-specific 
The predominance of lgG1 in the immune response to GalgD was already demonstrated in 
several reports (15, 16,17). To investigate the relation between cytokine-production and 
antibody production, we analyzed the development of lgG expression in the spleen after 
RalgD injection. In non-immunized mice we observed only a few lgG+ AFC. Five days after 
injection of RalgD a gradual increase in the number of lgG+ cells was observed, leading to 
maximum frequencies of lgG+ AFC at day 7. Thereafter, the number of lgG+ cells decreased 
gradually. To investigate the antigen-specificity of the antibody response, we incubated 
cryostat sections with RPAP, which revealed that the Rig-specific AFC started to develop at 
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day 5 and reached peak levels at day 7 after injection of RalgD (Fig. 2c). Double staining for 
lgG and Rig at day 7, revealed that about 42±6% of the lgG' cells were specific for Rig. 
Incubation with swine-lg peroxidase conjugate, Gig alkaline-phosphatase conjugate, KLH-
HRP, or TN P-AP revealed only a few AFC specific for these antigens. 
Serum JgG1 increases substantially and is in part specific for Rabbit-/gO. 
Several experiments have suggested that the isotypes lgG1 and lgE are regulated by IL-4, 
whereas IFN-y was suggested to have a regulating role in the lgG2a isotype selection (15, 
38). Therefore, we assessed the serum levels of lgG1 ,2a and lgE after injection of RalgD. As 
expected, both the total-lgG1 as well as the total-lgE serum levels increased about 7 times, 
whereas no increase of the serum lgG2a was observed (Fig. 3). lgM levels reached at day 
5 maximum levels but were not specific for RalgD (Fig. 3). In BCBA.F1 mice, the increase of 
serum lgE and lgG1 did not reach such high levels, as found in the high responding BALB/c 
mice after RalgD injection (compare Fig. 3 and 6, (16)) but the levels were still remarkably 
high for a primary antibody response. To determine the specificity of the lgG production we 
tested immune sera on different antigens. We found that the total lgG antibody response after 
RalgD injection reached a titer of 104 against RalgD, whereas no specific response was found 
against OVA-TNP, KLH, CGG or rat lg, which is in agreement with the results found in splenic 
cryosections of RalgD immunized mice. 
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Figure 3. lgG1 and lgE serum levels increase markedly after injection of RalgD. BCBA.F1 mice were injected with 
BOO J..19 RalgD and bled at the indicated time-points. lgM, lgG1, lgG2a and lgE serum levels were determined by 
ELISA. Data presented are the mean ± SD of three mice at each time-point. 
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Treatment of mice with anti-gp39 mAb suppresses the antibody response after AalgD injection. 
In vitro and in vivo studies indicated that gp39-CD40 interactions are essential for TO humoral 
immunity (4, 5, 14). To address whether cognate T-B interactions were essential in this model 
polyclonal immune response, we assessed the effect of anti-gp39 treatment on the antibody 
response after RalgD injection. Seven days after immunization with RalgD a fouriold increase 
in splenic weight was observed in BALB/c mice. As shown in Fig. 4, anti-gp39 treatment 
completely prevented the increase in splenic weight after immunization with RalgD. 
In contrast, the increase of lgM expression on follicular B cells after RalgD injection, was not 
affected by the anti-gp39 treatment, confirming the T cell independency of the RalgD induced 
lgM expression. Furthermore, the administration of anti-gp39 mAb did not significantly 
influence the splenic cytokine production and gp39 expression after RalgD injection, 
indicating that gp39' cells and cytokine-PC were not depleted by this treatment (table 2). 
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Figure 4. Increase in spleen weight after RafgD injection is completely prevented by the treatment with anti-gp39 
mAb. BALB/c mice were immunized with BOO f-Ig Ral gD and simultaneously injected with 250 JJg anti-gP39 mAb 
(MR1), control hamster antibodies or PBS on days 0, 2 and 4. At 7 days after injection mice were killed and spleens 
were removed and weighed. Data presented are the mean ± SO weights of spleens from four mice. 
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Table 2 
Effect of anti-gp39 treatment on the expression of gp39 and cytokines in spleens of mice 
after RalgD immunization. 
Treatmenta Cell typeb 
GP39+ cell IL-2-PC IL-4-PC IFN-y-PC 
RalgD + MR1 37.7 ±5.3c 30.5 ±4.5 25.8 ±3.6 7.8 :!:0.5 
RalgD + control 31.2 :!:7 28.3 ±5.2 25.3 ±2.7 7.7 ±1.4 
RalgD +PBS 35.2 :!:3.5 25.5 ±3.6 27.1 ±4.1 6.6 ±1.4 
aBCBA.F1 mice were injected with 800 pg of RalgD. Mice were treated at day 0, 2 and 4 with anti-gp39 mAb, control 
antibodies or PBS. At day 4, two hours after the last treatment, mice were sacrificed. Cryostat sections were 
prepared from spleens and immunohistochemical demonstration of gp39 and cytokine-PC was performed as 
described in the materials and methods section. cvalues represent mean ± SO of number of positive cells per 
square mm of three spleen sections from three mice. 
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Figure 5. RalgD-specific antibody response is completely suppressed after treatment with anti-gp39 mAb. BALB/c 
mice were immunized with 800 f./9 RalgO and simultaneously injected with 250 f./9 anti-gp39 mAb (MR1), control 
hamster antibodies or PBS on days 0, 2 and 4. Mice were bled and killed 7 days after immunization. RalgO-specific 
JgG was determined by EUSA. Data presented are the mean ± SO absorbance of sera from four mice after twofold 
dilution starting at 1/100. Solid, broken and dotted line represent, respectively, the sera of PBS, hamster-antibody 
and anti-gp39 treated RalgO immunized mice. 
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By using the hamster-specific HRP-conjugate, we tried to detect at day 4, 2 h after the last 
injection, the i.p. administered anti-gp39 mAb (MR1 ). Only a faint staining, identical to that 
observed after injection of control hamster antibodies, was observed in the marginal zone of 
the spleen (data not shown). No individual cells binding anti-gp39 were detected in situ, 
indicating that not all gp39 molecules on activated Th cells were covered with anti-gp39 mAb. 
ss 
I 
.2' 
u 
~ 100000 
g. 
I g, 
~ 
10000 
RalgD 
lli'a lgG 
I' I lgM 
RalgD + control RalgD + MR1 
Immunization + treatment 
Figure 6. RafgO-specific antibody response in the spleen is completely suppressed after treatment with anti-gp39 
mAb. BALB/c mice were immunized with 800 /-19 RalgD and simultaneously injected with 250 /-19 anti-gp39 mAb 
(MR1), control hamster antibodies or PBS on days 0, 2 and 4. Mice were killed 7 days after immunization and 
RalgD-specific ELISPOT assay was performed. Data presented are the mean ± SO number of RalgD-specific 
antibody-secreting cells in spleens of four mice. 
Analysis of the RalgD-specific antibody response, showed a complete disappearance of 
RalgD-specific antibodies in sera of RalgD immunized mice after treatment with anti-gp39 
mAb (Fig. 5). In agreement with serum data, hardly any RalgD-specific antibody secreting 
cells in vitro (Fig. 6) and Rlg-AFC in situ (data not shown) were found in spleens of anti-gp39 
treated mice at 7 days after RalgD injection. Since modulation experiments were performed 
in the high responding BALB/c mice the increases of serum lgG1 and lgE were about 3-5 time 
higher as found in BCBA.F1 mice (compare fig. 3 and 7). Even this pronounced increase of 
serum lgG1 was completely blocked by anti-gp39 treatment (Fig. 7). Interestingly, only the 
increase of lgE serum levels after RalgD injection, was not completely suppressed by the anti-
gp39 treatment. In conclusion, this data indicates that gp39+ cells are essential for the 
antigen-specific and polyclonal antibody response after RalgD injection. 
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Figure 7. Effects of anti-gp39 treatment on the generation of po/yc/ona! lg responses in RalgD antibody-injected 
mice. BALB/c mice were immunized with 800 119 RalgD and simultaneously injected with 250 J19 anti-gp39 mAb 
(MR1), control hamster antibodies or PBS on days 0, 2 and 4. Mice were killed 7 days after immunization and total 
lgM, lgG1, lgG2a, and lgE was determined by ELISA. Data presented are the mean± SD of four mice. 
DISCUSSION 
In this in vivo study we demonstrated that RalgD is localized, as RalgD-IgD immune 
complexes, in the follicles of the spleen shortly after i.v. injection. Thereafter, a simultaneous 
increase of gp39+ cells and cytokine-PC was observed which were predominantly localized 
in the PALS and around the TA of the spleen. At day 3·5 after RalgD injection, gp39+ cells 
and cytokine-PC were found in close conjunction to activated lgM+ B cells. In vivo blocking 
experiments suggested that these T-8 cell interactions were essential for the high !gG1 and 
lgE serum levels observed at later time-po·lnts. Furthermore, cytokine-PC with an unrestricted 
cytokine profile were demonstrated, though Th2-like cells were found to dominate in the 
antibody response after RalgD injection. 
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The localization pattern of the injected RalgD in the splenic follicles was similar as observed 
for immune-complexes (30,35,36). It is likely that the injected RalgD binds to free lgD in the 
circulation and to mouse-lgD shedded from the by RalgD activated lgD' B cells. During the 
whole experimental period we could detect RalgD-IgD immune complexes in the follicles of 
the spleen, indicating that Rig specific epitopes were continuously presented to the circulating 
B cells. Finkelman et al. (42) showed that injection of FITC-Gig after GalgD treatment 
increased the specific FITC response, indicating that a sustained availability of antigen was 
responsible for the increased specific antibody response. Consequently, the observed 
persistence of antigen in the follicles may explain the relatively high Rlg·specific antibody 
response observed after RalgD injection. The trapping of RalgD-IgD immune-complexes in 
the follicles of the spleen may also contribute to the high cytokine·production and antibody 
production observed after RalgD injection, as has been demonstrated after injection of 
preformed immune-complexes (39,40,4 t). 
None of the injected RalgD was detected in the inner-PALS of the spleen, the compartment 
where dendritic cells are localized. The impossibility to detect RalgD in this compartment 
could be due to the very low amount of antigen in antigen-presenting cells, or due to 
processing by antigen presenting cells which may change their antigenic structure. Kyewski 
et al. (43), showed in vitro that after i.v. injection of myoglobin, splenic DC were the major cell 
types that could stimulate myoglobin-specific T cell clones, in spite of the fact that no 
myoglobin was detected in the dendritic cells of the spleen. Our study suggests that B cells 
are the important antigen-presenting cells in the antibody response after RalgD injection. 
However, it does not exclude the absolute requirement of dendritic cells for the activation of 
naive Th cells (44,45). 
Analysis of gp39 expression revealed already 36 h after injection of RalgD an increase in the 
frequency of gp39' cells in the spleen, reaching maximum levels at days 3 and 4. At day 2-5 
after injection we observed gp39+ cells in juxtaposition to activated B cells, predominantly 
localized in the PALS and around theTA of the spleen. The observation that treatment of mice 
with anti-gp39 mAb resulted in a complete suppression of the polyclonal antibody response, 
suggests that the in situ revealed interactions between gp39+ cells and lgM+ cells represent 
functional T-B cell interactions. As gp39 is exclusively expressed on CD4+ cells (5, 13), these 
results are in agreement with experiments showing that CD4 + cells are essential for the large 
increases of lgE and lgGt serum levels at day 7 after injection of GalgD (20). We 
demonstrated that anti-gp39 treatment did not affect the in situ cytokine production and gp39 
expression after RalgD injection (table 2), indicating that activated gp39+ cells were not 
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depleted by this treatment. This supports previous experiments (14), which demonstrated that 
unaltered Th function can be transferred from mice treated with anti-gp39, suggesting that 
blockage of gp39 was responsible for the in vivo suppression of TD antibody responses. The 
observation that we were not able to detect in situ the injected anti-gp39 mAb on gp39+ cells, 
suggests that blockage of only a part of the gp39-molecules on activated Th cells is sufficient 
to prevent 8 cell activation by gp39+ Th cells. These results are in agreement with 
experiments of Morris et al. (49), which showed that for the generation of an lgG response 
after GalgD injection, intense physical interactions are required between antigen-presenting 
B cells and antigen-specific Th cells. This group (49) demonstrated that even bystander B 
cells , in spite of their close localization to IL-4-PC and gp39+ cells, were not stimulated to 
produce lgG1. The study of Morris et al. together with the herein presented data, suggest that 
injected algD antibodies are presented to antigen-specific Th cells, which are subsequently 
activated and express gp39. Most likely antigen-presentation results in a close physical 
interaction between Th cells and 8 cells, which may be essential for the binding of gp39 to 
the CD40 molecule on the antigen-presenting B cell. In that way, antigen-specific interactions 
may be preserved and will lead to the initial activation of B cells required for the differentiation 
into AFC. The localization and function of gp39-CD40 interactions, as demonstrated in this 
study, resembles a previous in vivo study in KLH immunized mice (13), and indicate that the 
immune response after RalgD injection, albeit polyclonal, behaves like other TD antibody 
responses. 
The kinetics of IL-2 protein expression in this study are in agreement with experiments of 
Svetic et al. (46), who demonstrated that maximum IL-2-gene activity is found 3 days after 
injection of GalgD. The observation that peak IL-2 protein secretion coincides with peak IL-2-
gene expression, supports in vitro experiments of Kelso et al. (50), who showed that IL-2-gene 
expression and protein production by T cell clones were correlated. In contrast, in vitro 
studies by this group did not show a correlation between cytokine-gene expression and 
protein production for IL-4 and !FN-y. The experiments of Svetic et al. demonstrated maximum 
expression of IL-4-genes between day 3 and day 6 after GalgD injection (46), whereas in our 
study maximum IL-4 protein expression was found 3 and 4 days after RalgD injection. A clear 
discrepancy was only found for IFN-y gene expression and protein production, as in our study 
peak production was observed at day 3 and 4, while in the study of Svetic et al. IFN-y gene 
expression started to raise at day 2 reaching maximum levels at day 7. The lack of correlation 
could be explained by the cellular heterogeneity in mRNA expression, and/or by differences 
in translational or secretarial regulation (50,51 ). The in vivo kinetics of IL-4-PC as described 
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in this study, is consistent with experiments of Finkelmann et al. who showed that anti-IL~4 
treatment of Gal gO immunized mice was only effective in blocking lgEHproduction when it was 
administrated from 0-4 days after immunization with GalgD (47,48). 
At the peak of the immune response we observed relatively high frequencies of IL-2-PC and 
IL-4-PC in the outer-PALS and around theTA. As these cytokine-PC were observed in close 
conjunction, it is likely that these cells create a microenvironment which is rich in IL-2 and IL-
4. Such a microenvironment was suggested to be essential for the development IL-4-PC, as 
was demonstrated in vitro (52,53,54). These experiments suggested that IL-2 was required for 
the optimum proliferation of cytokine-producing T cells (52,53,55), while IL-4 would propagate 
the preferential development of IL-4-PC (52,53). The suggested role of IL-2 in T cell 
proliferation is supported by FAGS analysis, showing an increased IL-2R expression on T cells 
at day 3-5 after GalgD injection (19). The presented data, showing higher frequencies of IL-4-
PC relative to IFN-y-PC is consistent with the marked increase of lgE and lgG1 serum levels 
found after RalgD injection, as these isotypes are suggested to be regulated by IL-4 (9, 1 0). 
Peak IL-4-production was observed at day 3 and 4 after RalgD injection, 3 days before the 
maximum frequency of antigen-specific AFC was observed. Interestingly, at these time-points 
high frequencies of IL-4-PC were found juxtaposed to activated lgM+ B cells. This observation 
substantiates experiments of Finkelman et al. (42), which provided evidence that T-B cell 
interactions, leading to high lgG1 serum levels, occur at day 2-4 after GalgD treatment. 
Moreover, the evidence that produced IL-4 is functional at day 3 and 4, was provided by 
serum-lgE modulation studies with anti-IL-4 or anti-IL-4R antibodies (47,48). 
In this study, analysis of cytokine-profiles of cytokine-PC failed to define a clearcut Th1 {fh2 
dichotomy. The majority of IL-4-PC were not producing IL-2 or IFN-y and consequently 
compatible with Th2 cells. However, we found also ThO cells, although in relatively low 
frequencies (1-5%), producing IL-2 and IL-4, or IL-4 and IFN-y. In addition, we observed a 
relatively low percentage of cells producing simultaneously IL-2 and IFN-y, compatible with 
Th1 cells. These results may be explained by the strong Th2 character of this antibody 
response (47,48,52), resulting in high frequencies of cells producing only IL-4. The 
observation that low percentages of cells were producing both IL-2 and IL-4 is supported by 
experiments of Powers et al. (55), who demonstrated, by limiting dilution of KLH stimulated 
lymph node cells, that in vitro produced IL-2 and IL-4 was not derived from the same cells. 
This study clearly showed that injected RalgD localized in the follicles (Fig. 1 a), one of the 
major B cell compartments, whereas cytokine-PC and activated B cells were localized in the 
PALS and around theTA (table 1). Consequently, antigen acquisition and antigen-presentation 
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may occur in different compartments, which would imply that in the spleen antigen presenting 
B cells migrate from follicle to PALS and TA. The localization pattern of RalgD suggests that 
follicular B cells are the major antigen-presenting cells in this antibody response. The 
dominant presentation of RalgD by B cells can lead to the preferential activation of Th2 cells 
(56,57) and may explain the observed high frequencies of IL-4-PC, relative to IFN-y-PC, after 
RalgD injection. 
Figure 2 summarizes the successive immunological phenomena of antigen localization, gp39+ 
cytokine production and specific-antibody production, and suggest the following sequence 
of events after RalgD injection. lgD' B cells, which are predominantly found in the follicles, 
are activated by RalgD, and subsequently migrate to the PALS and TA where they encounter 
Rig-specific T cells. In these compartments B cells will present processed Rig to specific T 
cells, leading to T cell activation, proliferation and cytokine production. As the 
microenvironment of cytokine-PC is rich of IL-2 and IL-4, the development of IL-4-PC will be 
preferentially propagated. Activated Th cells express gp39 and provide B cells the initial 
activating signal. This stimulus in conjunction with IL-4 rich microenvironment, created by IL-4-
PC, propagates the preferential development of B cells, producing lgGt and lgE. In case of 
an antigen-specific antibody response Rig-specific lgM+ cells acquire RalgD in the follicle and 
follow subsequently the same pathway as described for !go+ B cells. 
In conclusion, in this in vivo study we demonstrate for the first time in situ, that IL-2-PC and 
IL-4-PC are dominating over IFN"";-PC in the antibody response after RalgD injection. 
Moreover, 3-5 days after RalgD injection high frequencies of gp39+ cells and cytokine-PC 
were observed in close conjunction to activated lgM+ B cells. Functional studies suggest that 
these T-8 cell interactions, predominantly restricted to the PALS and around the TA, are 
essential for the high lgGt and lgE serum levels found in the antibody response after RalgD 
injection. 
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CHAPTER9 
GENERAL DISCUSSION 
A part of the discussion has been and will be published in: 
Immunological functions and in vivo cell-cell interactions of 
T lymphocytes in the spleen 
Alfons J.M. Van den Eertwegh, Wim. J.A. Boersma, and Eric Claassen 
Grit. Rev. lmmunol., 11: 337-380, 1992 
In vivo T-B cell interactions and cytokine-production in the spleen 
Alfons J.M. van den Eertwegh, Randolph J. Noelle, Wim J.A. Boersma 
and Eric Claassen 
Seminars in Immunology (in press) 
167 
9.1 Cells involved in antibody formation 
A variety of cells are involved in the development of antibody responses. Antigen-present-
ing cells (APC) like macrophages, dendritic cells (DC) and B cells take up antigen, 
process it and present fragments of the antigen (T cell epitopes) to T cells. The presenta-
tion of the T cell epitope in the context of MHC molecules, together with the costimulatory 
signals, provided by antigen-presenting cells, results in the activation of T cells. Under 
specific conditions 8 cells are not able to activate naive T cells (1 ,2}. Therefore, it has 
been proposed that DC or macrophages are required for the primary activation of naive T 
cells. Thereafter, T-8 cell interactions have a central role in the development of humoral 
immunity (Fig. 1 }. 8 cells capture antigen via their antigen-specific receptor (membrane 
immunoglobulin) and present the processed antigen to specific T-helper (Th) cells. The 
recognition of fragments of processed antigens bound in the groove of MHC class II 
molecules on B cells, together with the interactions of the costimulatory molecule 87 on B 
cells with CD28 on Th cells (3), leads to the initial class II restricted, antigen-specific 
activation of Th cells. These activated Th cells express gp39 and produce cytokines, which 
enable them to regulate B cell differentiation. Binding of gp39 to its receptor C040 on B 
cells results in the initial activation of B cells (4,5), while Th cell derived cytokines are 
thought to regulate the differentiation of B cells into antibody-forming cells (6,7,8). The 
pattern of cytokine secretion of Th cells appears to be crucial in the selection of isotype 
produced by antibody-forming B cells (9, 10,11 ). The cell-cell interactions and regulatory 
role of cytokines in antibody responses, as discussed above, is mainly based on a 
combination of results from in vitro experiments which may not be applicable to in vivo 
antibody responses. 
In this thesis, the critical events in the development of antibody responses, as suggested 
by in vitro experiments, were investigated in vivo. Most of the presented studies were per-
formed in the murine spleen, as this secondary lymphoid organ is the major site of 
antibody production after primary i.v. immunization. The localization of injected antigen 
and the subsequently induced expression of gp39 and cytokines were investigated in the 
spleen. Furthermore, the localization and kinetics of appearance of gp39+ cells and 
cytokine-PC was related to that of antigen-specific antibody-forming cells (AFC). Func-
tional studies were performed to analyze the role of cytokines and gp39 in experimental 
antibody responses. In this last chapter, we shall discuss the main points presented in this 
thesis. Finally, in vivo models are presented, which show the cell-cell interactions in the 
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B cell Th cell 
Figure 1 An "immunological synapse" formed beMeen B celfs and Th cells assures the antigen-specific 
activation of B cells by activated Th cells. B cells capture antigen via their antigen-specific receptor (mig) and 
present fragments of the processed antigen (. ;T cell epitope) to specific T-helper (Th) cells. The recognition 
of the T cell epitope bound in the groove of MHC class II molecules on B cells, together with the interactions of 
the costimulatory molecule 87 on B cells with CD28 on Th cells, leads to the class ll restricted, antigen-specific 
activation of Th cells. These activated Th cells express gp39 and produce cy1okines, which enable them to 
regulate B cell differentiation. Binding of gp39 to its receptor CD40 on 8 cells results in the initial activation of B 
cells, while Th cell derived cytokines (@) regulate the proliferation and differentiation of B cells. 
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spleen during thymus dependent (TO) and thymus independent type 2 (TI-2) antibody 
responses. 
9.2 Localization of antigens in the spleen 
A. Localization of particulate antigens in the spleen 
In chapter 3.2 we described the splenic localization of i.v. injected heat killed Group B 
streptococci, particulate Tl-1 antigens. After injection, Group 8 streptococci were predomi-
nantly found in the marginal zone macrophages and to a lower degree in red pulp 
macrophages. These results are in agreement with studies which showed that i.v. injected 
particulate antigens, irrespective of their nature (TO: TNP-SRBC, BSA-Iiposomes; Tl: TNP-
Iiposomes, Brucella abortus), localize in the marginal zone, taken up by marginal zone 
macrophages and marginal metallophils (13). The similar localization observed for all types 
of particulate antigens suggests a common function of these macrophages. Since 
marginal zone macrophages do not express detectable MHC class II antigens (14), it is 
highly unlikely that these cells are active as antigen-presenting cells. In vitro (15, 16) and in 
vivo (17,18) experiments suggested that macrophages can be active as pre-processors of 
particulate antigens. Specific elimination of marginal zone macrophages in vivo resulted in 
a decreased antibody response against liposome-associated albumin (18) and TNP-SRBC 
(17). These experiments indicated that marginal zone macrophages fragmentate (pre-
process) particulate antigens, which subsequently are transferred to either B cells or DC 
(19). The latter cells enter the spleen via the marginal zone and migrate to the 
periarteriolar lymphocyte sheath (PALS) were they can present the processed antigen to 
specific T cells (chapter 2). These data suggest that marginal zone macrophages clear 
particulate antigens from the circulation, and may have a role as pre-processors in 
antibody responses against particulate antigens/bacteriae. 
B. localization of soluble TO antigens in the spleen 
Using immunohistochemical techniques we tried to detect injected TO antigens in the 
spleen, e.g. TNP-KLH and TNP-BSA. In the first days after injection these haptenated TO 
antigens were exclusively localized in the red pulp macrophages (chapter 3.1 ). The 
localization in red pulp macrophages could represent the scavenging of bulk antigen, 
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whereas antigen which is involved in the induction of the humoral immune responses may 
be localized in other compartments. The impossibility to detect these immunological 
relevant antigens in situ could be due to the very low amount of antigen in APC, or due to 
the rapid processing of protein antigens by APC which may change their antigenic struc-
ture, as was suggested by experiments of Kyewski et al. (20). They demonstrated that 
after i.v. injection of myoglobin, splenic DC were the major cell types that could stimulate 
myoglobin-specific T cell clones in vitro, although the antigen could not be detected in the 
inner-PALS of the spleen. 
Immune complexes are formed as soon as antigen-specific antibodies appear in the 
circulation and bind to injected antigen. Immune complexes are also formed if specific 
antibodies recognizing the antigen are already present in the circulation when antigen is 
administered, e.g. during secondary antibody responses. In these situations or after the 
injection of preformed immune complexes, we were able to detect immune-complexes 
(peroxidase-anti-peroxidase and TNP-Ficoll-anti-TNP immune complexes, chapter 3.1, 6; 
mouse-lgD-RalgD immune complexes, chapter 8) in the follicles of the spleen. These 
antibody-complexed antigens are trapped by the processes of follicular dendritic cells 
(FDC) via Fe receptors or complement receptors and can be retained for long periods of 
time (21, 22). The trapped complexed antigen plays a crucial role in B cell memory and 
regulation of antibody responses (22, 23). The follicles have also been suggested to have 
a role in affinity maturation of B cells (24), which is the result of the competition between 
free antibody, antibody trapped in the form of immune-complexes by FDC and membrane 
lg on B cells that are undergoing somatic mutation. Since T cell memory for soluble 
protein is also antigen-dependent (25) and FDC are the only cells known which can 
preserve antigens for months to years, it is likely that follicular trapped antigen also plays 
a role in the maintenance ofT cell memory. 
The data discussed suggest that the localization of injected TO antigens in the spleen is 
not identical for primary and secondary immune responses. In both responses 
macrophages take up the bulk of antigen. However, after the first antigenic challenge 
antigen localizes in the inner-PALS, containing DC and T cells, and plays a role in the 
induction of the primary immune response. Whereas after a secondary challenge, antigen 
localizes also in the follicle, containing FDC, B and T memory cells, which may be crucial 
for induction and maintenance of secondary immune responses. 
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C. Localization of Tl-2 antigens in the spleen 
In chapter 3, the immunohistochemical detection of injected haptenated Tl-2 antigens in 
lymphoid tissue was described. Within minutes after i.v. injection, Tl-2 antigens (TNP-Ficoll, 
TNP-HES) localized in the marginal zone, attached to marginal zone macrophages and B 
cells. Twenty minutes after injection the antigen was also detected in the follicles and 
gradually accumulated there up till 7 hours after injection. Thereafter, the amount of 
follicular antigen gradually decreased but was still detectable up to 14 days after immuniz-
ation (chapter 2: fig. 6). It was demonstrated that the immediate follicular localization of 
TNP-Ficoll was complement dependent and not antibody mediated. lmmunohistochemical-
ly, it is difficult to determine whether FDC or B cells are the principal Tl-2 binding cells in 
the follicles. However, the staining pattern suggests that injected Tl-2 antigens are 
predominantly bound by FDC. 
Because of their specific uptake of fluoresceinated Tl-2 antigens, it was thought that 
marginal zone macrophages play a role in the presentation of Tl-2 antigens (26, 27). 
However, in vivo elimination/blocking of marginal zone macrophages did not affect the 
antibody response against Tl-2 antigens (28,29,30), which suggested that other cells or 
mechanisms were involved in this antibody response. The data presented in this thesis 
show that injected TNP-Ficoll localizes in the major B cell compartments, namely the 
marginal zone and the follicle. In chapter 3.1 it was demonstrated that TNP-Ficoll can 
activate complement in vivo, as was described for other Tl-2 antigens (31 ,32,33,34). The 
subsequently formed complexes of TNP-Ficoll and C3d (a complement degradation 
product) are able to activate B cells directly (34,35,36), without the requirement of antigen 
presenting macrophages. Direct complement dependent activation of B cells by Tl-2 
antigens is compatible with the in vivo localization of Tl-2 antigens in the major B eel_! 
compartment of the spleen and with in vivo experiments, which indicated the trivial role of 
marginal zone macrophages in the induction of Tl-2 antibody responses (28,29,30). 
The localization pattern of TNP-Ficoll suggests that B cells in the marginal zone as well as 
B cells in the follicle can be activated by Tl-2 antigens. This is supported by experiments 
showing that 8 cells from these two compartments do not differ in their responsiveness to 
Tl-2 antigens (37). 
In chapter 3 it was demonstrated that in vivo macrophage elimination drastically increased 
the amount of injected TNP-Ficoll in the follicles. In a previous study it was shown that the 
antibody response against low doses of Tl-2 antigen increased significantly after in vivo 
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macrophage depletion (38). These data suggest that in intact animals, macrophages 
obscure the antigen from the immune system, by removing the injected TNP-Ficoll from 
the circulation, and prevent in that way the direct activation of B cells by Tl-2 antigens. In 
contrast, complement depletion of mice abrogated the localization of Tl-2 antigens in the 
follicles (chapter 3), and was found to lead to a decreased humoral Tl-2 immune response 
(39, 40). These results together suggest that follicular-trapped Tl-2 antigens, FDC and B 
cells have a role in the induction of antibody responses against Tl-2 antigens. Further-
more, it is concluded that the role of marginal zone macrophages in Tl antibody 
responses is not primarily antigen-presentation but rather removal from the circulation (TI-2 
antigens), killing and pre-processing of particulate antigen/bacteriae. 
9.3 The expression of gp39 in the spleen 
In vitro studies revealed that upon activation (by ConA or anti-CD3 mAb) Th cells express 
gp39, a 39 kD surface protein. Further analysis indicated that gp39 is the ligand for the 
CD40 surface molecule on B cells. It was demonstrated that a mAb specific for gp39 and 
a CD40-IgG1 fusion protein block the activation of B cells by activated Th cells, suggest-
ing that these molecules are critical for antibody responses against TO antigens (5). 
The studies presented in this thesis investigated the expression of gp39 in lymphoid 
tissues after immunization with TD and Tl-2 antigens. Furthermore, the function of gp39 in 
TD and Tl-2 antibody responses was assessed. In chapter 7 it was shown that in vivo 
gp39 was exclusively expressed on CD4+ cells. High frequencies of gp39+ cells were 
observed in spleens of mice after immunization with TD (KLH, RalgD) and Tl-2 (TNP-Ficoll) 
antigens. During all antibody responses examined, gp39+ cells were localized predomi-
nantly in the (outer)-PALS and around the terminal arterioles of the spleen. After immuniz-
ation with RalgD and during secondary antibody response against KLH, relatively few 
gp39' cells were also observed in the splenic follicles. Lederman et al. (41) demonstrated 
in human lymphoid tissue that the T-ceii-B-cell activating molecule, the human equivalent 
of gp39, was expressed on CD4+ cells in the PALS of the spleen, like was described in 
this thesis. In contrast to our studies, they found relatively high frequencies of gp39+ cells 
in lymphoid follicles of tonsils, lymph nodes and spleens. This discrepancy could be 
explained by the relatively undefined character of the lymphoid tissue examined by 
Lederman et al. In non-immune murine lymphoid tissue hardly any gp39+ cells were 
detected, whereas in the study of Lederman high frequencies of activated T cells were 
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observed. Since gp39 is only temporarily expressed on T cells (42), the results obtained 
by Lederman et al. are an indication that the lymphoid tissue examined was most likely 
chronically inflamed and consequently not comparable with lymphoid tissue of the labora-
tory mouse, mounting a well defined antibody response against a non-replicating antigen. 
In the murine spleen, gp39' T cells were localized in the outer-PALS and around the 
terminal arterioles, the same compartments where activated B cells are found. These 
results suggest that T-8 cell interactions occur predominantly in these splenic compart-
ments. Indeed, double staining experiments revealed multiple (antigen-specific) activated 8 
cells in close conjunction to gp39' T cells both during TD (KLH, RalgD) and Tl-2 antibody 
responses. To determine whether gp39+ cells had a functional role in these in vivo 
antibody responses, modulation studies were performed. Treatment of mice with gp39 
specific mAb resulted in a complete inhibition of the primary antigen-specific antibody 
response against TO antigens (chapters 7 and 8; 43). Even the huge increase in serum 
lgG1 levels, observed after RalgD injection, was completely suppressed by the anti-gp39 
treatment. Only the secondary antibody response against KLH and the polyclonal increase 
of lgE after RalgD injection were not completely suppressed. Examination of spleens of 
immunized mice revealed that cytokine-production and gp39 expression were not affected 
by the anti-gp39 treatment. Collectively, these observations suggest that the unchanged 
cytokine-production after anti-gp39 treatment provides a microenvironment which 
stimulates activated memory B cells and memory lgE+ AFC to secrete antibodies. The 
observation that anti-gp39 treatment did not affect the frequency of gp39+ cells substanti-
ates previous experiments (43), which demonstrated that unaltered Th function can be 
transferred from mice treated with anti-gp39, and suggests that blockage of gp39 is 
responsible for the in vivo suppression of TO antibody responses. It was not possible to 
demonstrate in situ that injected anti-gp39 mAb were binding to gp39+ cells, which 
suggests that blockage of only a part of the gp39-molecules on activated Th cells is 
sufficient to prevent B cell activation by gp39+ Th cells. These results are in agreement 
with experiments of Morris et al. (44), which showed that for the generation of an tgG 
response after GalgD injection, intense physical interactions are required between antigen-
presenting B cells and antigen-specific Th cells. This group (44) demonstrated that even 
bystander B cells, in spite of their localization close to IL-4-PC and gp39+ cells, were not 
stimulated to produce lgG1. Most likely antigen-presentation results in a intimate physical 
interaction between Th cells and B cells, which may be essential for the binding of gp39 to 
the CD40 molecule on the antigen-presenting B cell (Fig. 1 ). These interactions assure the 
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preferential activation of antigen-specific B cells, which is required for the development of 
an antigen-specific antibody response. 
The experiments presented indicate that gp39 is essential for TD antibody responses in 
vivo. A similar molecule was identified on activated Th cells of humans (42). Its essential 
role in humoral immunity was clearly illustrated in patients with the X-linked hyper-lgM 
syndrome, whose defective lgG production was found to be caused by mutations in the 
gp39 molecule (45,46,47,48). 
After immunization with TNP-Ficoll, a Tl-2 antigen, high frequencies of gp39+ cells were 
obseNed in the outer-PALS and around the terminal arterioles of the spleen (chapters 6 
and 7), indicating that T cells were activated during Tl-2 antibody responses. The 
observation that antibody responses against TNP-Ficoll were unaffected in vivo after 
administration of anti-gp39 mAb (43, chapter 7) confirms that the initiation of this response 
is not dependent on gp39 and therefore actually T cell independent. These data indicate 
that gp39 is a marker for activated T cells and consequently not always related to T cell 
dependent B cell activation. The process of T cell activation, revealed in vivo as an 
increase in the frequency of gp39+ Th cells, can be explained as was suggested by 
DeKruyff et al. (49), who showed that B cells, activated by Tl-2 antigens, were able to 
activate T cells in vitro. Similar results were described by Zisman et al. (50), who demon-
strated that Tl-2 antigens composed of D-amino acids and binding directly to class ll 
molecules of antigen-presenting cells, were able to activate T cells. The observation of 
high frequencies of gp39+ cells during Tl-2 antibody responses is also in agreement with 
experiments showing that rigorous depletion of presumedly activated Th cells reduces the 
antibody response against Tl-2 antigens (51 ,52,53). As will be discussed in the next 
section, the cytokines produced by activated Th cells have an important regulating role in 
the proliferation and differentiation of B cells activated by Tl-2 antigens. 
Independent of the route of administration and the nature of the antigen, gp39+ cells and 
activated antigen-specific B cells were found in the PALS and around the terminal 
arterioles of the spleen. These observations suggest that T-8 cell interactions occur in 
restricted compartments of the spleen. This was already suggested by van Rooijen et a!. 
(54), who found that specific-AFC were localized in the same compartments during TD, 
Tl-1 and Tl-2 antibody responses. They hypothesized that there was only one migration 
pathway in the spleen for antigen-reactive B cells which are differentiating into AFC and 
that this pathway is independent of the type of antigen. Our experiments, describing the 
localization of antigen-specific B cells and activated T cells in the spleen, support this 
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hypothesis and suggest that T-8 cell interactions occur in the PALS and around the 
terminal arterioles of the spleen during all types of antibody responses. 
9.4 Cytokine-production in the spleen 
Besides a rote in the initial 8 cell activation, Th cells have also a major function in B cell 
differentiation. This regulatory ability is exerted by the cytokines produced by Th cells 
(Fig. 1 ). Several different in vitro models have been used to study the effects of cytokines 
on proliferation and differentiation of 8 cells (55, chapter 2). These in vitro experiments 
indicated the potential interactions of immune cells a:nd cytokines, but did not show 
whether these cytokines are active or have similar effects during in vivo antibody 
responses. Therefore, in vivo validation of in vitro observations is required to delineate the 
precise role of cytokines in immune responses. 
The role of IL-4 and IFN-y in in vivo antibody responses has been extensively studied (56, 
chapter 2). In this thesis the actual in vivo participation of cytokines in TD and Tl-2 
antibody responses is described. Furthermore, cytokine-production was related to antigen-
localization, gp39 expression and antibody production in the spleen during TD and Tl-2 
antibody responses. 
The historical definition of a Tl antigen reflects its ability to stimulate antibody responses in 
nude mice in vivo and in T cell depleted cultures in vitro (57). However, more recent 
experiments showed that rigorous elimination of T cells consistently reduced the in vitro 
antibody response against Tl antigens, indicating that these antigens are T cell dependent 
to a significant degree (51 ,52,53). Addition of cytokines to cultures of cells from secondary 
lymphoid organs, indicated a regulatory role of cytokines in in vitro antibody responses 
against Tl-2 antigens (53,58,60,61 ). 
Chapters 5 and 6 of this thesis describe the in vivo activity of cytokine-PC in Tl-2 antibody 
responses. After immunization with (non)-haptenated Tl-2 antigens relatively high fre-
quencies of IFN-y-PC were observed in spleens of mice. It was demonstrated that IFN-y 
was mainly produced by CD4 and CDS positive T cells and to a lesser degree by NK cells. 
Furthermore, it was demonstrated that these cells were actively secreting IFN"""Y· The IFN"""Y-
PC were predominantly localized in the outer-PALS and around the terminal arterioles. In 
these compartments high frequencies of IFN-y-PC were found in juxtaposition to TNP-AFC, 
suggesting a regulatory role of IFN1' in Tl-2 antibody responses. A regulatory role of IFN1' 
in Tl-2 antibody responses was also suggested by in vitro experiments of Snapper et al. 
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(60), which demonstrated that IFN-y stimulated the production of lgG2a and lgG3 of B 
cells activated by Tl-2 antigens. Interestingly, these results were supported by in vivo data, 
showing increased antigen-specific lgG3 serum levels after immunization with Tl-2 antigens 
(62). Altogether, these results suggest that the in situ visualized juxtaposition of IFN-y-PC 
and TNP-AFC represent T-B cell interactions which stimulate the development of lgG3+ 
antigen-specific AFC. However, in vivo treatment with anti-IFN-y mAb inhibited only slightly 
the lgG3 TNP-specific antibody response after TNP-Ficoll immunization (unpublished 
observation, Van den Eertwegh et al.). This observation may indicate that the physical 
interaction between IFN-y-PC and TNP-AFC does not allow the neutralization by IFN-y 
specific antibodies, or that IFN-y is one of the cytokines participating in the complex 
cytokine network that regulates Tl-2 antibody responses. 
Indeed, in chapter 6 it was shown that besides IFN-y-PC also high frequencies of IL-2-PC, 
IL-4-PC and IL-5-PC were found in close conjunction to TNP-AFC in spleens of TNP-Ficoll 
immunized mice. In contrast, relatively low frequencies of gp39+ cells and cytokine-PC 
were demonstrable in lymph nodes after s.c. immunization with TNP-Ficoll. Examination of 
the in situ antibody response, revealed significant frequencies of TNP-AFC in lymph nodes 
after immunization with TNP-Ficoll. Since no TNP-ASC were observed in TNP-Ficoll immu-
nized lymph nodes, these data suggest that the lack of cytokines in the microenvironment 
of lymph nodes from TNP-Ficoll immunized mice is responsible for the absence of TNP-
specific antibody secreting cells (TNP-ASC) in these draining lymph nodes. This was 
substantiated by the observation that simultaneous immunization with TNP-Ficoll and 
Brucella abortus, a particulate Tl-1 antigen, resulted in a simultaneous increase in the 
frequencies of cytokine-PC (IL-2, IL-4, IL-5 and IFN-y) and TNP-ASC in draining lymph 
nodes. Similar results were obtained by Goud et al. (61) in vitro. They demonstrated that in 
suspensions of peripheral lymph nodes, TNP-Ficoll could induce the priming and prolifer-
ation of hapten-specific 8 cells. However, the differentiation into TNP-ASC was not 
possible in the microenvironment created by lymph node cells. Only the addition of cytoki-
nes (IL-1, IL-5 and IL-6) could overcome this maturation defect. Therefore, we investigated 
the effect of in vivo IL-4 and/or IL-5 treatment on the antibody response against TNP-Ficoll 
in draining lymph nodes of immunized mice. Continuous in vivo administration of these 
cytokines did not significantly increase the frequencies of TNP-AFC or TNP-ASC in lymph 
nodes of TNP-Ficoll immunized mice. These results may indicate that administered 
cytokines do not increase the cytokine-concentrations in the microenvironment of lymph 
nodes to the level required for differentiation of TNP-ASC or that other cytokines are 
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involved as well in the differentiation of TNP-AFC into TNP-ASC. In conclusion, it appears 
that the lack of cytokines in the microenvironment of lymph nodes is responsible for the 
absence of TNP-ASC after TNP-Ficoll immunization. Furthermore, presented data suggest 
that during Tl-2 antibody responses the initial activation of B cells is T cell (gp39) indepen-
dent, whereas the further differentiation into antibody-secreting cells is dependent on 
cytokines produced by, e.g. T cells, NK cells, and macrophages. 
In antibody responses against (TNP-)KLH, a TO antigen, lgG1 is the principal isotype 
expressed by the antigen-specific AFC (63,64). In addition, lgE is produced only after 
immunization with TO (protein) antigens (65). Since IL-4 is suggested to be involved in the 
isotype selection of lgG1 and lgE, a role for this cytokine might be predicted in the 
response to KLH. We examined the in vivo cytokine-production during the antibody 
response against (TNP-)KLH. In the spleen IL-2-PC and IL-4-PC were observed in relatively 
high frequencies as compared to IFN-y-PC. Similar results were observed after immuniz-
ation with RalgO, a TO antibody response which is also dominated by lgG1 and lgE. The 
observation that all cytokine-PC reached maximum frequencies at day 3 and 4 after 
immunization with KLH and RalgO are consistent with experiments of Bradley et al. (67), 
who demonstrated that the kinetics of appearance of effector C04+ T cells, that produce 
cytokines upon restimulation with KLH in vitro, were similar for each of the cytokines 
investigated. These results suggest that after immunization and subsequent antigen 
presentation, T cells with potency to produce IL-2, IL-4, IL-5 and/or IFN-y are activated at 
about the same time and differentiate into cytokine-PC, following a similar time course. 
The dominance of a particular cytokine-PC (IL-4-PC or IFN~·-PC) in an antibody response 
most likely regulates the isotypes produced by individual AFC. Analysis of the in situ TO 
antibody response revealed high frequencies of antigen-specific AFC at days 3 and 4 after 
TNP-KLH immunization. These lgM+ antigen-specific-AFC were found in juxtaposition to 
predominantly IL-2-PC and IL-4-PC and preceded the antigen-specific lgG1 production, 
suggesting that these cytokines play a role in isotype-switching. Indeed, cultures of 
purified KLH-specific C04+ cells, predominantly secreting IL-2 and IL-4, and hapten-
specific B cells resulted in a relatively high production of antigen-specific lgG1 (67), 
confirming the suggested role of IL-4 in lgG1 production (1 0). Furthermore, the observa-
tion that in vivo anti-IL-4 treatment can completely block the increase in serum lgE after 
immunization with TNP-KLH (68), indicates that IL-4 is involved in the regulation of lgE 
production. 
Finkelmans group described extensively the model immune response observed after 
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injection of a high dosis of GalgD (56). The high degree ofT cell activation and cytokine-
production, which is critical for the huge increase in serum lgG1 and lgE, makes this 
model suitable for the analysis of in vivo TD antibody responses. In chapter 8 we investi-
gated the in vivo cytokine expression in the antibody response after RalgO injection. High 
frequencies of IL-2-PC and IL-4-PC relative to IFN-y-PC were observed in close conjunction 
to cytoplasmic-lgM+ B cells 2-5 days after immunization. The high cytokine-production 
preceded the lgG1 and lgE production which started 5 days after injection. These 
observations substantiate in vivo experiments, which suggested that T-B cell interactions, 
required for high lgG1 serum levels, occur at day 2-5 after GalgD treatment (65). This is 
consistent with the observation that lgE production is blocked by the injection of mice with 
anti-IL-4 mAb at day 3 and 4 after GalgD immunization (69,70). These data together, 
suggest that the in vivo visualized interactions between IL-4-PC and lgM+ cells, localized in 
the PALS and around the terminal arterioles of the spleen, are essential for the high lgE 
production observed after injection of RalgD. 
In vivo studies demonstrated that anti-IL-4 mAb treatment did not completely inhibit lgG1 
responses (70). In addition, the substantial amount of lgG1 demonstrable in sera of IL-4 
deficient mice (71 ), indicates that isotype switching to lgG1 is IL-4 independent. Recently, 
it was demonstrated that activated Th cell membranes, most likely expressing gp39, 
induced the germline transcription of Cy1, suggesting that this mechanism was respon-
sible for the switching to lgG1 (72). These in vitro data were substantiated by the studies 
described in this thesis, which showed in vivo that anti-gp39 treatment completely 
abrogated the lgG1 response after RalgD injection. 
In contrast to the large differences in lgG1 and lgE production after RalgD and KLH 
immunization, the splenic cytokine-production revealed similar frequencies of cytokine-PC 
in these two TD antibody responses. These results suggest that the type of cytokine (IL-4) 
determines the quality (isotype) of the antibody response, whereas other factors may be 
responsible for the quantity of antibody production. Analysis of the gp39 expression in 
both types of antibody responses revealed 3-4 times more gp39+ cells after RalgD 
immunization. In addition, in vivo blocking of gp39 prevented the four-fold increase in 
splenic weight, as is observed after RalgD injection. This suggests that differences 
observed in B cell proliferation/antibody production may be attributed to different fre-
quencies of gp39+ cells. 
Another important difference between the antibody responses against KLH and RalgD 
may be found in the APC. Because of the relatively low frequency of antigen-specific B 
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cells in non-immune mice, DC are most likely the important APC during the primary 
antibody response against KLH. In contrast, after injection of RalgD, the antigen binds 
directly to lgD+ B cells. Hence it is likely that B cells are the principal APC in the immune 
response to RalgD. This implicates that in the antibody response against KLH, a large part 
of the gp39+ cells is activated by DC and does not interact with antigen-specific 8 cells. 
This in contrast to the immune response q.fter RalgD injection, where most gp39+ cells are 
activated by antigen presenting 8 cells, which increases the frequency of T-8 cell 
conjugates. The formation of these T-8 cell conjugates (Fig. 1) facilitates the activation of 
B cells by activated Th cells, and will lead to the activation of relatively high frequencies of 
8 cells. In the secondary response against KLH, high frequencies of KLH-specific memory 
8 cells are present in the spleen, which will preferentially bind KLH and increase the 
relative contribution of the antigen-presenting 8 cells in the activation of Th cells. This will 
increase the frequency of T-8 cell conjugates, and may explain the significant increase in 
antigen-specific AFC after secondary immunization (chapter 7). 
At the peak of cytokine production relatively high frequencies of IL-2-PC and IL-4-PC were 
observed in the PALS and around the terminal arterioles during the antibody responses 
against KLH and RalgD. As these cytokine-PC were observed in close conjunction, it is 
likely that these cells create a microenvironment which is rich in IL-2 and IL-4. Such a 
microenvironment was suggested to be essential for the development IL-4-PC, as was 
demonstrated in vitro (73,74,75). It was suggested that IL-2 provides the optimum 
conditions for proliferation of cytokine-producing T cells (73,74,76), while IL-4 propagates 
the preferential development of IL-4-PC (73, 74). Ex vivo evidence that IL-2 was involved in 
T cell proliferation was provided by FAGS analysis, showing an increased IL-2R expression 
on T cells at day 3-5 after GalgD injection (77). 
Gp39+ cells, antigen-specific AFC, but also cytokine-PC were predominantly found in the 
PALS and around the terminal arterioles of the spleen, irrespective of type of antibody 
response (primary, secondary, TO, or Tl). These results support the hypothesis of Van 
Rooijen et al (54), who suggested one single differentiation pathway for B cells in the 
spleen during all types of antibody responses, as was discussed in the previous section. 
Cytokine-PC were never observed in the follicles of the spleen, similar to studies in 
humans (78,79,80), which demonstrated that none of the putative B cell differentiation 
factors, such as IL-2, IL-4 and IFN-y, were localized in the follicles of lymphoid tissue. 
Butch et al (81) showed in vitro that IL-4 mRNA was the only cytokine expressed by 
human germinal center T cells, whereas these T cells expressed no mRNA of the other 9 
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tested cytokines. Levels of mRNA expression in vitro, however, not always correlate with 
protein synthesis in vivo (82). Therefore these data are not incompatible with our in vivo 
results. Since cytokines are thought to be the determining factors in the regulation of 
isotype-switching and hardly any evidence was found for the expression of cytokines in 
the follicles, it is likely that isotype-switching does not occur in the follicles, as has been 
suggested by Kraal et al. (83). They demonstrated that during a primary antibody 
response follicular 8 cells were mlgM-positive, whereas after secondary immunization 
germinal center 8 cells were mlgG positive, suggesting that isotype switching occurred in 
the follicles. However, they could not exclude that these mlgG' B cells were generated in 
another compartment, as is suggested in this thesis. 
The studies described in this thesis show that gp39+ cells and cytokine-PC were predomi-
nantly localized in the PALS and around the terminal arterioles of the spleen. Jn vivo 
experiments suggested that B cell migrate from the PALS to the follicle (84). Based on the 
localization and migration of the immune cells involved, we hypothesize that part of the 
differentiating B cells regulated by activated Th cells switch from lgM to lgG1 in the PALS, 
and migrate subsequently to the follicle. In this compartment, B cells undergo follicular 
processes, such as 8 cell selection, somatic mutation, affinity maturation and will stay 
there as memory lgG' B cells (85,86). In conclusion, in situ analysis of cytokine- and 
antibody-production suggests that T-B cell interactions occur predominantly in the PALS 
and around the terminal arterioles of the spleen. 
9.5 In vivo cell-cell interactions in the spleen 
In this thesis we described the localization and cytokine production of the cells which are 
assumed to be involved in antibody formation in the spleen. The characteristic localization 
of T cells, B cells, macrophages, DC, gp39' cells, cytokine producing cells, antibody-
forming cells, and other immuno-competent cells within the splenic compartments was 
discussed in relation to antigen presentation. In addition we tried to evaluate the vast 
amount of in vitro data on the role of various cytokines and cell-cell interactions suggested 
to be involved in the generation of antibody responses. As a basis for understanding of in 
vivo processes, discrete phenomena of in vivo immune responses, like cell migration 
patterns of immunocompetent cells, antigen localization/trapping, T cell activation, 
cytokine production and antibody formation in the different compartments of the spleen, 
were related to in vitro observations for individual cells as well as bulk populations. 
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In this section we will try to bring order to the sequence of events that occur in the spleen 
after antigenic challenge. Both in vitro and in vivo data will be incorporated in the models 
presented. As antigen localization and T cell activation are completely different for Tl and 
TD humoral immune responses, these models will be discussed separately (Figs. 2-4). 
A. In vivo cell~cell interactions during Tl-2 antibody responses 
Alter i.v. injection, Tl antigens arrive in the marginal zone of the spleen (Fig. 2). Particulate 
Tl antigens (e.g. Brucella abortus) are taken up and processed by marginal zone 
macrophages. These processed antigens will subsequently be transferred to neighbouring 
B cells or act as soluble Tl antigens. Soluble Tl-2 antigens activate complement and bind, 
mediated by complement degradation products, to B cells in the marginal zone, and to B 
cells and FDC in the follicles. In these compartments, Tl-2 antigen-complement complexes 
can activate B cells directly, without the requirement of antigen presentation by marginal 
zone macrophages. Apart from direct B cell activation in the marginal zone, FDC expose 
the antigen to B cells which migrate through the follicles, resulting in the activation of 
virgin B cells with appropriate specificity. Tl-2 antigens drive resting Tl-2 antigen binding B 
cells into the G1 stage of the cell cycle, resulting in the acquisition of the competency to 
respond to T cell derived cytokines. Subsequently these primed Tl-2 antigen binding B 
cells migrate through the outer-PALS of the spleen and have cell-cell contact with T cells 
migrating from the inner PALS. These T cells will be activated by the Tl-2 antigen activated 
B cells and will then express gp39. Subsequently activated T cells will secrete cytokines 
which in turn regulate the proliferation and differentiation of G1 B cells into antigen-specific 
antibody-forming and -secreting B cells. These differentiating antigen-specific B cells and a 
part of the antigen-binding G1 B cells leave the white pulp along the sheaths of lymphoid 
tissue surrounding terminal arterioles. A part of these antigen-specific differentiating B cells 
will stay in the lymphoid tissue surrounding the terminal arterioles and develop into 
antigen-specific antibody-forming cells, whereas another part will leave the spleen through 
the red pulp into the circulation and migrate into extrasplenic sites, such as bone marrow 
and other lymphoid tissues. 
The role of marginal zone macrophages is not primarily antigen-presentation but rather 
removal (TI-2 antigens), killing and pre-processing of particulate antigens/bacteriae, 
whereas FDC and B cells are most likely involved in the induction of antibody responses 
to Tl-2 antigens. Cytokines secreted by T cells seem to be crucial for B cell differentiation 
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Figure 2. Schematfc representation of activation and migration of immune cells in the spleen during T/-2 
antibody responses Arrows migration of B and T cells in the spleen. C= central arteriole, iP= inner-PALS, 
F= follicle, Fe= follicle corona, MZ= margins: zone, op= outer-PALS, R= red pulp, S= sinus, ta= lymphocyte 
sheath around terminal arteriole, • =antigen, 0= B cell, D= activated antigen-specific B cells (G,), 
1J = differentiating antigen-sper.ific B cell, • = antibody-forming cell, 0 = T cell, 0 = activated T cell, 
() = differentiating T cell, 8 = cytokine producing T cell, * = FDC, * = marginal zone macrophage. 
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and isotype selection in the antibody response to Tl-2 antigens (Fig. 2). 
B. In vivo cell-cell interactions during TO antibody responses 
Like Tl antigens, TD antigens also arrive primarily in the marginal zone of the spleen after 
i.v. injection (Fig. 3; see also Van Rooijen [19]). Particulate antigens will be taken up and 
pre-processed by macrophages in the marginal zone. The macrophages in the marginal 
zone will transfer the processed antigen to B cells in the marginal zone, or migrate into the 
while pulp and there transfer the antigen to DC in the inner-PALS. Alternatively, the DC 
may pick up the antigen in the marginal zone and migrate subsequently into the PALS of 
the spleen. Upon contact with antigen, non-antigen specific T cells leave the clusters 
formed by IDC and T cells, while antigen-specific T cells are activated to proliferate. The 
induction of proliferation of antigen-specific T cells by IDC leads to an expansion of 
antigen-specific T cells. B cells which bind soluble or processed antigens migrate from the 
marginal zone into the adjacent outer parts of the PALS. On arrival in the PALS, B cells 
encounter numerous T cells, among which are T cells of the appropriate antigen-specificity 
activated by !DC, migrating in an opposite direction. The counter flow of antigen-specific 8 
and T cells optimizes the chance that these two cell types meet and interact with each 
other. Antigen-specific B cells will process and present the antigen in context of MHC 
class II to antigen-specific T cells, by forming a T-B cell conjugate (Fig. 1 ). Antigen-
presentation results in the activation of Th cells and the expression of gp39 by these cells. 
The T-B cell conjugate formed, facilitates the binding of gp39 to the CD40-molecule on the 
8 cells, which will lead to the initial activation of 8 cells. Besides the expression of new 
membrane antigens, activated T cells will also produce cytokines which will regulate the 
proliferation and differentiation of B cells into antibody forming cells. All these cell-cell 
interactions occur most likely during their migration from the PALS along the sheaths of 
lymphoid tissue surrounding the terminal arterioles towards the red pulp (Fig. 3). Whether 
T cells or 8 cells will migrate as single cells, as T-8 cell conjugates or encounter more 
than one antigen-specific B or T cell is not yet clear. After all these interactions B cells 
eventually differentiate into antibody-forming/secreting cells. The primary antibody 
response will be reflected in increasing serum concentrations of antibodies. These 
antibodies will form complexes with circulating antigen. A minor proportion of the 
antibody-antigen complexes will be trapped by FDC and can be retained there for long 
periods of time. These complexes provide the proper microenvironment for B cell affinity 
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Figure 3) Schematic representation of the activation and migration of T and B cells in the spleen during TD 
antibody responses. Arrows indicate migration of B and T cells in the spleen. C= central arteriole, ip= inner-
PALS, F= follicle, Fe= tomcle corona, MZ= marginal zone, iP= inner-PALS, oP= outer-PALS, R= red pulp, 
S= sinus, ta= lymphocyte sheath around terminal arteriole. • =antigen, 0 = resting B cell, ,1!1 = memory 
B cell, Ill""' differentiating antigen-specific B cell, ··• = antibody-forming B cell, 0 = resting T cell, 0 = activated 
antigen-specific T cell (gp39 positive), e = cytokine-producing T cell, * = FDC, l::J.. = IDC. 
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maturation and are involved in the generation and maintenance of 8 cell and possibly T 
cell memory. 
After secondary challenge with the same antigen, the majority of the formed antigen-
antibody complexes are phagocytized by macrophages in the marginal zone and red pulp. 
A part of the immune complexes or free antigen is trapped in the follicles (Fig. 3). The 
FDC dendrites bead and form iccosomes, which are dispersed in the developing germinal 
centers where they are trapped and endocytosed by germinal center memory B cells. 
Germinal center 8 cells process the iccosome derived antigen, and present the antigen to 
T cells. The exact localization of the assumed T-8 cell interaction is not known. On one 
hand the presence of many T cells, with unknown specificity, in the light zone of the 
follicle suggests that this interaction may occur in the follicle. On the other hand the high 
rate of T cell circulation in the PALS and the predominance of antibody-forming cells as 
well as gp39+ /cytokine-producing cells in this compartment after the initiation of the 
secondary immune response are more suggestive for the occurrence of T-8 cell interac-
tions in the PALS, as was discussed for primary antibody responses. The cytokine profile 
of T cells will determine the isotype of antibodies produced by B cells: e.g. Type 1 
pathway regulated immune responses with a predominance of IFN-y-PC may lead to a 
preferential production of lgG2a, whereas the type 2 pathway regulated immune 
responses with a predominance of IL-4 may favour the preferential production of lgG1 and 
lgE. These cytokine-producing T cells can only exert their regulatory role when they are 
localized in juxtaposition to antigen-specific 8 cells. During formation of T-8 cell conju-
gates (Fig. 1), the expression of gp39, CD40, cytokines, cytokine-receptors are all critical 
for the further differentiation of the antigen-specific B cells. Part of these isotype switched 
high affinity B cells will localize in the follicle as memory B cells and will follow the above 
described route when FDC present a free epitope of the antigen. In the case that all 
epitopes of antigen are covered with antibody no 8 cell activation will occur. In this way 
follicular trapped antigen is able to fine-tune the antigen-specific antibody response. 
Furthermore, by presenting the antigen to antigen-specific T cells, B memory cells may 
preserve T cell memory. 
9.6 CONCLUDING REMARKS 
In this thesis we demonstrate that the spleen participates significantly in host defence 
mechanisms. All immune cells and pathogens present in the circulation will pass the 
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spleen, where their sequestration may lead to a variety of antigen-specific immune 
responses. The characteristics of an antigen, i.e. soluble vs. particulate, protein vs. 
polysaccharide, complement-activating capability, determine the fate of the antigen in the 
spleen. The splenic compartments where antigen localizes and the cell types which take 
up the antigen have a decisive role in the selection of immune cells that will be involved in 
the development of immune responses. 
Macrophages, DC and B cells are the main APC, although their relative contribution to in 
vivo immune responses requires more study. In vitro experiments characterized the 
properties of isolated APC and suggested different roles of each of the APC in immune 
responses. However, ;n vitro experiments did not reveal the actual cells and compartments 
which are involved in antigen-presentation. In vivo studies on the localization of injected 
antigen and antigen presenting cells, combined with in vivo elimination studies of 
particular antigen presenting cells provide more direct clues to the contribution of each of 
the APC in the development of in vivo immune responses. 
The possible role of T cells, B cells, macrophages, gp39+ cells, cytokine producing cells 
and cytokines in in vivo immune responses, as suggested by in vitro experiments, was 
discussed. However, it was demonstrated that not all in vitro models correspond to the 
actual in vivo situation. We emphasized the advantages of the in vivo approach, which is 
powerful in the combined description of localization, characterization and activity of 
immune cells and the factors they produce in separate stages of immune responses. 
Furthermore, we demonstrated the valuable qualities of in vivo modulation studies for the 
understanding of antibody responses. 
The in vivo studies presented indicate that immune responses are regulated by a complex 
cytokine network, and show that the treatment of mice with cytokines or their neutralizing 
antibodies do not reveal the same clear-cut effects, as in vitro. These observations indicate 
that the delineation of the regulating role of the cytokine-network in in vivo antibody 
responses first requires a detailed in vivo description of all the cells and factors involved. 
Only after this stage of research, when cytokines and cell types producing cytokines 
during particular immune responses are characterized, modulation studies with multiple 
antibodies and/or cytokines may give us insight in the role of cytokines in in vivo immune 
responses. In conclusion, this thesis clearly shows that a combined in vitro/in vivo 
approach increases our comprehension of the important events during in vivo antibody 
responses. 
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SUMMARY 
The aim of the studies presented in this thesis was to investigate in vivo the immunological 
events taking place during the development of various types of antibody responses. Special 
emphasis was put on time-course and localization of the different immunological events, e.g. 
antigen-presentation, T cell activation, cytokine-production and antibody-formation in the 
spleen, as these processes are thought to have a decisive role in the development of in vivo 
antibody responses. To this end we have investigated cryostat sections of lymphoid tissue 
from mice immunized with various types of model antigens at different time points. The results 
revealed by specific immunohistochemistry is taken to be representative for the in vivo 
situation at that moment of the immune response. Furthermore, in vivo modulation 
experiments were periormed to determine the role of antigen, cytokines and immune cells 
during in vivo antibody responses. 
Chapter 2 discusses the complex anatomical organization of the spleen, consisting of distinct 
compartments which are characterized by the localization of unique and specialized cell 
types. The migration patterns of B cells, T cells and dendritic cells are described. The model 
antigens used in immunological experiments were characterized and their localization in the 
spleen after injection is discussed. Furthermore, the vast amount of in vitro data dealing with 
antigen~presentation, cell~cell interactions, T and B cell activation, and the immunoregulatory 
role of cytokinesis reviewed. Finally, the experimental questions addressed in this thesis are 
presented. 
Chapter 3 describes a highly sensitive immunohistochemical technique for the detection of 
trinitrophenylated antigens in the spleen and lymph nodes. The localization pattern of Tl-2 
antigens is compared to the localization of particulate Tl-t, soluble Tl-1 and soluble TO 
antigens. It is demonstrated that Tl-2 antigens and particulate antigen localize in the marginal 
zone of the spleen. The rapid uptake of these antigens by marginal zone macrophages 
emphasizes their important role in the primary defense against bloodborn pathogens. 
Furthermore, the putative role of marginal zone macrophages as important pre-processors 
of particulate antigens is discussed. It is demonstrated that Tl-2 antigens localize in the 
follicles of lymphoid organs, a hitherto undescribed phenomenon. Evidence is provided that 
the early follicular localization of TNP-Ficoll is mediated by complement. In vivo macrophage 
elimination drastically increased the amount of TNP-Ficoll in the follicles, and enhanced the 
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humoral immune response to relatively low doses of antigen. In contrast, complement 
deprivation of mice abrogated the follicular localization of Tl-2 antigen and led to a decreased 
antibody response, suggesting that the follicular localization of antigen plays a role in the 
induction of Tl~2 antibody responses. The mechanisms and in vivo cell~cell interactions which 
occur during the development ofTI-2 antibody responses are discussed. It is suggested that 
marginal zone macrophages are not primarily involved in antigen~presentation, but rather in 
removal (i.e. of Tl-2 antigens), killing and pre-processing of particulate antig~n/bacteriae, 
whereas follicular dendritic cells and 8 cells are most likely involved in the induction of 
antibody responses against Tl-2 antigens. 
In chapter 4, a new method is described for the immunohistochemical detection of cytokine-
producing-cells (cytokine-PC) in murine spleens. To this end, the in situ detection of IFN-y 
was used as example. Immunization with Bacille Calmette Guerin (BCG) was used as model 
immune response, since experiments have indicated that such a protocol might result in a 
high splenic IFN-y production. In order to detect IFN-y-PC, a monoclonal antibody directed 
to IFN-y was conjugated to alkaline-phosphatase. After incubation of cryostat sections with 
this conjugate and immunohistochemical revelation, IFN-y-PC, characterized by a blue stained 
cytoplasm, were detected. Immunization with BCG resulted in increased frequencies of IFN-y-
PC in the spleen. However, no raised IFN-y serum levels were detected in BCG immunized 
mice, indicating that IFN-y is locally produced and consumed in the splenic microenvironment. 
Only i.v. administration of Concanavalin A, aT cell mitogen which activates probably aii!FN-y-
PC, resulted in increased IFN-y serum levels in BCG immunized mice. Simultaneous 
incubation of the IFN-y-specific conjugate and an antibody specific for a membrane marker, 
followed by a secondary peroxidase conjugate, enabled the characterization of IFN-y-PC. It 
is concluded that immunohistochemical techniques indeed are suitable for the detection and 
characterization of cytokine-PC, provided that specific antibodies are available. 
Chapter 5 describes the development and localization of IFN-y-PC during immune responses 
against various Tl-2 antigens. It is demonstrated that the frequency of IFN1•-PC is markedly 
upregulated during Tl-2 antibody responses. The IFN-y-specific ELlS POT assay confirmed the 
results obtained in vivo and suggest that IFN-y is not only produced but also secreted in the 
spleen. Double staining experiments revealed that IFN-y is predominantly produced by CD4+ 
and cos+ cells, while relatively few IFN-y-PC were found to be NK cells. These data 
substantiate previous reports which suggested that T cells are involved in Tl-2 antibody 
194 
responses. IFN-y-PC were predominantly localized in the outer-PALS and around the terminal 
arterioles of the spleen after immunization with TNP-Ficoll. No IFN-y-PC were localized in the 
follicles and marginal zone of the spleen. Antigen-specific antibody-forming cells (AFC) were 
localized in the same compartments as IFN-y-PC. Furthermore, double staining revealed that 
TNP-AFC were localized in juxtaposition to IFN-y-PC, suggesting a regulatory role ofT cells 
in the antibody response against Tl-2 antigens. 
In chapter 6 the investigation of the putative defect of peripheral lymph node cells to mount 
an antibody response against Tl-2 antigens is described. Unexpectedly, analysis of the in situ 
antibody production revealed the presence of TNP-AFC in draining lymph nodes after s.c. 
immunization with TNP-Ficoll. Splenectomy experiments indicated that these TNP-AFC did not 
originate from the spleen. However, ELISPOT assays did not show TNP-specific antibody-
secreting cells (TNP-ASC) in draining lymph nodes, whereas in the spleen relatively high 
frequencies of TNP-ASC were observed after TNP-Ficoll immunization. These results suggest 
that TNP-Ficoll can prime TNP-specific lymph node B cells, but the microenvironment of 
lymph nodes appears not capable to provide the signals required for the final differentiation 
of TNP-AFC into TNP-ASC. Only after simultaneous injection of TNP-Ficoll and Brucella 
abortus, a particulate Tl-1 antigen, relatively high frequencies of TNP-ASC were detected. To 
investigate the cause of the differential ability of the spleen and peripheral lymph nodes to 
mount an antibody response against Tl-2 antigen, we compared the micro-environment of the 
(high responding) spleen and (low responding) lymph node after immunization with TNP-
Ficoll. It was demonstrated that injected TNP-Ficolllocalized in the follicles and macro phages 
of the lymph nodes, as was described for the spleen. Analysis of T cell activation and 
cytokine-production revealed relatively high frequencies of activated T cells (gp39+ cells), 
IL-2-, IL-4-, IL-5- and IFN-y-PC in spleens of mice immunized with TNP-Ficoll. Cytokine-PC 
were found in the same compartment as where TNP-AFC were localized, namely the outer-
PALS and around the terminal arterioles, suggesting a regulatory role of these cytokines in 
Tl-2 antibody responses. In contrast, hardly any expression of gp39 and cytokines was 
observed in lymph nodes after immunization with T!-2 antigens. These results suggest that 
the absence of activated cytokine-producing T cells is responsible tor the lack of TNP-ASC 
cells in lymph nodes after TNP-Ficoll immunization. Consistent with this suggestion was the 
observation that the simultaneous injection of Brucella abortus and TNP-Ficoll resulted in the 
development of high frequencies of gp39+ cells, cytokine-PC and TNP-ASC in draining lymph 
nodes. However, treatment of TNP-Ficoll immunized mice with alginate encapsulated IL-4 
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and/or IL-5-producing cell lines did not result in increased frequencies ofTNP-ASC in draining 
lymph nodes. These data indicate that combinations of cytokines or other cytokines than IL-4 
and IL-5 are required for the in vivo maturation of Tl-2 antigen activated lymph node B cells 
into TNP-specific antibody-secreting cells. In conclusion, the in vivo data presented in chapter 
6 substantiate previous reports which suggested that activated T cells and cytokines are 
actively participating in Tl-2 antibody responses. 
Chapter 7 describes the detection and activity of gp39+ cells and cytokine-PC in the antibody 
response against a TD antigen (KLH) and a Tl-2 antigen (TNP-Ficoll). Gp39+ cells were 
detected using a specific mAb, or a fusion protein of the receptor of gp39, CD40-IgG1. 
Immunization with TNP-Ficoll and KLH resulted both in the upregulation of the frequency of 
gp39+ cells. It was demonstrated in vivo that gp39 is only expressed by CD4 + cells, as was 
suggested by in vitro experiments. Gp39+ cells were predominantly localized in the outer-
PALS and around the terminal arterioles of the spleen, but only incidently in the corona of the 
follicles. The cytokine-PC were only observed in the outer-PALS and around the terminal 
arterioles of the spleen. Gp39' cells produced IL-2, IL-4, and IFN1'· and the kinetics of the 
development of gp39+ cells and cytokine-PC were superimposable. In the antibody response 
against Tl-2 and TD antigens, the gp39+ cells and cytokine-PC were demonstrated in close 
conjunction to antigen-specific B cells, suggesting a role of these cells in B cell activation and 
differentiation. Indeed, treatment of TNP-KLH immunized mice with anti-gp39 antibodies 
completely inhibited the antigen-specific antibody response, indicating that gp39-C040 
interactions are essential for TO immune responses. As expected, the antibody response 
against TNP-Ficoll was unaffected after in vivo treatment of mice with anti-gp39 antibodies, 
confirming the T cell (gp39) independency of this antibody response. The high frequencies 
of IL-4-PC, relative to IFN-y-PC, observed after injection of TNP-KLH were consistent with the 
relatively high amount of antigen-specific lgG1 and lgE demonstrable in sera of mice 
immunized with TO antigens. In conclusion, it is shown that during primary and secondary 
antibody responses against TO and Tl-2 antigens T-B cell interactions and cytokine-
production occur in the outer-PALS and around the terminal arterioles of the spleen. 
Chapter 8 describes immunological events such as antigen-localization, gp39 expression, 
cytokine-production and antibody formation in spleens of mice after injection of rabbit 
antibodies directed to mouse-lgD (RalgD). Immunization with RalgD results in high 
frequencies of activated T cells and cytokine-PC, which are critical for the huge polyclonal 
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lgG1 and !gE production observed beyond day 7 after primary immunization. Therefore, this 
is a suitable model to investigate the localization and function of (activated) immune-cells and 
cytokines in in vivo TO antibody responses. Shortly after i.v. injection, RalgD localized in all 
the follicles of the spleen as RalgD-mouse lgD immune complexes. A relatively high frequency 
of gp39+ cells was detectable 36 h after injection and reached maximum frequencies 3 and 
4 days after RalgD injection. The maximum frequencies of IL-2-PC and IL-4-PC observed at 
day 3 and 4 were about 5 times higher than the maximum frequencies of IFN"")'-PC, and were 
followed by a striking raise in the serum levels of lgG1 and lgE. Analysis of the in vivo 
cytokine profile revealed low frequencies of cells producing IL-2 and IFN--y, or IL-4 and IFN--y, 
or IL-2 and IL-4 consistent with the Th2 character of this response. Gp39+ cells were 
predominantly found in the PALS, around terminal arterioles and incidently in the follicles. The 
high frequencies of activated T cells, induced after RalgD injection, may explain the 
observation that in this polyclonal response gp39+ cells were not only localized in the outer-
PALS, but also in the inner-PALS. Analysis of the antibody response revealed a striking 
increase in serum lgG1 and lgE after RalgD injection. It was demonstrated that a part of the 
polyclonal antibody response was directed to the injected RalgD. The in situ antigen-specific-
antibody response reached maximum levels at 7 days after immunization. Earlier during the 
immune response, at days 2-5 after RalgD injection, gp39+ cells and cytokine-PC were 
observed in close conjunction to clgM+ B cells, suggesting that activated T cells have a role 
in B cell activation and differentiation. Indeed, treatment of RalgD immunized mice with gp39-
specific antibodies resulted in an almost complete inhibition of the polyclonal antibody 
response. These data suggest that the in situ visualized T-8 cell conjugates represent 
functional gp39-CD40 interactions, which are essential for the antibody response after RalgO 
injection. This study substantiates the hypothesis presented in chapter 7, by showing that, 
even in a strong polyclonal antibody response, T-B cell interactions occur in the PALS and 
around the terminal arterioles of the spleen. 
In chapter 9 the main points emerging from the experimental studies are discussed. Results 
are related to in vitro and in vivo data dealing with antigen-localization/presentation, immune 
cell localization/migration, cell-cell interactions and the immunoregulatory role of cytokines. 
In spite of the fact that antigen-presentation, T cell and B cell activation are completely 
different for Tl-2 and TO antibody responses, no differences were found between these two 
types of antibody responses with regard to the splenic compartmentalization of T-B cell 
interactions and cytokine production. These observations suggest a common differentiation 
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pathway for B cells into clones of AFC in the spleen. Finally, models are presented which 
show the cell-cell interactions in the spleen during Tl-2 and TO antibody responses. 
GENERAL CONCLUSIONS 
Tl-2 antigens also localize in the follicles of lymphoid tissues which may have an important 
role in the induction of Tl-2 antibody responses. 
T cells are activated and produce cytokines during in vivo Tl-2 antibody responses. 
Thymus independent antibody responses are dependent on the cytokines produced by T 
cells but not on the gp39 molecule expressed by activated T cells. 
In vivo gp39-C040 interactions are essential for TO humoral immunity. 
T-B cell interactions and cytokine-production occur in the periarteriolar sheaths and around 
the terminal arterioles of the spleen during Tl-2 and TD antibody responses. 
T-8 cell interactions leading to isotype switching of B cells do not seem to occur in the 
follicles of the spleen. 
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SAMENVATTING 
De mens komt gedurende zijn Ieven in contact met een grate verscheidenheid aan 
infectieuze micro-organismen, zeals bacterien, schimmels, virussen en parasieten. Het feit 
dat deze micro-organismen niet de kans krijgen ons lichaam te infecteren, is voornamelijk 
te danken aan het immuunsysteem. 
Het immuusysteem heeft een specifiek en een niet-specifiek gedeelte. Het laatste, ook wei 
genoemd het aangeboren immuunsysteem, is de primaire defensie tegen micro-organis-
men en bestaat uit de huid, trilhaarepitheel, mucus, maagzuur, cel-dodende enzymen in 
lichaamsvloeistoffen, acute fase eiwitten, fagocyten etc .. De tweede lijn van defensie wordt 
het specifieke, oak wei verworven immuunsysteem genoemd, dat bestaat uit een cellulair 
en een humoraal dee!. In de cellulaire immuniteit spelen cytotoxische en helper T cellen 
een centrale rol. Cytotoxische T ce!len doden o.a. virus geTnfecteerde en tumor cellen, 
terwijl T helper ce!len de functie van andere immuuncel!en reguleren door de expressie en 
secretie van eiwitten (cytokinen). 
In de humorale immuniteit spelen de antilichaam-vormende 8 cellen een centrale rol. 
Antilichamen zijn eiwitten die worden gesecreteerd in lichaamsvloeistoffen en die met hoge 
specificiteit aan een klein onderdeel van een ziekteverwekker (antigeen) binden en deze 
daardoor onschadelijk kunnen maken. Hierbij spelen neutralisatie, complement activatie, 
opsonisatie en antilichaam gemedieerde cytotoxiciteit een belangrijke rol. Er worden vijf 
klassen immunoglobulinen onderscheiden op basis van hun grootte, lading, aminozuur 
compositie en glycosylering: lgA, lgD, lgE, lgG en lgM. In de muis bestaan er nog 4 
subklassen (isotypen) van lgG, namelijk lgG1, lgG2a, lgG2b en lgG3. De diversiteit in de 
structuur van deze subklassen bepaalt de functie van deze effector moleculen in de 
immuniteit. 
8 cellen rijpen in het beenmerg waar ze uitgerust worden met antigeen-specifieke 
receptoren, membraan immunoglobuline, en migreren vervolgens naar de perifere lymfoTde 
organen. Daar kunnen zij differentieren tot antilichaamvormende cellen, mits zij het juiste 
antigeen tegen komen in het geschikte micromilieu. De interactie tussen antigeen en 
membraan immunoglobuline op de 8 cel·is de eerste interactie in een antilichaamrespons. 
De meeste antigenen kunnen de 8 eel niet direct activeren en hebben de hulp nodig van 
dendritische cellen, macrofagen en T cellen voor de inductie van een antilichaamrespons. 
Macrofagen en dendritische cellen zijn potente antigeen-presenterende cellen en hebben 
een rol in de initiele activatie en expansie van virginals T cellen. Na activatie brengen T 
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cellen nieuwe membraan-antigenen (o.a. gp39) tot expressie en gaan cytokinen produce-
ran, hetgeen hen in staat stelt de 8 eel activatie en differentiatie te reguleren. De interactie 
tussen het gp39-molekuul op geactiveerde T cellen en het CD40-molecuul op B cellen is 
essentieel voor de initiele activatie van B cellen gedurende thymus afhankelijke (TO) 
immuunresponsen. Dit in tegenstelling tot T eel onafhankelijke antigenen (TI) die in staat 
zijn B cellen direct te activeren. De door diverse cellen, waaronder T cellen, geproduceer-
de cytokinen regu!eren vervolgens de verdere differentiatie van geactiveerde 8 cellen tot 
antilichaam-vormende 8 cellen. Cytokinen zijn kleine geglycosyleerde eiwitten, ge'produ-
ceerd door zowel hematopoTetische alsmede non-hematopoTetische cel!en. Oorspronkelijk 
werden ze oak wei lymfokinen, monokinen of interleukinen genoemd, doelend op hun 
bran of rol in de communicatie tussen leucocyten. Het bleek echter al snel dat deze 
polypeptiden door meer dan een eel kunnen worden geproduceerd en dat ze effect 
hebben op verschillende cellen. Daarom wordt de term cytokinen nu algemeen gebruikt 
binnen het onderzoek. Cytokine-producerende cellen zijn parakriene cellen, dat wil zeggen 
dat hun regulatoire functie gericht is op de doel-cellen welke in de buurt zijn gelegen. Er 
komen steeds meer aanwijzingen dat met name interleukine 2 (IL-2), IL-4, IL-5, IL-6 en 
interferon-y (IFN•;) betrokken zijn by de B eel proliferatie en differentiatie. 
Om de interacties tussen immuuncellen te vergemakkelljken, zijn deze cellen georgani-
seerd in een aantal weefsels en organen, het lymfoi"de systeem. De primaire lymfoi"de 
organen zijn verantwoordelijk voor de vorming van de lymfo"lde cellen. De thymus verzorgt 
de rijping van T cellen, terwijl in de foetale lever en het beenmerg de B cellen uitrijpen. De 
secundaire lymfoi"de organen, zeals de lymfklleren, milt, en het darm-, huid- en long-
geassocieerd lymfo"id weefsel, vormen een micromilieu voor de immuuncellen dat hen in 
staat stelt tot een immuunrespons tegen antigenen. De lymfklier en milt kunnen worden 
gezien als de immunologische filters van respectievelijk de lymfe en het bleed. Oat wil 
zeggen dat antigenen die in het bleed voorkomen een immuunrespons opwekken in de 
milt, terwijl de antigenen die voorkomen in de lymfe dat primalr doen in de drainerende 
lymfklleren. Het lokale micromilieu van de lymfo"ide organen speelt een belangrijke rol in 
de totstandkoming van een immuunrespons. Oit micromilieu bestaat uit de extracellulaire 
matrix, niet-lymfoTde ce!len en lymfoTde cellen. De niet-lymfoTde cellen bestaan uit twee 
groepen. De eerste zijn de interdigiterende dendritische cel!en en macrofagen en de 
tweede groep zijn de stromale cellen, die bestaan uit reticulaire cellen, folliculaire dendriti-
sche cel!en en endotheelcellen. De Jymfoi"de cellen produceren cytokinen en antilichamen 
die op een antigeen-specifieke wijze bijdragen tot het micromilieu. AI deze lokaal actieve 
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cellen en factoren hebben een sturende invloed op de vorming van een antilichaamres-
pons. Daarom is voor een geed begrip van de mechanismen die leiden tot een antili-
chaamrespons inzicht vereist in het micromilieu van lymfoTde organen. 
Het doel van de studies beschreven in dit proefschrift was om in vivo te onderzoeken 
waar en wanneer de verschillende immunologische gebeurtenissen plaatsvinden in 
lymfoTde organen gedurende een aantal verschillende typen antilichaamresponsen. Daarbij 
is speciaal gekeken naar de timing en lokalisatie van antigeenpresentatie, T eel activatie, 
cytokine-produktie en antilichaamvorming in de milt, omdat deze processen een beslissen-
de rol spelen in de ontwikkeling van een anti!ichaamrespons. Hiervoor zijn vriescoupes 
van lymfoi'd weefsel van muizen onderzocht op verschillende tijdstippen na immunisatie 
met antigenen. De resultaten verkregen na specifieke immunohistochemie worden als 
representatief beschouwd voor de lokale in vivo situatie in het onderzochte lymfo'ide 
orgaan op dat tijdstip gedurende een antilichaamrespons. Daarnaast zijn in vivo modulatie 
experimenten gedaan om de rol van antigeen, cytokinen en immuuncellen in antilichaam-
responsen te bepalen. 
In hoofdstuk 2 wordt de complexe anatomische organisatie van de milt besproken, welke 
bestaat uit duidelijk gescheiden compartimenten die gekarakteriseerd worden door de 
lokalisatie van unieke en gespecialiseerde celtypen. De migratiepatronen van 8 cellen, T 
cellen en dendritische cellen worden beschreven. De antigenen die gebruikt worden in 
immunologisch onderzoek worden gekarakteriseerd en hun lokalisatie in de milt na injectie 
wordt beschreven. Verder worden in vitro experimenten besproken betreffende antigeen-
presentatie, eel-eel interacties, T en 8 eel activatie en de immuno-regulatoire rol van cyto-
kinen. Als laatste worden de experimentele vragen geformuleerd die in dit proefschrift 
onderzocht worden. 
In hoofdstuk 3 wordt de lokalisatie van geinjecteerde thymus onafhankelijke type 2 (TI-2) 
antigenen in de milt en lymfklieren beschreven. Deze lokalisatie wordt vergeleken met die 
van particulate (deeltjes) Tl-1, oplosbare Tl-1 en thymus afhankelijke (TD) antigenen. Het 
blijkt dat Tl antigenen en particulate antigenen beide in de marginale zone lokaliseren. De 
sne!le opname van deze antigenen door de marginale zone macrofagen benadrukt nog 
eens hun belangrijke rol in de primaire bescherming tegen infecties in de circulatie. 
Daarnaast wordt een geheel nieuw fenomeen beschreven, namelijk dat Tl-2 antigenen oak 
in de follikels van lymfoi'de organen lokaliseren. Het blijkt dat deze vroege folliculaire 
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lokalisatie van Tl-2 antigenen complement gemedTeerd is. In vivo depletie van de margina-
le zone macrofagen resulteerde in een opmerkelijke toename van folliculair gelokaliseerd 
Tl-2 antigeen, terwijl de antilichaamrespons tegen lage dosis antigeen ook bleek toe te 
nemen. Complement depletie resulteerde juist in een verminderde follieulaire lokalisatie 
van Tl-2 antigenen, en gaf ook een verlaagde antiliehaamrespons te zien. Dit tezamen 
suggereert dat de follieulaire lokalisatie van Tl-2 antigenen een rol speelt in de induetie 
van Tl-2 antiliehaamresponsen. De meehanismen en de in vivo eel-eel interaeties welke 
plaatsvinden in de milt gedurende Tl-2 antilichaamresponsen worden besproken. Er wordt 
geeoncludeerd dat marginale zone maerofagen niet primair bij antigeen-presentatie 
betrokken zijn, maar wei by de verwijdering (in het geval van Tl-2 antigenen), zuivering van 
het bleed, doden van bacterien, en "pre-processing" van particulate antigenen. Terwijl 8 
cellen en follieulair dendritische cellen betrokken zijn bij de inductie van Tl-2 antilichaam-
responsen. 
In hoofdstuk 4 wordt een nieuwe methode besehreven voor de immunohistochemische 
detectie van eytokine-produeerende cellen (eytokinen-PC) in lymfoi'd weefsel van muizen. 
De in situ deteetie van IFN-y werd gebruikt als model voor de ontwikkeling van de 
techniek. Muizen werden geTmmuniseerd met Baci/le Ca/mette Guerin (BCG), aangezien dit 
protocol zou moeten resulteren in een hoge IFN-y produktie in de milt. Om IFN-y-PC te 
kunnen detecteren werd een IFN-y-specifiek monoclonaal antilichaam gekoppeld aan 
alkalische fosfatase. lncubatie van een vriescoupe met dit conjugaat, gevolgd door het 
juiste substraat, stelden ens in staat de IFN-y-PC, gekarakteriseerd door een blauw 
eytoplasma, te detecteren. lmmunisatie met BCG resulteerde inderdaad in verhoogde 
frequenties van IFN-y-PC in de milt. Echter de IFN-y serum spiegels bleken niet verhoogd 
te zijn. Oat wijst erop dat IFN-y aileen lokaal in de milt werd geproduceerd en gebonden. 
Aileen in geval van de toediening van Concanavaline A, een T eel mitogeen welke 
waarschijnlijk IFN-y-PC activeert tot IFN-y seeretie, leidde tot een toename van de IFN-"; 
serumspiegels in met BCG geTmmuniseerde muizen. !ncubatie van een vrieseoupe met het 
!FN-y-speeifieke alkalische fosfatase conjugaat en een antilichaam dat specifiek is voor 
een membraan antigeen (CD4 en CDS), maakte de karakterisering van IFN-y-PC mogelijk. 
Er wordt geconcludeerd dat immunohistochemische technieken geschikt zijn voor het 
detecteren en karakteriseren van cytokine-PC in vivo, mits de juiste reagentia beschikbaar 
zijn. 
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Hootdstuk 5 beschrijft de ontwikkeling en lokalisatie van IFN--y-PC gedurende antilichaam-
responsen tegen verschillende Tl-2 antigenen. De frequentie van IFN--y-PC bleek aanmer-
kelijk te stijgen na immunisatie met Tl-2 antigenen. ELISPOT assay bevestigde deze 
resultaten en suggereerde bovendien dat deze cellen ook IFN-y secreteerden. Dubbelkleu-
ringen lieten zien dat IFN-y werd geproduceerd door CD4' and CDS' cellen, terwijl relatief 
weinig IFN-y-PC tot de natural killer cellen behoorden. Deze resultaten bevestigen voor-
gaande studies die suggereerden dat cytokine-producerende T cellen betrokken zijn bij de 
regulatie van Tl-2 antilichaamresponsen. De IFN--y-PC waren voorname!ijk geloka!iseerd in 
het buitenste deel van de periarteriolaire lymfocyten schede (outer-PALS) en random de 
terminale arteriolen. IFN-y-PC werden niet gevonden in de margina!e zone of follikels van 
de milt. Antigeen-specifieke antilichaam-vormende cellen bleken in hetzelfde compartiment 
te !okaliseren als waar IFN-y-PC gevonden werden. Dubbelkleuringen lieten zien dat IFN-y-
PC dicht tegen de TNP-specifieke antilichaam-vormende cellen (TNP-AFC) lagen, hetgeen 
een regulatoire rol suggereert van !FN--y-producerende T ce!len in de anti!ichaamrespons 
tegen Tl-2 antigenen. 
In hoofdstuk 6 wordt het vermeende defect van perifere lymfklieren, met betrekking tot het 
vermogen om een antilichaamrespons tegen Tl-2 antigenen te ontwikkelen, onderzocht. 
Onverwacht gat de im munohistochemische in situ analyse van de antilichaamrespons tach 
een relatief grate hoeveelheid TNP-AFC te zien in drainerende popliteale !ymfklieren (PLN) 
van met TNP-Ficoll ge'immuniseerde muizen. De verwijdering van de milt had geen effect 
op de frequentie van TNP-AFC in PLN, hetgeen betekent dat deze TNP-AFC niet uit de 
milt komen. De ELISPOT assay kon echter geen TNP-specifieke antilichaam-secreterende 
cellen (TNP-ASC) aantonen in drainerende PLN, terwijl grate hoeveelheden TNP-ASC 
werden aangetoond in de milt. Deze resultaten suggereren dat TNP-Fico!l wei in staat is 
TNP-specifieke B cellen in PLN te activeren, maar dat het micromilieu in de PLN niet de 
juiste stimuli kan verschaffen voor de uiteindelijke differentiatie tot TNP-ASC. Co-immunisa-
tie van TNP-Ficoll en Brucella abortus (BA). een particulaat Tl-1 antigeen, resu!teerde in 
relatief hoge frequenties van TNP-ASC in drainerende PLN. Om te onderzoeken waarop dit 
het verschil tussen milt en lymfklier berust, werd het micromilieu van deze lymfo'ide 
organen vergeleken na immunisatie met TNP-Ficoll. De lokalisatie van het geTnjecteerde 
TNP-Ficoll in de macrofagen en follikels van de lymfklier was vergelijkbaar met wat in de 
milt gevonden werd. Echter, de relatieve frequenties van geactiveerde T cellen en cytok-
inen-PC (IL-2, IL-4, IL-5 en IFN-y) in de milt bleken vele malen hager te zijn dan in de PLN 
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na immunisatie met TNP-Ficoll. Cytokinen-PC werden gevonden in hetzelfde compartiment 
als waar TNP-AFC waren gelokaliseerd, namelijk in de outer-PALS en rondom de terminale 
arteriolen. Oeze resultaten suggereren een regulatoire rol van deze cytokinen in Tl-2 
antilichaamresponsen en doen vermoeden dat de afwezigheid van cytokinen-PC in PLN 
na immunisatie met TNP-Ficoll verantwoordelijk is voor het maturatie defect van TNP-AFC 
in PLN. In overeenstemming met deze suggestie was de waarneming dat immunisatie met 
TNP-Ficoll + SA resulteerde in relatief hoge frequenties van geactiveerde T cellen, 
cytokinen-PC en ook TNP-ASC in drainerende PLN. Behandeling van TNP-Ficoll ge'immu-
niseerde muizen met in alginaat gekapselde IL-4 en/of IL-5 producerende cellijnen gat 
echter geen toename van het aantal TNP-ASC in PLN te zien. Dit zou mogelijk kunnen 
betekenen dat combinaties van cytokinen of andere cytokinen dan IL-4 en lL-5 vereist zijn 
voor de in vivo maturatie van TNP-AFC in TNP-ASC. Concluderend kan men stellen dat 
geactiveerde T cellen en cytokine-producerende cellen een rol spelen in anti!ichaamres-
ponsen tegen Tl-2 antigenen. 
In hoofdstuk 7 wordt de detectie en de activiteit van gp39+ cellen en cytokine-PC in de 
antilichaamrespons regen TO (KLH) en Tl-2 (TNP-Ficoll) antigenen beschreven. Gp39• 
cellen werden aangetoond met een specifiek monoclonaal antilichaam, of met een fusie-
eiwit van de receptor van gp39, het C040-IgG1. lmmunisatie met TNP-Ficoll of KLH 
resulteerde in een toename van de frequentie van gp39+ cellen. In overeenstemming met 
in vitro waarnemingen lieten dubbelkleuringen zien dat gp39 aileen tot expressie komt op 
CD4+ cellen. De gp39+ cellen werden met name gevonden in de outer-PALS en rondom 
de terminate arteriolen van de milt, en slechts enkele gp39+ ce!len werden gevonden in de 
corona van de follikels. Opnieuw werden de cytokine-PC aileen in de outer-PALS en 
random de terminate arteriolen van de milt gevonden. Er werden in de milt gp39+ cellen 
aangetoond die IL-2, IL-4 of lFN-y produceerden. De kinetiek van de ontwikkeling van 
gp39+ cellen en cytokine-producerende cellen verliep op een identieke wijze na immunisa-
tie met TNP-Ficoll of TNP-KLH. In zowel de antilichaamresponsen tegen Tl-2 antigenen 
alsmede tegen TO antigenen werden gp39• cellen aangetoond in dichte nabijheid van 
antigeen-specifieke 8 cellen. Deze resultaten suggereren een rol van deze cellen in de 
activatie en differentiatie van 8 cellen. De in vivo behandeling van met TNP-KLH geTmmuni-
seerde muizen met gp39 blokkerende antilichamen onderdrukte volledig de antigeen-
specifieke antilichaamrespons, hetgeen betekent dat gp39-C040 interacties essentieel zijn 
voor TO antilichaamresponsen. Zeals mocht worden verwacht, werd de antilichaamres-
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pons tegen TNP-Ficoll niet beTnvloed door de behandeling met gp39-blokkerende antili-
chamen. Daarmee werd het T eel onafhankelijke karakter van de antilichaamrespons tegen 
Tl-2 antigenen bevestigd. De hoge frequentie van IL-4-PC t.o.v. IFN-y-PC, die werd 
gevonden na immunisatie met TNP-KLH, is in overeenstemming met de relatief grate 
hoeveelheid antigeen-specifiek lgG1 en lgE dat aangetoond ken worden in sera van 
muizen geTmmuniseerd met TO antigenen. Geconcludeerd kan worden dat de T -B eel 
interacties en cytokine-produktie gedurende zowel primaire als secundaire antilichaamres-
ponsen tegen TO en Tl-2 antigenen plaats vinden in de outer-PALS en random de 
terminate arteriolen van de milt. 
In hoofdstuk 8 worden de antigeen-lokalisatie, gp39-expressie, cytokine-produktie en 
antilichaam-vorming beschreven in de milt van muizen na injectie van konijne-antilichamen 
gericht tegen muis-lgD (RalgD). lmmunisatie met RalgD resulteert in hoge frequenties van 
geactiveerde T cellen en cytokine-producerende cellen, die essentieel zijn voor de enorme 
polyclonale lgG1 and lgE produktie welke gezien wordt op dag 7 van de primaire 
immunisatie. Daarom is dit een zeer geschikt model om de lokalisatie en functie van 
(geactiveerde) immuuncellen en cytokinen gedurende in vivo antilichaamresponsen te 
bestuderen. AI kart na intraveneuze injectie ken het RalgD worden aangetoond als RalgD-
muis-lgD immuuncomplexen in de follikels van de milt. Een relatief hoge frequentie van 
gp39+ cellen werd aangetoond in de milt na 36 uur en bereikte maximale frequenties 3 en 
4 dagen na immunisatie. Op deze tijdstippen werd ook de maximale frequentie van cytoki-
ne-PC in de milt aangetoond. De frequenties van IL-2-PC en IL-4-PC waren daarbij 
ongeveer 5 maal hager als de frequentie van IFN-y-PC, wat in overeenstemming is met de 
enorme toename van de concentraties van lgG1 en lgE in het serum van de met RalgD 
ge'immuniseerde muizen. Analyse van het cytokine-profiel liet cellen zien die IL-2 en IL-4 
(ThO), IL-2 en IFN-y (Th1 ), IL-4 en IFN-y (THO) of aileen IL-4 (Th2) produceerden. Gp39' 
cellen werden met name gevonden in de PALS en random de terminals arteriolen van de 
milt. Slechts enkele gp39' cellen werden aangetoond in de follikels. Analyse van het 
serum lie! een opmerkelijke toename van lgG1 en lgE zien na injectie van RalgD. Zowel in 
het serum als in de milt werd aangetoond dat de polyclonale antilichaamrespons voor een 
deel specifiek was voor het geTnjecteerde antigeen. De in situ aangetoonde antigeen-
specifieke AFC bereikten maximale frequenties op 7 dagen na immunisatie met RalgD. lets 
eerder in de antilichaamrespons, op dag 2-5 na injectie van RalgD, werden relatief grate 
hoeveelheden gp39' cellen en cytokine-PC aangetoond dicht nabij clgM' cellen, 
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suggererend dat geaetiveerde T eellen de B eel aetivatie en differentiatie reguleren. 
Behandeling van muizen met blokkerende gp39-speeifieke antiliehamen resulteerde in een 
bijna volledige inhibitie van de polyclonale en antigeen-specifieke antiliehaamrespons. 
Deze gegevens suggereren dat de in situ gevisualiseerde T-8 eel conjugaten funetionele 
gp39-CD40 interaeties representeren die essentieel zijn voor de antilichaamrespons na 
RalgD injectie. Bovendien bevestigt deze studie de voorgestelde hypothesen, door aan te 
tonen dat zelfs in een zeer sterke polyclonale antilichaamrespons, T -B eel interaeties 
plaatsvinden in de PALS en random de terminals arteriolen van de milt. 
In hoofdstuk 9 worden de belangrijkste resultaten uit de voorgaande hoofdstukken bespro-
ken. Deze worden gerelateerd aan in vitro/in vivo experimenten betreffende antigeen-
lokalisatie/presentatie, immuuneel lokalisatie/migratie, eel-eel interaeties en de immunore-
gulatoire rol van eytokinen zeals die besehreven zijn in de literatuur. Ondanks het feit dat 
antigeen-presentatie, T eel en B eel aetivatie voor Tl-2 en TO antiliehaamresponsen 
volledig versehillen, werd geen versehillen gevonden tussen deze twee typen antiliehaam-
responsen wat betreft de eompartimentalisatie van T-8 eel interaeties en cytokine-
produktie in de milt. Deze waarneming suggereert dat er voor de differentiatie van B eellen 
sen gemeenschappelijke weg gevolgd wordt in de milt gedurende zowel Tl-2 als TO 
antiliehaamresponsen. Tenslotte worden modellen gepresenteerd die de eel-eel interacties 
in de milt Iaten zien gedurende de ontwikkeling van Tl-2 en TO antilichaamresponsen. 
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ALGEMENE CONCLUSIES 
Tl-2 antigenen lokaliseren ook in de follikels van lymfoid weefsel hetgeen mogelijk een rol 
speelt in de inductie van Tl-2 antillchaamresponsen. 
T cellen worden geactiveerd en produceren cytokinen in vivo na immunisatie met Tl-2, 
antigenen. 
Thymus-onafhankelijke antilichaamresponsen zijn afhankelijk van de cytokinen geprodu-
ceerd door T cellen, maar niet van het gp39-molekuul op geactiveerde T cellen. 
In vivo gp39-CD40 interacties zijn essentieel voor thymus-afhanke!ijke humorale immuniteit. 
T-B eel interacties en cytokine-produktie vinden plaats in de periarteriolaire lymfocyten 
schede en random de terminals arteriolen van de milt gedurende Tl-2 en TO antilichaam-
responsen. 
T-8 eel interacties die leiden tot isotype switching van B cellen lijken niet plaats te vinden 
in de follikels van de milt. 
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ABBREVIATIONS 
AP 
AFC 
APC 
/1-Gal 
BCG 
BA 
BSA 
BGG 
clg 
Con A 
CTL 
DC 
DNP 
DTH 
FCS 
FDC 
FITC 
ELISA 
Gal gO 
H 
HRP 
HSA 
Ia 
IDC 
lg 
IL 
IFN 
i.p. 
i.v. 
KLH 
LCMV 
LPS 
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alkaline phosphatase 
antibody-forming cell 
antigen-presenting cells 
p-galactosidase 
bacille Calmette Guerin 
Brucella abortus 
bovine serum albumin 
bovine y-globulin 
cytoplasmic Immunoglobulin 
concanavalin A 
cytolytic T cell 
dendritic cell 
2,4 dinitrophenyl 
delayed type hypersensitivity 
fetal calf serum 
follicular dendritic cells 
fluorescein isothiocyanate 
enzyme-linked immune sorbent assay 
goat antibodies anti-lgD 
hour 
horseradish peroxidase 
human serum albumin 
major histocompatibility complex class II 
interdigitating cells 
immunoglobulin 
interleukin 
interferon 
intraperitoneal 
intravenous 
keyhole limpet hemocyanin 
lymphocytic choriomeningitis virus 
lipopolysaccharide 
MHC major histocompatibility complex 
Min minutes 
mig membrane immunoglobulin 
NK natural killer cell 
NIP 4-hy d roxy -5-i od o-3-n itro phenyl 
OVA ovalbumin 
PC producing cell 
PALS periarteriolar lymphocyte sheath 
RalgD rabbit antibodies anti-lgD 
SRBC sheep red blood cell 
TA terminal arterioles 
Th T helper 
TO thymus dependent 
Tl-1 (2) thymus independent type 1 (2) 
TNP 2,4,6-trinitrobenzenesulfonic acid 
TNP-HES TNP-hydroxyethyl starch 
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NAWOORD 
Een viertal jaren wetenschappelijk onderzoek heeft geresulteerd in deze dissertatie. Velen 
hebben een bijdrage geleverd aan de totstandkoming van dit proefschrift en op deze 
plaats wil ik iedereen bedanken die op enigerlei wijze daaraan heeft meegewerkt. Van die 
vele mensen bedank ik met name Eric Claassen en Wim Boersma. Eric die met zijn 
enthousiasme en creativiteit voor mij een bran van inspiratie is geweest en Wim voor zijn 
kritische en constructieve inbreng aan het wetenschappelijke schrijfwerk van de afgelopen 
jaren. Oak de stagiaires Nicole Vermeulen, Sabita Ganesh en Marjan van Meurs ben ik 
zeer dankbaar voor de prachtige experimenten die zij met zo veel enthousiasme hebben 
gedaan. De medewerkers van het secretariaat, fotografie, dierverzorging, instrumentmakerij 
en automatisering van het MBL-TNO wil ik danken voor het perfecte vakwerk wat zij 
hebben afgeleverd. 
Lieve Esther, dank je wei voor alles wat je voor me gedaan hebt. 
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